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The use of Lean in healthcare as an improvement approach is commonplace with the results 
being widely reported in operational and academic literature. Despite the prevalence of Lean 
as an improvement approach, healthcare remains in a position of crisis which raises questions 
about the appropriateness of the historic approaches for Lean. In parallel the growing 
influence of technology to improve healthcare is evident with operational and policy 
decisions reflecting an ongoing appetite to improve healthcare through technology.  This 
thesis analyses Lean literature to understand the use of Lean and technology in healthcare for 
patients. It focuses on the growing ageing population with long term conditions prior to 
creating a high-level value stream map for cardiovascular patients from Northern Ireland. 
This exploratory research utilised available open data sources and expert focus groups over a 
5-year period to develop a Lean healthcare technology model as a contribution to Lean 
knowledge. The thesis identifies that Lean healthcare is focused on providers and not patients 
leading to unmet value for patients and system level non-value add activities across the 
patient journey. A Lean healthcare technology model can be utilised to identify and address 
both patient value and non-value add activities. A number of propositions are presented 
which provide a platform for further studies of other long-term conditions beyond 
cardiovascular disease which are likely to benefit from a similar research methodologies. 
Future studies could also extend the research beyond public health care systems to private 
healthcare systems as the literature highlights similar Lean healthcare failures in other 
geographies.  
The findings will assist operational, strategic and healthcare academics implementing 
healthcare reform. Healthcare managers should consider the role for technology and Lean to 
address wastes across the current silos to improve healthcare outcomes and address wasted 
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Chapter 1 – Introduction  
1.1 Introduction  
Healthcare provision is under pressure to provide high quality care at a time when people are 
living longer with growing care requirements from an ageing population (Dannapfel et al., 
2014). The increases in health expectation, low patient adherence to treatment, escalation in 
adverse medical events and high levels of political interest are in an environment of rising 
costs (Moraros et al., 2015). The cost inflation is in a period of severe financial austerity 
which recognises that healthcare is already absorbing large quantities of the national budgets 
and must seek to improve efficiency (Reijula et al., 2016). Currie and Finnegan (2011) 
summarises this by stating that “Healthcare now accounts for the largest portion of public 
expenditure after social security, with total expenditure now exceeding £100 billion and 
rising”. Simon Stevens, head of England’s NHS, speaking following the elections in May 
2015 stated “we’re going to need more funding year by year” and talked of the need to 
“stabilise NHS finances” (Neville, 2015) as they manage an ageing population. Over two 
years later following a change of prime minister, in November 2017, Simon Stevens 
reiterated the message and reported to the press and health service employees that without an 
increase in spending, waiting lists were set to rise by 25% to five million (Pym, 2017).  The 
NHS must therefore balance a need to improve for the future and address today’s healthcare 
challenges (Ham, 2017).  Healthcare spending pressure is a global issue and “many countries 
share an increasing concern that healthcare costs have exploded with no evidence of an 
equivalent improvement in healthcare” (de Souza, 2009, 125).  In this context of rising 
financial pressure and escalating demand there is a clear need to explore operational 
approaches and innovations that can address operational efficiencies at a scales suitable for 





1.2 Lean in Healthcare 
These challenges in healthcare and in other public services in the UK necessitate improved 
management practices in delivering services (Tortorella et al., 2017).  Lean is a recognised 
operational improvement approach used initially in the car manufacturing industries before 
being adopted by other manufacturing industries, services, government and healthcare 
organisations (Samuel et al., 2015). Samuel et al. (2015, Pg. 1388) states that “Lean has 
evolved to be one of the best-known, yet fiercely debated, process improvement 
methodologies”.  
It has been utilised in hospitals as a continuous improvement approach with implementations 
including Rapid Improvement Events (RIE) or “Kaizen” events which gather staff and 
resources to focus on specific challenge in care delivery through a series of workshops with 
an output of a new operational approach with measureable outcomes (Stelson et al., 2017). 
The use of Lean is not limited to RIE events and initiatives such as the “Productive Ward” 
series have been deployed in the NHS by focusing on quality and utilising Lean principles 
but rather than creating solutions for one location they have sought to disseminate this 
approach across hospitals (BMC, 2017). The reported results of Lean implementation 
include; reduced waiting times, reduced cost, reduced length of stay and increased capacity 
(Costa and Filho, 2016). Beyond the advocates of Lean there are significant critics with 
Moraros et al. (2016) highlighting the lack of peer reviewed evidence of improvement.  
1.3 Technology in Healthcare 
Unrelated to Lean improvements, technology has been developing to meet clinical and cost 
advantages and this is being adopted into healthcare to meet demands of commissioners, 





interactions with computers through voice, movement, touch and with the aid of devices to 
support virtual reality, augmented reality and devices which are worn (Hassan and Yu, 2017). 
The technology has far reaching impact in an “interconnected world” which is impacting 
citizen’s lives, homes and cities through interaction and automation (Nguyen and Simkin, 
2017). Emerging technology categories such as Internet of Things (IoT) and data technology 
provides opportunities for remote monitoring, machine learning use of sensors, real time 
feedback, faster processing, sending data and mining data for actionable patterns (Nguyen et 
al., 2017).  Within these emerging and current products, technology has the potential to 
improve service delivery in healthcare. Nguyen and Simkin (2017), highlight that many of 
the applications for the emerging technologies are still to be discovered. The adoption of 
healthcare technology has been “underpinned by the drive to improve the safety, quality, and 
efficiency of care” (Cresswell et al., 2016).  This emergent technology provides examples 
where healthcare needs have been met by technology and where there is opportunity to 
address both current unmet needs and emergent healthcare needs in medical technology, 
diagnostics and other medical uses (Campbell et al. 2017)  
1.4 Lean technology in healthcare and the overall Aims and Objective of the 
Thesis 
Diseases that would previously have been fatal are being managed as long term conditions 
and the English Department of Health (2012) reported that 15 million people in England have 
a long-term condition. Rising cost per activity and an ageing population with long-term 
conditions is resulting in healthcare demand that is outstripping the supply of care provision 
(Porter, 2016). This is an unsustainable position requires a new framework to guide 
healthcare decision makers. Lean as an operational improvement approach could contribute 





required to understand the criticisms that are emerging in literature reviews (Moraros et al., 
2016).  Technology has potential to contribute to the framework but critical analysis of the 
role for technology in developing Lean in healthcare is required. This thesis will therefore 
seek to provide a critical analysis of operational improvement insight from Lean and potential 
improvement opportunities for emerging technologies in healthcare. This analysis will reveal 
the strengths and gaps in knowledge which will create a theoretical model for the application 
of healthcare technology which utilises Lean operational improvement insight. The key thrust 
of the exploration will focus on discovering if Lean approaches and healthcare technology, 
uniquely or jointly, provide opportunities to identify non-value add activities within the 
healthcare system and address the demand pressures for healthcare decision makers.   
 
Therefore, the aim of the thesis is;  
 
To explore the role of Lean thinking in integrated healthcare patient pathway reform 
to identify opportunities for improved healthcare technology.  
 
The research will utilise data associated to healthcare provision to create a longitudinal data 
set to assist with action learning around Lean reviews of patient flows to assess technology 
adoption opportunities. 
The thesis objectives are as follows: 
 Objective 1 –  To perform a critical analysis of Lean related theory in healthcare 
reform and the use of technology within healthcare reform 
 Objective 2 – To develop an initial theoretical framework to guide empirical analysis  
 Objective 3 – To investigate use of emerging technology to address improvement 





 Objective 4 – Explore the development of theoretical framework for Lean healthcare 
technology models which utilises the learning and approaches of Lean and 
opportunities presented by technology.  
1.5 Outline of the Thesis Chapters  
This thesis will focus on the use of Lean within a context of continuous improvement in 
healthcare. The report is broken into a further nine chapters followed by appendices. 
 





 Chapter 2 will provide an introduction to Lean and a critical literature review of the 
application of Lean in public services. This critical analysis establishes a context to 
understand how a manufacturing based approach has been adopted in public services.  
 Chapter 3 will focus on healthcare and provide a critique of literature surrounding 
Lean in healthcare. This chapter will identify approaches, methods, tools and lessons 
learned.  
 Chapter 4 will focus on critiquing the use of technology in healthcare. The chapter 
will build on chapter 3 exploring the role of technology in healthcare reform and its 
impact on patient value and non-value add activities.   
 Chapter 5 will focus on the development of a theoretical framework and identifying 
the research questions emerging following the literature critique.   
 Chapter 6 will provide a discussion on the research methodology used and the 
rationale for adopting it.  
 Chapter 7 provides research results of cardiovascular disease within Northern Ireland 
as an exploratory case study of the application of Lean and technology to long-term 
conditions. 
 Chapter 8 provides a discussion of the emerging knowledge contributions from the 
thesis literature and research which are relevant to Lean and technology in healthcare. 
 Chapter 9 presents a revised conceptual framework which shows knowledge 
contribution, conclusions and recommendations for further research. 
 References  
 Appendices - Provide an overview of qualitative analysis, meetings, publications and 





Chapter 2 - Literature Review of Lean and the Application to Public 
Services  
2.1 Introduction   
The aim of this thesis is to explore the role of Lean thinking in integrated healthcare patient 
pathway reform and to identify opportunities for improved healthcare technology. To 
understand how Lean continuous improvement approaches were adopted by healthcare it is 
important to first review the principles of Lean and the historical context. This chapter 
presents these origins of the Lean principles and provides the link between its historical 
context in the manufacturing industry and the transfer to public services of Lean. The 
application of Lean outside of manufacturing has been challenging and applying Lean 
thinking to other sectors has required an ability to “evolve” Lean thinking and “localise” the 








Figure 2.1 – Chapter 2 Overview  
2.2 Lean Context and Historical Journey  
To understand how Lean thinking applies to healthcare it is important to firstly understand 
the origins of Lean (Samuel et al., 2015), how it transferred to the public sector including 
health (Radnor, 2009) and if Lean based improvement initiatives can assist in addressing 
the budget shortfalls of public sector organisations (Antony et al., 2017). Lean is primarily 
linked back to the Toyota motor company who developed a Toyota Production Systems to 
create a competitive business model at a time when cash flow was restricted and they were 
competing against cash rich mass production companies such as Ford (Womack et al., 





efficiency by removing waste from the system. The Japanese manufacturers had to learn 
to build each product according to individual needs and move away from mass production 
practiced by American manufacturers such as Ford in the post war era. (Ohno, 1988). 
Lean’s origins can be found in these early Toyota production system and linked to the 
leadership of Taiichi Ohno in the 50’s, 60’s and 70’s (Hines et al., 2004) Samuel et al. 
(2015) notes that the term Lean was initially used by Krafcik (1988) to compare western 
approaches to the less resource intensive “Lean” Toyota production systems but was made 
popular by Womack’s management book “the machine that changed the world” Womack 
et al., 1991). The Lean way of thinking explored in the book provided a high focus on 
quality, employee engagement, value creation in each activity and the removal of wasteful 
activities within a continuous improvement culture. The continuous improvement culture 
provides short term quality improvements and efficiencies with longer term system wide 
improvements. (Hung et al., 2017). The approach has a heavy focus on quality and flow 
which was counter to the mass manufacturing and batch processing evident in the 
production environments at the time of writing the book (Womack et al., 1991).  The 
translation from the original Toyota Manufacturing System to the Lean practices evident 
today has not been without issue as a misunderstanding of the meaning of the Toyota 
Production System can lead to a tools based approach rather than understanding the 
culture and approach that it requires for success (Liker and Rother, 2011, pg. 1). This 
failure is not limited to the other companies as Liker and Convis (2011) note that even 
Toyota had to be reminded of this return to basics when quality production failures 






This continuous improvement approach was outlined in the early seminal work of 
Womack, Jones and Roo’s in their work “The machine that changed the world: The story 
of Lean production.” (Womack et al., 1991). It draws out a number of case studies and 
examples in the manufacturing industries highlighting what they refer to as a “Lean” 
approach. The ideas from this were developed further, structured and presented in the 
“Lean Thinking” book by Womack and Jones in 1996 and updated in 2010 (Womack 
2010). Lean has had many critical reviews over time with a body of academic literature 
critiquing its style, evidence, staff impact, suitability for transfer and financial benefits 
(Samuel et al.,2015). Based on this critique Samuel et al. (2015) concludes that Lean has 
impacted on many aspects of “everyday life”, education, healthcare and manufacturing. 
From the seminal work the authors presented the 5 lean principles which are outlined in 
various forms across most Lean literature. Miller (2015) records these five principles as;  
 Identification of customer value; 
 Management of the value stream; 
 Developing a flow production; 
 Using pull techniques; and 
 Striving to perfection. 
The principles are the foundation of Lean continuous improvements, including healthcare, 
despite challenges about being developed around a Japanese culture and the car 
manufacturing industry (Bowerman and Fillingham, 2007).  The early work focused 
primarily on the manufacturing industries; however it made a number of attempts to 
consider the application of the principles to other areas such as medical care (Womack, 
2010, 289). The authors challenge the healthcare professionals about “entering a world of 





care from the “standpoint of organisation charts, functional expertise and “efficiency”. 
The criticism reflects the core argument of the Toyota Production System where 
traditional business owners were more concerned about keeping the machines moving 
than on producing a quality outcome (Womack et al., 1991).  The publications exploration 
of “waste” features in a large number of Lean transformation approaches such as the 
“Unipart way”, which was used in the first applications to public services (Radnor 2013). 
Waste in the Lean context means activities which add no value from the perception of the 
customer and can be an output of “Value Stream Mapping” which looks at processes from 
the start to the finish (Tortorella et al.,2017). A crucial element of Lean is not just to 
understand the process but to remove these wastes. Recent articles highlight the continued 
use of the Lean five principles as a means of identifying waste and highlight processes 
such as arrival and scheduling as creating wastes in healthcare Miller (2015). Nordin 
(2017) also highlights that the adoption of Lean is not a guaranteed success as many 
manufacturers have failed where they did not consider reshaping the purpose, system and 
work culture.  
In summary, the use of the Toyota Production System, which was later labelled as Lean, 
was a success in providing high quality cars at lower costs (Samuel et al., 2015). The use 
of Lean in UK public services reflected a desire from the public services to implement 
business process improvement techniques to increase efficiencies (Radnor, 2009). The 
promise of high quality delivery for less cost and resources appealed to public services 
budget holders under pressure to provide outputs with less money and to avoid alienating 
staff (Radnor and Walley 2008). Lean continues to have many challenges for adoption in 
the public services with benefits and evidence not fully established (Antony et al., 2016) 
and a number of critics have challenged the sustainability of improvements (McCann, 





criticism that “Lean can be described as polymorphic; meaning different things to 
different people” (Samuel et al., 2015, 1388). Lean has been accused of focusing on tools 
and quick wins and a more holistic approach is needed (Antony et al, 2016). Despite the 
criticism and the lack of clarity on its definition it has had a clear influence as a 
management improvement approach (Samuel et al., 2015). This influence and impact has 
included the public services which will be discussed further in the next section.  
2.3 The Application and Appetite for Lean in Public Services  
As the purpose of this thesis is to understand Lean healthcare it is important to understand the 
bridge from the manufacturing industries to public service which then became adopted in 
healthcare (Radnor 2009). Lean was initially applied to process oriented elements of the 
public services such as HMRC before being deployed in healthcare sites (Radnor 2009). This 
reflects an observation from that there is a historical trend of transferring management 
philosophies from large companies to government with examples including Business Process 
Reengineering and Total Quality Management (Moffett, 2015). Leseure (2010) documents 
the early Lean transfer to UK government through the application of an approached branded 
as the “Unipart way” which was applied to the HMRC’s exploratory projects which were 
referred to as “Pathfinders”. The application of Lean in public services should not be 
assumed to have been a predetermined outcome as there are context considerations that 
challenge its application such as the lack of process consistency in public services (Radnor 
and Walley, 2008). The key issue is that Lean tools and techniques requires underlying 
process understanding and linkage to strategy that may not be there in public services and 
could create instability as the improvements have no sustainable platform (Radnor and 
Walley, 2008). Despite the criticisms outlined in the previous section,  the combination of 





due to the emphasis on front line staff engagement and a political and managerial desire to 
show evidence of improvement (Radnor 2009). While recognising the critiques of Lean, it 
has been a significant influence on public services such as Health and Education (Samuel et 
al., 2015). The Operational Efficiency Programme, Treasury (2009, 83) documents how tools 
such as Lean can “harness staff insight and expertise and identify the redundant or avoidable 
steps…” leading to more efficient service”. The participative nature of Lean has an attraction 
to the public services as a means of improvement and to address the potential resistance to 
change (Radnor, 2010). One of the recommendations from the report (Treasury 2009) is the 
need to “use continuous improvement tools such as Lean more systematically across the 
public services, and develop capacity to examine themes that cut across organisational 
boundaries”, moreover suggesting that public service improvements are interested in Lean as 
a proven route to improvement. This has manifest itself in the years after this report with the 
English Police service using Lean as an improvement approach to address budget pressures 
(Barton and Mathews, 2017). Radnor’s (2008) article reiterates this appetite for public service 
improvement and the interest in Lean as a potential route to improvement. Her research 
quotes examples of interest in public services organisations who have applied Lean 
approaches, including healthcare, government agencies, local authorities and an RAF base. 
More recent literature critiquing the application of Lean in public services includes; education 
(Antony, 2015), police (Barton and Mathews, 2017), health (McCann, 2015), public road 
works (Aziz et al., 2017).  
The interest in Lean compared to other approaches was underlined in the Institute of 
Management review of business process improvement methodologies in the public services 
(Radnor, 2010). Other approaches included Six Sigma, Lean Six Sigma, Business Process 
Reengineering (BPR), Total Quality Management (TQM) and European Foundation Quality 





improvement approaches being used across the public services but of the 165 sources of 
improvement initiatives identified the majority, 51%, focused on Lean.  More recent 
literature describes how Lean has been deployed widely in a “fragmented” manner but with 
evidence of some successful application (Antony et al., 2016). Radnor (2008) explores the 
application of Lean in public services and the potential conflict with the culture. She 
emphasises the need to adapt to the context of the public services but not to use this as “an 
excuse for avoiding manufacturing methodologies as a means of efficiency gain”. Antony et 
al. (2016) support a similar position by stating that there needs to be a better evidence base 
and more holistic approaches.  
To explore this further this section will critique literature under the following topics;  
 Potential benefits for public services  
 Challenges and cautions to the case for Lean 
 Gaps in Lean literature for public services 
 Summary of Lean in public services 
2.3.1 Potential Benefits for Public Services  
The purpose of this thesis is to explore literature in healthcare. By understanding the benefits 
of developing and applying Lean in public services one can begin to appreciate the 
opportunity for healthcare. The literature emphasises the challenge of adapting Lean to the 
public services (Radnor 2008) and tangible benefits emerging from the application of Lean 
such as reduction in waste and lead times (Tortorella et al, 2017). Radnor’s (2008) reports on 
a diverse set of improvement activities across the public services with activities providing 
positive outcomes such as productivity increases, cost reductions, faster turnaround times, 





review of business process improvement methodologies in the Public services (Radnor 2010) 
supports this view that Lean implementations have a strong evidence base of providing 
significant improvements. The “Operational Efficiency Programme: Final report”, Treasury 
(2009), makes reference to Lean initiatives in the Department of Work and Pensions in a 
programme called the “Lean Way”. The report highlights savings, at the time, of 
approximately £10M. Further improvements were documented with other references to 
initiatives, such as the Job Centre Plus, with efficiency, quality and staff satisfaction. The 
literature has not been consistent about all these positive aspects but Samuel et al.(2015)  
analysis show the movement of Lean from manufacturing to public services as having a 
significant impact and maintaining the interest of both academic and service improvement 
organisations.  
 
A gap not addressed in literature is the lack of progress. Samuel et al. (2015) highlights 25 
years of Lean literature as a success yet the same wastes and issues are present in each 
academic review without a significant step forward. The wastes reported in Tortorella et al, in 
2017 are the same wastes reported in public sector studies by Radnor (2008) which will map 
back to Womack (1991). The gap that is emerging is where there is recognised benefit which 
is not evolving to become larger benefits or where there are failures these are not becoming 
systematic lessons learned which should not be repeated. The failures of the past are 
repeating themselves and Lean is not codifying the lessons learned.    
 
In summary, one can see a strong evidence base of appetite and application in the public 
sector. A literature gap is emerging where Lean is identifying wastes which were evident 
back in 2008 literature (Radnor, 2008) and these where recognised by the public sector 





somewhat static with more recent literature in Higher Education (Antony, 2015), Policing 
(Barton et al., 2017) and Health (Cheng et al, 2015) showing the repetition of the experience 
of the early adoption of Lean in public services. In literature where there are improvements 
there are also challenges identified that will be considered in the next section.  
2.3.2 Challenges to the Case for Lean in Public Services 
Despite positive reviews of Lean, “many criticisms” have been made of various aspects of 
Lean (Samuel et al., 2015). In addition to the criticism, various challenges have been 
identified which provide lessons learned in public services that could be applied to healthcare 
(Radnor 2013). Two areas emerge from literature critiques. One is about Lean deployment 
and one being about the public services readiness for Lean.  
 
The criticism and challenges of Lean deployment include a lack consistent definition and 
purpose with no shared understanding of what is meant by Lean (Samuel et al., 2015). 
Samuel’s critique of 25 years of Lean since the publication of “The machine that changed the 
world” highlighted that Lean has evolved over time without clear definitions. A Lean 
deployment may focus on tools such as value stream mapping (Aziz et al., 2017) while 
another deployment may seek other goals around leadership, quality or staff engagement 
(Antony 2015). The outcomes, such as cost reduction in a period of austerity, may be the 
prime driver (Smith, 2016) which removes any longer term vision and ultimately leads to 
“eroded” improvements and Lean being referred to as a management “fad”. The lack of 
definition creates challenges and criticism which if addressed alongside better evidence could 
demonstrate a more acceptable adoption (Antony, 2016). Secondly, a lack of focus on the 
customer has also been highlighted by Radnor (2013) where she stated that Lean will fail 





customer is reflected in academic literature where the focus was on tools (Linskog, 2017), 
budget pressures (Barton 2017) or staff (Eriksson, 2017). Radnor (2008b) highlighted these 
as including a lack of clarity on who the customer is the presence of functional silos and a 
lack of system or joined up thinking beyond one’s own function. Radnor (2013) report on the 
failure of Lean in the public services and identifies “a lack of understanding of the centrality 
of the customer,” as being a key challenge. The potential barriers of not achieving buy-in 
from staff were highlighted by Radnor (2008a) and if this is taken in the context of needing 
front line engagement (Treasury 2009) then potentially there is a fundamental failure.  
 
Similarly, Lean implementations identified a number of barriers linked to the nature of public 
services as a result of its approach which challenged the successful application to public 
service. The challenges include a lack of basic process knowledge by public service providers 
and availability of process data that would be expected in manufacturing environments 
(Radnor, 2008b). This highlighted a failing in the organisations to understand their current 
processes and data which was also part of the critique of Lean for higher education (Antony, 
2015) where collecting data of relevance was identified as a challenge. The application of 
approaches such as Lean in an immature process which lacked relevant data is somewhat 
risky as Lean will initially destabilise an unstable environment (Radnor 2013). In addition, 
the implementation of the Lean approach also revealed a capability gap in the area of change 
management. The 2009 “Operational Efficiency Programmes Final report” (Radnor 2010) 
highlighted the need not only to deliver improvement programmes but also to build the 
capacity and capability within the system to introduce and manage continuous improvement. 
This reflects Radnor (2013) comments that Lean implementations placed too much emphasis 
on workshops and tools. A fuller more complete view of the organisations is needed at an 





services (Antony et al., 2016). Continuous improvement is a fundamental element of Lean 
beyond the tools and workshops and was unfamiliar to many public service organisations. 
The point of capacity building is often missed in academic articles which are reviewing the 
success or otherwise of an initiative as it highlights “short sighted” objectives at point in time 
rather than a development of “genuine improvements” and a capability to continue improving  
(Smith, 2016). Similar to the Operational Efficiency, the review of business process 
improvement methodologies in the public services (Radnor 2010) reported the need for 
capability and capacity building. There is a need for strong and committed leadership or 
improvement infrastructure and the programmes to build a strong capability base to manage 
change Radnor (2008b). The Radnor (2010) review went further and provided a criticism of 
some of the organisations not adopting the true philosophy of continuous improvement.  The 
use of a “House of Lean” diagram (below) attempted to introduce the concept of a more 
holistic approach to continuous improvement. This attempts to move the organisations away 
from short sighted improvements towards a scientific management continuous improvement 
approach. A criticism is that the absence of this continuous improvement capability means 
that improvements are “Championed”, “diluted” and “eroded” McCann (2015).  
 
In addition to the Lean challenges that are emerging from the analysis of the Lean literature 
one area that is not addressed in the public services literature is the role of government. What 
was clear in the 2007-2010 literature and historical journey was that government politics was 
putting the civil service under pressure to increase efficiencies. At this time the UK 
government were spending heavily under a Labour government but needed to show evidence 
of improvement (Radnor 2007). With the 2007 credit crisis beginning to make an impact on 
the decision making of the country in 2010 the government switched to a conservative 





explore this linkage between government policy and the success of Lean despite evidence of 
it impacting front line services. Literature, such as Smith (2016), make reference to services 
dealing with cuts in budgets and Antony (2016) make reference to efficient and effective 
public services being the context of their work. What is not clear is the linkage between an 
austerity agenda of the last seven years versus a more prosperous government environment in 
creating a culture of continuous improvement.  
 
In summary, there are number of key challenges to introducing Lean in the public services 
both in Lean application and also in the manner in which public services prepare for, and 
adopt, Lean. Many of these challenges apply to healthcare and will be explored further in the 
chapter on Lean healthcare. Within the public services Lean literature, a number of gaps or 
criticisms has been identified and are listed in Figure 2.2.  
 
Figure 2.2 –Key Challenges to Lean in Public Services 





When investigating the literature one must recognise that the implementations were being 
completed at a time of rising technology investments in UK public services. UK public 
services spending on science and technology rose from £1.4bn in 2000/01 to £4.8bn 2015/16 
(Statistica, 2017).  Despite the level of investment, there is a paucity of Lean literature on its 
potential. Authors such as Radnor (2008a) do not draw out the potential that technology 
could provide in addressing the gaps, establishing a baseline process data, building capacity 
or converting short term wins gained into longer term business as usual.  
 
Gaps additionally appear in identifying the purpose of the system in public services (Seddon, 
2005). Seddon draws on the titles of  previous books on “Freedom From Command & 
Control” (Seddon 2003) and “Systems Thinking in the Public Sector” (Seddon 2005) and 
reveals a number of insights in the area of public services reform that are often absent from 
the Lean reviews and terminology (Seddon 2008). He challenges the concepts of “command 
and control” reforms and the target culture that is dominant in public services. By doing this, 
the purpose of the system is being missed and the performance targets are creating false 
drivers for managers which don’t align with customer value. Gubb (2009) goes further by 
highlighting that Lean can expose “the fallacy of targets” and the need to look at the system 
as a whole.  He overlays this point by emphasising that staff can become obsessed with data 
about targets instead of data about the demand from consumers. Seddon’s (2008) overarching 
theme is about understanding the purpose of the system from this perspective one can build 
processes and systems, which use real data, which the organisation can utilise to improve. He 
introduces a concept of failure demand which is “demand caused by a failure to do something 
or do something right for the customer”, essentially demand created due to a failure 
elsewhere in the system. Antony (2016) makes some attempt to address purpose of the 





Similarly McGrath (2015) makes reference to “cross-boundary conflict” to initiate 
governance at a higher level in the system. In both cases these were recommendations rather 
than observed in Lean deployments and lacked the direct linkage to value for a citizen or 
removing wastes in the system which Seddon (2005) had identified.  The concepts of “failure 
demand” which is largely missing from Lean, but relevant to public services, are explored 
later in reference to Lean and healthcare demand.  
 
In summary, within the public services literature for Lean there is absence of technology 
discussion and the value it could bring to addressing value for the citizens and addressing 
waste within the service provision. This lack of technology consideration is at odds with the 
increasing levels of technology investments within public services. Additionally the 
challenge of system thinking for customers is not addressed in Lean literature despite work in 
public sector reform revealing issues such as failure demand which is linked to not delivering 
value for the citizen. There is therefore a gap in Lean system thinking which crosses silos of 
service provision to address failure demand and improve value for the customer. Finally, 
there is a general lack of quality literature which evidences the benefits of Lean (Antony 
2016) despite Lean “rapidly diffusing” in public services (McCann and Hazzard, 2015).   
2.4 Summary of Lean in Public Services  
As the purpose of the thesis is to explore the role of Lean thinking in healthcare and identify 
opportunities for improved healthcare technology one can draw a number of conclusions 
from this chapter on public services. Firstly the Lean principles have a strong application 
outside of car manufacture with significant evidence of an appetitive to deploy Lean (Radnor 
2009). This has led to encouraging outcomes for those who have adopted this approach 





existing staff through the approach (Eriksson, 2017). Secondly the Lean approach exposes a 
number of gaps in process understanding, data maturity and understanding who the customer 
is (Radnor, 2013). These are negative in terms of speed of deployment but positive in terms 
of introducing an approach to identify weakness. Furthermore, gaps within this are the ability 
to support continuous improvement rather than a short term improvement which will 
diminish rapidly with time (McCann, 2015).  Part of this longer term improvement will 
require an ability to identify the relevant capabilities, including leadership, to move beyond 
basic rapid improvement events towards a Lean philosophy (Antony, 2015). This need to 
build improvement capacity is reiterated as a threat of failure if not addressed (Radnor, 2013).  
Finally there are gaps in Lean literature which are shown in table 2.3. These include a lack of 
development of the Lean approach beyond repeating the approach shown in Lean literature in 
2008 - 2010 in more locations and geographies around the world (Costa et al., 2016). This 
gap fails to address some of the challenges emerging in any meaningful way. Similarly a gap 
emerges around the lack of addressing the role of technology in Lean literature which does 
not align with a growing trend for the public sectors increasing investment in technology 
(Statista, 2017). This will be explored further in this thesis due to its paucity in the review of 
the Lean literature. System thinking which crosses functional silos to address real demand 
from customers rather than artificial targets (Gubb, 2009) will also be explored in more depth 
in this thesis as Lean should reflect customer value and not focus on providers value as this 
can create failure demand (Seddon, 2005) The next section will move from a general public 
service focus to specifically assess the impact of Lean within the context of healthcare. 













Chapter 3 - Lean in Healthcare  
3.1 Introduction  
The overall aim of the thesis is to explore the role of Lean thinking in healthcare and to 
identify opportunities for healthcare technology. The previous chapter highlighted that the 
Institute of Management review of business process improvement methodologies in public 
services (Radnor 2010) detailing that of the 165 sources of public service improvement 
initiatives identified, 51% of them focused on Lean. The largest proportion of these, making 
up 35% of the total, applied to healthcare. Healthcare has been of interest to Lean experts 
with one of the key influencers in Lean, Jones (2006), highlighting the comparison between 
the early Toyota model and the NHS by drawing on the need to engage staff to make 
improvements. Lean continues to be a key operational improvement tool in healthcare with 
recent Lean examples including implementations to address patient safety issues (Cheng et 
al., 2015), address quality issues (White et al.,2017), improving medication dispensing (Jung-
Ing et al., 2014), improve laboratory services (Hayes et al, 2014) and to increase efficiency 
(Patton et al., 2015).  
This section will analyse the literature addressing Lean in healthcare to identify the successes 
and criticisms. This will cover the following four areas; 
 Critique of Lean in healthcare  
 The appeal of Lean to healthcare 
 Challenges in adopting Lean healthcare  
 Summarise the learning and emerging gaps in the literature  






Figure 3.1 – Chapter 3 Overview  
3.2 Critique of Lean in Healthcare  
A number of systematic reviews of Lean in healthcare will be critiqued in addition to specific 
academic case studies. From this literature review key tools and techniques across the Lean 
literature will be derived to identify patterns and approaches which will progress the 
understanding of Lean in healthcare. This literature based critique assists in addressing the 
aim of the thesis by identifying opportunities for improved healthcare technologies for 
integrated healthcare patients. This section will identify the key points emerging in the 
literature critique before progressing to the appeal of Lean and Challenges in sections 3.2 and 





 Purpose of Lean in Healthcare  
 Definition of Lean in Healthcare 
 Leadership and Staff Engagement 
 Addressing Quality in Healthcare  
 Provider Focus, not Patient 
 Lack of Clarity on the Lean Customer 
 Defining Value 
De Souza (2009) provides a heavily cited systematic review article identifying key Lean 
literature and outlines a useful perspective on the application of Lean in healthcare in the UK 
pointing to NHS Modernisation agency work, in 2001, being the first appearance of Lean in 
UK Healthcare. Lean healthcare deployments are recorded across the world including small 
deployments through to large scale deployments impacting 6 million participants (Moraros et 
al., 2016). De Souza (2009) summarise the context in which Lean is applied to healthcare to 
address concerns shared by many countries of rising healthcare demand, rising healthcare 
costs and no related improvement in care. Lean was introduced to healthcare to address 
productivity issues linked to cost (Cheng et al., 2015) and also to address quality issues 
(White et al., 2017). Within Lean implementations there is a tension in understanding if 
health quality outcomes or process productivity are the key output. The mortality or 
morbidity of a patient is an important but equally the financial status of a healthcare 
organisation is also important for sustainability despite being seen as secondary (Jorma et al., 
2016). De Souza (2009) although over seven years old, the article provides a seminal relevant 
piece of critique of Lean in Healthcare highlighting the context of healthcare needing to do 
more with less. This realisation of his prediction is articulated in the current NHS England 
strategy document “Five Years Forward” (NHS 2014) which addresses budget deficits within 





capacity without adding cost, quoting Silvester (2004), as challenging NHS beliefs on 
capacity by saying:  
“They argue that “it is possible to eradicate queues in the NHS” without using the 
“failed approach of continually adding capacity”. 
de Souza (2009) picks up on points from Womack (1996) about decreasing the average 
length of stay by 50% in hospitals to increase capacity. Pointing to the early NHS 
Modernisation Agency (2001) as being one of the early healthcare adopters of Lean in 
healthcare, he then goes on to highlight improvements in patient flow, process step reductions 
and providing balanced scorecard approaches. Silvester (2004) also reviews a waiting list 
reform focus.  From this critique of Lean healthcare literature one can see common purposes 
for Lean implementations being linked to cost control, productivity, quality and patient 
improvements. This is repeated across in Lean healthcare literature from different use cases 
within healthcare which each linking to quality, cost and productivity. For example Cheng et 
al.( 2015) focusing on productivity and quality linked to referral information, Patton et al. 
(2015) focused on lower cost and resource utilisation linked to Chronic coughs and Gavriloff 
et al. (2017) focused on higher throughput though better use of scheduling in medicine. A 
critical aspect of this however is that although there are common purposes one aspect of the 
purpose, such as reducing errors, may dominate a deployment and cause conflict with the 
overarching purpose of providing high quality at a lower cost.  
While the purposes of Lean within Healthcare have some degree of clarity, the definition of 
Lean is less clear. One can see an umbrella of Lean activities reflecting a diversity of 
approaches or alternatively Lean has a lack of a “formal definition” (Samuel et al., 2015). 
Young and McClean (2007) describe Lean implementations as a pragmatic practice rather 





length of stay, reduced waiting times, reducing missed appointments, improving team work 
and reducing waits  (Moraros et al., 2015). These focus areas and others may have utilised a 
Lean title on an improvement initiative but this may only reflect utilising one or two Lean 
principles or tools without any intention of a wider scale Lean implementation (de Souza, 
2009). This can be viewed as Lean being a broad approach or alternatively there is a criticism 
that Lean is not a standard approach allowing comparisons between implementations.  This 
lack of definition influences critiquing Leans effectiveness which is reflected in Moranos 
(2016) systematic literature review of Lean interventions with the key question of “do they 
actually work”. The conclusion of the systematic review was that from the studies they 
analysed the interventions had negative impact on financial impact and worker satisfaction, 
no statistically relevant link to patient satisfaction and inconsistent benefits on process 
outcomes.  The report however is at odds with other published work and fails to sufficiently 
draw out what do they mean by Lean. What has been referred to as Lean is inconsistently 
deployed approaches across the healthcare providers. There is no standard Lean 
implementation as care providers target various tools or outcomes for their own purposes 
rather than an aspiration to have a Lean implementation. This reflects the previous point 
linked to Silvester (2004) where there was a description of Lean being a broad umbrella of 
activities rather than a single approach. Secondly the Moranos (2016) study had filtered out a 
high proportion of the unique articles with only 22 out of 892 articles covered. This leads 
more to question about if there is a lack of quality literature and studies rather than an 
assessment of the impact of Lean implementations. What is unclear in the literature is if this 
is a lack of effectiveness or a lack of evidence of effectiveness which is picked up as a 
tension between the practitioner and the academic communities (Samuel et al., 2015). What is 
clearly emerging in the critique of the literature is lack of definition of Lean and a need for 






Burgess and Radnor (2012) draws out some key points on staff and leadership within their 
research on service improvements within the English NHS which provides a critique of the 
Lean implementations across three hospital trusts case studies in England. The article 
compares two hospital trusts seeking a foundation trust status which would allow more 
autonomy and a hospital trust that has already achieved that foundation trust status.  
Reporting that despite difficulties of leadership, discussed later, all the implementations had 
evidence of improvement. This points to somewhat of a conflict for Lean in that there is a key 
assumption that Lean will need clear leadership when in reality healthcare leadership is in 
flux. Senior management commitment and organisational culture are seen to have a potential 
impact on outcomes (Chiarini et al.,2016); however it is recognised that staff are operating in 
a chaotic situation with frequent structural changes to leadership (Serr Roszell, 2014). 
Similarly the organisation culture of decision making centralised with doctors and a lack of 
teamwork or decentralised authority make Lean difficult to implement in healthcare (Drotz 
and Poksinska, 2014).  One can see a tension within the research that there is a best practice 
need for leadership buy in; however there are improvements and acceptance of Lean despite 
this lack of stable leadership and organisational stability.  
 
Another key area emerging in the Lean literature critique is in addressing quality to improve 
patient safety and removing errors (White et al., 2017). Mazzacoto’s (2010) identified 
approximately 1000 Lean healthcare articles and provided a systematic review with 112 of 
these articles being relevant and 27 containing empirical studies. The research identifies four 
influences to understand Lean literature which are context, interventions, mechanisms and 
outcomes. The methods used focused on methods to understand process, promote 





identification of error detection and failure in the health provision can avoid costs and save 
lives (Spears, 2005). This is pivotal research in Lean healthcare as Spear (2005) had 
previously written about decoding the DNA of Lean and this research transfers the lessons 
learned into healthcare. The article goes further by identifying potential saving of $20-40 
billion dollars (Spears, 2005, 81) in USA hospitals if the care providers can eliminate the 
ambiguity and workaround found in healthcare practice. The linkage between errors and cost 
is absent in other Lean literature and the concept of the cost of failure is not explored across 
most of the literature resulting in a choice in a Lean implantation between a quality focus and 
a cost focus which doesn’t align with core Lean principles of poor quality being a waste 
leading to a cost. There are some different principles to waste in healthcare versus the cost in 
a car manufacturing line as the cost in healthcare may be about disease complexity, additional 
procedures or litigation which does not translate from manufacturing. For example Spear 
(2005) identified costs linked to medication errors, infections and medical errors, and while 
the medical errors can find parallel application to procedure errors in car manufacture, the 
medication errors and infection issues are more difficult to find parallels with manufacturing 
processes.  The Spear (2005) report was significant for healthcare as it critiques poor care 
outcomes in terms of medical error and infections. For example, according to the article, 
98,000 people die in US hospitals each year as a result of medical error.  It also challenges 
the notion that costs can’t be released from the system at the same time as providing 
improvements in care. This is reflected in the outcomes measures highlighted in Morraros et 
al. (2015) where the outcome focused on either “Health Outcome” linked to death or 
infection or “Process Outcome” such as reduced waiting time or faster procedure. A research 
gap therefore emerges in the cost of errors and failure and reluctance for both cost and quality 
to be addressed in the same Lean activity. This gap may be linked to the poor definition of 





deployed or an underlying reluctance to quantify quality errors costs and to hold on to a belief 
that healthcare improvements must come at a cost rather than as a route to saving money. In 
each of these cases the error waste is counter to patient value which emerges in the literature 
critique of Lean healthcare.  
 
A key literature gap emerging is that Lean in healthcare focuses on the healthcare provider 
and not the patient. Moraros et al. (2015) systematic review of Lean Healthcare lists the 
application of Lean to hospitals, intensive care units, emergency departments, operating 
rooms, clinics and other departments. In chapter 2 of this thesis, the five Lean principles were 
outlined to reflect the Womack et al. (1991) codifying of the Toyota Production System. 
Miller (2015) paraphrased the first two principles as 1) Identification of customer value and 
2) Management of the value stream. However, when we critically analyse the Lean literature, 
the Lean value delivery is based on the care provider and no attempt is made to understand 
the full value stream for the patient. If one looks at the value stream for a patient, the 
activities that add value will begin before the specific healthcare providers department and 
end after leaving this department. For example a patient in an operating theatre will have had 
appointments, reviews, tests and decisions prior to the operating theatre being used and after 
leaving the theatre they will have post-operative care, discharge and rehabilitative therapy. 
This means that Lean has been applied to the provider’s value stream and not the patients. 
The focus is on single hospital wards, operating theatres and activities which fail to consider 
multiple elements of a patient journey beyond these hospitals (Spear, 2005). Porter’s (2013) 
challenges healthcare departmental silos and although not specifically badged under a Lean 
review it uses Lean language and approaches. The article contradicts some of the previous 
Lean applications as it begins to questions the ability of healthcare in defining proper goals. 





define value for the customer. Porter argues that the wrong goals which support high volumes 
and related profit are being sought rather than health outcomes.  
 
Linked to the literature gap of Lean being focused on healthcare providers and not the patient 
is the issue of who is the customer in Lean healthcare implementations. Healthcare RIE 
events utilise language around the patient being the customer within the boundaries of their 
clinic or department (Baril et al., 2016). Lean literature however reveals a complex set of 
relationships with numerous stakeholders such as patients, health plans, employers and 
suppliers seeking to balance financial performance, patient satisfaction and clinical 
governance (Dobrzykowski et al., 2016). Porter’s (2013) review however states that the 
overarching goals should be patient value and health outcomes that matter to the patient. This 
patient focus is contrary to Lean application in many of the institutions who have attempted 
to apply Lean for processes outcomes rather than against a patient value concept (Moraros et 
al., 2015). This is also evident in Lean healthcare literature such as Balle and Regnier, (2007), 
Bowerman (2007) and Hayes (2014). Young (2008) provides a discussion on the concept of 
value to a single customer and notes the complexity around this in healthcare. The article 
does not resolve the tensions about who is the customer in Lean healthcare but summarises 
customer value as having three dimensions of clinical, operational and experiential. This 
highlighted Lean in healthcare as having an absence of a single or unique customer.  This 
customer definition can be somewhat problematic due to separations between users, 
consumers and on occasions the patient being a co-producer of the product. One could argue 
that an appeal of Lean in healthcare is that even if it is failing to adequately identify the 
customer (Young 2008) or properly define value (Porter and Lee, 2013) the use of Lean 





away from the clinician being the purpose of the system. In the absence of alternative 
approaches the approach is appealing, even if not perfect.    
 
Related to the debate on who the Lean customer should be is the question of what is meant by 
value to the patient as the customer? This real patient value Porter and Lee (2013) states is 
not measured in current Lean or healthcare delivery as although outcomes about survival are 
measured other patient quality measures are not. For example in the case of prostate cancer 
this may include other outcomes such as incontinence and decreased sexual function which 
are not routinely measured and may even lead to different clinical interventions if they were 
measured. Other diseases will have similar patient health outcomes around mobility, pain, 
ability to return to work, anxiety, speed of recovery and sustainability of health and function. 
Attempts have been made to focus on patient value in initiatives such as the “productive 
ward” series in the NHS which have used language around releasing “time to care” by 
improving quality and delivery of care however it is unclear if they result in better patient 
value delivery or if it is just more engaged or productivity staff within the organisation 
metrics (White et al., 2017). Other initiatives have been more explicit in achieving a primary 
goal for a Lean healthcare initiative of doing more with less through rapid improvement 
events therefore leaving patient value as a secondary objective (Sanders et al., 2015). To 
improve healthcare, the Porter and Lee (2013) author argues, one must move from specialty 
activity to a “Value Agenda”. This “Value Agenda” or purpose of the system reflects 
Seddon’s (2005) views on understanding the purpose of the system rather than targets. This 
value agenda (Porter and Lee, 2013) must be supported by six components which are 
integrated practice units, measuring outcomes, bundling payments for care cycles, integrating 
care delivery, expanding excellence across geographies and build an enabling information 





stream is beginning to emerge in Lean and other healthcare improvements (McFarlane, 2014) 
which provide an opportunity to recognise that Lean healthcare has not been patient focused 
but provider value focused (Henrique et al., 2016). 
 
In summary the overarching learning from a critique of Lean applied to healthcare is that 
there is no standard definition of what Lean deployment is therefore there can be some 
difficulty in comparing deployments or in being definitive that Lean is successful or 
otherwise due to the variety of “Lean” deployments styles and depths of implementation.  
Leadership in particular in healthcare can be challenging due to changes in leaders and Lean 
must assume a degree of change as improvements are being made with clear outcomes 
despite evidence of inadequacies in leadership. Addressing quality in healthcare is an area 
that attracts a lot of attention and is a potentially highly attractive as a route to adoption 
although implementations appear to believe there is a choice or trade-off between quality and 
productivity which is not reflective of Lean principles.  Definitions of the value stream for the 
Lean case studies focus on providers and provider value not patient value. The concept of 
patient value is not clear in Lean literature and appears to be confused with healthcare 
provider value. To develop this understanding of why Lean should be used, it is worthwhile 
considering the appeal or motivation of using Lean. Figure 3.2 provides as summary of the 







Figure 3.2 – Key Challenges and Gaps to Lean in Healthcare 
3.3 The Appeal of Lean to Healthcare  
To understand the potential of how technology can improve healthcare in line with the aim of 
the thesis it is worthwhile considering the appeal of Lean to healthcare as this may provide 
linkage to what works well for healthcare reform. Porter and Lee (2013) recognises that “hard 
work” and “well intentioned” clinicians are not sufficient and have little impact on the overall 
improvement of healthcare. Spears (2005, 89) highlighted that “Like many hospitals, 
Shadyside found that its nurses spent a disproportionate amount of time nursing not with the 
patient but the system – tracking down material, services and information.” This leads to the 
assumption that working harder will not fix the problems but potentially increase the 
frustration of well-intentioned staff managing ambiguity, workarounds and medical errors. 





that was not seen as clearly in other part of the public sector described in chapter 2 and this 
was that health providers are struggling to deliver healthcare in a time of rising demand, 
escalating costs and failure to make progress on core quality issues (McIntosh et al., 2014). 
Where (Radnor, 2009) had recorded the adoption of Lean in public sector was about proving 
effectiveness and efficiency when processing various government transactions Healthcare has 
an unmet need which “hard work” is not going to solve (Porter and Lee, 2013). The appeal of 
Lean in healthcare starts therefore from a need to find a new way of delivering healthcare. 
This new way of delivering healthcare has sought to utilise Lean in a number of ways or 
similar to the finding in chapter 2 Lean has been deployed in an inconsistent manner with 
various understandings of what Lean is (Samuel et al., 2015). Three key common groupings 
of approaches appear of across Lean Healthcare literature with these being; addressing 
quality, productivity and engaging staff.  
 
Firstly, quality is evident as one of the main groupings as initiatives to improve patient safety 
and release “time to care” (White et al., 2017) have appeal both at the management level and 
staff level. Initiatives have recognised the linkage between benefits of safety and financial 
stability (Dobrzykowski et al., 2016) and some have targeted performance issues such as 
emergency department turnaround (Mazzocato et al., 2014). Spear (2005) identifies major 
quality issues with a particular focus on infection control. Similarly the Hospitals application 
of Lean (Wysocki 2004) to intensive care units discusses the use of one of the Lean quality 
approaches, known as the Andon Cord, where all activity is stopped until the quality issue is 
addressed. The approach led to reduction of infections which would have cost the hospital 
significantly and had a serious or critical impact on the patient. An approach which identifies 





Bowermann (2007) supports this opinion through the Royal Bolton NHS Trust 
implementation and discusses the Lean journey that began in late 2005.  
 
Secondly productivity appears as a second main grouping in the purpose of Lean 
deployments. Specific measureable productivity outcomes including 42% reduction 
paperwork, reduced time to operating theatre, faster recovery time, reduced average length of 
hospital stay by 33%, blood processing reduced from 5 hours to 60 minutes and mortality 
reduced by 36% appear in one of the main NHS deployments of Lean (Bowerman and 
Fillingham, 2007). In addition, Bowerman and Fillingham (2007) reports on non-clinical 
improvement focused on laundry provision also releasing £300K in savings. Outside of the 
NHS other countries have reported on Lean implementations producing similar 
improvements such as reducing outpatient waiting times and labour productivity (Miller et al, 
2015).  Clearly these outcomes are appealing to both those working within the healthcare 
system and management alike. Similar outcomes are reported in Mazzacoto et al. (2010) with 
the most common improvements being; time saving, cost reduction, productivity 
improvement, quality improvement, staff morale improvements, patient satisfaction 
improvement and reduced mortality. Implementations additionally have reported 
improvements in terms of the number of patients being seen within the available time 
(Gavriloff et al., 2017). Time or costs improvement were frequently reported although a 
number of the academic studies have questioned the validity of the savings (Bowermann, 
2007). For example in the event of a time saving, was this converted to a real cost saving or 
health outcome or was this just absorbed by the existing staff and costs within the system 






The third key group was around staff and finding new ways of working. Treasury (2009) 
report investigated the public service need for improvement. The report recognised that the 
Lean approach attempted to harness the knowledge of existing staff which was critical in 
gaining buy-in. Similarly Guthrie’s (2006) work focused on the Royal Bolton hospital and 
draws out the staff engagement focus by highlighting “at its heart is a selective devolution of 
power to the shop floor, where workers redesign processes to raise quality and cut waste.” 
The productive ward series which is heavily based on Lean appealed to staff by highlighting 
the benefits of releasing “time to care” with their initiatives which led to higher engagement 
from the staff in improvement activities (White et al, 2017). Young (2008) compares the 
concept of value stream mapping, used in Lean implementations, to the patient pathway 
which can be appealing to healthcare staff stating “The intuitive line between value streams 
and patient pathways is compelling…” This implies that staff engagement and a link to 
redefining patient pathways appeals to staff in a way that can often be absent in technology 
focused or top down reforms can be positive for staff. Lean interventions also reported 
positive impacts for staff such as reduced steps in a processing, reduced staff walking, 
increased process understanding, improved staff engagement, increased willingness to 
collaborate, calmer more focused working environments, reduced problem resolution time 
and improved error detection  (Mazzacoto et al., 2010). These outcomes of fewer clinical 
incidents reduced medication errors and higher staff morale underlines the point of Lean 
quality leading to more productive staff with higher morale (Bowerman and Fillingham, 
2007). In an environment with more pressure on staff than ever before and waiting lists set to 
rise by 25% to five million (Pym, 2017) there is an appeal to seeking reform options that 






In summary, the appeal of Lean in healthcare is multi-faceted as it impacts the patients, staff, 
managers, clinicians, and budget holders. Creating clarity, removing ambiguity, streamlining 
work activity, reducing paperwork time and addressing quality are all appealing to care 
providers. All of these are achieved through engaging frontline staff which again appeals to 
the culture of health providers. Some caution about the evidence of improvement (Morraros 
et al, 2016) and sustainability of improvements (McCann et al., 2015) are appearing in the 
Lean literature which repeats a gap emerging from the public sector Lean of a need for more 
evidence. Despite this caution, the healthcare demand to do more with less and to increase 
staff satisfaction is an appealing offering and in particular within a public healthcare system 
such as the NHS. To explore this further, the thesis will provide a literature critique of how 
Lean is used in healthcare by analysing the evidence based improvement opportunity of Lean, 
healthcare case studies and the approaches and tools used. This will develop the thesis in 
continuing to address objective 1 of a critical analysis of Lean related theory in healthcare 
reform and begin to collect relevant data to develop an initial theoretical framework to guide 
empirical analysis.  
3.3.1 Evidence Based Improvement  
An important point that emerges from the Lean literature which is relevant to its appeal is the 
use of scientific management underpinning as improvements sought empirical evidence 
(Samuel et al., 2015). This point can be missed in Lean healthcare implementations which 
focus on RIE’s or improvement tools but an evidence based scientific management approach 
can be of value. This evidence base has parallels to clinical evidence based medicine such as 
demonstrated by the National Institute for Clinical Excellence for cardiovascular disease 
guidance (NICE 2017). Perla et al. ( 2013) draws this out by looking at the application of 
scientific and Lean approaches in healthcare and attempts to analyses options for hospital 





explores opportunities with simple and complex patient pathways and the use of System 
Dynamics, Markov Model, Tree Diagram, Lean Thinking and Discrete Simulation. Lean has 
also been identified and deployed in healthcare as a tool to address statistically significant 
medication errors in their quality and implement a scientific management basis of 
improvement against “work progress factors” (Hussain, 2015). Similarly evidence of 
disappointing safety evidence for patients has been highlighted as a reason for initiating Lean 
with an expectation that these quantitative measures can be addressed through Lean where 
other softer management approaches may not be as evidence based (McIntosh et al., 2014).  
Lean scientific management approaches such as feedback loops, continuous improvement, 
testing and learning, plan-do-study-act cycle, repeatable process, variation control, predictive 
studies, multi-disciplinary, different states of stability all appeal to a science based healthcare 
(Perla et al., 2013). The Perla et al. (2013) article draws out the quantitative evidence base 
element frequently used in Lean when applied as a scientific management approach. The Plan 
Do Study Act (PDSA) cycles are relevant within healthcare as it brings an improvement 
focus of planning activities, measuring the outcomes, investigating the outcomes and 
implementing changes which then are part of cycle of continuous improvement. Clinical 
environments can be sceptical of improvement initiatives and Lean reviews will assess if this 
is the latest management fad to be endured  (McCann et al., 2015) but the PDSA cycles 
applied to clinical environments provides a method to reassure clinical leads that the 
approach is not a latest management fad but has an evidence base.   
A gap however emerges, linked to an earlier point from Samuel et al. (2015) where it was 
identified that there is no consistent definition of a Lean deployment therefore clinicians may 
see workshops and RIE events that do not introduce a scientific approach such as 
demonstrated in the PDSA cycles and therefore assume that Lean is a management fad in line 





healthcare to support a need to build scientific management into the improvements 
(Bowerman and Fillingham, 2007) but this is dependent on the definition of Lean being 
deployed. Evidence based healthcare is a fundamental principle of western healthcare 
delivery and the use of scientific principles to achieve improvement in activities aligns with 
this basic principle. A Lean healthcare literature gap therefore is in understanding the level of 
adoption of continuous improvement deployments of Lean healthcare which could appeal 
more to clinicians versus the RIE events that are short term fixes. A reason for less focus on 
this aspect compared to manufacturing may be found in Radnor (2008b) public services 
reviews where it was believed that the basic data and process maturity was missing as a 
precursor to Lean improvements. This lack of maturity in process design means that baselines 
of performance are more difficult therefore applying continuous improvement requires the 
identification of baseline information. Other reasons of why scientific approaches may be 
missing in some healthcare examples may relate to a short sighted focus on rapid 
improvement events or tools which are later “diluted” and then “eroded” rather than 
continuous improvement culture (McCann et al, 2015). Continuous improvement examples of 
a scientific improvement which targeted a culture of improvement rather than a RIE event are 
however evident in healthcare (Manno, 2014) which takes us back to the point that Lean 
deployments are sometimes inconsistent in their application.  
In summary the evidence base for Lean as a scientific approach is attractive to healthcare to 
address emerging failures in healthcare delivery around quality and safety. The link to a 
scientific approach for Lean can however be missed where basic building blocks of baseline 
data are not available or the purpose of the Lean implementation is short term in nature. 
Scientific approaches which focus more on longer term improvement through continuous 
improvement are likely to address concerns about Lean being a management fad and deliver 





healthcare case studies in the literature. This is to further understand Lean in Healthcare with 
the tools or approaches used which may be relevant in considering technology adoption in 
line with the thesis aim.  
3.3.2 Healthcare Case Studies  
To explore the key issues further, specific case studies have been examined to identify 
lessons learned and improve our understanding of how Lean healthcare can benefit from 
technology adoption.  The approaches reflect different emphasises which are discussed below 
and includes;  
 Lean tools and capability  
 Focus on specific issues 
 Continuous Improvement focus 
The Lean tool focus reflected in Nord 92 hospital in France where “Lean as a learning system 
in a hospital” was implemented (Balle and Regnier, 2007). A significant number of Lean 
tools were applied which largely focused on clarity of roles. They attempted to develop an 
improvement or “Kaizen mentality” in the staff rather than “applying Lean tools to every 
process”. Balle and Regnier (2007) however this draws out the details of an improvement 
process which took up to two years to implement and achieve results. Much of the recorded 
success was due to the improvements obtained by gathering the relevant process owners 
together as part of the implementation team. This research and the case study are significant 
as it reflects intent to utilise Lean as a capability development tool in itself as well as utilising 
specific Lean tools to fix a process. This capacity building is not always the case and a 
number of Lean implementation have clearly been focused on Lean tools to “promote 
individual innovation” (Lindskog et al, 2017). Within the Lean deployments, specific tools 
such as value stream mapping, waste identification, root cause analysis and visual 






This tool focus can be less dominant in other Lean applications which focus on specific 
issues within hospitals such as the Royal Bolton NHS Trust which linked an improvement 
journey to address specific issues and create the Bolton Improving Care System (Bowerman 
and Fillingham, 2007). Their approach used a series of RIE and focused on areas of specific 
need such as high mortality rates. Bowerman (2007) argues that this approach with Lean can 
save lives and has positive staff outcomes such as “a touch of inspiration” on staff attempting 
to improve the service they deliver. Bowerman (2007) highlights specific issues in healthcare 
such as drug errors, falls, infections and misdiagnosis which can have a direct impact on 
lives, costs and efficiency which can be addressed in Lean deployments. The Bolton 
deployment is a seminal deployment of Lean within the NHS and documented in Bowerman 
and Fillingham (2007) and de Souza (2009) which are both heavily cited papers. The 
approach however of targeting specific goals in healthcare has been repeated in other Lean 
implementations since which address areas such as reduced infections, reduced waiting times, 
reduced mortality (Moraros et al., 2015).  Similarly the “Productive Ward” series has focused 
on specific quality issues and utilises Lean to address these (White et al., 2017). The 
approach has some degree of benefit in gaining buy in from staff and providing some focus 
for the project with significant benefits centred around a shared goal and diagnostic  
turnaround time for specimens in emergency departments (Sanders and Karr, 2015). This 
outcome focus instead of a tool focus may provide some insight into gaining buy in for 
healthcare staff with a common and shared goal in the outcome rather than learning Lean 
tools. This outcome focus may however reflect a short term wins approach which Lummus et 
al. (2006) draws out from the learning within a mid-western USA clinic. The case study 
discusses a busy medical facility with various disciplines and departments. With the 





state and considered the various wastes, inconsistencies, and errors created prior to creating a 
future state. The future state was made up of various scheduling boards and processes to 
reduce wait and make decisions quicker. As a result the patients had a faster smoother 
process but the Lean application is limited to making a specific processes faster and does not 
question the value being delivered other than within the restrictions of this care provision 
facility. Similarly, Hayes et al. (2014) investigates applying Lean flows in pathology 
laboratory remodelling and explores the use of Lean in Campbelltown Hospital in Sydney, 
Australia. The example provides wastes in overproduction, motion, transport, repeats due to 
error and exploration of the use of “Takt” time in reform.  This also draws on the experience 
of reform and linkage between the emergency department and the supporting pathology 
laboratories. RIE’s involving the two departments was used to explore new approaches and 
the results provided were positive for patient and healthcare provider. Again there was an 
attempt to make a process faster however limited exploration of value with the assumption 
that faster with less errors by the care providers is better. There was however limited 
questions about if the service was needed or was it delivering the right service mix. The 
approach is also somewhat short sighted as rapid improvement events provide short term 
improvement and excitement but fail to unpick route cause issues or build an approach to 
address changing needs in healthcare. For example as healthcare demands change but the 
process remains the same a RIE with and outcome focus will have a decreasing return as the 
solution quickly becomes out of date and the initial staff involved in the RIE move on to new 
roles. A gap or critique of the literature is around the long term value of the improvement as a 
short term measure may be to create measureable value made but can it be sustained and does 
it consider real value for patients or just process value? This leads to a critique that 
continuous improvement or the Lean principles of perfection (Womack et al. 1991) are 





term improvements which leads to the question of a third approach around continuous 
improvement.   
 
In the tools and outcomes focus one can see evidence of engaging staff for early wins which 
can be attractive. This however does not necessarily adopt a culture of improvement and the 
absence of this improvement culture could lead to gains being “eroding” over time (McCann 
et al., 2015). In contrast to a short term win approach, Virginia Mason Hospital introduced a 
Virginia Mason Production System based on a longer term investments (Kaplan and 
Patterson, 2008). Over a 6 year period the outputs were reduced capital requirements, reduced 
inventory, reduced staff walking, reduced labour and reduced patient treatment time. Similar 
longer term investments reflect “culture change” within the organisation and moving from 
reacting to the latest crisis to having “methods, processes, and strategies” which address 
emerging issues (Mannon, 2014). In the Virginia Mason Production System over 8000 patient 
safety alerts were raised which highlighted the volume of quality issues that in a normal 
healthcare environment would be unresolved however a system was introduced to address 
quality and safety issues, defect rates, labour process issues, medication errors and wasted 
capacity. Some of the key implementations included standardisation of significant parts of the 
business through a modified 5S and introduction of a “Quality Safety Alert”. The safety alert 
was similar to a Lean “Andon Cord” in a classic Toyota quality management system where 
work is halted until the quality issue is resolved. The tools and approaches therefore in this 
example reflect longer term capacity building integrated with specific improvements within a 
continuous improvement environment. Where criticism has been directed at Lean there is 
often a misunderstanding of the potential of Lean in continuous improvement and a poor 





Kolberg et al. (2017) where the authors had such a narrow view of Lean that they began to 
build in other factors beyond Lean that would be part of a continuous improvement approach. 
This again reflects Samuel et al. (2015) finding of a lack of consistent definition leading to 
criticisms that may not be accurate. Similarly the criticism of Lean not delivering 
improvements can show evidence of comparing short term tools approaches with continuous 
improvement approaches leading to a poor comparison (Moraros et al. 2015). 
 
In summarising the various approached of the case studies one can draw some differences 
between shorter term problem based initiatives or tools focus against longer term continuous 
improvement approaches. The continuous improvement approaches can be difficult to 
maintain due to changes in leadership (Radnor 2013) but provide larger gains which are more 
sustainable (Mannon, 2014). The short term problem based or tools can bring some early buy 
in and early evidence of improvement but evidence suggests this will be diluted with time 
and may lead to a frustration that Lean is just a fad. The next section outlines the 
opportunities and tools used in Lean improvements across the literature this contributes to the 
understanding of where technology could assist in addressing waste.  
3.3.3 Approaches and Tools  
The application of Lean as an approach to improvement in healthcare is the most frequently 
documented approach in literature (Mazzocoto et al. 2014).  Lean healthcare literature and 
about deployments is dominated by the UK and USA but continues to extend to other 
countries such as Brazil and the Netherlands (Costa et al., 2016). The Saskatchewan 
deployment of Lean is notable as the largest deployment in healthcare and utilises outputs 
such as the productive ward series from the NHS in its deployment (Kinsmen et al., 2014). 
Other notable deployments include Sweden where 9 out of 10 hospitals have a claim of 





aim of drawing out the main Lean tools and improvement opportunities which will be 
summarised after the table. From this review of existing Lean Healthcare literature the thesis 
will begin to develop a theoretical framework of where Lean is used and the tools supporting 
this use. This will provide a theoretical framework to be applied to empirical evidence in line 
with objective 1 and 2. The Lean literature is critiqued to focus initially on the UK NHS and 
USA deployments due to these being the key promoters of Lean in healthcare (Mazzocoto et 
al. 2014).  
 
Table 3.1 – Lean Tools Applied in Healthcare 
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A critique of some of the key deployments is that recent literature has focused on 
deployments begins to repeat itself with limited development of the Lean approach to 
healthcare. Also more recent literature reveal less new tools and approaches due to a lack of 





dissemination strategy (Dannapfel et al.,2014), “staff perceptions of Lean” (Kaltenbrunner et 
al. 2017) and measuring levels of engagement (White et al., 2017). This lack of development 
in Lean literature may reflect a lack of novelty for academics but not necessarily any less buy 
in from government and practitioners (Samuel et al., 2015). Recent deployments repeat the 
experience of the early work from the NHS with both Saskatchewan (Kinsmen et al., 2014) 
and Ireland (White et al., 2017) mirroring the productive ward work. Similarly the work in 
Virgina Mason, USA has being replicated across other USA hospitals with limited 
development of the tools or approaches.   
 
The aims and objectives of this research is to utilise learning from Lean interventions and 
explore the potential for technology to address potential improvements either in patient 
enhancing patient value or addressing waste. The improvement opportunities and tools 
identified in the literature are therefore useful in considering the application of technology as 
it provides an unmet need to address.  From the literature regarding the applications of Lean 
as an improvement approach, the following list consolidates the wastes that have been 
identified in the case studies. These wastes while negative in themselves identify potential 
improvement opportunities within healthcare and provide an opportunity to develop 
theoretical framework to be applied to empirical evidence at a later stage in the thesis. The 
consolidated wastes are shown in 3.2.   
Table 3.2 – Lean Waste Categories Identified in Lean Healthcare Literature  
Consolidated Waste Category  
Identified in Literature 3.1  
Example  
Waiting times  Awaiting treatment to begin 
Delays  Waiting for activities, results while being treated 





Diagnostic  Turn-around times 
Medical Complexity  Increasing strokes risks and amputations 
Additional healthcare Visits –  Follow up, review or further appointments than 
necessary 
Co-ordination of healthcare 
resources  
Often lack of coordination producing additional 
activities 
Stress/overload of staff  Often drive by lack of clarity and inefficient 
processes   
Repeated Procedures  Missing test result, records or updates requiring 
repeated work 
Motion/Transport  Including staff walking 
Length of Stay   Average length of stay is a key measure of hospital 
performance but needs to be balance with 
readmission rates 
Cost   Wasted money and processing additional claims or 
costs   
Quality  Errors in practice or administration of care    
Emergency Admissions   Unplanned, avoidable admissions regarded as a 
failure in the system. For example an escalation in 
a condition which could have been prevented.   
Death  Unnecessary mortality due to falls, infections, 
Turn-around times 
Medication errors  Wrong drug, dosage or administration   
Infections  Caused by the medical interventions or 






The review of the Lean healthcare literature also identified a consolidated list of Lean tools 
used in healthcare which are of significance as Lean practitioners will adopt and adapt the 










Figure 3.3 – Lean Healthcare Tools from Literature 
What is clear from the improvement opportunities and tools used is that the wastes or 
opportunities often come at the join between people and disciplines. The tools such as value 
stream mapping and RIE which are frequently used across the literature, bringing staff from 
overlapping areas together in a structured manner to generate ideas and help to facilitate 
innovation within the staff (Lindskog et al., 2017).Visual management tools also appear 
frequently with some of their use being in facilitating continuous improvement (Mannon et 
al., 2014). This is an important point when considering how technology can strengthen 
healthcare reform and identifying areas for improvement. 5S also features heavily as a 





where equipment not being available or simple mistakes can have catastrophic consequences 
(Delise et al., 2014).   
Summarising this section the following key challenges and gaps identified have been 
identified along with key Lean healthcare wastes and tools. The Lean healthcare wastes are 
relevant to creating a theoretical framework for exploring empirical evidence to be applied to 
at a later stage to consider the relevance for technology.  The next section moves on to 
addressing specific challenges and barriers in adopting Lean in Healthcare. Figure 3.4 
provides a summary of the Lean Healthcare Approaches in the literature.  
 





3.4 Challenges to Lean Healthcare 
While there are significant reasons why a Lean approach is attractive there are also a number 
of key challenges in addressing these improvements. These are documented in the sections 
below and are important to consider as part of investigating technology options. These 
challenges are;  
 Leadership and buy in 
 Redefining value and demand  
 Lack of system thinking 
 Limited reference to technology adoption 
3.4.3 Leadership and Buy in – We are Not Japanese and we don’t make cars  
The concept of buy in is a challenge for Lean due to it being adopted from the manufacturing 
industries since 2000 (Samuel et al., 2015). As the Lean approach has been sourced from 
manufacturing one cannot assume that the approach can be translated to healthcare without 
adaption (Bowerman and Fillingham, 2007). A notable difference from the early Toyota 
production system and healthcare today was that that the Toyota developments removed 
waste to allow better efficiency during low post war demand where in contrast the NHS and 
other health systems today are attempting to remove waste to manage high demand. (Ohno, 
1988). Bowerman and Filligham (2007) highlights Lean adoption issue at the Royal Bolton 
NHS Trust by revealing practical difficulties of implementation in terms of releasing capacity 
for training and service improvement initiatives such as RIE. The report states that staff may 
have an attitude of “we’re not Japanese and we don’t make cars” (Bowerman and Fillingham, 
2007, 232). This was reflected by Wysocki (2004) in his Wall Street Journal article which 
discussed the possibility of hospitals taking tips from the manufacturing factories. In this 





think of themselves as assembly line workers or their patients as anything resembling a 
Camry (Toyota Car) under construction” (Wysocki, 2004, 2). Similarly Waring and Bishop 
(2010) makes reference to the staff resistance which was documented in the business process 
improvement methodologies 2009 report (Radnor, 2010).  
Beyond the specific issues of adopting approaches from manufacturing is the issue of gaining 
staff buy in. Quality improvements in healthcare are clearly needed due to increases in 
demand from an ageing population but have typically failed to engage clinicians and 
healthcare worker leading to questionable results (White et al., 2017). Change can be difficult 
as healthcare is in a constant state of reform and practitioners can be wary of the latest 
improvement initiative and attempt to understand if this is just another management “fad” to 
be weather rather than adopted (McCann et al., 2015). A lack of staff commitment and buy in 
can lead to both poor results in performance improvement or reduced performance 
improvement (Chiarini et al., 2016). Staff can however recognise that Lean can provide an 
opportunity to address the “Chaos” of the current roles and bring some degree of order and 
control which can specify activities and address frustration in organisation design (Roszell et 
al., 2014). This new level of flow and control can result in a less reactionary environment to 
one of more control (Mannon, 2014).  
Related to the staff buy in issue is the area of Leadership. Burgess and Radnor (2012) reports 
on NHS service improvements, discussing the issues and necessity of strong leadership in 
healthcare reform. The most significant findings from their research relates to the learning 
around the impact of leadership on Lean implementations. This is reflected in the “Gemba” 
tool which appears in a number of the Lean Healthcare literature case studies and encourages 
leaders to go and see the healthcare activities themselves which encourages a “Lean 





healthcare as Burgess and Radnor (2012) report that in one trust during a three year 
implementation period the chief executive had changed three times and the chief operating 
officer had changed five times.  This was reported not as an outlier case but a normal pattern 
with NHS chief executives lasting on average 23 months in post. Burgess and Radnor define 
the NHS environment as in “persistent policy reform, reduced budgets and tough regulation” 
(Burgess and Radnor, 2012, 1) which leads to high turnover of senior staff.  The changes at 
the senior level, awaiting new direction and conflicts of policies as the old direction and new 
directions overlap each other were clearly outlined as impacting the Lean implementations. It 
was however notable that despite this lack of stability and the lack of clear direction, all three 
of the case studies had evidence of a positive impact for Lean “leading to numerous 
improvements large and small” (Burgess and Radnor, 2012, 8). Where Lean change 
programmes have not been sustained or have succeeded there is largely a link to the success 
of employee engagement and clear leadership (Lucey et al., 2005). This need for leadership 
also reflects the difference between a short term gain which focuses on the tools but is 
unsustainable and a longer term continuous improvement which may need to address 
functional silos in the organisation (Van Rossum et al., 2016).  
 
In summary, one cannot assume Lean is without challenges as the issues of translating Lean 
from manufacturing, gaining staff buy in for hearts and minds is difficult as it engages the 
logic of improvement as well as the emotion. This is highlighted in White et al., (2017) where 
the logic of the engagement was agreed but the programme then adopted the marketing 
concept of “releasing time to care” to engage a more emotional side of the change.  In 
addition the practical consideration of releasing time to enable attendance at workshops and 
RIE events is raised in a number of the literature reviews. Finally, the issue of leadership buy 





Lean implementation; however the reality is that Healthcare leadership is in a constant state 
of flux.  
3.4.4 Redefining Concepts such as Customer Value and Demand  
A key critique of the Lean literature is that it reflects processes and provider value and not 
patient or customer value. For example providers may recognise a “perfect storm” in 
healthcare but the Lean application assumes addressing improvements in the hospital rather 
than considering if the service which they are attempting to streamline is delivering value for 
the patient or will meet the need of this perfect storm (White et al, 2017).  Similarly Lean in 
an emergency department focuses on turn-around-time for samples in the emergency 
department but assumes that patient value must start with the arrival at the emergency 
department (Sanders et al., 2015).  Limited questions are made about why the patient had to 
go to the emergency department and if this is an escalation of a health condition that could 
have been detected prior to needing to visit the emergency department. The critique therefore 
is that if the first principle of Lean is to focus on value for the customer (Womack et al. 1991) 
then the question of value must rest with patient value and not with the provider such as the 
Emergency room. Initiatives outside of Lean such as Accountable Care Organisation 
(McFarlane, 2014) have sought to redefine delivery and consider bundles and packages of 
care that cross silos in healthcare but this is absent from most of Lean healthcare literature.  
The literature focuses on productive wards (White et al., 2017), clinics (Mannon, 2014), labs 
and emergency departments (Sanders et al., 2015) which represent provider value not patient 
value. Porter (2010) explores and challenges the clinical professions understanding of patient 
value by arguing that healthcare is measured in volumes of procedures and shifting focus to 
value or outcomes must be a central challenge. Reforms which focus only on activity and cost 





which could potentially limit care. There is a tension between healthcare leads and clinicians 
as they attempt to improve patient throughput, resource utilisation and co-ordinating staff 
while minimising disruption (Waring and Bishop, 2010). The competing priorities of staff, 
budgets, waiting lists and the need to clearly articulate common goals around patient value 
are potential barriers to improvement and must be addressed. Porter (2010) takes this further 
by arguing that limiting care can create a need to spend more on other services therefore 
becomes a false saving. The view of not defining value properly is supported by Young and 
McClean (2008) which provides a discussion on the concept of value to a single customer 
and notes the complexity around this in healthcare. Radnor (2013) provides a more robust 
attack on Lean deployments and states there is a “lack of understanding of the centrality of 
the customer..” which is linked to the reason for failures in implementations. Her conclusions 
also point towards a need for a deeper understanding or “end user value”. While Radnor is 
pointing at this gap in the Lean deployments her criticism is still within the context of 
hospitals and failing to go far enough in identifying the real patient value which may relate as 
much to prevention an avoidance of hospitals as Value within a hospital. Porter (2010) 
extends the idea of patient value proposing that healthcare outcomes need to be specific to the 
medical condition. Rather than a need for “focused factories” there is a need for integrated 
care units which bring together the care needs of a patient. He states that these should track 
patient outcomes and cost across the long term care of the patient and patients with multiple 
conditions should have risk adjustments made to understand their care and related costs. 
Similar to Radnor, Porter is still viewing the patient value within the confines of healthcare 
delivery and not patient value which may include avoidance of care. Linked to this 
narrowness of focus on patient value is the topic of measurements within the hospital and 
with healthcare providers.  The current Northern Ireland NHS measurements (Information & 





for patients and what the hospital does is too broad to be of concern to a patient. Porter 
(2010) highlights that measuring performance based on what is billed does not align with 
patient values or needs therefore we need a redefined patient focused value. Waring and 
Bishop (2010) supports this view of redefining value as he highlights a number of lessons 
learned. Of particular relevance are the need to avoid healthcare provider interest in 
specifying value, the use of flow for inter-disciplinary approaches and the need to avoid 
negative arguments of efficiency versus quality. 
To emphasise this point about not understanding what value is or how to measure it, Porter 
(2010), points to quality and process measures found in healthcare effectiveness data and 
information set measures. He emphasises that 73 of the 78 are process measures and not 
outcome measures. In the article he proposes a switch to a more appropriate patient value and 
breaks this down into three tiers;  
 Tier 1 - Health status achieved or retained 
 Tier 2 - Process of recovery  
 Tier 3 - Sustainability of health  
In the Royal Bolton NHS trust (Bowerman and Fillingham, 2007) Lean implementation the 
definition of value was explored using a number of tools. These included observing, patient 
diaries, questionnaires, interviews and focus groups. The report on the Lean implementation 
recognised that this was a challenge to the staff as the perception was that staff knew what 
patients wanted already without the need to explore this. Through the exercise; areas such as 
pain relief, information clarity, coordinated information, cleanliness, hygiene and infection 
were all raised as part of patient value therefore the definition of value even in a restricted 
hospital setting was extended substantially.  From the patient value definitions they were then 
able to create better value stream maps detailing the patient journey from arrival at A&E, 





Reinforcing this view that the staff may not know what is value for the patient is Porter and 
Lee (2013) report on “strategy that will fix healthcare”. He notes that “entrenched interests 
and practices” are part of the need for transformation and can present as a barrier. Payment 
structures and structures which have been in place for decades are believed to reinforce or 
incentivise problems which produce “erratic quality and unsustainable costs”. Young and 
McClean (2008) provides a discussion on the concept of value and comparisons to quality 
adjusted life years (QALY) as perhaps helping to define value from a patient view but again 
complexity is added as patients will have a wider view of value that QALY. The research 
summarises value as having three dimensions; clinical, operational and experiential. The 
research also highlights Lean in healthcare as having an absence of a single customer. The 
review looks at the role of IT and medical device manufacture in understanding value as the 
role definitions built into the user requirements provides some insights. Additionally their 
review of Lean comes to the conclusion that patient value should be defined within the scope 
of the healthcare provider. Although this is useful it still limits the outcomes to the hospital 
location which is different to Porter (2010) review which recognised that value will extend 
beyond the hospital to recovery time and return to maximum function. Similarly Olga and 
Brown (2016) conclude that Lean in Healthcare in the NHS must move to improving the 
whole patient journey. In the USA healthcare system there are exploratory moves towards 
“Value based reimbursement” which encourages payment incentives for the care provider to 
meet the needs of the patient rather than the system (Porter and Kaplan, 2016).  
 
Moving beyond the question of what is value from a patient perspective to redefining demand 
which is linked to Lean tools such as value stream maps Lindskog et al., (2017) explored the 
Swedish health system. It had difficulty with demand as the concept of a presenting demand 





of an aching leg may end up with a heart transplant following assessment and diagnostic 
work (Kollberg et al., 2006). From this there is a recognition that where the demand for a 
Toyota car may be a reasonably solid concept with limited complexity linked into managing 
sales variability, in healthcare however there is a lack of clarity about what demand is and 
competing organisational goals adding to the treatment complexity (Dobrzykowski et 
al.,2016) . Understanding demand is challenging and specifically understanding if long waits 
are a mismatch of demand and capacity are important questions (Silvester et al., 2004). While 
it is recognised that an ageing population is bringing additional demands to the healthcare 
system (Dannapfel et al., 2014) there is a lack of exploration of what healthcare demand 
consists of and if the demand is valid in Lean healthcare literature. Related to this is the 
concept of failure demand that is again not evident in the Lean healthcare literature (Seddon, 
2008). For example a GP visit may reflect loneliness rather than a healthcare need but the 
clinician must deal with the presenting patient. Similarly, a patient may attend A&E because 
their need was not met by a GP. This is a relevant Lean healthcare question and one which is 
not easily answered as a broken bone may have a clear need for A&E however there are 
significant number of patients attending GP’s or A&E with mental health or alcohol related 
issues which may be due to a failure elsewhere to address their need. This concept of failure 
demand would not typically be addressed by Value Stream Mapping applied to the A&E 
process as it would be assumed that all demand is valid and should be addressed as part of the 
process. This lean Healthcare literature gap of understanding failure demand is therefore 
important for Lean as well.  
 
In summary, definition of patient value will need to be redefined beyond traditional 
approaches that focus on the activities and providers towards value that has the patient at the 





demands may not be appropriate and may represent failure elsewhere. The area of demand is 
not served well in Lean literature as most focus is on processes.  
3.4.5 Lack of System Thinking: Single Discipline Focus 
The next challenge is the lack of system thinking. The role of Lean has been shown to 
provide evidence of improvement and outcomes based on measures within the existing 
practice (Mannon, 2014). It could however be argued that it is limited in its scope as it has 
been practiced. If Lean is not widely deployed it will be some time before cross department 
and cross organisations will be demonstrated to reflect a true Lean focus on the patient rather 
than the provider de Souza (2009). A review of classifications and analysis of Lean literature 
investigated developments 5 years after de Souza’s work and found little development of 
thinking and implementation (Costa and Godinho, 2016). Costa and Godinho (2016) did 
however note that some work was moving to implement Lean across a hospital as a whole. 
Although this is encouraging it is still a significant distance from a patient view of value 
across their care provision.  Similarly Mazzacoto et al. (2010) reports that the scope was 
found in most cases to relate to a specific process in a specific location with very little 
evidence of organisational boundaries crossed. The study concludes that “while Lean theory 
emphasises a holistic view, most cases report narrow technical application with limited 
organisational reach.” The early focus of Lean was on single hospital wards and not 
necessarily considering multiple elements of a patient journey (Spear, 2005) and largely this 
has not changed in more recent publications such as within the productive ward series (White 
et al., 2017). Balle and Regnier (2007) again focused on individual hospital wards and Young 
and McClean (2008) notes the lack of longer term initiatives. Radnor (2009) highlights the 
piecemeal approaches that have been evident and Waring and Bishop (2010) focused again 





patient journey. This point emerging from Lean is focused on the provider rather than the 
patient as emphasised in a closing statement in the abstract of Hwang et al., (2014) where it 
states that “nursing practices …. are good candidates for lean practice” as this highlights the 
focus on the on making the provider Lean rather than an understanding of lean value stream 
delivering value for the patient.   
 
A second point on the lack of system thinking is related to sustainability. The topic of 
sustainability is covered by Young and McClean (2008) noting that long term embedding in 
the culture is more difficult to achieve. The benefits which start well but evaporate as good 
intentions disappear and changes in staff impact the improvement (McCann et al., 2015). The 
literature research also notes the lack of longer term initiatives beyond the simplistic process 
mapping and a lack of transferring best practice beyond the initial learning site (Matthias et 
al., 2016). A focus or over-reliance on Lean workshops and tool kit approaches are perceived 
as challenges to the long term success of Lean (Burgess and Radnor, 2013). The 2009 
Operational Efficiency Programmes Final report (Treasury, 2009) reflects this position by 
highlighting the need not only to deliver improvement programmes but also to build the 
capacity and capability within the system to introduce and manage continuous or longer term 
improvements. 
 
In summary of this section one can find that the approaches taken have been narrow in scope, 
not crossing boundaries to reflect patient value. Secondly the approaches often fail to grasp 





3.4.6 Limited Reference to Technology Adoption  
The final Lean healthcare challenge or criticism of the literature is the limited reference to 
technology as a potential route to improvement. Throughout the Lean literature review a 
small number of references have been made to technology such as the need to invest in 
technology to consolidate patient information, scheduling, medication, clinical support, and 
communication with professionals (Porter and Lee, 2013). A limited reference is made to 
medical device manufacturers design in defining who the customer is but not as a tool to 
improvement (Young and McLean, 2008) and medication distribution systems appear in Lean 
literature (Ker et al., 2014). One of the few articles bringing Lean, healthcare and technology 
together is Yusof (2012) which provides an “Evaluation of the clinical process in a critical 
care information system using the Lean method”. This provided a case study focused on lean 
applying to system development. The work targets a critical care information systems which 
provide - charting, vital signs, bedside device data, laboratories, pathology reports, 
medication orders, planned interventions, nursing care, anaesthesia care and surgical care. 
The author attempts to understand technology opportunities in line with the Lean 
opportunities to consider waste in the processes. As part of this application wastes were 
identified in delays to start, delays to patient readiness, lack of consistent process and 
communication with staff with Health Information systems being part of the improvement 
technologies. The article is limited in scope but does provide some potential notes on the use 
of technology.  
 
In light of this positive role that healthcare technology can have in Lean deployments and 
addressing patient value the absence of Lean healthcare technology is a significant gap in 
deployments. Technology can create significant improvements in care provision and this has 





Lean literature previous gaps have emerged that could be addressed by technology but these 
are not explored in Lean literature but will be addressed in this thesis.  In summary a number 
of key points emerge that are summarised in figure 3.5. 
 
Figure 3.5 – Summary Diagram 3.3  
3.5 Summary of Lean Healthcare 
In summary the literature critique shows that far from Lean being inappropriate in healthcare 
there is significant learning to adopt (Mannon, 2014). Large returns for public services have 
been experienced in trials of Lean and this reflects the “low hanging fruit” due to the lack of 
processes or organisation (Radnor, 2008). There is sense that approaches are only currently 
scratching the surface of potential improvements in healthcare. The evidence of appetite may 
reflect similarities between patient flow and the manufacturing process. The approaches 
which encourage staff engagement and the high focus on quality as a means to improvement 






In addition to the appetite there is empirical evidence of outcomes (Samuel et al., 2015). 
Examples of these healthcare outcomes reflect the identification of wastes such as staff travel, 
waiting for equipment, waiting for medicines, lack of out of hours capability, waiting for 
referrals, excessive process time, diagnostic wait time, unnecessary steps, reworking 
activities, quality defects and many others. These reflect a large return for investment for the 
improvement programmes.  
 
Challenges will need to be addressed in capability as the sustainability of improvements are 
questionable beyond the Rapid Improvements Events (McCann et al., 2015). Also the scope 
appears too narrow and doesn’t focus on real value for patients beyond a clinic or hospital 
which will be demanded to meet the challenges of long term conditions.  
 
There are unresolved gaps between the Lean healthcare identified in the literature and the  
definitions of Lean. There is a need to understand patient value and not the healthcare 
provider which is what emerging approaches such as accountable care organisations are 
attempting to do in the USA (McFarlane, 2014). There will need to be a wider investigation 
into the purpose of the system to understand how to get all staff to look for improvements 
rather than improve a distinct process. As part of understanding patient value one can also 
begin to understand if the presenting demand is valid demand or failure demand.  
 
Finally, there is limited reference to technology adoption in Lean reform therefore further 
investigation beyond Lean literature is needed to understand the role of technology in 
healthcare improvement to address the aims of this thesis. This will be explored further in the 






Chapter 4 - Technology Healthcare  
4.1 Introduction  
The aim of this thesis is to explore the role of Lean thinking in healthcare and to identify 
opportunities for improved healthcare technology. What was evident in the Lean healthcare 
literature was the absence of technology discussed as a tool in improvement or to aid Lean 
implementations with some exceptions such as exploring informatics tools with a focus on 
medications (Ker et al. 2014). This is in contrast to the appetite for technology in NHS 
healthcare strategy as a route towards improvement (Ham, 2017). This may be due to the 
focus on Lean tools or reflect caution in adopting healthcare technology due to sensitive 
nature of patient data in healthcare (Burns and Johnson, 2015). This literature gap was 
addressed in this thesis by expanding the literary search for the impact of technology on 
healthcare with a specific focus on the UK healthcare technology and recent healthcare 
technology studies from the USA. The selection of USA and UK was to align with the 
evidence that the majority of the Lean publications are from these countries (Costa et al., 
2016).  
Health technology thought leader cardiologist Eric Topol in his book on the “Creative 
destruction of healthcare” presents the use of technology in healthcare and recognises the 
barriers to adoption and the slowness in progress with technology (Topol, 2012). Topol 
highlights that technology which has resulted in the emergence of new data sources has still 
to be fully grasped in the healthcare delivery. He argues that  
“our health - has thus far been largely unaffected, insulated, and almost 





This is in contrast to the way that technology has infiltrated our lives in other sectors such as 
retail, banking and entertainment and may reflect barriers to adoption such as ethical 
concerns around holding personal data (Sharon, 2017). Health Technology can however 
provide improvements is areas such as patient safety, clinicians productivity, reducing error, 
improving quality of care and increasing the patients adherence to medication regimes 
(Seblega et al., 2015). The healthcare technology literature does not specifically refer to Lean 
but Lean language such as quality and value is frequently used with discussions around 
attempting to understand value from the patient’s perspective reflecting Lean principles 
within the literature (Antoñanzas et al., 2016). The removal of non-value added activities 
which are common Lean approaches such as waiting or medications that do not address the 
patient’s needs are also evident in considering technology (Topol, 2012).The implications of 
value stream mapping and waste identification are also illustrated in Yock et al.( 2015). Yock 
et al. (2015) explores the argument that US healthcare is not sustainable and requires 
redefining value from the patient perspective which would reflect the attractiveness of Lean 
identified  in chapter 3. The rest of this chapter will explore this further by critiquing as 
outlined in figure 4.1.  
  





4.2 Strategy Consideration for Healthcare Technology  
Government healthcare strategies represent a source for understanding technology in 
healthcare as deployments can be seen by policy makers as a method of addressing the 
healthcare crisis and addressing productivity (Jofre-Bonet and McGuire, 2014). Governments 
are seeking cost savings and health improvements through technology however they can 
struggle to achieve the benefits that other industries achieve due to the fragmented nature of 
healthcare and lack of interoperability (Seblega et al., 2015). They are often grappling with 
the reality of maintaining the current service and assessing the potential “clinical and cost 
advantages” of emerging research and technology (Campbell et al., 2017). The healthcare 
strategies also reflect a degree of political caution as they must align with the wider public 
appetite and ability to deliver. The Northern Ireland E-Health and Care Strategy (Department 
of Health, 2016) focuses on principles of citizen centred, connections, consistency, creativity 
and cost effectiveness but shows evidence of lots of consultation rather than leadership in 
defining a route to better productivity. The NHS England’s “5 Years Forward strategy” from 
2014 was a significant leadership piece and continues to stimulate major debate due to 
identification of major funding gaps and shifts to care models needed for the future (Ham, 
2017). The strategy is a call for change and emphasises the need for improvements in 
performance efficiency and better use of innovative technologies to address the many 
challenges. While the Lean terminology is not used the underlying principle of the document 
is that value for the patient should be redefined and this will require a move from illness 
interventions towards creating and maintaining healthcare that avoids illness (Stevens, 2014). 
Additionally the concepts of new care models reflect system thinking with the value chain 
focusing on the patient, not the care provider. The value chain will start outside of the 
hospital in the community and may cross in and out of a care facility or multiple care 





The USA are also attempting to reform healthcare with changes to healthcare under President 
Obama causing significant political debate and discussion (Rak and Coffin, 2013). The  
Patient Protection and Affordable Care Act (PPACA) and the Health Information Technology 
and Economics Clinical Health (HITECH) Act has driven the implementation and adoption 
of Electronic Health Records in the USA and stimulated interest in Technology integration 
with the challenges and benefits caused by adopting this (Burns and Johnson, 2015).Through 
these legal changes the USA Government provided a structure for changes with related 
funding and specific parts of the law stating that providers must be a meaningful user of the 
Electronic Health Records or face financial penalties. The law changes were phased to move 
to a point of providing more use of electronic patient portals.  
In line with the focus of this thesis and the identified Lean Healthcare literature for Northern 
Ireland, UK and USA are outlined in 4.1.  
 Table 4.1 –Government Health Strategies  




Care Strategy -  
(Department of 
Health, 2016)   
The strategy was launched 
in late 2014. This comes 
after a series of significant 
investments over the last 
20 years including unique 
health and care numbers 
across the Northern 
Ireland population, 
regional electronic health 
record and the regional 







and maintaining and 
improving what is 
already in place. 
 Data will play a 




 The linkage of 
data to support 
service  efficiency 
 The collection 
and sharing of 
patient data 
enabling patients 












(NHS, 2017)  
Launched in October 2014 
providing a strategic 
overview of the challenges 
and needs of the English 
NHS. Strategy emphasises 
the sense of urgency and 
that “doing nothing” is not 
an option. The budget 
won’t be available to 
sustain as-is and the 
patient needs are 
changing. 
Prevention of disease 
and early 
intervention in the 
care delivery. 
Addressing sharp 
rise of avoidable 
illness. The need for 
co-creation and 
ownership of care by 
the patients. 
Additionally, the 
need to cross silos of 
care and address 
where a patient may 
have multiple 
diseases and not just 
one is a key 
message.   
 Recognises care 
is across 
collection of care 
providers (Value 
Stream).   






and social care 
staff. 
 Change in patient 
demands as more 
people living 
longer and often 






The PPACA and the 
HITECH acts which were 
initiated under President 
Barrack Obama and 
commonly referred to as 
Obamacare. While a 
significant amount of 
media attention is focused 
on providing Health 
The first stage of the 
HITECH act focuses 
on Electronic Health 
Records (EHR) and 
on data collection. 
Stage two of the 
HITECH Act was to 
focus more on 
interoperability. 
 Use of data and 
providing better 
data to inform 
decisions as the 
patient level seen 
as key.   
 Creation of 
meaningful use of 





insurance access the 
HITECH was broken into 
a number of stages to 
direct and stimulate the 
adoption of technology 
and information exchange 
in healthcare. This 
addresses key challenges 
of sharing patient level 
data between care 
providers. President 
Donald Trump has 
attempted to repeal parts 
of these laws in 2017 and 
has been successful in 
some areas such as fines 
for the uninsured but large 
parts of the law and 
direction are still in force.    
Every provider must 
have a patient portal. 
Stage three, was to 





 Use of technology 
to link patients to 
care providers.  
 
In summary, the one can see an increasing focus on technology that can collect and utilise 
data in new ways both at the individual patient level and the provider level. Secondly the 
growth of the understanding of prevention, co-morbidity and long term conditions is a 
common interest which is seeking new models of care. Another notable related critique is the 
contrast between the healthcare technology strategy work and the Lean healthcare literature. 
In the healthcare technology strategic direction is the centrality of patient value in the 
discussions compared to Lean healthcare which has the provider’s activities at the centre. 
This patient centrality is however diluted at times by the perceived conflict of limited 
resources and demand outstripping supply. This particular area of understanding return on 





technology to remove activities could be directed, measured and calculated within Lean in a 
way that technology would not identify as technology may focus on making a bad process 
faster where Lean will question which processes should be addressed for value in the new 
system.  Figure 4.2 highlights the key challenges and gaps identified in healthcare 
technology. This will be built upon further in the next section which broadens out the 
literature search beyond strategies.  
 







4.3 Literature Review of Healthcare Technology 
To progress the aims of this thesis there is a need to look beyond the strategy documents 
mentioned in the last section and the NHS implementations reviewed by Currie and Finnegan 
(2011). Peer reviewed articles on healthcare technology may provide some insight into 
healthcare and the use for health technology, the issues or complexities that are being dealt 
with in technology deployment and the types of technology that is being used. From these 
one can begin to see the relevance of health technology to healthcare improvement and 
explore potential overlaps or build on a Lean healthcare model. This could lead to a position 
of addressing the Lean healthcare gaps and consider models for Lean and healthcare 
technology to collaborate.  
 
The literature search focused on technology literature from 2010 to 2017 with a recognition 
that the rate of change in technology can make older technology reviews less relevant. The 
search focused on peer reviewed literature and excluded technology which was not patient 
facing such as construction in healthcare technology or would not lead to patient 
improvement. The critique focused on NI, UK and USA healthcare technology literature in 
line with the majority of Lean Healthcare literature. Table 4.2 provides a summary of the 
technology healthcare literature.  
Table 4.2 – Summary of Technology Healthcare Literature 
Area  High Level Summary References  
Health use 
Case  
Ageing in Place  
Assisted Living Technology  
Clinical Decision Support  
Unnecessary Procedures  
Assisted Living Technology  
Enhance Productivity 
Reduce Cost  
Holliday et al. 
(2015), Forbes et 
al.(2013),  Storey 
(2013), Spaulding et 







Reduce medication error  
Wireless vital signs  
Accurate billing  
Inventory Control  
Collaboration, sharing information, accessing 
reports, accessing results, medication and procedure 
history.  
Diabetes  
Evidence of billing which reduces questions from 
insurers 
Standard work  
Efficiency and co-ordination  
Evidence based medicine  
Decision support  
Ordering  
Rare disease  
Complex case support  
Information Sharing and Management 
Paperless Operations  
and Li (2016), 
Caldeira et al. 
(2012), Reddy et al. 
(2012), Adams et al. 
(2011), Hung et 




Barriers to technology adoption in elderly people  
Sustainable business models for technology (Use of 
technology for prevention) 
Assessing Health Technology  
Quality Assurance  
Usability  
Adoption  




Implementation of Electronic Medical Record (EMR) 
Imprecise Data for Evaluation  
Regulation  
Antoñanzas et al. 
(2016),  Turan and 
Palvia (2014), Yang 
et al. (2013), 
Vondrak (2012), 





Storey et al. (2011)  
Venkatesh et al. 
(2011), GOH et al. 





Developing Countries  
Electronic Health Record (EHR) return on 
investment  
Change Management issues  
(2011), Currie  and 
Finnegan (2011) 
Spil et al. (2011), 
Sugrue (2010), 
Parks et al. (2010) 
Types of 
Technology  




AI/Decision Support  
picture archiving and communication system (PACS) 
Assistive Communication Technology (ACT) 
Patient Practitioner Communication  
Ordering medication  
Interoperability  
Medical Histories 
Health information Exchange  
Inventory  
Voice Recognition Software  
Social Media  
Mobile apps and services  
Prescribing Systems 
Lab Reporting   
Service Oriented Architectures (SOA)  
Business Intelligence  
Mansfield-Devine 
(2016), Holliday et 
al. (2015), Ming-
Tsang et al. (2013), 
Carlson (2013), 
Wamba et al. 
(2013), Bhakoo and 
Choi (2013), Storey 
(2013), Yang et al. 
(2013), Bardhan 
and Thouin (2013), 








Ferrand et al. 
(2010), Carr et al. 
(2010)  
Lee and Meuter 









(2010), Parks et al. 
(2010), Pope and 
Turbill (2017) 
 
While the use of technology is wide and varied there are some key themes emerging from the 
current technology literature which are summarised as;  
1) Emerging Legislation: The use of electronic records in healthcare has largely been driven by 
USA government legislation (Peng et al., 2014) linked to the Obama administration. Related 
research then emerges which is related to the value of the health records and their 
interoperability.  
2) Emerging technologies: The technology push continue to be part of research as products are 
discovered and trialled in healthcare to explore their value and usability. Examples of this 
include  the use of data analytics (Vaughn-Cooke et al. 2015) and Artificial Intelligence 
(Carty, 2017)  
3) Emerging challenges is an additional theme of the technology research as technology 
providers attempt to respond to specific challenges. This can include topics such as 
healthcare infections (McGukin et al., 2015), non-adherence to medication (Vaughn-Cooke 
et al, 2015) or security issues (Mansfield-Devine, 2016). 
The contrast between Lean healthcare and technology healthcare is also relevant to the thesis 
and what emerges from 4.1 in the use-cases is an overlap of objectives in both areas. Areas 
such as unnecessary procedures, enhance productivity, and reduce cost and the reduction of 
medication errors is common in Lean and technology implementations. In figure 4.2 one can 
see there are a number of areas in healthcare technology which are beyond the scope of Lean 
healthcare, such as data security, and although relevant to the patient and patient value these 
are clearly a technology challenge which must be addressed fully. There are areas such as 





reflect a shared requirement. There are also areas emerging in the healthcare technology 
however that are Lean healthcare literature gaps. For example the challenges of an ageing 
population with long term conditions appears in the gaps for Lean healthcare literature 
however technology is addressing these challenges (Holliday et al,, 2015). In addition there 
are example of where Lean healthcare is addressing issues such as standard work and 
technology is also addressing this however Lean is not fulfilling this requirement completely 
and has room for improvement as many of the critiques reflect this. For example Lean faces 
criticism for a lack of definition (Samuel, 2013), short sighted nature of deployments 
(McCann, 2015) and lack of continuous improvement with capability building (Smith, 2016) 
which with technology could be addressed as the scale of deployments tend to be wider and 
standardisation across many locations is required for the technology to be a success. This is 
not without its challenges as buy in and adoption of technology is slow despite the major 
benefits (Peng et al., 2014).   
 
While the Lean and Healthcare Technology literature has focused on USA and UK there is 
some notable  Lean literature in Sweden where it is claimed that 9 out of 10 hospitals have 
some element of a Lean deployment (Dannapfelet al., 2014). Also Saskatchewan, Canada has 
the largest deployment of Lean which is based on the productive ward series from the UK 
(Sazi et al., 2017). Finally, other countries such as the Netherlands and Brazil feature in 
literature reviews for their deployments. Across these wider deployments is a repeated pattern 
of adopting tools within wards, departments and hospitals but not following the patient or 
considering the impact of technology on patient value. Figure 4.3 illustrate the overlaps and 








Figure 4.3 – Illustrating the Overlaps and Gaps between Lean Healthcare and 
Healthcare Technology  
Beyond the contrast with Lean healthcare and Lean Technology a number of other points 
which emerge in the critique of technology healthcare literature. The volume of technology 
implementations are substantially higher than the Lean implementation in healthcare as most 
hospitals have elements of technology and many hospitals have been on technology journeys 
over a substantial period of time (Peng et al., 2014). Specific technology such as an 
Electronic Health Records, which are not available in every hospital, may impact across a 
whole hospital where Lean healthcare can be limited to a function such as pharmacy (Ker et 
al., 2014) with some minor exceptions of Lean deployments being widespread across the 





silos to share data and communicate in ways that are not illustrated in Lean deployments as 
the focus on specific provider areas such as emergency departments or pharmacy providers. 
Healthcare technology focusing on data acquisition and sharing reflects the US HITEC stage 
three plan which focused on the “exchange of healthcare information” with the target 
outcome of improving care and reduce unnecessary procedures through better sharing of 
information. Similarly, in 4.1 one can see how technology is being used to address the 
sharing of information, joint working, collaborations, sharing information, accessing reports, 
accessing results, providing medication details and sharing patient procedure history. This 
need for sharing which is present in technology based reform reflects some of the areas 
described in the Lean criticisms and gaps such as the functional silos preventing value being 
achieved (Radnor and Walley, 2008). In addition the focus of technology includes long term 
conditions such as diabetes, rare disease and complex conditions which reflect an emerging 
need for healthcare to focus on conditions and identifying patient value (Porter and Lee, 
2013).  
 
Technology however can faces challenges in gaining staff “buy-in” and adoption with 
significant numbers of clinicians reporting to not use the technology available to them which 
provides issues in terms of waste but also in the collection of consistent patient information 
and standards in creating complete care records. Health Technology programme can suffer 
significantly from a lack of buy in and significant negative public backlash which is 
illustrated in the NHS Connecting for Health Programme which included the implementation 
of Electronic Health Records for 50 million citizens and absorbed an estimated £12.4bn 
investment billions of pounds of public money and was widely regarded as unsuccessful 
(Currie and Finnegan, 2011).  The Currie and Finnegan (2011) seven year study suggests that 





behaviour patterns significantly slowed progress. However the complexity of the problems 
makes it difficult to draw specific conclusions.  The research recognises the need for 
technology not to be viewed in isolation from the organisation but must become embedded. 
This area of buy in and evidence is an area where Lean healthcare has some advantages as the 
processes of Lean can build the evidence base of improvement (Burgess and Radnor, 2012) 
that may be necessary for technology adoption.   
Patient buy in to health technology can also be difficult as evidenced in the English NHS 
“care.data” programme as negative patient data and privacy issues attracted widespread 
negative media attention and patients distrust (Carter et al., 2015).  This Carer et al. (2015) 
paper highlights that technology use in the health service and specifically the use of data can 
struggle in both data protection issues and also in perceived data management or ethics issues 
where the public is putting a level of trust in health systems. This issue is summed up in the 
BBC headlines “Care.Data: How did it go so wrong?” as the article summarises a difficult 
change programme which had attracted the condemnation of the British Medical Association, 
privacy campaign group Big Brother Watch and Medical Research Charities (Triggle,2014). 
Patient buy in can also be difficult for new technology as patients may struggle to understand 
the technology, may not trust it and may be scared of it (Kayyali et al., 2017). Additionally 
gaining sufficient evidence for approval of medical devices can be problematic and result in 
significant numbers of technologies being rejected and evidence of the patient benefits can 
result in medical devices being rejected (Campbell et al., 2017). 
 
In summary, one can see overlaps between technology and Lean implementations with 
strengths in technology of wider adoption and identification of data that may assist in 
improving care. Lean strengths of adoption may be valuable for Technology which struggles 





4.4 Bridging Lean, Technology and Healthcare Together  
While this thesis has been critical of the lack of technology present in Lean Healthcare there 
have been some references to better use of “information flow” through the use of systems 
(Umachandran, 2016), reference to the implementation of prescribing systems that use Lean 
methods (Ker et al., 2014) and targeting of the “technology enabled” groups as having  
potential for Lean deployments (Hwang et al., 2014).  Additionally, although not specifically 
focused on healthcare Riezebos and Klingenberg’s (2009) article discusses the changing role 
of technology and emphasises the need to recognise Lean’s background being routed in 
scientific management and the potential role for technology within Lean deployments. These 
small bridges between health, Lean and technology appear to reflect a natural join on the 
collection and use of data to create evidence for decision making. Advances in technology 
mean that the data available from modern IT systems can provide the ability to support 
decision by patients, clinicians and researchers which can lead to more patient participation 
and personalising care (Sharon, 2017). This need for significant data to make decisions is 
reflected in many Lean healthcare deployments such as the Bolton NHS deployments which 
make makes reference to the Lean PDSA cycles which were supported by data alongside 
rapid improvement events (Bowerman and Fillingham, 2007).  
 
The small number of Lean healthcare technology overlaps point toward the emergence of 
new technology that can focus on patient needs or value through the acquisition of better data 
which is appropriately shared. An emerging position for Lean healthcare technology is to 
focus on technology related to data acquisition and use. This would support the understanding 
that Lean is built on the principles of decisions being made and tested based on data 
(Riezebos and Klingenberg’s, 2009). Topol (2012) supports and extends this view by 





transfer from Riezabos and Klingenber’s (2009) findings to healthcare one can infer that 
technology sourced data can bring us closer to that scientific data which in the hands of 
health managers and clinical decision makers could provide significant decision making tools 
to address waste and provide improvements in the ability to address patient value across more 
complete patient value chains. This position which connects technology data to Lean 
improvements can be triangulated against healthcare technology where cost improvement are 
associated to the use of Electronic Health Record adoption leading to cost reductions (Shen et 
al., 2015). Figure 4.4 below provides and overview of the main learning points from section 
4.3 and 4.4. 
 





4.5 Summarising Healthcare Technology  
To summarise the view of healthcare technology one must return to the purpose of the thesis 
as one seeks to identify opportunities for improved healthcare technology the following are 
clear;  
 A large overlap between the value created by healthcare technology and Lean.  
 Emerging desire for better use of data within healthcare systems 
 An emerging need to address long term conditions in technology healthcare.  
The first point about an overlap of goals between healthcare technology and Lean application 
is evident in areas such as unnecessary procedures; enhance productivity, reduced cost and 
the reduction of medication errors. Further opportunities are available to address Lean 
healthcare gaps in Collaboration, sharing information, accessing reports, accessing results, 
medication and procedure history. The second point on better data reflects technology 
advancement where more data is being created by more systems, devices and citizen centric 
social media. Global healthcare providers have an interest in the use of technology to address 
healthcare challenges at a scale of deployment and sustainability that Lean is unable to reach. 
The final point is on the opportunity to address better care for long term conditions. This 
reflects an emerging opportunity for improvement that has not been fully explored in Lean. 
Utilising new technology to gather data could provide new models of lean healthcare 
addressing patient value for Long Term Conditions. Technology advances in particular could 
address emerging challenges in understanding long term conditions such as Diabetes, rare 
disease and complex conditions which span between different clinical disciplines and 
facilities. This reflects points raised by Porter and Lee (2013) about focusing on specific 






To bring Technology, Lean and Long Term Condition focus together will require a 
modification to existing models of implementing Lean in healthcare.  This brings us to the 
next section of considering the learning and theoretical development to guide the empirical 









Chapter 5 – Theoretical Development of the role of Lean thinking in 
integrated healthcare patient pathway reform to identify opportunities for 
improved healthcare technology 
5.1 Introduction  
The aim of the thesis presented in chapter 1 is to explore the role of Lean thinking in 
integrated healthcare patient pathway reform to identify opportunities for improved 
healthcare technology. This thesis seeks to consider the question of originality and utility to 
provide a theoretical contribution to knowledge and a contribution for practitioners 
considering healthcare reform (Corley and Gioia, 2011). To achieve the initial objectives 
from the research, the literature reviews have focused on Lean in public services and Lean in 
healthcare to reflect the nature of healthcare being a public service in the UK. The literature 
revealed a lack of reference to technology which therefore required a review of literature and 
strategy documents focused on technology in healthcare. Jointly the critical analysis of Lean 
related theory in healthcare reform and the use of technology within healthcare reform were 
completed to achieve objective one of the thesis and move towards a theoretical framework to 
guide empirical analysis in line with objective 2 prior to addressing objectives 3 & 4.  This 
chapter and chapter 6 will focus on theoretical development and methodology in order to 
position the thesis to meet objectives 3 & 4 which focus on investigating emerging 
technology to address improvement areas identified (objective 3) and explore the 
development of a theoretical framework for Lean healthcare technology models which 
utilises the learning and approaches of Lean and opportunities presented by technology 








Figure 5.1 – Chapter 5 Overview  
5.2 Theory building 
The review of the literature that has been discussed in the previous chapters has led to a 
number of conclusions that will be discussed below before being brought together into a 
framework for the gathering of empirical evidence.  
5.2.1 Lack of Consistent Definition of Lean 
The lack of consistent definition of Lean is a frequent challenge throughout the literature and 
is highlighted by Samuel et al. (2015) by describing the different “discourses” of Lean. While 
this pragmatic approach may have some advantages in allowing Lean to be adapted to various 
approaches and people groups this has created distinct challenges (Young and McClean, 
2007). The lack of consistency means that interventions can’t be sufficiently measured and 
this will lead to a lack of quality evidence (Antony et al., 2016) making it difficult to measure 





reflected in criticism of Lean in healthcare Moraros et al. (2015) where comparisons between 
lean implementation were assumed to be the same yet there was no consistent definition of 
what a Lean implementation was. This is reinforced by Samuel et al. (2015) who codified the 
different approaches to Lean and highlighted that the practitioner view of Lean was different 
things for difference people. Extending this criticism further the issue of continuous 
improvement is often absent as a poor definition of what Lean is? leads to an inability to 
gather evidence of improvement and therefore leads to reduced ability to improve the 
approach. This can be due to the short term nature of many deployments seeking “quick 
wins” or service improvement (McCann et al., 2015) without understanding the implication 
of Lean “Perfection” principles. 
5.2.2 Healthcare Demand is Poorly Defined  
There is limited challenge in healthcare about what real healthcare demand is versus 
presenting demand. This is due to the focus on the individual activities rather than the 
purpose of the system. Error and quality failure are clearly evident in healthcare delivery and 
leading to a demand in the system as activities are generated to address value not met 
elsewhere (de Souza, 2009) such as A&E visits due to the preventative activities not being 
addressed by the GP or the patient. By placing the provider as the centre of Lean the 
assumption is that all that engagements with the patient is going to lead to value creation 
which may not be true as the patient may be there due to previous failure in the system 
(Porter, 2013). This ill-defined demand or failure demand (Seddon, 2008) is not adequately 
explored in Lean healthcare literature as shown in chapter 3.  
5.2.3 Provider Focused Value Not Patient Focused  
The first of the Lean principles as defined by Womack et al. (1991) has defining value for the 





other principles of Lean are applied. The definition of Lean in healthcare however starts with 
the context of the provider and attempts to define Lean value in relation to the lab, operating 
theatre, hospital or clinic. Value is limited to a provider focus with the care activities being 
addressed for flow rather than value for the patient. Despite the growth in Long Term 
Conditions from an ageing population (Dannapfel et al., 2014), the application of Lean 
continues to be limited due to the focus on care providers not patients. Patients increasingly 
have a number of health conditions and will therefore be sent to a selection of specialists who 
have silos of care without understanding value for the patient. Essentially they are treating 
symptoms or a condition not a patient and Lean healthcare approaches reinforce this by 
applying Lean to the provider’s silo. There are limited case studies or applications of Lean 
healthcare applications that go beyond an individual care provider or specialty. 
5.2.4 Absence of Technology in Lean Healthcare Transformation  
Healthcare technology application was largely absent from Lean healthcare literature despite 
the interest from provider in the use of technology to address unmet needs in healthcare 
(Ham, 2017). Healthcare technology literature shows early evidence of addressing the health 
outcomes of working in ageing populations with Long Term Conditions and extending them 
to address value outside the hospital which could provide opportunities for Lean (Holliday et 
al.,2015). Healthcare technology is being used to promote information sharing through data 
gathering, sharing and analysis technology which is of particular relevance to addressing 
wastes identified in Lean healthcare and promoting a Lean scientific management approach 
suitable for continuous improvement. Staff engagement is also a key issue with Lean 
healthcare (White et al., 2017) which can be clearly evidenced in the use of technology as 
clinicians and healthcare workers utilise technology as a core part of their role. There is 
potential of the engagement seen in technology to provide a consistency in approach often 






Based on these points from the previous literature analysis chapters, the research gaps 
outlined in figure 5.2 have emerged as a theoretical framework that recognises the literature 
outputs, the emerging gaps, the unrealised technology opportunity and the emerging 
healthcare trends.  
 
 
Figure 5.2 –Key Gaps and Trends in Technology, Lean and Healthcare 
In addition to the literature gaps reflected in figure 5.2, a series of key Lean wastes from Lean 
healthcare literature have been identified to assist in developing a theoretical framework 
which could be applied to empirical evidence. The development of this initial Lean healthcare 
wastes framework for long term conditions in itself is a contribution to theoretical knowledge 
that has value academically and to practitioners. The use and further development of this 
would assist in addressing objective 3 and 4 by investigating emerging technology to address 
improvement areas and exploring the development of a theoretical framework for Lean 
healthcare technology. The Lean healthcare wastes identified in healthcare (Chapter 3) are 






Table 5.1 – Consolidated Lean Healthcare Wastes from Healthcare Literature 
Healthcare Failure Area Identified in 
Chapter 3  
Description  
Waiting times  Awaiting treatment to begin 
Delays  Waiting for activities, results while being treated 
Activity Transaction Speed  Related to activities within the value stream 
Diagnostic  Turn-around times 
Medical Complexity  Increasing strokes risks and amputations 
Additional Healthcare Visits  Follow up, review or further appointments than 
necessary 
Co-ordination of Healthcare 
resources  
Often lack of coordination producing additional 
activities 
Stress/overload of staff  Often driven by lack of clarity and inefficient 
processes   
Repeated Procedures  Missing test result, records or updates requiring 
repeated work 
Motion/Transport  Including staff walking 
Length of Stay  Average length of stay is a key measure of 
hospital performance but needs to be balanced 
with readmission rates 
Cost  Wasted money and processing additional claims 
or costs   
Quality  Errors in practice or administration of care    
Emergency Admissions  Unplanned, avoidable admissions regarded as a 
failure in the system. For example an escalation 
in a condition which could have been prevented  
Death  Unnecessary mortality due to falls, infections, 
Turn-around times 
Medication errors  Wrong drug, dosage or administration   
Infections  Caused by the medical interventions or 





Emerging from this research and 
not covered in Lean Healthcare 
Literature 
In each of the sections there will be a final row to 
highlight waste and non-value add activities that 
have been identified in the analysis which were 
not included in Lean healthcare Literature from 
Chapter 3. This will assist in addressing research 
question 1about how Lean can be adapted from 
Long Term Conditions.  
 
In summary, the literature gaps identified in previous chapters along with the Lean wastes 
identified throughout the literature critiques provide key areas to build a conceptual 
framework to apply to develop further empirical research. Healthcare literature has identified 
emerging trends in patient needs with Long Term Conditions being a key focus due to 
crossing the institutional silos. Healthcare technology provides opportunities to cross the silos 
and identify opportunities to address waste and improve healthcare delivery. These are 
explored in the conceptual framework in the next section.  
5.3 Theoretical Framework  
What is clear is that a literature gap emerges from Lean healthcare literature and healthcare 
technology literature where the value stream for a long term condition patient who cross a 
number of care providers is not addressed and the opportunities presented by healthcare 
technology are not considered. Lean healthcare literature presents a series of wastes which 
have been discovered in the Lean deployments. Although these focused on specific 
healthcare providers, rather than the patient, they provide insight on wastes within the 
healthcare system. To address these gaps and utilise the emerging Lean literature findings the 
thesis will identify a patient value stream for a long term condition patient that crosses the 
various healthcare providers to identify the wastes and non-value add activities. The analysis 





these across the long term condition value stream defined in this thesis to explore new wastes 
not represented by this framework. In addition a technology assessment will also be applied 
across the long term condition value stream to identify opportunities for technology to 
address waste which is present for patients. This emerging theoretical model is illustrated in 
figure 5.3 with a Long Term Condition Value Stream to be defined from this research. A 
technology focus and Lean focus for the analysed literature alongside targeted research into a 
long term condition will reveal a new theoretical framework for Lean Healthcare Technology 
Models.  
 
Figure 5.3 - Theoretical Framework for Lean Healthcare Technology Models 
From the theoretical model the following research questions emerge to be addressed in the 
remainder of the thesis. The literature review of Lean in healthcare has revealed a focus on 
care providers and departments rather than specifically on patients (White et al., 2017). This 
is often for specialties and may not deal with the value for the patient. Healthcare demand 
however is increasing for an ageing population group with comorbidities requiring a much 





one has been developed to consider the implication of an ageing population with long term 
conditions.  Specifically, how can Lean be adapted for long term conditions?  
Secondly, there is a research gap in the use of technology within Lean deployments. This is 
despite the technology language of value, evidence and improvement being a shared goal 
between Lean and technology innovation (Holiday et al., 2015). In addition the use of data 
focused technology to identify waste and build evidence needed for visual management and 
Lean decisions are a synergy that is appropriate to this research (Bowerman and Fillingham, 
2007). For this reason the second research question explores if healthcare technology from 
data focused technology; assist in redefining patient value? 
Finally, in developing the third research questions there was an interest in considering how 
technology can address the gaps in healthcare delivery emerging from the literature around 
addressing non-value add activities. Technology research had revealed that issues emerging 
in long term conditions can be addressed with technology and there was opportunity to if 
Lean and technology could address non-value add activities which are evidence in current 
healthcare provision (Porter and Lee, 2013).  The third research question asks if health 
technology can assist in identifying and addressing Lean non-value add activities. 
To summarise, the three research questions to be addressed are;  
 RQ1 - How can Lean be adapted for Long Term Conditions?  
 RQ2 – How can healthcare technology from data focused technology; assist in 
redefining patient value?  
 RQ3 - Can health technology assist in identifying and addressing Lean non-value add 
activities?  





Chapter 6 – Research Methodology 
6.1 Introduction  
This chapter outlines the research methodology adopted and explains the choices that were 
made to further the aims, objectives and research questions of the thesis. It also details the 
types of data analysed and the methods that were used to obtain data to address the research 
objectives and questions. The research design recognises the need for a research philosophy, 
explaining the methodological choice, strategies and time horizon (Saunders and Tosey, 
2013) before explaining factors around validity, reliability and limitations. Finally, the 
chapter will explore the research generalisability.  Figure 6.1 provides an overview of the 
structure of the chapter.  
 





6.2 Research Philosophy 
6.2.1 Understanding the Research Philosophy  
For research to be successful, an appropriate paradigm should be selected as this will 
influence what data the researcher will see as important and useful (Saunders and Tosey, 
2013). Key research methodologies include Positivism, Interpretivist and Pragmatism (Patel, 
2015). Positivism is useful to “propose and test theories with data which are highly structured 
and usually measureable” (Saunders and Tosey, 2013, 58). Interpretivisim focuses on 
research related to social value and people in their natural environment with the research 
being “value bound” (Saunders and Tosey, 2013). Pragmatism is often referred to as a 
research design which will help to seek out reliable and relevant data that will support future 
actions with “the importance is in the findings practical consequences” (Saunders and Tosey, 
2013, 58). The adoption of one of these methodologies will reflect the researchers view and 
also the methods of using data and the types of data.  Table 6.1 highlights a comparison 
between these main methodologies; drawing out the ontology, epistemology, theoretical 
perspective, methodology and method for each of the paradigms. This has been adapted from 
Patel (2015) to highlight the main methodologies.  
Table 6.1 – Research Methodologies Comparison – Adapted from Patel (2015) 
Paridigm  Ontology 
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6.2.2 Choice of Research Philosophy  
 
Following a review of the various approaches it was possible to narrow identify the suitable 
approaches required to provide successful research to meet the aims and objectives of the 
thesis. The Saunders and Tosey (2013) research ‘Onion’ diagram provided a useful model to 
reflect the different elements from the philosophical approach through to data collection 
methods. This is reflected in figure 6.2. 
 






From the various available approaches, the research philosophy of pragmatism was selected 
for the study. Positivism had some appeal due to the desire to look at quantitative data and 
produce finding that were based on data; however the position of a single reality was not 
possible when exploring Lean healthcare value which led to this being rejected as a research 
philosophy (Patel, 2015).  Patient value can also be difficult to measure as this is evolving as 
life expectancy increases (Dannapfel et al., 2014). Interpretivisim was not deemed to be 
suited to the thesis as the research had no concern for protecting or understanding the 
research as research subjects but understanding and exploring the actions that will lead to a 
future improved results for patients in a more outcomes based approach (Patel, 2015). The 
understanding of outcomes was of interest to the thesis and whether the presence or absence 
of alternative actions would lead to positive or negative outcomes which create value in 
healthcare (Porter, 2010). 
 
Pragmatism provided a more suitable philosophy for the research as findings which lead to 
practical consequences reflects the Lean approach (Mannon et al., 2014)). The reality of what 
“value” is for a patient is constantly evolving as evidence and explorations reveal new 
medical discoveries about treatment and therapy therefore a pragmatism approach research 
leads to practical consequences which fits well with the changing healthcare environment 
which (White et al. 2017) Healthcare demand is also “changing” as an ageing population 
creates a new reality with different care needs (Dannapfel et al., 2014). Lean healthcare has 
not discovered or removed many of the Lean wastes as it has focused on providers and not 
patients. The pragmatism selection is an appropriate methodology for adopting of 
longitudinal analysis learning approach and using both quantitative data and qualitative data 





that will result in new applications of Lean, therefore uses mixed method provides an 
opportunity to explore the data from a number of angles. With mixed methods being known 
as a positive contribution to research as a way of “triangulation” of research, it allows for a 
stronger understanding and support for any relevant findings (Jogulu and Pansiri, 2011).  
Pragmatism provides an opportunity to discover problems and assist in developing potential 
solutions which utilise qualitative and quantitative approaches which are consistent with the 
thesis aim, objectives and research questions:  
- Big data mining that will reflect changes in demand and service provision over a time 
period.  
- Ability to identify Lean wastes in the system and requirement to uncover where there 
is opportunity to address waste.    
- Ability to create theoretical models and data models to assist expert reviewers in 
identifying healthcare wastes.  
- Methods of identifying emerging opportunities in technology that could identify or 
address waste within the healthcare system and become part of a future lean 
healthcare model.  
6.2.2 Theory building with pragmatism research philosophy  
The research within this thesis developed with a pragmatism research philosophy seeks to 
conduct exploratory theory building to develop a theoretical framework for Lean healthcare 
technology models. To achieve this goal the research utilises the learning and approaches of 
Lean and seeks to understand opportunities presented by technology to improve Lean as a 
management approach and identify opportunities for technology to deliver better value for 
patients. The research was concerned with the cause and impact of various Lean health 
interventions and the effect they have on achieving patient value but also on understanding 





implications of change thus requiring both qualitative and quantitative data. The selection of 
the pragmatism research philosophy reflects the methodology of Lean with the origins of 
Lean being linked to empirical evidence comparing production quality and quantity levels but 
also utilising frequent RIE events and guiding the view of reality (Samuel et al., 2015). While 
some Lean literature has focused on qualitative aspects such as understanding staff 
engagement (White et al. 2017) or classifying Lean healthcare (Costa et al., 2016) there is 
also a need for healthcare technology to justify its cost value in health technology 
assessments before being adopted (Antoñanzas et al., 2016) which benefits from a 
quantitative analysis therefore Lean must continually seek an evolving view of reality and 
utilise data from both qualitative and quantitative sources for theory building as new services 
are introduce to healthcare (García-Soleto et al. ,2013). This thesis will focus on theory 
building and will utilise research questions and results to develop theory as suggested by Yin 
(2011). This combined use of qualitative and quantitative data will require both deductive and 
inductive reasoning as has been utilised in hospital at home studies (Mendoza et al., 2009), 
From quantitative big data sets, key findings will be deduced in a deductive reasoning 
approach where the findings will be in the form of data representations and trends. These key 
finding will then be subject to qualitative enquiry (e.g. based on interviews and focus groups) 
inductive theory building using inductive reasoning in interpreting the quantitative and 
qualitative findings and representing them within an overall narrative as utilised in 
technology and healthcare assessments (Patel et al., 2008). Future research may benefit from 
theory testing, which will be discussed further in chapter 10. The research philosophy is 
illustrated further in 6.2 by revisiting the Patel (2015) and extending the view of Pragmatism 
to this thesis topic area.  
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requirements.   
 
6.3 Research Approach 
The thesis adopts a pragmatism research philosophy which supports the use of mixed 
quantitative and qualitative data and a combination of both inductive and deductive research 
reasoning. Quantitative research focuses on the use of objective measures from statistics, 
mathematics, data collection, questionnaires and surveys utilising various statistical 
techniques (Patterson et al., 2014). Healthcare has a vast volume of data that has been 
collected over a number of years that provides an array of options for quantitative analysis. 
The qualitative research seeks to understand the underlying reasons for actions and driver for 
behaviours to assist in exploratory theory building (Greene, 2012). Due to healthcare being 
influenced by many stakeholders and delivered by a large number of staff from various 
organisations it is important to understand opinions and behaviours that may lead to actions 
(White et al., 2017).  
 
From the quantitative data, the research utilises deductive reasoning to identify key findings 
from the analysis in relation to data trends and comparisons. These deduced key findings 
were then presented to focus groups and expert leaders to gather qualitative data which used 
inductive reasoning to further build understanding through social exchange leading to a 
theoretical framework for the future use of Lean in healthcare and opportunities for 
technology.  The reason for choosing a mixed methodology with a combination of both 
inductive and deductive research reasoning was the importance of utilising the right sources 






6.4 Research strategy 
The research utilised a mixed method design that would require healthcare and technology 
data from a number of different sources. The research flow diagram illustrated in figure 6.2 
shows how the literature review led through to the quantitative data gathering using open 
source big data and analysis of this data. Figure 6.2 also shows how the qualitative data was 
used in reviewing and interpreting the quantitative data findings to further build theory. The 
theory building also utilised evidence from grey literature, operational procedure information 
and technology horizon scanning.   
 
Figure 6.3 - Research Flow Diagram 
There was a need for significant ethical consideration in the study and a number of decisions 
were made in consideration of the ethical issue and related  to this the availability of data to 
allow for the research to be completed. During the thesis an exploration was made about 





called the regional Honest Broker Service (BSO, 2018). The service was launched in June of 
2014 and provides joined big data sets across the hospitals in Northern Ireland and also into a 
number of the community healthcare data sets. The thesis author was involved in one of the 
early applications to the service for a dataset for a small patient group of children with a 
congenital heart disease. The process of completing all the ethics applications necessary to 
gain access to data in partnership with a cardiologist revealed that gaining access to this data 
for the purposes of the thesis was not possible. The process includes university filter 
committees, health trust ethics committee’s and national ethics (IRAS) linked to the NHS. 
Aside from the issues of the timescales and extensive volume of forms the ethics process 
requires clearly defined outcomes for the data rather than exploring the relationships and 
attempting to identify unusual patterns. It would not be possible to gain ethics approval for a 
Lean exploratory study using patient data. For this reason the focus remained on open data 
sets which provide completely anonymised data. While the data is immediately available and 
there is no requirement for ethical approval. There are some limitations, such as the ability to 
cross correlate between patient activities, but they allow freedom to explore data. This idea of 
data access being a key consideration in the research is highlighted in the research 
methodology flow diagram of figure 6.3 with the “Gatekeepers” role in the diagram. A 
summary of quantitative data challenges are listed in figure 6.4. These are limitations of the 
research and it would be possible for future research which is less exploratory in nature to test 
theories with specific data sets following an ethics application.  
 
6.4.1 Utilising Quantitative Data  
The quantitative data was sourced from healthcare providers, public health agencies and 
public open data providers. This data is from big data sets that have been collected for 





for the thesis and use of the data reveals new insights beyond the initial data collection, 
consistent with big data analysis rationale (Dominic et al., 2015).  
The selection of the appropriate data was informed by a pragmatism research philosophy with 
the data gathering focused on cardiovascular disease patients. The use of cardiovascular 
disease data was selected due to this being an example of a long term conditions which 
emerged as a literature gap in chapter 5. Other long term conditions would also have been of 
value to study but cardiovascular disease is one of the largest healthcare activity areas. 
Further justification for selecting this will be explained in chapter 7. The quantitative data 
identification, capturing and analysis were used to identify Lean wastes within the data. The 
thesis used data from a variety of sources which again will be explained in details in Chapter 
7 however this included the following sources;  
1. Open data sources from healthcare providers in Northern Ireland 
2. Open data from public bodies responsible for public health initiatives.   
3. Open procurement data related to medicines  
The exclusion of data was as important as the analysis of the selected data. The data was 
selected based on the long term condition of cardiovascular diseases and a time periods for 
the analysis. A key issue in the quantitative data was that there are large volumes of data sets 
and being able to select and consolidate the data can be difficult. This process was aided by 
the fact that the author of the thesis has previous experience of working with the health data 
and implementing large healthcare systems and databases. This need for experience was 
underlined during a focus group meeting with a cardiologist, healthcare data specialist and 
health service technology leader. The group could not come to a shared understanding on 
where they could find the regional data as the clinicians only understands data based on what 
they see on the screen of a single hospital, not all hospitals, and the healthcare data specialist 





facing data, clinical coding of specialist procedures and the technical infrastructure that maps 
many regional hospitals data to a big data set is a barrier to analysis. The complex data is 
lacking meta-data documentation that can join the common language to the specific data sets 
which was addressed during the quantitative data analysis.   
 
Figure 6.4 – Quantitative Data Challenges in Healthcare 
The open data utilised in the research came from various healthcare providers which are 
listed below. It should be noted that within Northern Ireland, Health and Social Care (HSC) is 
provided by integrated health and social care trusts. This is a somewhat unique position 
within the UK as Scotland, Wales and England will manage their care provision frequently 
separate from the health trust. The implications for the thesis are that data providers are 
unique to Northern Ireland and to duplicate the research in other localities would require 
some amendment to the approach from other localities, such as Scotland, may require some 
additional insight to understand the local HSC structures. An additional context point is that 
each of the HSC trusts will have a number of hospitals within their responsibility and the 
Business Services Organisation is a shared service provider across the whole of Northern 





regional centres for commissioning and payment purposes. This is largely in line with the 
QOF data used across the rest of the UK with minor local variations. This data comes from 
multiple internal healthcare providers including;  
 The Department of Health and Social Services in Northern Ireland  
 Belfast Health and Social Care Trust  
 Northern Health and Social Care Trust 
 Southern Health and Social Care Trust  
 South Eastern Health and Social Care Trust 
 Business Services Organisation  
 GP providers  
These are all public healthcare organisations who gather the information for commissioning, 
performance and payment related purposes. There are limits on how much can be derived 
from the open data as the data is not unique to an individual but to a cohort of patients.  There 
is no ability to join together various outcomes such as the number of patients who have an 
operation followed by readmitting to hospital. In this case one can see the volume of patients 
who have the operation and separately one can see patients admitted to hospital on a date 
after the operation but there is no ability to join these activities together for analysis purposes.   
6.4.2 Qualitative Data Sources 
During the research preparation and early explorations of the open data it became very clear 
that although there was a wealth of quantitative data available there was a significant risk to 
the thesis in not understanding the context; historically, in current practice and in modelling 
for future Lean models. The quantitative data could provide trends, changes and identify 





data. For example a spike in costs for a medicine in quantitative data may lead to a false 
assumption that it may be very bad yet the context may reveal that this reflects cost saving 
elsewhere in the system. For this reason, qualitative data was deemed to be necessary to bring 
a richer more complete picture.  
Clinicians and other healthcare professionals were used to develop an understanding of the 
data utilising qualitative approaches. The pragmatism research philosophy supports mixed 
method research (Jogulu and Pansiri, 2011) with the use of qualitative information to seek the 
opinion of individuals within the system following quantitative analysis. The opinions were 
used to clarify information, seek explanation of trends and data that were discovered and seek 
opinion on research theory emerging. This qualitative approach brought consolidated 
information, insight and evidence together into interim theory building. In the qualitative data 
expert opinions derived from interviews were used as suggested by Yin (2011). The expert 
opinion included;  
 Cardiologists  
 Heads of Medicines and Pharmacy 
 Health Technology Company Leaders  
 Heads of Healthcare Service Improvement  
 EHealth Directors  
 HSC R&D Leaders 
The approaches used to gather qualitative data included focus groups, expert opinion 
meetings and presenting models to various stakeholders at discussion workshops. Due to the 
nature of the people involved and roles of the participants, many of the discussions were 
sensitive and it was not appropriate to record conversations. The topic areas that were being 
discussed were potentially of relevance to major procurements, legal proceedings, media and 





attended with a permanent secretary whose is currently involved in a public enquiry which 
brought down the Northern Ireland Government in the weeks after the workshop. As the 
purpose of the thesis and the qualitative data capturing was to seek opinion and engage in 
discussion, notes from the discussions were taken and written up immediately after each 
event which served the purpose of the qualitative data and avoided any fear of specific 
statements being made that could be subject to public scrutiny beyond their purpose.   
Focus Groups were used at various stages to input to the thesis as shown in Figure 6.3. 
Quantitative data was presented to provide a structure data set reflect Lean thinking around 
wastes and opportunities to improve. Opinions and challenge was sought from the 
participants to guide the research models emerging. The thesis author led a number of these 
throughout the time period of the research to guide the outcomes. These included;  
 End of Life System Thinking event in Manchester.  
 Northern HSC Trust Innovation Group  
 NI AMR Network  
 NI Cardiology Network 
The method of collection of qualitative information was informed by an outline process to 
maximise the contribution to the thesis. Firstly there was a need to identify the relevant 
decisions makers based on the Lean value stream map along the care pathway. In some cases 
this was relatively straightforward as their role was focused on cardiovascular patients. In 
other cases there was a need to understand that their role may cover a number of areas and 
cardiovascular patients may only be one part of this. Secondly, where possible the interviews 
and focus groups were based on emerging data to explore opinions and insights related to the 
quantitative data. This was to ensure there was a focus and the interviews were in the context 
of the quantitative data and not distracted by subjective opinions or a current priority. The 





identify the information of relevance to the data and the stage of the patient value stream.  On 
occasion information may be discarded as not being related to the cardiovascular scope or not 
being relevant to the data or value creation for the patient. Following a number of the 
discussions some topic emerged that required a follow up e-mail or conversation to clarify 
something stated or where there has been a conflict of opinion. The notes were then used with 
the chapter 7 research and mapped against the relevant analysis. The notes are available in 
appendix 2-6.   
Examples of where expert opinion brought a richer view of the quantitative data via 
interviews and focus groups included Cardiologists and Medicines experts due to the 
specialist knowledge required to understand specific emerging trends in the quantitative data. 
For example large changes in the reported figures had an explanation around commissioning 
changes that were not evident from the data and were not publically recorded but understood 
by experts.  
Healthcare technology improvement initiatives were used to provide insight on technology 
trends and the impact of the emerging research model. The initiatives had their own purpose 
but the research utilised insights from these research to influence the agenda and explore its 
utility with various experts. From these insights initiatives that were already underway and 
barriers that might be encountered where discovered. The changes that were underway are a 
particularly interesting area as this is often missed because it is not fully documented. 
Specific information on the qualitative meetings and summary conclusions are available in 







Table 6.3 - Sample of other data supporting the thesis – Further details in Appendix 1 
and 6 
Data was also obtained from the Conferences and 
Exhibitions: 
 
Name: Magazine interview via a round discussion with 
health leaders in the NI Life & Health Sciences Sector.  
Participants:  
December 2017 – Published 
in Agenda NI Magazine in 
January 2018  
Name: Industrial Strategy Challenge Fund Workshops on 
the Future of Industry   
Participants: Selected life and health science leaders from 
academia, business and government.  
Three sessions throughout 
2017 in Belfast and 
Westminster (Linked to 
Prime Minister Teresa May 
Strategy) 
Name: Innovate UK – LPWAN IOT Healthcare Focus for 
Northern Ireland  
Participants: NI Councils and Technology Companies  
January 2018 
Name: NI Life and Health Science Action Planning for 
Northern Ireland 
Participants: Chaired by NI Permanent Secretary of Health 
and Permanent Secretary of Enterprise with support from 
Chief Medical officer and panel of experts from Industry 
and Academia (PVC & VC nomination).  
Sessions in 2016 and 2017.  
Name: Industrial Strategy Challenge Fund Workshops – 
Healthy Ageing workshop – Leading to Government 
Funding Decisions 
Participants: Selected health and technology leaders across 
UK. Invitation only from head of Innovate UK.  
June 2017 
Name: Health Innovation award 2017 
Participants: Entry to competition with Professor Jim 
McLaughlin and Dr David Steele. Reviewed in Interview 
with head of E-health from NI and Ireland. Winning entry 
for most Innovate solution. Pitch was based on Lean 
Healthcare approach from thesis.  





6.4.3 Other Data Utilised  
Other information utilised included the analysis of grey literature, academic literature and 
technology horizon scanning. The grey literature and academic literature included working 
instructions, clinical guidance notes, publications on cardiology and health strategic 
documents with a focus on cardiovascular disease. Technology horizon scanning was also 
utilised to collect data through the use of strategic documents, health conferences and 
exhibitions. These provided information on emerging technologies and were used to identify 
novel technology that has not been adopted yet but may lead to future patient value. Section 
7.7 explores this as a method of identifying trends and developments. A full list of 
conferences and workshops attended are available in Appendix 6 and workshops of note are 
highlighted below to show a breadth of input to the thesis from N.Ireland, England USA and 
Qatar. This is a necessary method of collating data on emerging healthcare technology as the 
time gap from new technology to literature publication can be extensive due to the rate of 
change of technology and the length of time for technology to be adopted in healthcare.  
In figure 6.2 one can see that the data collected in these horizon scanning and focused 
literature searches was used alongside the quantitative data to shape the research framework 
which were explored and tested in the qualitative analysis. Examples of some the horizon 







Table 6.4 - Sample of Health Technology Conference and Exhibitions - Further details 
in Appendix 6 
Health Conferences and Exhibitions  
Name: Ulster University Health sandpits for mental health 
and public health  
Participants: Wide interdisciplinary academic group of 
healthcare leaders in Ulster University 
February 2017  
Name: EHI Live Birmingham (Largest health technology 
conference in UK )  
Participants: Healthcare technology companies.   
November 2016 
Name: E-Health Ireland and Northern Ireland  
Participants: Healthcare technology companies, health 
leaders and academia.   
December, 2016 
Name: World Innovation Summit for Health: Doha, Qatar. 
Participants: Invitation only conference. Attended with the 
permanent secretary of enterprise. Meetings with 
companies, heads of pharma and medical charities. 
December 2016 
Name: Longitude Prize workshop in London  
Participants: Longitude Prize participants. 
September 2017 
6.5 Data collection and analysis methods 
The data has been primarily collated and analysed over the period from late 2015 through to 
late 2017. Earlier data set building of quantitative data was completed to understand the 
possible data and to develop an understanding of the information available. Similarly 
explorations of qualitative engagements were completed with focus groups to explore how 
healthcare providers engaged with Lean, technology and improvement in a healthcare setting 
but these were later discounted as being out of the scope of the thesis. Figure 6.5 provides 






Figure 6.5 – Data Collection Timeline  
6.5.1 Quantitative Data 
What has been collected for the research is a longitudinal database focusing on a 5 year 
period from 2011- 2015 inclusive. This has been collected from open source information as 
mentioned previously in this chapter. The development of the big data set during the thesis 
required a significant amount of work in identifying and isolating the data. The isolation of 
the data was due to the large volumes of data that were not relevant to the scope of the thesis 
such as general surgery or procedure codes that were for other diseases. The data also had to 
be consolidated across the 5 years to develop a common big data set to compare across the 
years. Again this required significant amounts of work as the data is not published in this 
format but published in yearly or quarterly increments. The data also required some cleansing 
and formatting as groupings or category may have been modified during the time period. 
Some of the measures may also have been consolidated or removed as a measurement. An 
assessment of the impact on the thesis of each of these factors has been discussed in chapter 7 
at the relevant data section. An example was the removal of obesity measures. The specifics 
of the data sets are discussed in more detail in chapter 7 and the use of the quantitative data 
was aligned in the thesis with qualitative data where expert focus groups and individuals were 





6.5.2 Qualitative Data  
Figure 6.2 shows how the quantitative data was used to build up data that was then reviewed 
by focus groups and was a key point of discussion with various experts. The NI Cardiology 
Network has provided a common grouping to review emerging data and technology. Over the 
period of the thesis the author has met with the grouping headed by a leading cardiologist of 
the Ulster hospital on 5 occasions. With the focus of the thesis research being on cardiology 
this was a very relevant group to work with. He has linked the thesis author with various 
cardiology related staff at various stages. This was to present and share insights emerging 
from the analysis and discuss potential options for future health technology within their 
service to improve quality or address wastes in the system. Further details on this group are 
available in Appendix 3.  
A second group with the Northern HSC trust was started with Una Cunning who was the 
Director or Elderly care. The remit of the group was to explore waste in the system and the 
potential for healthcare technology based on emerging data exploration as an evidence trail 
for improvement. Una retired during the thesis and Gill Smith took on the role of considering 
innovation and change in the trust and has acted as a link for research. The reason more than 
one group was identified was due to the nature of the cardiologists focusing on hospital care 
and the Northern group having more of a community focus.  Their separate interests were 
needed to cover the scope of the patient journey. Further details on this group is available in 
Appendix 2. 
A medicines focus group utilised the expertise of a leading doctor from a medicines 
optimisation centre, the assistant Chief Pharmacist from the department of health and other 
staff they would invite to meetings dependent on the availability and interest. This group 
focused more on medicines data and innovation with the sharing of insights and potential 





other two groups therefore the consolidation of the three groups was needed for the thesis 
scope. Further details on this group are available in Appendix 4. 
 
An improvement manager’s focus group was made available to the thesis author through the 
support of the research supervisors. The group of continuous improvement managers had 
been engaged with the Ulster University for improvement training and the thesis outline was 
presented to this group for challenge, comment and criticism. This was then followed up with 
a workshop with leads from the South Eastern HSC trust. Further details on this group are 
available in Appendix 5. 
Research Ethics  
6.6 Research validity 
Burns (2003, p. 160) stresses that “validity is an essential criterion for evaluating the quality 
and acceptability of research therefore mixed methods have been used to allow “qualitative 
methods to explain quantitative results” (Jogulu and Pansiri, 2011, p. 690) therefore 
improving the quality of the research data collection methods and the conclusions the 
research reaches.   
The data collection is based on data which is openly published as government data. The level 
of professionalism in creating the data and level of scrutiny that the data is under brings 
reassurance that the quantitative data is valid. The use of data in the health service is 
dependent on the quality of data and this is known to be linked to the age of the data, which 
entered the data and the level of buy in for the quality. The collection of quality data was 
initially low on the priorities within healthcare providers as it was largely seen as an 
accounting exercise and delegated to junior clinical or admin staff who would complete 
various forms that had limited impact on operational activity. As the use of data in healthcare 





to improve as clinical decisions are based on the data and the related governance has 
improved. Clinical coding standards, such as ICD 9 and 10 coding, have changed over time in 
terms of the definition of the coding, quality of the coding and use of coding. In expert 
discussions during the thesis it was suggested that the hospital data was robust due to the 
number of years it has been operational and tested. Public health and community based data 
was under less scrutiny and open to more risk of errors and lack of robust adherence to 
standards. The qualitative data reliability depends on its credibility as suggested by Yin 
(2011) and Burns (2003). The interviews were all conducted by recognised experts in the 
field of healthcare and the area of cardiology in particular. Similarly the focus groups 
participants all were recognised experts and leaders in their respective fields thus adding 
validity to the research findings. Furthermore, as suggested by Saunders and Tosey (2013) 
the longitudinal nature of the data added validity by overcoming point in time observation 
limitations. The mixed method approach involving different data sources also added to 
validity through strengthened triangulation of the data as suggested by Jogulu and Pansiri 
(2011).  
6.7 Reliability 
Reliability deals with the dependability of the information and the ability to replicate any 
piece of research (Kolbe et al., 1991). The quantitative data is reliable as the ability to 
recreate the information from the open data is available to any potential user due to it being 
open source. Moreover the method of analysing this data has been made explicit through the 
research with assumptions and rules stated, Observation or conclusions reached from the 
qualitative data have been open to scrutiny within the thesis. With qualitative data, achieving 
the identical results is difficult because the data is in narrative form and subjective. Lincoln 





the dependability and consistency of the data. The purpose is to agree that given the same 
data collection processes the findings are consistent and dependable. Throughout the 
qualitative data gathering this was achieved by using expert opinions over a longitudinal 
period. Moreover, these qualitative sources were iteratively compared and contrasted in 
establishing findings. Overall, the mixed methods also add some reliability by ensuring the 
dependability of the findings rather than relying on single sources or methods (Lincoln and 
Guba,  1985).  
6.8 Generalisability 
Generalisability of the quantitative research can be made for the concepts and principles that 
have been drawn out however the thesis data is focused on cardiovascular disease data for 
Northern Ireland within a specific timeframe from 2011 – 2015. For this reason, although the 
patterns are likely to be transferable to other conditions, locations and time periods this will 
need to be tested. Generalisability of the qualitative research findings is usually not an 
expected attribute; however, analytical generalisation can be applied where the extent to 
which the current findings can be generalised to another using the theoretical framework 
developed in the research as a basis for further study (Brinkmann and Kvale, 2015). This 
analytical generalisation in the thesis draws upon both the quantitative and qualitative data 
synthesis in the theory building process (Zimmer, 2006) which is discussed in chapter 9.  
6.9 Research Limitations 
In relation to the quantitative big data sets the author ultimately had to make a choice to focus 
on cardiology. This omitted other big data sets relating to other healthcare conditions, such as 
respiratory diseases, where there is substantial opportunity to explore the research aim 





Chapter 10. The qualitative data had limitations consistent with all qualitative research due to 
the number of sources of data, however concept building data saturation (Yin, 2011) which 
helped addresses this limitation. Another limitation was that due to the sensitivity of the 
expert interviews and focus groups the conversations could not be recorded adding a 
limitation on data accuracy. However the longitudinal nature of the research coupled with 
note taking during and immediately after the qualitative events mitigated this risk. 
6.10 Summarising the Methodology and Revising the Aims and Objectives 
The aims and objectives were outlined in section 1.4 and as objectives 1 & 2 have now been 
completed, a fuller explanation of the aims and objectives has been created and can now 
develop with the research. This utilises the identified gaps in the literature and learning from 
the literature review on Lean and Healthcare technology and the potential wastes. The 
research in chapter 7 focuses on gathering empirical evidence which is focused on 
understanding cardiovascular patients as an example of a long term condition. The research 
data collected will use quantitative and qualitative data approaches to identify new wastes 
from data sources related to a defined patient group within cardiovascular disease. The Lean 
wastes which have been identified within the literature in chapter 3 will be a target area for 







Chapter 7 – Cardiovascular Disease Analysis and Results  
7.1 Introduction  
Chapter 5 identified a gap for academic research to explore where Lean healthcare reform 
and emerging data related technologies could reveal novel insights if focused on healthcare 
delivery for long term conditions. To develop the thesis further, this section will focus on 
cardiovascular disease related conditions as an example of a long term condition. The section 
will examine the various silos of healthcare delivery to identify the current Lean wastes and 
non-value add activities before bringing the overall healthcare delivery value stream together. 
The same approach could be applied to other long term health conditions and the lessons 
learned although benefiting from a focus on cardiovascular disease patients will be developed 
in a way to allow them to be transferable to other conditions. As a long term condition, 
cardiovascular disease impacts high volumes of patient activity requiring management in the 
hospital, in the community, with medication and impacting personal dietary decisions. It is 
one of the dominant non-communicable diseases on the global disease list. The World Health 
Organisation (2017) reported in May 2017 that;  
 Cardiovascular disease is the number one cause of death globally  
 17.7m people died from cardiovascular disease in 2015  
 31% of deaths worldwide were cardiovascular disease related in 2015 
 Over 75% of cardiovascular diseases occur in low and middle income countries  
 It is possible to prevent the majority of cardiovascular diseases 
The World Health Organisation (2017) statistics also note that much of the disease can be 
prevented by addressing risk factors. The risk factors include diet, exercise, alcohol and 
tobacco (NICE, 2017). It also highlights that people with known risk factors should be the 





Cardiovascular disease was selected for the thesis due to the scales of the disease, the impact 
on patients, and the evidence of the disease being preventable.   
 
To develop the thesis further and address objective 3 and objective 4, the remainder of this 
chapter will analyse cardiovascular disease as outlined in figure 7.1.1. Objective 3 aims to 
“investigate use of emerging technology to address improvement areas identified” and 
objective 4 aims to “explore the development of a theoretical framework for Lean healthcare 
technology models which utilises the learning and approaches of Lean and opportunities 
presented by technology”. Chapter 7 will identify the areas for improvement and existing 
technology with the theoretical models being discussed and developed in chapter 8 & 9.  
 
 





7.1.1 Overall Aims and Objectives for This Research Chapter  
Taking into account the research methodology laid out in chapter 6, the aim of this chapter of 
the thesis is to explore cardiovascular disease as an example of a long term condition which 
requires an integrated healthcare pathway. The chapter will address the aim of the thesis by; 
Exploring the role of Lean thinking in cardiovascular disease activities to identify 
opportunities for improved healthcare technology.  
This chapter will study the delivery of healthcare and management of patients with 
cardiovascular disease as an example of a long term condition to allow research question 1 to 
be addressed. The thesis will also consider how the application of new technology can 
identify waste or non-value within the system to address research question 2. Thirdly the 
chapter will assess which activities bring value to cardiovascular disease patients and how 
data can assist this to address research question 3. The thesis will analyse activities related to 
the delivery of cardiovascular disease healthcare with the aim of exploring a new model to 
assist in considering Lean healthcare waste and technology adoption. The analysis will 
include a number of types of technology used for care delivery in cardiovascular disease 
today such as heart monitors, bio markers, pacemakers and blood pressure monitors. The 
research will utilise open data associated to cardiovascular disease healthcare provision to 
create a longitudinal data set to assist with analysis of patient flows. From this an assessment 
of technology adoption opportunities will be identified in line with the research questions. 
This approach will allow the thesis to answer the research questions of identifying how Lean 
can be adapted for long term conditions, can health technology assist in identifying and 
addressing Lean non-value activities and can healthcare technology assist in redefining 





7.1.2 Approach  
The research utilises the core Lean principles (Womack and Jones, 2010) as a template to 
consider how cardiovascular disease treatment is delivered today. These core Lean principles 
are reflected across the majority of Lean literature today including Miller (2015). The core 
Lean principles are addressed in this chapter in the following way;  
 Identify Value – Value for the cardiovascular disease patient is analysed as an 
example of a long term condition in section 7.2.  
 Identify Value Stream – Section 7.3, 7.4, 7.5 and 7.6 reflect the key value stream 
activities for cardiovascular disease.  
 Make it Flow - The Lean failure and non-value add activities have been identified in 
chapter 3 based on available Lean healthcare literature. The outputs from section 3 
will be used as a template to be populated with the specific evidence of cardiovascular 
disease wastes and non-value add activities found through the use of available 
articles, grey materials and open data 
 Pull to customer – Analysis of the Northern Ireland cardiovascular disease open data 
and statistics to understand the demand for various activities will be analysed through 
a longitudinal data set for over 5 years.  
 Strive for Perfection – In each section from 7.3 to 7.7 there will be an exploration to 
understand emerging models of care and also the future use of technology. The use of 
wider insights from health and academic leads through qualitative analysis will also 
complement existing exploration of data and guidance.  
The uses of these approaches are explained through the remainder of this section and will be 





7.1.2.1 Defining Value 
Defining value is a first step for all Lean approaches and the analysis will start with 
considering Lean for the cardiovascular patient. While the intention is that a combination of 
referrals, diagnostics, tests and procedure are intended to address health and social care needs 
this section will assess value for the patient from a Lean perspective using qualitative 
analysis. Section 7.2 will consider value prior to addressing the questions about the specific 
activities in healthcare. This is an essential starting point to address research question 3 which 
is focused on health technology being used to redefine patient value. It is also a key part of 
research question 1 for considering how Lean can be adapted to address long term conditions.  
  
7.1.2.2 Identify the key activities currently performed  
Following a review of qualitative analysis, quantitative data analysis, existing literature, 
exploration of the subject areas and exploration of Lean in health care the following areas 
were identified as the main activities or topic categories which have a direct impact on 
cardiovascular disease patients.   
 Prevention, Primary Care,  Community Care and Personal Health (7.3)  
 Diagnostics (7.4)  
 Hospital Based Care (7.5)  
 Medicines (7.6) 
 Technology (7.7) 
Each of the categories provides insight on healthcare delivery or Lean non-value add and 
jointly they provide a patient pathway view of healthcare value. These areas emerge from 
reviews of literature and cardiovascular disease best practice guides. The reason for their 






7.1.2.3 Analysis of Current Interventions Globally in Research Articles and Grey Materials 
In each of the sections 7.2 – 7.7 there will be an analysis of the current interventions which 
are brought together from qualitative analysis, academic papers and grey documented 
materials. This will assist in addressing research question 2 about identifying the Lean non-
value add activities. Healthcare has a significant amount of grey materials and guidance 
which is uncommon to other industries and this thesis makes use of the availability of such 
material to identify potential non-value add activities. This will complement quantitative data 
collection as there are activities that are not measured and don’t have significant quantitative 
data associated to them.  
 
The primary focus is on cardiovascular disease from the Northern Ireland region therefore the 
guidance focus will be on NICE guidance which is the recognised standard for the HSC in 
Northern Ireland. The use of clinical guidance, instructions and procedural best practice 
instructions provide an insight into the key activities and wastes within a system. NICE 
guidance documentation will be used as a method of understanding non adherence to best 
practice. The NICE guidance documents in table 7.1.1 have been identified as relevant to the 






Table 7.1.1 – Standard Operating Procedures from the National Institute of Clinical 
Excellence (NICE) - “Cardiovascular conditions: general and other” 
Standard Operating Procedure Title  Reference  
Cardiovascular disease prevention  PH25 (NICE 2010) 
Cardiovascular disease: identifying and supporting people 
most at risk of dying early 
PH15 (NICE 2008) 
 
Cardiovascular disease: risk assessment and reduction, 
including lipid modification  
CG181 (NICE 2016)  
Prophylaxis against infective endocarditis: antimicrobial 
prophylaxis against infective endocarditis in adults and 
children undergoing interventional procedures  
CG64 (NICE 2016)  
 
The details in the NICE guidance in table 7.1.1 provides some insights into the clinical non-
value activities, however in researching the topic it becomes clear that there is large volumes 
of material covering the mapping of services, diagnostic guidance, innovation briefings, 
quality standards, appraisal guidance, technologies guidance as well as “in development” 
documents. This was all within one category of cardiovascular disease called “Cardiovascular 
conditions: general and other”. There was similar information available for 13 other 
conditions such as acute coronary syndromes and aortic aneurysms.  
 
As the purpose of the thesis is not clinical the thesis has focused on “cardiovascular 
conditions: general and other” (NICE 2017) as an example of the types of guidance at the 
centre of cardiovascular disease rather than spread into specific clinical specialty. From this, 
sufficient contribution should be made to the research questions which would have 
application to the other areas. Also as this analysis is being “triangulated” with other 
qualitative and quantitative data there is an opportunity to identify any gaps from this 





7.1.2.4 Analysis of Current Measures and Data within the System  
This will focus on the quantitative data available and specifically on cardiovascular 
quantitative data. A longitudinal data set for over 5 years has been used for analysis. The data 
sets are based in the section topic such as medicines or diagnostics linked to cardiovascular 
disease. Analysis of relevant data for the topic and discussing the strengths and weaknesses 
of the data within the Lean context of identifying non-value add and waste will assist in the 
research questions. Open data sets are available to cover areas such as waits, procedures and 
medicines. This provides a rich source of information to compare, contrast and identify 
potential Lean non-value add activities and variances in practice and outcomes.  
 
The majority of the data used in the quantitative analysis in the area of cardiovascular disease 
is sourced from a data silo such as the GP, hospital or medicines provider. The thesis has 
provided a new contribution by developing analysis across these data silos. Figure 7.1.2 
provides an overview of the various data sets and providers that the analysis is collected 
across. This figure is repeated in each of the section with the area being focused on in that 







Figure 7.1.2 – Cardiovascular Disease Data Set  
This required grouping together of data in common formats and the exclusion of data which 
is appropriate to other conditions. On occasion data definitions and recording methods have 
caused some gaps or changes. For example the recording for one year may have been 
grouped as 1-6 weeks in one year’s data and in the following year that group was not 
available but had been replaced by another 2 groups called 1-3 and 4-6. Comments and 
methods of dealing with these changes are documented at the relevant section. The below 






Table 7.1.2 – Longitudinal Data Set for Cardiovascular Disease 
Data Area  Location Description  Comment   
GP Data  Northern 
Ireland 
Region 
Quality Outcomes Framework 
(QOF) Data.  
Primarily Collected to 
quantify payments to 








Outpatient Activity and Rates 
by Specialty 
- Outpatient Activity by 
Trust – Cardiac  
- Outpatient Activity by 
Trust – Cardiology 
- Episode based Activity  
- Episode Primary Diagnosis  
- Episodes All Diagnosis  




Management of the 5 NI 
Health and Social Care 








Diagnostics Data  Collected for 
Performance 
Management 








Prescription Cost Analysis 
Northern Ireland - Consolidated 
from Across 2010 - 2014   
Collected for 
Transparency of 
Government spending.  
(Business Services 
Organisation 2017)  
7.1.2.5 Lean Wastes/ Lean Non Value-Add Activities 
The literature review in chapter 3 focused on Lean wastes or non-value add activities in Lean 





use the findings from chapter 3 literature review as a template to apply to cardiovascular 
disease activities.. The chapter 3 template is provided in Table 7.1.3 for ease of reading. This 
approach reflects the original manufacturing application of Lean where they utilise the “seven 
wastes” (Womack and Jones, 2010) as a guide to identifying non-value as these can be 
common issues across industries. The purpose of the thesis is to discover these wastes in a 
long term condition and to develop a model of relevance to Lean healthcare technology 
adoption for long term conditions.  
Table 7.1.3 - Chapter 3 Literature Review Output of Lean Healthcare Non-Value Add or 
Waste 
Healthcare Failure Area Identified in 
Chapter 3  
Description  
Waiting times  Awaiting treatment to begin 
Delays  Waiting for activities, results while being treated 
Activity Transaction Speed  Related to activities within the value stream 
Diagnostic  Turn-around times 
Medical Complexity  Increasing strokes risks and amputations 
Additional Healthcare Visits  Follow up, review or further appointments than 
necessary 
Co-ordination of Healthcare 
resources  
Often lack of coordination producing additional 
activities 
Stress/overload of staff  Often driven by lack of clarity and inefficient 
processes   
Repeated Procedures  Missing test result, records or updates requiring 
repeated work 
Motion/Transport  Including staff walking 
Length of Stay  Average length of stay is a key measure of 
hospital performance but needs to be balanced 
with readmission rates 





or costs   
Quality  Errors in practice or administration of care    
Emergency Admissions  Unplanned, avoidable admissions regarded as a 
failure in the system. For example an escalation 
in a condition which could have been prevented  
Death  Unnecessary mortality due to falls, infections, 
Turn-around times 
Medication errors  Wrong drug, dosage or administration   
Infections  Caused by the medical interventions or 
environment of medical intervention 
Emerging from this research and 
not covered in Lean Healthcare 
Literature 
In each of the sections there will be a final row to 
highlight waste and non-value add activities that 
have been identified in the analysis which were 
not included in Lean healthcare literature from 
Chapter 3. This will assist in addressing research 
question 1 about how Lean can be adapted for 
long term conditions.  
 
7.1.2.6 Use of focus groups and expert opinion cardiologists to complement existing 
exploration of data and guidance 
The approach of the overall thesis as laid out in chapter 6 has been to utilise a mixed method 
approach therefore in addition to the quantitative data mentioned qualitative data has been 
sought from leading experts. Expertise has been sought through focus groups, meetings and 
discussions listed in appendix 2-6 and with the following being example of the types of 
contributors;  
 Cardiologists 
 Pharmacy Leaders  
 Health Technology Businesses  





7.1.2.7 Review of Technology 
The approach of the overall thesis has been to utilise Lean as a method of identifying 
opportunities for technology to address the non-value add for patients. The thesis explores 
technology match to cardiovascular disease through the following three separate sources;  
 National Strategic Healthcare Programmes, Implementations and Literature – 
This reflect the demand side where healthcare providers either have the technology or 
have an intent to adopt it.  
 Emerging Supplier Commercial Offerings – The technology providers are often 
developing new offerings that may address a need in healthcare. Analysis is provided 
in section 7.7.  
 UK Government Innovation Funding - The thesis has made use of published data 
from Innovate UK funds awarded to emerging innovations in healthcare. 
This approach for healthcare technology will complement the research. When combined with 
the quantitative data and qualitative data this will provides a more complete picture to assist 
with research questions 2 & 3 which will utilise technology for the Lean wastes (question 2) 
and for the redefining value (question3).  
7.1.2.8 Summary of Research Approach  
To summarise the approach of the remainder of this chapter, the thesis research questions will 
be addressed by analysing the following key topics which are relevant to cardiovascular 
disease; 
 Defining Value  in section 7.2 
 Prevention, Primary Care,  Community Care and Personal Health  in section 7.3 
 Diagnostics  in 7.4  
 Hospital Based Care in 7.5 





 Technology in 7.7 
Within each topic, the analysis will include a common approach in each section of the 
addressing the following areas;  
 A brief introduction to the topic area 
 Analysis of current interventions globally in research articles and grey materials 
 Analysis of current measures and data within the system 
 Reflection on what is not measured  
 Lean wastes/ Lean non value-add activities 
By completing the analysis, this will lead to a discussion aligned to the thesis aims, objectives 
and research questions. A short discussion will be available in each section which will then 
be consolidated to provide a wider discussion bringing together findings from academic 






7.2 Defining Value  
Central to Lean is the importance of starting by defining value (Womack and Jones, 2010). 
To begin analysing cardiovascular disease from a Lean perspective one must prioritise 
consideration of value and the purpose of the system prior to progressing to the processes and 
activities. This section will explore the understanding of what “value” is for cardiovascular 
disease prior to defining the activities which are required to deliver this value.  
 
Figure 7.2.1 – Cardiovascular Disease Data Set – Focus on Value  
7.2.1.1 Definition of Value  
The definition of value will be explored throughout this section but setting some context to 
what value is, Porter (2010, pg. 2477) highlights that value has an “overarching goal of 
healthcare” and is linked to health outcomes rather than dollars spent or activities performed. 





based on activity and volumes and not patient outcomes. The value that will be discussed in 
this chapter will therefore refer to patient value and measurements around the patient rather 
than the system.  
7.2.1.2 The Role of Value  
Arguably the role of value has been limited in care provision with providers focusing on care 
activities. The result is disjointed services than can conflict, create gaps and lead to 
duplication. This is however changing as value is a key focus of emerging reform and Porter 
(2016) notes that USA public health organisations Medicare and Medicaid are moving 
towards a value based reimbursement. 
7.2.1.3 The Future Development of Value  
The research question of how Lean can be adapted for long term conditions has to consider 
value for patients. The current healthcare system is designed on sequential activities followed 
by review and discharge. There is limited consideration of how to manage a long term 
condition patient who may have multiple care engagements over a number of years dealing 
with many different care providers (Patton et al., 2015). Similar to the sequential way the 
healthcare system has been designed around a linear process, Lean has the flow concept and 
sequential activities as the main basis of its approach. The question to be explored therefore is 
about what would need to be adapted for Lean to work with long term conditions.    
7.2.1.4 Value in this Thesis  
The remainder of section 7.2 will analyse what is meant by value for long term condition 
patients and specifically cardiovascular disease patients. Value, while not a key activity in 
itself defines the activities that will be completed. Understanding value will have major 






 Analysis of current diagnostic interventions in academic and grey papers  
 Analysis of current measures and quantitative data within the NI healthcare system 
 Consider what is not measured  
 Map the activities against the Lean non-value add activities identified in academic 
literature chapters 2-4. 
From this analysis one can then contribute to answering the three research questions of how 
Lean can be adapted for long term conditions (research question 1) and contribute to 
identifying methods for healthcare technology to address Lean non-value add activities 
(research question 2). The analysis will help identify where value is not being delivered. This 
will assist in building the case for technology addressing a redefined value in research 
question 3.  
7.2.2 Analysis of Current Interventions Globally in Research Articles and Grey 
Materials 
Current healthcare delivery is based on a series of activities, often described as episodes of 
care, such as a medical intervention. The activities will be joined together as a care pathway 
which can reflect the Lean value stream. Where activities are beyond the responsibility of an 
organisation then a referral is made to another provider, such as a social worker. The complex 
nature of care provision may mean that the care pathway does not address holistic patient 
needs such as respiratory problems or depression issues (Mazzocato et al., 2014). The result 
is that complete patient value may be inadequately addressed or waste may have been created 
through the conflicts of treatment, handovers and lack of flow.  The combination of activities 
is dictated by the commissioner of the service rather than the patient. This largely reflects 
guidance from clinical experts however local decisions can result in variance across the UK 






While the term value creation is not frequently found in the care provision the pursuit of 
“quality” is a dominant term (White et al., 2017). Waiting list measures, number of 
procedures, length of hospital stays, infection occurrences and measures associated to life 
after a procedure are often measured. Service improvements, quality, training and 
commissioning models are built around these operational and clinical measures. Process 
measures linked to quality have sought to find ways to compare and contrast best practice 
which has led to care plans, care pathways and guidance emerging. Examples of these are 
NICE guidance and the productive ward series of improvements (White et al., 2017). These 
standardise best practice processes when applied begin to reduce errors, control infection and 
manage risks. The various measures used in healthcare are not without criticism with the 
media and politicians advocating or criticising various measures. Evidence of “gaming” the 
measure has also been seen as senior health leaders have sought to avoid the repercussions of 
perceived poor performance. The Guardian on the 17 Dec, 2014 reported on the Care Quality 
Commissions investigations into two separate inquiries in Colchester Hospital around the 
manipulation of cancer waiting times and accusations of staff being bullied to change data to 
meet targets. In this incident there was no evidence of system wide manipulation however 
there was recognition of sub-optimal care being provided and staff under pressure to meet 
targets. This enquiry is representative of similar investigations in other hospital and raises 
questions about the measures and if they are incentivising unintended consequences that 
don’t relate to patient value.   
 
The concept of value based models have been considered with Chris Ham, Chief Executive 
of the Kings Fund, highlighting that “in a cash constrained public health service with 
ambitious targets being required in the “five years forward” strategy focusing on “..better 





(Ham, 2016, pg. 1). Similarly in the USA, the 2015 report to congress highlighted that fee for 
service programmes lead to overprovision and perverse provider incentives (Congress, 2015). 
These shifts towards value based models, away from activity models, is of interest to this 
thesis as it recognises that value is not the current focus of healthcare delivery therefore 
moving to alternative commissioning models linked to health outcomes has significant merit 
(Reuben and Tinetti, 2012). The challenge for Lean in cardiovascular disease is that one must 
understand;  
- Who is the customer?  
- What do they value?  
- Barriers to delivering value.   
The rest of this section explores further the understanding of value from the patient’s 
perspective. The implications are that Lean wastes will be evident as value has not been 
clearly defined from the customer’s perspective.  
7.2.2.1 Who is the Customer?  
The Lean “customer” is complex in cardiovascular disease as there are various budget 
holders, commissioners, trusts, patients and family members as users and contributors acting 
in a consuming way. The compliance of the patient to health and medical guidance will mean 
that patients are not only a consumer but also a contributor to better health outcomes (World 
Health Organization, 2017). Lean seeks to define value for the customer (Womack et Al., 
1991) but in the case of healthcare, defining who the customer is can be challenging.  Brill 
(2013) focusing on American healthcare, highlights that the insurer, employer who chooses 
the insurance and the patient who chooses the insurer all have an influence on the care 
provided and the costs of care. Multiple stakeholders result in conflicting interest, multiple 





impossible to create unified goals in a manner not evident in other industries (Eldabi, 2009). 
Due to the issues outlined, this thesis will focus on value creation for the individual patient.  
The patient will be the customer in Lean terminology and all waste will be measured from 
this viewpoint. The consequence of focusing on other stakeholders is to drive non-value 
creation which may reduce patient outcomes and increase costs. This is illustrated within a 
Time article that highlights US healthcare organisations incentives to provide surplus tests, 
over-treat and address system goals where patient value is not the focus (Brill, 2013). In 
summary, placing the patient as the customer and seeking to deliver value for them is an 
important approach for Lean in cardiovascular disease.  
7.2.2.2 What is Value for the Patient?  
A number of studies have been published which explore differences between hospital care 
and a “hospital at home” provide insight around defining value for the patient ((Patel et al., 
2008, Garcia-Soleto et al., 2013 and Mendoza et al 2009). The studies are relevant as moving 
care away from the hospital has required the authors to consider patient value. Table 7.2.1 
highlights the variety of measures of value used that recognises that clinical improvement 







Table 7.2.1 Cardiovascular Disease Trial Reviews - Measures of Comparison used to 
Represent Value  
Clinical 
Trial Paper  
Number of 
Patients 
Country  Measures Used to Represent Value 
Patel et al., 
2008 
31 Sweden (1) Was symptomatically stable or improving,  
(2) had stable falling weight,  
(3) had no signs of pulmonary rates and  
(4) had no oedema above the ankle 
Mendoza et 
al., 2009 
71 Spain Avoiding readmissions  
Absence of symptoms or reduced symptoms  
Blood measures which indicate decline or 
improvement such as– pro BNP,  
Health related Quality of Life 
Functional status * 
Health-related quality of life ** 
Garcia 
- 
Soleto et al.,  
, 
2013  
71 Spain Functional Status** and Health Related 
Quality of Life ** & ***Minnesota Living 
with Heart Failure Questionnaires which focus 
on quality of life. 
*Barthel Index –Short questionnaire which makes an assessment based on 10 items around 
quality of life. **SF-36 – Structured quality of life questionnaire covering physical, social, 
emotional and mental health. ***EQ-5D – Rating score based on 5 dimensions of mobility, 
self-care, daily activities, pain/discomfort and anxiety/depression.   
 
Garcia-Soleto et al. (2013), reported in the discussions about quality of life as distinct from 
the physical, bodily function and general health. They recognised that in many cases the 
baseline for quality of life can be complex as initial “decomposition” or clinical incident will 
result in lower quality followed by a ramp of improvement to a new baseline. The studies 
report no significant difference in clinical incidence between the home or hospital care 





cost. Value has also been explored further in healthcare simulation work where seven axis of 
values were identified including; prolonging the absence of illness, minimising pain, 
maximising periods of health, maximising mobility, maximising independence, contributing 
to society, reducing isolation  and enjoying a quality of life (Kuljis et al., 2007). From these 
studies one can see that the value for cardiovascular disease patients is complex and falls 
beyond the direct clinical activities which could be summarised in the categories outlined in 
the table 7.2.2.  
Table 7.2.2 – Analysis of Wider Measures for a Cardiovascular Patient 






 Discharged Alive  
 Reduced Readmission  
 Mortality - Preventing 
people from dying 
prematurely  
Example: The epidemiology of 
cardiovascular disease in the UK 2014 








 Speed to Re-ablement - 
post-hospital return to 
maximum independence and 
recovery from episodes of ill 
health or following injury  
 Exercise Tolerance 
Cardiac rehabilitation programmes being 
regarded as best practice but not 





The system wide measures include; 
 Quantity of patients 
managed by GP with 
specific cardiology diseases 
such as Heart Failure  
 Waiting list statistics  
 Appointment details, 
Episode details, procedure 
counts.  
Department of health official published 
waiting times for figures such as waiting 
statistics and activity measures.  











 Patient experience  
 
Public Satisfaction Surveys are completed 
infrequently by commissioned surveys 
such as National Centre for Social 
Research’s British Social Attitudes. 
Commissioned surveys are also completed 
by various trusts and commissioners and 
charities to progress a number of agendas 





End of Life Plan in Place – people 
at end of life are often not 
identified and therefore treated 
incorrectly  
Treatment and Care Towards the End of 





Table 7.2.2. highlights a maturity in the measures around process but a weakness in all other 
areas. This is reflected in the qualitative discussion where the cardiologists suggested that 
they focused on clinical intervention first before considering the patient consideration of end 
of life. Similarly the lack of quantitative measures around quality of care across the whole 
care of the patient reflects missing value measures. In these other areas, the measures are 
often absent of regular data with those that are completed representing a one off 
measurement, infrequent measurement or inconsistency across regions. This reflects the 
earlier outputs of the thesis that measures and Lean literature has focused on organisation 
silos rather than patient value. The term quality appears frequently as a proxy for value which 
may not be true as a quality measure will look at the how a diagnostic procedure was 
completed but may not question if the procedure was needed or value to the patient’s 





other countries in reference to the number of procedures or diagnostic tests without the 
resultant improvement in health outcomes (Brill, 2013).  
 
In summary, the existing measures may not correspond with patient value measures for 
cardiovascular patients. Some of the areas that are measured are not relevant and some of the 
areas of value are not measured. Although not connected to the cardiology study the 
following quote reflects the position on understanding value well;  
“Alan A. didn’t care how much time his cancer or heart doctor spent with him or how 
many tests he got. He cared only that he got better” (Brill, 2013, pg. 36).  
 
This lead to a position of needing to understand what is preventing value from being 
delivered in cardiovascular disease. 
7.2.2.3 Barriers to Delivering Value  
A number of barriers emerge from healthcare studies and grey materials when looking at 
cardiovascular disease. The organisation of healthcare workers is one area of failure as 
healthcare with a lack of interdisciplinary work targeted at patient value can produce waste 
(Reiter et al., 2016). Secondly, patients themselves can be a barrier as the levels of adherence 
to medication, smoking cessation, weight control, exercise participation, positive mental 
health and participation in community activities all have an influence on cardiovascular 
disease therapy and the related outcomes (World Health Organization, 2017). The area of 
medicines adherence was a significant topic for the medicines focus group (Appendix 4) in 
the qualitative analysis as they are currently engaged in a number of explorations of 
technology to address patient adherence issues in medication. Thirdly, a lack of 





decisions which are not understood by healthcare providers as part of managing their 
condition. For example a patient may choose additional pain over the side effects of a toxic 
drug which reduces their ability to take part in a social event or milestone family event such 
as a daughter’s wedding. NICE cardiac rehabilitation services guidance recognises the patient 
as being a co-creator in Value and the need to ensure the patients ability to manage their own 
condition, access support and make personal decisions about care (NICE, 2017). Fourthly 
treatment can fail to consider the full patient value with some treatments being inappropriate 
for patients approaching end of life and therefore bringing discomfort. This area emerged in 
the qualitative analysis with the heart failure nurse (Appendix 3), as patients with heart 
failure may be moving towards end of life which may require different treatments and 
approaches to care. Examples include treatments which focus on short term biological 
measures which may be appropriate on healthy patients but be inappropriate for severe 
disability, multiple conditions and those with a short life expectancy, prolonging the process 
of dying and causing unnecessary pain (Reuben 2012). Finally, “bad care” which will harm 
the patients is a barrier to value. With $4.4BN paid by Medicare in the USA for patients 
harmed in hospital in 2009 this is evident of “bad care” in todays practice (Brill, 2013).  
In summarising, one can see that healthcare staff silos, patients adherence, inappropriate care 
for those at the end of life and the impact of bad healthcare can all be barriers to healthcare 







7.2.3 Analysis of Current Data within the System to Build a Lean Value Stream  
To understand value for the patient of a long term condition, such as a cardiovascular disease, 
a review was completed to identify where the patient engages with the care providers which 
will enable a value stream map to be created to understand flow and wastes. Figure 7.2.2 
highlights the main areas where quantitative data is available to reflect a cardiovascular 
patient’s value stream. The data is analysed and discussed in future sections as indicated in 
the diagram. The waits between the various parts of the value stream are also discussed when 
analysing the data. It should also be noted that no end-to-end measure was found within the 
current system measures in the department of health or the HSC. All measures are from the 
providers and not the patient pathway which joins together the providers.  
 
Figure 7.2.2 – Developing a Lean value stream for cardiology patients from available 
data 
GP data is the community based doctor who will assess initial needs and make a referral to 
the appropriate care. The GP quantitative data is collected through “QOF” reporting which is 
incentivised through various payments to manage patients within the community. For 
example GP’s are paid additional payments to address specific disease conditions with 





by specialist assessment, are monitored under activity and waiting times targets. Outpatient 
assessment data and hospital based care are again measured around waits and activity. 
Medication data is primarily linked to volumes and costs from the procurement organisation 
of the health service.  
7.2.3.1 Gaps in Using a Value Stream Approach  
The end to end system value stream map while useful in understanding the flow of patients 
from GP referral through to treatment however misses a number of key points. The 7.2.3 
highlights some missing elements for a Lean value stream map. These will be explored 
further in the chapters related to that specific stage.  
Table 7.2.3 Cardiovascular Disease: Gaps in Value Stream Approach  
Unplanned 
Admissions  
Unplanned admission arriving in Ambulances or via Accident and 
Emergency. (Identified in quantitative data for hospital activity) 
Domiciliary Care 
Provision and  
Care Homes 
Many elderly patients with cardiovascular disease provided care 
outside of the health service in social care. Observational data is often 
missed and changes often are not fed back to the clinical decision 
making. (Identified in Qualitative Analysis with Performance 
Improvement leaders) 
Palliative Care End of life of palliative care is often missed from care pathways with 
care planning for end of life being poorly dealt with. The result is that 
patient’s wishes are not addressed and in Lean terms over processing 
of patients can occur as unwelcome treatments are provided.   




Individual Patient Responsibility – individual responsibility for diet, 
exercise, medicines adherence etc. is not included in the value stream. 





7.2.4 Lean Wastes/ Lean Non Value-Add Activities 
In section 7.3 to 7.7 the Lean waste identified from the literature review in Chapter 3 will be 
mapped to the quantitative data activities in the healthcare area for that section. Although this 
section does not contain quantitative analysis a number of wastes have emerge from 
qualitative analysis of value. Firstly there is no evidence of patient pathway measurements in 
the care provision as all measures are limited to specific activities. Secondly there is no 
evidence of understanding the impact of unplanned admission, as illustrated in figure 7.2.3, 
of the Lean value stream for cardiology patients or how this could be addressed. Thirdly there 
is a failure to capture the full patient journeys data in areas such as domiciliary care and care 
homes which has an impact on the patient value and demand in the healthcare system.  
7.2.5 Discussion on the Value Analysis  
In summary, understanding “value” in cardiovascular disease can reveal a complexity not 
found in other industries. To avoid the creation of waste there is a need to focus on the patient 
as the customer in a Lean reform. The analysis highlights that for long term conditions, such 
as cardiovascular disease, a value stream can be created that crosses the current providers of 
healthcare activities and reflects the current patient journey. This is currently not done in 
Lean healthcare and may have some merit in identifying waste and improving patient 
outcomes. This has limitations as areas such as unplanned admissions and activities not 
within the current care providers may have an influence on the patient journey and will need 
addressed. Additionally the patient will have some co-production elements in value creation 
in areas such as medication adherence which are not addressed in Lean healthcare literature. 
The topic of value for the patient is not being fully addressed as care delivery is focused on 
current process measures predominantly yet there is evidence of a need to consider other 





The topic of unmet value is not significantly addressed in the Lean healthcare literature of 
chapters 2-4.  Figure 7.5 provides a summary overview for section 7.2.  
 





7.3 Prevention, Primary Care, Community Care and Personal Health  
The previous section of the thesis analysed data and evidence from cardiovascular disease 
patients in relation to value. This began to address the thesis aim of analysing the role of Lean 
thinking application to integrated healthcare pathways. This was represented in Figure 7.1.2 
of the overview diagram of key cardiovascular disease areas. Similarly prevention will have 
implications on Lean thinking for cardiovascular diseases. Understanding prevention applied 
to cardiology will assist in addressing the research question of how Lean can be adapted to 
long term conditions. Prevention however is rarely addressed without considering the General 
Practitioner (Primary Care) who will be the entry point to healthcare. For this reason this 
section will analyse quantitative data for prevention and primary care focus areas.  
 
Figure 7.3.1– Cardiovascular Disease Data Set – Focus on Prevention, Primary Care 





7.3.1.1 Definition of Prevention, Primary Care and Community Care 
Prevention, primary care and community care is provided outside the hospital. The public 
health agency makes reference in its annual report to activities such as screening, public 
information, engagement and reducing health inequalities as part of its prevention role 
(Public Health, 2016). Primary care and community care is defined concisely by NHS 
England as; 
“Primary care services provide the first point of contact in the healthcare system, acting as 
the ‘front door’ of the NHS. Primary care includes general practice, community pharmacy, 
dental, and optometry (eye health) services” NHS (2017) 
7.3.1.2 The Role of Prevention, Primary Care and Community Care 
In progressing analysis for cardiovascular disease it is important to explore prevention prior 
to early intervention activities. The World Health Organisation highlighted in its “Action 
Plan for the Global Strategy for the Prevention and Control of Non-communicable Diseases” 
(World Healthcare Organisation, 2015) that the four areas of physical inactivity, unhealthy 
diets, harmful use of alcohol and tobacco use are key factors in the prevention of non-
communicable diseases. These diseases include cardiovascular disease, diabetes, chronic 
respiratory disease and cancers. They cause 60% of all deaths. The key point being that many 
of the deaths are preventable. 
7.3.1.3 Future Development of Prevention, Primary Care and Community Care 
Simon Stevens (2014) NHS strategy document clearly articulates that preventable illness is 
widespread and the links to health inequalities are deep rooted. There is a need to address the 
disease burden fairly and equitably with an approach that considers risk factors for specific 
population groups (Bauer et al., 2014). When analysing long term conditions, such as 





intervention to improve health outcomes and avoid costs. Despite this there is limited 
coverage of prevention in Lean healthcare. Some exceptions being linked to preventing errors 
(Morrow et al., 2012) or preventing falls in cancer patients (Wolf et al., 2013). In both of 
these cases the prevention is linked to an error or incident being avoided as opposed to 
prevention of a condition escalation which is relevant to long term conditions. In summary, 
one can see a desire from healthcare strategy to address prevention but limited Lean 
healthcare studies addressing this.  
7.3.1.4 Prevention, Primary Care Community and Personal Health in This Thesis 
The remainder of section 7.3 will analyse the potential for prevention approaches to address 
Lean healthcare for cardiovascular disease with a focus on public health interventions. This 
will analyse;  
 Current diagnostic interventions in academic and grey papers  
 Current measures and data within the NI healthcare system 
 What is not measured  
 Map the activities against the Lean non-value add activities identified in academic 
literature in Chapters 3. 
From this analysis one can then contribute to answering the research questions of how Lean 
can be adapted for long term conditions (research question 1) and contribute to identifying 
methods for health technology to address Lean non-value add activities (research question 2). 
The analysis will also build some insight into addressing research question 3 where health 






7.3.2 Analysis of Current Interventions Globally in Papers and Grey Materials  
Specific guidance from healthcare authorities highlights the promotion of high level 
programmes and interventions. The following highlights a number of these  which are 
relevant to cardiovascular disease including;  
 NICE (UK Based Health Authority and provider standards)  
 World Health Organisation  
 World Heart Foundation  
 US Center for Disease Control and Prevention (CDC) 
Table 7.3.1 – Leading Authorities Strategies for Prevention  










Physical inactivity  
Unhealthy diets 








Improving access to preventative medicines such as oral anticoagulants,  
Reducing the dependence on highly trained experts,  
Improving capacity for therapy  
Strengthening Health Information systems.  





et al., 2014) 
Epidemiology and surveillance to monitor trends and inform programmes; 
Environmental approaches that promote health and healthy behaviours;  
Health system interventions to improve the effective use of clinical and 
other preventive services; and  
Community resources linked to clinical services that sustain improved 





From analysis of these various approaches the key public health inclusion topics with the 
cardiovascular disease focus are identified as; 
• Exercise 
• Education  (Including Diet, Smoking and Alcohol) 
• Psychological support  
• Behaviour and self-management  
• Preventative medication policy    
• The role of public health, treatments and surveillance  
These topics will be explored below with a focus on cardiovascular disease and consideration 
of their contribution to a Lean healthcare approach.  
7.3.2.1 Exercise  
Analysis of public health strategy documents highlight common acceptance of the need for 
exercise or activity as a tool for prevention of cardiovascular disease. As an example, NICE 
Clinical Guidance 67 advises the use of social prescribing referrals to leisure centre and 
classes with relevant trained staff and exercise instructors. Professional barriers are however 
reflected in the ACSM health screening recommendations (Thompson et al., 2013) where 
they consider the weakness of the current advice which insists on various healthcare 
screening exams and supervised exercise regimes before exercise can be undertaken. The 
research challenges the lack of evidence behind advice and highlights that the barrier to 
exercise may be too heavy for patients and significant risk exists for do no exercise while 
waiting for a perfectly formed review, assessment and clinically monitored exercise regime 
(Thompson et al., 2013). Mitigating risk through health screens is known to lower the barriers 





exercise. This reflects the idea of prescribing social interventions as an alternative to 
medication. This will be addressed further in the technology section 7.7.        
7.3.2.2 Education (Including Diet, Smoking and Alcohol) 
There is a need for education in the prevention phase before getting cardiovascular diseases 
and also after a clinical intervention to prevent further damage in cardiac rehabilitation 
groups. Frequently the education will address diet, lowering cholesterol, blood pressure, 
smoking cessation and alcohol management (NICE, 2017). Public health advice however is 
not without criticism as evidence suggests that health messages worldwide contradict each 
other and lack clinical evidence or where there is evidence it can be biased by focusing only 
on specific groups of people such as those with a baseline high blood pressure (Graudal, 
2016). For example the article highlights the focus on reducing salt intake and blood pressure, 
however low sodium is evident in Yanomami Indians, Brazil and they do have low blood 
pressure however they also have a lower life expectancy. In this one must conclude that the 
evidence base for prevention should be questioned and proxy measure of health such as blood 
pressure levels need to be approached with caution.  Similarly other studies provide caution 
on applying preventative health interventions to asymptomatic people (healthy people) where 
the studies resulted in new risks due to the therapies (Yusuf et al., 2016). The evidence base 
behind some public health messages may need to be questioned if focused on value for an 
individual patient. The nature of public health messages means that advice is generic and will 
not be of any value to certain people or population groups. 
 
Smoking cessation is a key part of all programmes associated to cardiovascular disease 
however studies have revealed that the effectiveness is questionable as although they 
participating in the clinic, only a small amount collected the related medicines which 





cigarettes to reduce harm from tobacco has some promise but questions around the role of e-
cigarettes still remains despite the evidence that it can reduce harm by as much as 95% 
(Tobacco Advisory Group of the Royal College of Physicians, 2016). Despite this evidence 
the Northern Ireland Health Promotion agency continues to advocate tobacco removal and 
not support e-cigarettes (PHA, 2015). From a Lean perspective of value for the patient this 
may be a questionable approach and lack clinical evidence as it will result less harm 
reduction as an ineffective strategy. This is underlined by the data showing that current 
strategy not impacting certain social economic group such as manual workers (Semi skilled, 
skilled and unskilled) with close to 30% of the population in these groups being smokers 
(PHA, 2012).  
  
In summary and considering where Lean can be adapted to address waste and where 
technology could be considered one can find the advice often lacks the evidence which is 
appropriate to personalised care therefore advice may have limited or no benefit. Goals may 
be inappropriate for specific patient groups and technology may provide an opportunity to 
build better outcome based engagement with patients.   
7.3.2.3 Psychological support  
General prevention and public health advice reflects the area of mental health should be 
considered as a significant part of cardiovascular patient management with guidance making 
reference to considering depression anxiety and stress within the operational management of 
the patient (NICE, 2017). It is known that psychological factors that depression leads to 
higher numbers of Cardiac events and higher readmissions (Khayyam-Nekouei  et al., 2013)  
The research also highlights a number of studies that link anxiety to cardiac events and 





“They realized that loneliness is one of the important risk factors for patients with 
heart failure, and the more the patients feel lonely the more severe the heart failure 
is” (Khayyam-Nekouei  et al., 2013, Pg. 104)   
Data is difficult to gather in this area with no open data for existing patients in Northern 
Ireland. This lack of data does not reflect a lack of relevance but a gap in operational delivery 
or in Lean terms and unmet value demand. This thesis is not a medical exploration of cardiac 
interventions or mental health and the exploration will be limited for that reason. The use of 
technology however may be of relevance to future studies in attempting to quantify the levels 
of psychological need and potential support.  
7.3.2.4 Behaviour and Self -Management 
Encouraging self-management is documented on many of the health strategies to reflect a 
need to move from paternalistic (Topol, 2016) care to a patient leading their own care. NICE 
guidance, CMG40, recognises that long term care management is important and that 
providers must put in place pathways to address these as part of cardiac rehabilitation. In the 
guidance they recognise a role for cardiac services and for the patient’s own responsibility. 
The patient’s own responsibility is included in a push towards empowering patients to 
manage their own health, accessing services and personalising support to match their own 
need. Self-management APPS are a key creation of the smart phone emergence and the apple 
store alone had 165K healthcare apps however only about 5% of them have any significant 
download figures as credibility (Jack,  2016).  Some evidence is emerging of networks and 
peer support being of positive benefit in long term conditions and studies are attempting to 
understand how networks can assist with better health outcomes and reduced the burden on 
the health providers (Reeves et al., 2014). In summary, there is an appetite for self-care and 





material linked to operation practice that might guide this in cardiovascular disease beyond 
basic leaflets.  
7.3.2.5 The role of Public Health, Treatments and Surveillance  
The general practitioner has a role in prevention and intervention after symptoms have been 
identified. NICE guidance highlights the role of the GP operating with the cardiovascular 
patients (NICE, 2017). In addition the commissioners have outlined specific areas within 
their requirements for identifying, treating and preventing the escalation of high risk patients. 
The interventions include the promotion of lifestyle changes around diet, physical activity, 
weight management and smoking which will be discussed further in the next section around 
the quantitative data from the Quality Outcome Framework – QOF (Department of Health, 
2017). The QOF measures identify high risk patient groups and define interventions for these 
higher risk groups with the aim of preventative interventions for cardiovascular disease.   
7.3.2.6 Summary  
In reviewing the material related to the delivery of cardiovascular disease treatment in the 
grey and academic publications in the area of prevention, primary, community care and 
personal health one can see a number of gaps where Lean could be adjusted for long term 
conditions such as cardiovascular disease. These include the absence of prevention in Lean 
value stream activities, use of education to inform prevention, absence of psychological 
support, lack of evidence around self-management and the potential to utilise primary care in 













7.3.3 Analysis of Current Measures and Data within the System  
To gain insight on the prevention, primary care, community care and personal health data 
with a focus on cardiovascular disease, one must look at the available quantitative public 
health data and general practitioner data. The quantitative data available of relevance to 
cardiovascular disease can be divided into two strands with one being linked to public health 
interventions and the secondly linked to the activities of GP’s. The public health interventions 
will include advertisements or workshops to encourage citizens to eat healthy, walk more or 
stop smoking. Initiatives will also be commissioned through community groups such as stop 
smoking groups and research related interventions. The data around these is less easily 
accessible and appears in various Public Health reports. The GP quantitative data is provided 
from over 350 GP practices located across Northern Ireland and is structure to reflect the 
Quality Outcomes Framework (QOF) which are part of the GP procurement returns priorities 
(Department of Health, 2017).The QOF data is similar to other parts of the UK with some 
variance between commissioners to reflect local commissioning needs. The large collection 
of QOF data is available as open data sets and in 2015 there were 57 separate indicator 
measured and reported on by each GP practice.  Each of the indicators have a data set which 
was comparable to all other GP practices across Northern Ireland for that year. In addition 
each data set is available over the number of years that indicator has been in use. This has 
created an extensive publically available big data set.  
 
As the thesis research question is focused on specific measures of relevance to cardiovascular 
disease the following areas have been targeted. These represent the cardiovascular disease 
specific measures and the areas identified in section 7.2 as being relevant to cardiovascular 
disease prevention;  





 Obesity  
 Smoking  
 Cardio vascular disease management 
 Public health measures 
 Summary of available data analysis  
Opens source data such as sexual health and female cancer have been excluded from the 
scope in the analysis due to not being directly related to the thesis topic. 
7.3.3.1 Cardiovascular Disease Primary Prevention 
The public health focus on cardiovascular disease is targeted at patients with a new diagnosis 
of hypertension within the age range of 30-75. This excludes patients who are presenting with 
other conditions such as chronic heart disease and diabetes. The concept of primary 
prevention is useful from a healthcare perspective as it is using risk factor to identify and 
target specific individuals. From a Lean healthcare perspective it is also very positive to 
utilise data for interventions. The data in figure 7.3.3 analysis is presented to cover a 
longitude view of a 5 year time period to show change and year on year comparisons for 
cardiovascular disease.  The year-on-year comparisons are not currently used within the 








Figure 7.3.3 – GP Longitude Data in Cardiovascular Primary Prevention Activities  
What is clear is significant changes in the recorded interventions. This potentially reflects 
underlying service delivery incentives and disincentives which brings into question the 
patient value being the driver for change and intervention. Public health agendas are being 
driven by incentives outside of patient value. 
7.3.3.2 Obesity  
Obesity is a key focus for cardiovascular disease and many related conditions such as 
diabetes. Obesity has again been analysed over the same 5 year longitudinal data period that 
has been used in all other data and one can see that obesity measures are evident for three 
years before being dropped as a measure from the GP QOF payments. This is despite the 
measure actually revealing increases in obesity over the period. Obesity has an impact on 
many health conditions and it is unclear why this would be removed from the measurement. 
This may reflect a reluctance of public health bodies to measure something that they are not 
perceived to be making an impact into or a view that measuring the number does not lead to 
positive action. From a Lean perspective the failure to measure and address this would be a 
significant concern if this is clearly something that will impact on future healthcare. Equally 





reflects data on the need to adapt the approach to address issues which are difficult but impact 
on patient value.    
 
Figure 7.3.4 – GP Longitude Data on Obesity (Department of Health 2014)  
7.3.3.3 Smoking  
Smoking is also a key focus for cardiovascular disease related conditions such as diabetes, 
respiratory related conditions and cancers. Smoking data counts the smoking status and at one 
stage provided a numeric count of smokers with a chronic condition. The measures were 
changed during the period and moved from counting the number of smokers with a condition 
to counting the number of patients where the smoking status has been recorded. While it may 
reflect a degree of moving to a newer method of engagement between the GP and the patient, 









Figure 7.3.5 – GP Longitude Data on Smoking  
To explore further what has been measured in the 2013/14 period before the change to the 
various measures some analysis has been completed to consolidate data. The QOF metrics are 
designed to incentivise the GP’s through a payment associated with each patient. Therefore 
for every data entry associated to a patient there is an associated payment. For illustrative 
purposes, there may be a £25 payment for every consultation about stopping smoking. In 
some cases the incentives are high level and generic to begin the engagement with the patient. 
“The contractor supports patients who smoke in stopping smoking by a strategy which 
includes providing literature and offering appropriate therapy” - QOF Indicator 
Definition - Health and Social Care Information Centre 
The number of successful counts is the same as the number of GP practices in Northern 
Ireland therefore the GP is being incentivised to provide a service of signposting support with 
limited outcome measures. The lack of focus on outcomes leads to considering metrics 
beyond the GP interventions in public health. The Northern Ireland public health authority 








The stop smoking service have a focus on the following metrics;   
 Number with Set Quit Dates  
 Number who Quit 4 Weeks Later  
 Number not quit at 4 week follow up  
 Age  
 Sex  
 Region  
 Deprivation Factor  
 Therapeutic Intervention  
 Pregnancy Focus  
 Referral Type 
 Number of Cigarettes  
 Previous Participation 
The data reveals a number of important factors when considering the research questions of 
this thesis and in particular the question one about how Lean can be adapted for long term 
conditions. Firstly the data is largely proxy data such as “setting a quit date” rather than 
evidence of longer term quitting which in our Lean focus would be required for improved 
health outcomes or patient value. Secondly the reporting is generally self-reporting which is 
open to false reporting, misuse or leading to a potential incorrect assumption that a short term 
improvement will be maintained. The PHA Annual Report and Accounts 2015-16 (Public 
Health Agency 2016) reports that 59% of patients using a stop smoking campaign were 
stopped at 4 weeks but it is unclear of the longer term benefit and sustainability of this. The 
use of proxy information and self-reporting are areas that technology may be able to assist in 





research question 2 about the use of health technology will be analysed. Also further analysis 
reveals that 59% of patients stopping smoking as a result of interventions masks a decline in 
interventions. The smoking intervention level when compared to the populations in a 5 year 
longitudinal view highlights that although the interventions are providing some level of 
evidence for success at 59%, the number of interventions have been declining and the volume 
of patients registered at the GP practice has been increasing. The public health agency 
messages are therefore masking issues with value for individual patients. Research question 1 
questions how Lean can be adapted for long term conditions and a key element here is that 
Lean must be addressed at the patient level and provide clarity on interventions where 
agencies may be incentivised to present data that highlights their own value. The high level of 
reductions in interventions is highlighted below in figure 7.3.6 
 
Figure 7.3.6 – Data Amalgamation of Smoker Number and Intervention Levels  
The number setting quit dates has decline over the period 2011/12 – 2015/16 with a reduction 
of 53%. The data appears to suggest that investment is being taken away from prevention 
interventions which is counter to patient value. To address the research question on how Lean 





investment should be a key consideration. This data was however not visible to most people 
through the open data sets as it required a combination of a number of data sets which is 
reflected in 7.3.2 and perhaps highlights an unwillingness of some of the providers to use 
data for continuous improvement.  
Table 7.3.2 – Derivation of the Complementary Data  
Data Analysis derived from a number of sources  
1. Quantity of citizens taking part in Smoking Cessation programmes - data-smoking-
cessation-database-2015-16 
2. Population size data sourced from GP Practice lists quantities 




7.3.3.4 Cardiovascular Disease Management 
Table 1 in appendix 7 highlights the volumes of patients and some of the GP activities that 
align with payment incentives (QOF) and the related directives for intervention. AF (atrial 
fibrillation) is a common heart condition which is monitored due to a link with heart attacks 
and stroke. Heart Failure is one of the key areas for Cardiovascular Disease and is one of the 








As highlighted in table 1 in appendix 7, Heart Failure Patients are monitored and various 
interventions are encouraged with the GP. The open data available allows consideration of 
various analytics techniques to reflect on the distribution of patients across the GP Practices.  
By analysing the heart failure patient data sets one can explore how Lean thinking can be 
applied to long term conditions such as cardiovascular disease. Figure 7.3.7 data analysis 
highlights a number of novel approaches, not currently used on the data, to understanding the 
available long term condition open data.  
Pareto Analysis, shown in figure 7.3.7 is a statistical tool used to highlight if large volumes of 
activity are being taken up by a small number of actors. This is a general tool and not specific 
to healthcare.  This analysis reveals that that 210 (Total 351) of the GP surgeries make up 
80% of the Heart Failure patients while volume wise 281 GP  practices would be the 80% 
marker. While it is significant that a smaller number of GP practices (210) are absorbing a 
bigger volume of the heart failure patients it is not so significant that this would highlight a 
new approach.  
 





Analysing the data per GP practice in more details one finds that the open data records the 
number of patients with HF per 1000 patients in their practice. This data then allows us to 
provide a comparison across practices to identify outliers and look for patterns in the outliers. 
The x axis is a random ID for the practice and what the analysis highlights is that there is 5-
10 heart failure patients per GP surgery with a 7.27 average. Outliers exist beyond the 15 
patients per/1000 per practice and below 3. This can potentially be explained by geographic 
difference, age of the population in certain area and many other factors. Analysis of the 5 
highest outliers did not reveal a particular focus on a single area of Northern Ireland or a 
pattern to focus on high deprivation based on the GP practice address. This would not cause 
you to significantly adjust the approach. The distribution of heart failure patients is 
reasonable and although there are outliers these can be looked at on a case by case basis, the 
outliers do not collectively make up an exceptional volume level.  
 
What the data does however highlight is that if the GP practice is dealing with on average just 
over 7 HF patients and each practice may have a number of GP’s then the volume of patients 
is a low number as a percentage of their overall workload. This may lead to difficulties in 
ensuring the GP is up to date in latest good practice and interventions. Research question 3 
focuses on how health technology can assist a GP in delivering high value care to a small 







Figure 7.3.8 – Heart Failure Per 1000 patients: Distribution Comparison  
7.3.3.5 Additional Public Health Measures  
Beyond these key measures linked to the GP, the public health authorities also provide data 
on strategic prevention target areas including the following;  
 Alcohol statistics 
 Drugs statistics 
 Physical activity statistics 
 Obesity and Diet  
 Tobacco statistics 
The data and statistics in these areas becomes significantly lighter as they represent a sample 
of 3915 people. While the statistics are proportionate to the population they are still less than 
a quarter of 1% of the population.  
The thesis does not attempt to draw out all of the healthcare messages of the survey but 
highlight areas that have relevance to the research questions a number of key areas emerge 





- Respondents in high deprivation areas eat more chips, processed meat, snacks, sweets/ 
chocolate, sugary/fizzy drinks, and less fruit and vegetables.  
- The proportion of the population who are obese or overweight is highest in the 55-64 
age categories, with 74%, with it slightly dropping after this age. The 55+ age group 
has the highest levels of heart failure with approximately 2/3 being overweight or 
obese.  
- Most deprived areas have 3% higher overweight/obese population than least deprived.  
- Smoking prevalence is 23% higher in high deprivation areas than least deprived areas.  
- Most deprived areas more than twice as likely to use e-cigarettes 3% v 8%.  







 Figure 7.3.9 – Public Health Authority Data (Department of Health, 2016) 
In summary and considering the research question one about how Lean can be adapted for 
Long Term Conditions, analysis has led to the following key areas:  
 Public health measures highlight the wide variation in adherence to health prevention 
activities including smoking, diet and obesity.  
 Public health interventions are not significantly impacting certain groups in a 
population and in particular high deprivation areas.  
 Behaviours known to impact poor long term health are known to be substantially 
worse in high deprivation areas.  
 Use of E-cigarettes higher in high deprivation areas and are known to reduce tobacco 
harm, yet are not promoted by public health.  
If Lean value is defined at the patient level then the factors around a lack of adherence, 
response and success from prevention activities must be addressed at the intervention level. 
Technology may have a role in identifying waste and personalising interventions which is 
relevant to research question 2. This could assist in redefining value which is relevant to 





7.3.4 What is Not Measured  
What is not measure but creates value for the patient is an important consideration. Firstly, 
the long term success of public health interventions is a key gap as although a patient may 
give up smoking, eat better food and exercise there is limited evidence to link health proxy 
measures with outcomes.  
Impact of Changing Public Health Policies - There is evidence of changing measurements 
within the GP QOF data so that even within the 5 years longitude data the measures had 
changed and year on year comparisons were not always possible. This did not necessarily 
reflect solving a particular issue and moving on to a more important issues but could be 
perceived as issues of measures being changed for PR purposes and failing to focus on 
patient value. An example of this was the obesity measures which were rising before being 
scrapped.  
Changes in Intervention Activities - Similarly the data presentation can sometimes mask 
changes which are important. The evidence above shows that the % of smokers setting quit 
dates is declining rapidly over the 5 years yet the information in the PHA document 
highlights the success rate of the few that are stopping smoking. The smaller number of 
interventions within a growing populations is masked in the data potentially for political or 
performance management purposes. Similarly poor evidence of impact in areas of social 
deprivation are masked by averages.   
Physiological Interventions – While there is evidence of the negative outcomes of mental 
health issues such as depressions, anxiety and loneliness there is very little data available to 







Figure 7.3.10 – Summary of Data Gaps in Prevention, Primary Care, Community Care 
and Personal Care 
7.3.5 Lean Wastes/ Lean Non Value-Add Activities 
This section explores the previously defined Lean waste activities in healthcare identified 
from the literature review in Chapter 3.  There is limited academic coverage of prevention in 
Lean healthcare or the management of long term conditions which makes this section 
relevant to exploring how Lean could be applied to long term conditions. The quantitative 
data illustrated in 7.3.3 shows that this is an area of potential relevance when considering the 
thesis research question two about “can health technology assist in identifying and addressing 
Lean non-value add activities”. The NHS Five Year Forward Strategic Document, (Stevens, 
2014) makes a significant point on the cost of not implementing successful prevention 
strategies as he highlights  
 
“it makes little sense that the NHS is now spending more on bariatric surgery for 
obesity than on a national roll-out of intensive lifestyle intervention programmes that  






The Lean wastes below have been identified as being relevant to prevention and primary care 
in cardiovascular disease patients. These will be relevant in understanding future Lean 
healthcare models. 
Table 7.3.3 – Literature Review Lean Waste Categories Aligned with Cardiovascular 
Disease: Prevention and Primary Care Focus   
Healthcare Failure 
Area Identified in 
Chapter 3  
Evidence in Cardiology  
Waiting times   Delays awaiting GP appointments 
 Evidence of long delays awaiting referral to outpatients and 
diagnostics providers result (Data in section 7.4) 
Delays  Waiting time associated to referrals is addressed in later section 7.4 
(diagnostics) and 7.5 (Hospital Based Care).  
Medical Complexity  Increasing evidence of comorbidity appearing in qualitative 
discussions. Specifically the understanding that clinical 
advancement is helping people live longer but this leads then to 
managing multiple conditions into older age. Requirement for 
ability to manage decision support.  
Additional 
Healthcare Visits  
 Additional visits, appointments, procedures and 
interventions as the service provider is measured based on 
provision of activity (emerged in Northern Trust focus 
group).  
 Patient groups can receive activities which do not add value 
to them as individuals - medicines for example improve 
patient groups, not individuals.  
Co-ordination of 
Healthcare resources  
 Managing multiple different healthcare groups around a 







 GP appointment times are short and overloaded leaving 
room for error and omissions. People with dementia find the 
rush of short visits particularly distressing 
Repeated 
Procedures  
 Lack of information in the GP surgery may result in 
duplicate diagnostic tests and overlapping medication 
(emerged in medicines qualitative analysis).  
Cost  Less relevant as care in community deemed to be more cost 
effective.  
Quality   Incorrect advice – for example on omega 3 fatty acid.  
 Maintaining current best practice an issue for clinical 
guidance of General Practitioner. Inappropriate referrals to 
hospital as locums or less experienced doctors avoiding 
decisions (emerged in cardiology qualitative analysis). 
Death  Death on waiting lists not measured  
Infections   
Emerging from this 
research and not 
covered in Lean 
Healthcare 
Literature 
 PHA messages with minimal impact or evidence of 
outcomes. – Salt, obesity, exercise.  
 Cardiac rehab in the community. Best practice but not 
standard availability across country. 
 Emerging evidence that genetics may result in some advice 
having limited or low impact on risks such as blood 
pressure. 
 Reference in the NICE guidelines to provide wider package 
of support which is personalised and builds on what the 
client can do.  
 Service provision fails to address individual value as patient 
may want to trade-off longevity or symptoms against 
quality of life aspirations. E.g. tolerate pain but avoid side-
effects of medications which prevent family engagement. 





 Limited use of technology to complement service delivery 
 The impacts of loneliness on health and wellbeing are well 
documented as leading to worse health outcomes therefore 
can be a false economy (emerged in Northern Trust 
qualitative analysis).  
 Overfitting of big data (google flu surveillance)  
 Due to the drive for cost cutting any innovation has focused 
on either proof of service delivery or reducing costs and no 
focus on continuous improvement,  
 Limited use of real time data in community to inform the 
care needs (emerged in Northern Trust qualitative analysis).  
 Examples of technology have struggled to define route to 
adoption  
 
7.3.6 Discussion on the Prevention, Community and Personal Health Analysis  
In summary, this section has continued to explore healthcare with a Lean thinking perspective 
in line with the title of the thesis. The limited evidence of Lean literature in primary care or 
prevention published papers is in contrast to a search for patient value. Ultimately patient 
value will be at its highest when avoiding healthcare interventions or avoiding more complex 
interventions requiring surgery. The analysis highlights areas for considering how Lean can 
be adapted to long term conditions and specifically cardiovascular disease. A number of 
technology related issues have emerged which are relevant to research question 2 however 
this will be covered in section 7.8. Section 8 will discuss research question 3 in more details 
in regard to data related to technology redefining patient value. The below points highlight 
the main discoveries in this section with a focus on the research question 1 from the thesis.  
 





1. Prevention of health conditions is absent from Lean interventions in healthcare 
despite many of the conditions being avoidable.  
2. Specific known issues are evident in practice that will make a difference including 
physical inactivity, unhealthy diets, harmful use of alcohol and tobacco. 
3. Specific patient groups (high deprivation areas) face a higher disease risk which is 
referred to as health inequalities.  
4. Specific patient groups will perform less well in the known issues of health 
prevention. 
These prevention issues can clearly be applied to new Lean models, however further analysis 
is needed into the specific interventions which would address the Lean wastes.  Additional 
specific issues around personalisation of care may be identified and address through 
technology. Finally, analysis of prevention and primary care in cardiovascular disease 
patients provides an opportunity to consider the aim of the thesis and opportunities for reform 
and improved healthcare technology. Prevention in particular is largely missing from Lean 







The previous section of the thesis analysed data and evidence from cardiovascular disease 
patients in relation to prevention, primary care, community care and personal health. This 
contributed to the aim of the thesis for analysing the role of Lean thinking application to 
integrated healthcare patient pathways. In figure 7.2.1 and duplicated in figure 7.4.1 below 
one can see diagnostic procedures are the next set of activities within the patient value chain.  
The diagnostic procedure interventions have a series of activities and outcomes which are a 
key element related to the patient pathway. As the aim of the thesis includes understanding 
the integrated healthcare pathway it is appropriate to review activities in this area. To 
continue addressing the research question of how Lean can be adapted for long term 
conditions this section will review diagnostic activity and identifying Lean wastes within this. 
It will continue to use cardiovascular disease as an example of a long term condition to 







Figure 7.4.1 – Cardiovascular Disease Data Set – Focus on Diagnostics  
7.4.1.1 Definition of Diagnostics 
To assist in understanding the impact of diagnostic activity on the research question it is 
important to initially define diagnostics within the context of cardiovascular disease.  
The term diagnostic is described in layman’s term in the British Heart Foundation 
communication as “Tests” in their booklet of the same name (British Heart Foundation, 
2017). As a further explanation of  what diagnostics is, the Northern Ireland waiting times 
statistics publications provides the following definition “A diagnostic  service provides  an  
examination,  test, or  procedure  used  to  identify  a  person’s disease  or  condition  and  






The types of diagnostics include tests such as those related to bloods, urine, saliva, bodily 
fluids, and electrical measures from the heart, and images of parts of the body or bodily 
temperature. The type and purpose of the test will influence where the test could be 
conducted. The NHS UK Website (NHS, 2017) lists the following types of tests as commonly 
used for cardiovascular disease; 
 Electrocardiogram (ECG) 
 Exercise stress tests 
 X-rays 
 Echocardiogram 
 Blood tests 
 Coronary angiography  
 Radionuclide tests 
 Magnetic resonance imaging (MRI) scans  
 Computerised tomography (CT) scans 
 
Change is evident in the type of tests used and the scientific advancements reflect a changing 
landscape of tests. There is long history of using blood biomarkers in diagnostics going back 
to the 1950 although the specific biomarkers used has changed as scientific evidence 
continues to develop (Gaze, 2016). From an operational management and Lean perspective, 
the type of test and the markers used will have quality impacts on decision making and 






7.4.1.2 The Role of Diagnostics 
To further understand the implication of diagnostics on the research question it is important 
to understand its purpose or reason within the context of cardiovascular disease. Diagnostic 
purpose can be varied with common uses including the assessment of clinical risk for a 
patient, monitoring disease progression, assessing the cause of presenting symptoms in a GP 
surgery, assessment of symptoms that have led to the patient presenting at the emergency 
room or therapy monitoring. In each of the cases the purpose is to provide quantifiable data 
gathered from the patient which can be compared against known clinical thresholds. The 
diagnostic output data can be used to investigate or confirm prognosis and in the example of 
heart failure, the uses echocardiogram is used as a method of confirming that a patient has 
heart failure in line with the commissioner’s guidance definitions. Various other functional 
measures within the diagnosis will also be used to indicate patients who need specific 
therapies from their GP. Diagnostics relies on quantifiable information rather than a patient 
opinion but can be used in conjunction to a patients reported symptoms. Diagnostic test are 
used with caution and clinical judgement as a test result may be explained by a number of 
factors which may or may not reflect the original assumed condition. The purpose of a 
diagnostic test is explored later in the chapter. From an operational management and Lean 
perspective the purpose of the test will influence the value of the test and the impact of non-
value activities or waste activities will vary. For example a delay of 10 minutes may be a life 
or death issue in one purpose or of limited significance in another. 
7.4.1.3 Diagnostic Future Development  
To understand the diagnostic implication on the research one must also reflect on the 
emerging solutions to ensure that new innovations which are in the cusp of deployment does 
not immediately make any findings redundant or alternatively provide data which enhances 





faster, with more accuracy and move towards a personalised healthcare that recognises the 
specific needs of an individual. The tailoring of medicines, interventions and therapies is an 
emerging theme in care delivery and diagnostics can contribute to achieving this. This need 
to improve diagnostics was underlined in the qualitative analysis with the Cardiology focus 
group as they were in the process of upgrading the cardiology imaging during the later stages 
of the thesis development.  
7.4.1.4 Diagnostics in This Thesis 
With the definition, purpose, types and future direction explained, the remainder of section 
7.4 will reflect the common approach of 7.2 and 7.3 of analysing;  
 Current diagnostic interventions in academic and grey papers with qualitative analysis 
 Current measures and data within the Northern Ireland healthcare system 
 What is not measured  
 Diagnostic activities against the Lean non-value add activities identified in academic 
literature in chapters 1-7. 
From this analysis the thesis can then contribute to answering the research questions of how 
Lean can be adapted for long term conditions (research question 1) and contribute to 
identifying methods for health technology to address Lean non-value add activities (research 
question 2). The analysis will also build insight into addressing where health technology can 
assist in redefining patient value which reflects research question 3.  
7.4.2 Analysis of Current Diagnostics Interventions Globally in Papers and Grey 
Materials  
As research question one focuses on understanding the Lean non-value add activities it is 
important to investigate how diagnostics operate and specifically the drivers that will dictate 





best practice guidance provide significant insight on the activities and challenges that are 
known in the current working practice. The qualitative analysis and in particular the work 
with the cardiology focus group also provide insight on the use and value of diagnostics. To 
address the research questions the diagnostic section will require analysis for Lean related 
issues and cardiovascular patient outcomes. The key points when analysing diagnostics are;  
 The purpose of the diagnostic tests  
 Waiting for diagnostics  
 Location of the diagnostic blood draw, test and analysis 
 Comparing laboratory versus point of care testing 
7.4.2.1 Purpose of the Diagnostic Tests  
Diagnostics covers a wide variety of purposes and patient value will vary depending on the 
purpose Gaze (2016). From this insight one can derive the impact of potential Lean wastes 
encountered. In cardiovascular disease there is a long history of using diagnostics at various 
stages of assessment, intervention and treatment. In current practice biomarkers, vital sign 
and exercise tests are used at many stages of managing the patient. Increasingly there is 
pressure to expand diagnostics to prevention and early intervention (World Health 
Organization, 2017). 
 
Monitoring and identifying the risk of cardiovascular disease to a patient in the early stages 
of engagement is a key purpose of diagnostics. The identification of risk is a measure which 
is highlighted in section 7.3. to reflect the desire to intervene earlier and prevent non-
communicable disease.  A number of risk factors, tests can be used for risk prediction such as 
assessing plaque formation in blood vessels. This can be determined through cholesterol 






Diagnosing the condition in an emergency department is a second purpose of diagnostics as 
patients presenting at a hospital emergency may need fast diagnostics tests to determine if a 
heart attack has occurred or if it is less serious such as heartburn. Qualitative analysis with 
the cardiology group revealed the complexity of these decisions as biomarkers or ECG tests 
in themselves do not always provide a definite position. An accurate diagnosis will lead to 
fast decisions about blood thinning medications and potential surgery to limit the immediate 
damage to the body, limit the long term damage and protect life or alternatively dismiss the 
patient as having an insignificant temporary discomfort. Gaze (2016) highlights that 2-7% of 
patients are inappropriately discharged and large percentages of patients will present at 
hospital with chest pains which don’t require urgent treatment therefore there can be waste in 
admitting a patient who didn’t need treatment. Lean waste can therefore be a Lean quality 
failure or admitting a patient that doesn’t need admitted which is Lean over-processing. 
These decisions to admit or not can be complicated by heart arrhythmias which are infrequent 
and blood bio markers that may take a number of hours to present.  
 
Therapy decisions are a third purpose of diagnostics which will determine the appropriate 
medicine or treatment. Diagnostics can inform primary therapy and the likely impact of a 
therapy.  This can allow patient value to be identified and provided earlier. For those being 
discharged from hospital or living with cardiovascular disease as a chronic condition, 
measuring the effectiveness of interventions and disease progression is important. This is to 
assess if any necessary changes to therapy or intervention are required and to assess the 
effectiveness of the current medication. For example, heart failure is a common and growing 
cardiovascular disease condition and reflects the heart not functioning correctly and will be 
monitored both for the disease progression and the impact of medication to reduce 





effects such as kidney damage or bleeding which also needs to be monitored with diagnostic 
tests.  
Table 7.4.1 – Diagnostic Purposes and Lean Implications  
Purpose of Diagnostic  Lean Value Implication  
Monitoring Risk   The results are less time sensitive and have a lower quality 
threshold for patient value.  
 Transportation waste likely to be higher due to distance 
from surgery to lab (emerged in Northern Trust 
Qualitative analysis).  
 Overhead of managing delay experienced by most 
organisations.  
 Uncertainty of the turn-around-time will create additional 
workload for surgery.  
Acute presentation – 
Presenting at hospital 
or in ambulance with 
problem symptoms.  
 Identification of critical and non- critical symptoms 
requires faster diagnostics to reduce damage and mortality 
(emerged in cardiology qualitative analysis).  
 Fast/accurate diagnostics required discharge of patient 
who needs intervention. Rule out diagnostics. (emerged in 
cardiology qualitative analysis).    
 High patient and financial cost of inaccuracy in diagnostic 
test.  
 The patient’s vital signs, symptoms and biomarkers may 
change during the period after a cardiovascular incident 
therefore a diagnostic test may have functioned accurately 
but not diagnose accurately. (emerged in cardiology 
qualitative analysis).    
Deciding Therapy    Diagnostics can inform primary therapy and the likely impact 
of a therapy.   This can allow patient value to be identified and 
provided earlier (emerged in cardiology qualitative analysis).    
 Evidence of known clinical issues related to medications not 
addressed. For example drug resistance is not understood at 





qualitative analysis).     
Monitoring Therapy   Diagnostics can inform dosage issue and the titration of 
medication. The length of time to get the titration right is a 
known waste however getting this wrong is also a waste.  
(emerged in cardiology qualitative analysis).    
 Diagnostics can identify negative or toxic side effects such as 
kidney failure due to cardiovascular disease medication 
(emerged in cardiology qualitative analysis).   
 
In summary, one can see that the purpose of a diagnostic test will have an impact on Lean 
patient value and more specifically will have an impact on the level of waste associated to not 
fulfilling that value. A diagnostic test delayed by one day in a GP surgery compared to a one 
day in an emergency room is significantly different therefore in quantifying waste in the 
delays for cardiovascular disease diagnostics it is important to separate these costs by more 
than time.  
7.4.2.2 Waiting for Diagnostics   
The primary waste evident in diagnostics is the classic Lean waste of waiting. The wastes 
evident however are broken down into waiting time for a diagnostic, Turnaround Time (TAT) 
for a diagnostic result and reporting time (Department of Health, 2017. These wastes are 
evident and recorded on the department of health statistics.  
 
The Lean issue however is that many of the measures do not capture the wait from the 
patient’s perspective but from the provider’s perspective. The definitions of the waits are 
documented as; 
 “the waiting time for a diagnostic service commences on the date on which the 





date  on  which  the  test  is performed.” (Department of Health, Diagnostics Waiting 
Time, 2016, Pg. 13) 
 
In this definition the patient will have been referred from a GP or other clinician yet the 
waiting time is not captured until the referral arrives with the diagnostic provider. 
Additionally the definition stops when the test is completed, yet the interpretation of the test 
and communication with the referring GP may take additional time. In summary the wait is a 
provider waiting time and does not reflect patient value. In carrying this thinking across to a 
Lean value stream map, a more complete measure would involve all activities and waits from 
the patient’s perspective. Figure 7.4.2 illustrates the difference between the patient view of 
value and the clinician’s view of value which has been the focus of Lean healthcare literature.  
 





In qualitative discussions with healthcare experts to understand the reason behind the 
reporting time there was a practice of batching cases which is counter to the concept of flow 
in Lean. The report writing can also be delayed due to the availability of resources with 
common issues such as busy ward rounds, sickness, holidays, and clinicians travelling to 
conferences being potential reasons for delays mentioned. The underlying discussion 
however links back to the system measures being the main focus rather than a patient view of 
time.   
 
Related to the issues of waiting times which don’t match patient value is the area of waiting 
times targets. The data to be discussed in section 7.4.2 will have been collected with specific 
targets and measures. There is consistent reference to performance measures which reflect 
ministerial targets such as  
 
“By March 2017, 75% of patients should wait no longer than 9 weeks for a diagnostic 
test, with no patient waiting longer than 26 weeks”. 
 
“From April 2016, all urgent diagnostic tests should be reported on within two days of 
the test being undertaken.” 
 (Department of Health, Diagnostics Waiting Time, 2016, Pg. 13) 
 
These targets have a number of issues which would be in conflict with Lean patient value.  
Firstly, the target of 9 weeks will not reflect patient value yet be seen as achieving success if 
met. Secondly the target assumes a further failure for 25% of the patients beyond the 9 
weeks, therefore even within the flawed 9 week target; 1 in 4 people will receive a 





patients waiting for echocardiography in Northern Ireland there are over 10K patients waiting 
which means that over 2500 patients will receive substandard performance even within a 
non-patient value measure of 9 weeks. The implication of this for management is that a 
service can fail so many patients and still be deemed to be successful. Thirdly, a system 
which target a turnaround time of 2 days is not working on any concept of Lean continuous 
flow as this will mean that they are batch processing the diagnostic tests. This is generally 
known to attract errors and waste.  
 
Table 7.4.2 – Understanding the Value Stream Activities and Waste 




Waiting time to see the referring GP     
Activity time of seeing the GP   
Activity time of writing referral    
Transportation of Referral (increasingly moving towards electronic 
referral but not universally) 
  
Waiting time to get test administered    
Activity time of processing the referral to the health providers system   
Activity time of triaging or prioritising referrals    
Activity time of completing the test    
Waiting time for the analysis and results of the test    
Activity time for the analysis and for the report to be written   
Waiting time for the report to be received by referring time    
Waiting time for appointment for the patient-GP discussion on therapy 
or referral  
  
Activity time for patient-GP discussion on therapy or referral   






The delays are not without health outcome cost as unlike a piece of equipment waiting for the 
next activity within a production line a patient’s condition may be deteriorating therefore 
waiting can lead to an exacerbation of a condition or result in an unplanned admission to 
hospital or death. In both cases there is a health outcome cost and a financial cost.  
7.4.2.3 Location of the Diagnostic Blood Draw, Test and Analysis  
In the above example the patient was in the GP and the test was at a separate clinical 
institution. This is not the case in all diagnostics and three factors have to be considered in 
understanding diagnostics for cardiovascular disease prior to making any assessment of how 
health technology can address Lean non-value add activities in line with the research 
questions. The three factors are; 
 Location of the diagnostic blood/fluid draw 
 Location of the test and  
 Location of the analysis 
The blood draw applies only to diagnostic tests requiring a urine or blood sample as this can 
be provided at a different location from where the test is completed. In cases of electronic or 
imaging tests these are completed at the same location. Understanding this is needed as the 
separate activities and the gap between them is of interest in a Lean value stream review.  
 
Table 7.4.3 highlights the key considerations and implication on Lean being adapted for Long 
term conditions, identifying Lean Non-Value add activities and opportunities to redefine 






Table 7.4.3 – Redefining Patient Value in Diagnostics  
Diagnostic 
Component   




 Home Based  
 GP  
 Community  
 Pre-Hospital/Ambulance 
 Emergency Department  
 Outpatient  
 Inpatient  
 
 Transportation waste to laboratory.  
 Evidence of Lean waste of errors 
and defects as samples sent in 
inappropriate containers from GP. 
Errors revealed in discussions. 
(Qualitative Interviews  - 
Medicine Focus Group) 
 Examples of where standard 
operating procedures state that 
sample is not to be sent for 
patients with certain existing 
conditions but these are still sent.  
Non-value based demand. Errors 
revealed in discussions. 
(Qualitative Interviews  - 
Medicine Focus Group) 
Location of 
the Test 
 Point of Care Testing  
such as in the community 
by the nurse, home based 
by the patient, in the GP 
surgery, bedside testing 
by the clinician or in the 
physician’s office,  
 Pre-hospital/ambulance 
 Lab in Emergency 
Department  
 Central Lab  
 
 Diagnostic good practice seen as 
high volumes machines with batch 
processing. This may be in conflict 
with general Lean best practice 
approaches.   
 Limited use point of care testing 
with the gold standard of testing 
still being seen as the lab. 
(Qualitative Interviews  - Northern 
Trust Focus Group) 
 Potential for over processing of 
diagnostics as decisions to treat or 
not treat may not require full 





diagnostic tests with lesser 
thresholds may be sufficient with 
local simple testing with lower 
quantification thresholds.  
Location of 
the Analysis  
 Immediate POC 
feedback  
 Report writing by expert 
 Validation and Quality 
checking -  
 Obtaining the results   
 
 Point of care testing both in small 
machines and lateral flow test may 
provide some alternatives to a 
need for written test results 
(Qualitative Interviews  - Northern 
Trust Focus Group) 
 Academic evidence of decision 
bias by clinicians when 
interpreting ECG results after they 
find something early that makes 
sense.  
 Machine learning Technology 
available to reduce the need for 
clinical analysis.  
  Evidence of lean value streams 
with long delay wastes between 
the diagnostic test and the 
reporting.  
 Potential for over-processing of 
analysis. 
 Analysis relies on standard 
approaches and reading of visual 
clues which can be open to human 
error even with experienced 
clinicians. Examples of clinician 






In summary, the analysis highlights a key issue of the separation between blood draw, test 
and analysis as being factors which will influence the quantity of lean waste and the value of 
improving turn-around times.  
7.4.2.4 Comparing Laboratory versus Point of Care Testing  
The analysis reveals a movement toward point-of-care diagnostics which is diagnostics at the 
side of the patient instead of in a lab. In some cases this will be a small machine or device 
which can be used to analyse blood, electronic signals from the body. In other cases it may be 
dip tests where a fluid of the body reacts to reveal a diagnostic decision. Commonly seen 
examples include pregnancy tests, diabetes blood tests, heart rate monitors, blood pressure 
cuffs, temperature measures and blood oxygen tests.  
 
Logically from a Lean perspective moving diagnostics closer to the patient has a potential to 
remove waste. It is not straightforward and introduction of this is not without challenge. 
Table 7.4.4 highlights the pros and cons of this type of diagnostics and reflects qualitative 
analysis with the Northern Trust focus group and cardiology focus group.  
 
Table 7.4.4 – Comparing Point of Care Test Advantages and Disadvantages  
Positives of Point of Care Testing  Negative of Point of Care Testing 
 Simple analytic handling  
 Faster results  
 Reduce pathology access barrier  
 More frequent tests for building 
longitudinal profile of the patients 
 Lack of Benefit - UK study of 1728 ED 
patients found that changes in patient 
management came 74 minutes earlier 
 Workload in community  
 Standard Operating and Error rate 
can be more difficult to control 
 Incompatibility of different tests and 
devices 
 Cost  
 Storage of results  





however it did not impact the clinical 
outcome of the length of stay in ED. 
(Kendall J – point of care testing: 
randomised controlled trial of clinical 
outcomes - 1998) 
 Cardiac markers - 263 patients with 
chest pain – Collinson et al – lower 
length of stay in emergency department 
and in hospital.  
 POCT lateral flow test and similar can 
be cheap.   
 
 More Hardware required per test  
 Maintenance and control of testing 
devices can be an issues  
 Single assay cartridge used with 
dedicated equipment  
 Low volume of tests completed per 
staff member 
 Lab machine can complete high 
throughput analysers with large 
volumes of tests and low TAT 
which make the use case in a 
hospital more difficult due to the 
efficiency of the alternative.  
 POCT quantification is an issue with 
the quantification of biomarkers 
may not be available.  
 
In analysing the mix of views on the use of point of care testing we find an ever growing 
number of devices will make point of care testing more available in the future. Quality and 
control however remain a large issue and the business case of moving the role of diagnostic 
tester to the front line roles has not been resolved yet as this will have an activity cost.  
 
Not largely covered above is the emerging collection of wearable devices on the market that 
allow quantification of the electrical signal from the body in terms of heart related signals. At 
the time of writing there was a lot of evidence of sporting and hobby interest in vital signs 
measures but largely this has not yet crossed over into clinical relevance yet. This is a 
changing space and many of the gadgets on the consumer space are attracting the attention of 
the FDA who has avoided regulation of the area as the majority were used for recreational 





device clinically relevant and create a differentiator or barrier from competition. An example 
of this is the American based company AliveCor which provide medical grade monitors 
which communicate with the mobile phone and provide ECG data (AliveCor, 2017). It has 
then targeted specific clinical conditions such as atrial fibrillation which can lead to strokes. 
Mobile clinical grade equipment will be part of the future offerings but the quality and 
consistency of the information is still questionable in most cases and largely not accepted by 
healthcare professionals. Qualitative analysis with the cardiology focus group revealed the 
clinicians were dismissive of hobby grade wearable heart rate monitors and point to grey 
literature studies than show comparison between various device highlight the large variance 
in measures however there was a number of products emerging that they found interesting 
and were exploring due to the speed and mobility of the devices.   
7.4.2.5 Summary  
In reviewing the delivery or cardiovascular disease related treatment in the grey and 
academic publications in the area of diagnostics one can see a number of areas where Lean 
and technology can be used to adjust care delivery. Diagnostics is an area that has been 
covered in Lean healthcare reform work (Dyas et al., 2015) but largely it has been in isolation 
from the complete patient pathway and often within the boundaries of the current measures 
for a specific provider. The Lean pathways frequently explored methods to accelerate the 
current processes rather than consider value from a patient’s perspective. What is revealed 
above is that the overlaps between the organisational silos can often reveal Lean patient 
wastes which are not addressed such as the time taken to complete the diagnostic from 
referral until receiving the analysed results.  
 
Thesis question 1 asks the question about “How Can Lean be Adapted for Long Term 





room can be difficult to diagnose (Gaze, 2016) for this reason diagnostics does not naturally 
fit within a sequential Lean flow as diagnosing is essentially fault finding rather than building 
through a series of steps. Errors in fault finding can lead to fatal consequences or increase the 
medical complexity for a patient with an undiagnosed condition. 
 
The analysis of diagnostics does however reveal elements where Lean can contribute to long 
term condition patients. The waiting times and series of measures have been divided up in a 
manner that does not reflect patient value but reflects organisation silos as the measurements 
start with the organisation and not the patient. In addition the performance targets do not 
reflect patent value (9 weeks) therefore there is no incentive towards improvement. 
Additionally the measures reward the providers when they have failed 25% of the patients 
which again has no basis for a Lean patient value centred organisation. These areas have an 
opportunity to rethink how Lean can be applied to long term conditions.  
 
More traditional Lean wastes in healthcare are also represented in waiting for a test to be 
started, waiting for the test to be reported on and the turn-around time of a lab test. These lead 
to wastes of waiting and effort managing waits, answering patient queries and administering a 
waiting system in surgeries. The batching of tests and reports are evident in the processes 
through the sending, administering and reporting of diagnostics which challenge Lean flow. 
Uneven resourcing of tests were also revealed in qualitative interviews as the transportation 
to the labs from the GP is available Monday to Friday therefore tests required over the 
weekend can often result in an unnecessary A&E visit or longer wait.  
 
Diagnostics can however result in Lean value delivery as the diagnostics of blood and vital 





appropriate interventions and therapies provided at the right time and in the right quantity. In 
research question 2 the question asks if health technology can assist in identifying and 
addressing Lean non-value add activities. One can see that technology is already emerging in 
use for risk scoring systems, decision supports and automated ECG interpretations to attempt 
to assist in managing the complexity presented and the tools aim to reduce the risk of 
inappropriate discharge as part of a clinical assessment.  
 
 






7.4.3 Analysis of Current Measures and Data within the System  
This section will present the quantitative data from diagnostics for cardiovascular disease.  
This relates to big data open source information from the 5 Northern Ireland Health and 
Social Care Trusts. The diagnostic data is reported under two key methods with the first 
being activity levels focused and the second being waiting times. For the purposes of this 
thesis the quantitative analysis has focused on the waiting times data due to the link with 
Lean waste and often the volumes of waiting tests provides a summary of the overall activity 
demand levels. The waiting times adhere to various rules and procedures around the counting 
of waits. This thesis will not dwell on these rules as they have a limited contribution towards 
understand Lean value from a patient point of view and reflect hospital administration 
procedures. Waiting is one of the seven classic wastes in Lean although the “seven wastes 
were originally for manufacturing. However, this also has application in many types of 
service” (Bicheno and Holweg, 2016, Pg. 21).  
 
A referral will be made to the specialist provider for a specific test to assist the clinicians in 
diagnosing the patient. Qualitative discussions with experts have revealed the terms “rule 
out” and “rule in” to indicate that a diagnostic test can be to confirm that the patient doesn’t 
need treated (rule out) or to confirm they do need treated (rule in).  A patient who has been 
referred for a diagnostic test will be recorded within the Health Trusts ICT system and the 
health trust will be required to report on the numbers of patients waiting on a quarterly basis. 
Diagnostic waits data from all the hospital trusts will be available and presented in the 







Figure 7.4.4 – Example of a Diagnostic Waiting Time Report Data 
The quantitative data analysis big data sets have been created from this reported information 
across all of the health trusts over a 5 year period. Qualitative interviews have revealed 
limitations within the data as a patients will appear on more than one quarterly report for the 
same test if their wait is for longer than a quarter of a year therefore there is no ability to 
calculate the demand across the whole year with this data. Secondly a small number of 
patients will be referred and the diagnostic test will be completed before entering a waiting 
list therefore their activity will not be visible. Finally the emergency procedures can have an 
impact on data as emergency slots can be taken and have an impact on available resources for 
waiting patients.   
 
The quantitative data for diagnostics is substantial and beyond the scope of this thesis to 
analyse all of this. The following diagnostic tests have been selected due to their relevance to 
cardiovascular disease as outlined at the beginning of section 7.4. This reflects the NHS UK 
cardiovascular diagnostics commonly used for cardiovascular disease (NHS, 2017).  
 Ambulatory ECG monitoring (24 hr holter) 
 Cardiology - echocardiography 
 Cardiology - perfusion studies 
 Cardio-respiratory exercise testing 
 Computerised Tomography 

















ECHOCARDIOGRAPHY 260548 206677 28152 12043 4799 3751 5126 
CARDIOLOGY - 
PERFUSION STUDIES 12518 3687 4919 2554 1002 319 37 
(blank) 
       






 Exercise tolerance testing 
 Magnetic Resonance Imaging 
 Plain Film X-rays 
The diagnostic waiting times data brings together approximately 17000 data points over the 5 
years with a correlation to cardiovascular related diagnostics. This was filtered from 97755 
data points from all diagnostics recorded back to 2008. One constraint is that the open source 
data does not highlight a diagnostic tests purpose therefore a test may be of relevance to a 
number of conditions such as a cardiovascular disease and respiratory illness. In the case of a 
plain file x-ray, a multitude of illnesses and injuries will use a similar diagnostics test with 







7.4.3.1  Cardiovascular Disease Diagnostic Waiting Time  
 
For the purposes of the thesis it was important to analyse the volumes of waiting days and 
shifts across the longitudinal data. Moving to a point where it would be possible to quantify 
the waste being created. In the below diagram the data has been used to calculate the waiting 
time for cardiovascular disease relevant diagnostic tests as a total waiting days for the patient 
cohort in the system. By doing this we begin to build an understanding of “cost” of waiting 
on the patients. In addition by doing this we allow comparisons across the time period which 
is not possible when just looking at the particular category of wait they are in.  
 
Figure 7.4.5 Graph – Number of Patient Days Waiting for a Cardio Vascular Related 
Tests (Y axis reflects patient wait days) 
This data analysis is calculated by multiplying the current volume of referrals in the system 
that are waiting on a diagnostic test by the mid-point in the waiting time category that they 
have been allocated to. For example 1043 people may be recorded as waiting 0-6 weeks 
therefore a calculation will use an estimate of 21 days as a mid-point and the actual number 
of people waiting to estimate that patients are waiting 21903. This calculation is then done for 






This has limitations as there is no way of understanding within the open data if the data 
points do average around the mid-point however it is a useful measure to compare across the 
time periods in a manner not currently used in the system. There was an expectation that 
presenting this material to the focus groups would attract criticism or defensiveness however 
this was not the case and the groups largely reflected that this was useful analysis and that the 
data visualisation reflected what they perceived to be the case but did not have data analysis 
available to them to reflect this.  
 
What the graph clearly recognises is that the number of waiting days in the system is 
growing. In Lean, waiting is a key waste which adds no value to a patient. This therefore is 
indicative of a growing waste in the system and movement away from patient value. In 
December the largest waiting days are; 
 1.3m patient days waiting for MRI’s  
 1.2m patient days waiting for Cardiology – echocardiography 
 0.5m patient days waiting for Computerised Tomography  
This data reflected the whole of Northern Ireland but the data is from 5 HSC trusts. To 
analyse more granular details it was important to consider comparisons across the service 







7.4.3.2 Comparisons across Healthcare Providers  
 
Figure 7.4.6 focuses on the Ambulatory ECG Holter Monitor test to allows a comparison 
across the 5 Health and Social Care Trusts.  
 
Figure 7.4.6 Graph – Number of Patient Days Waiting for Ambulatory ECG 
Monitoring (24Hr Holter) (Y axis reflects patient wait days) 
The rise in diagnostic waits can be indicative of a problem which has caused a spike in the 
number of waits or it can reflect a change in the overall system creating a spike in demand. 
For example a change in payments for the GP to incentivise the patients to take a holter 
monitor test or a change in clinical guidance from NICE can result in a spike in demand of a 
diagnostic test. The diagram also highlights that the vast majority of the patients waiting tests 
are with the Belfast Trust. Approximately 47% of all tests during the reporting period have 
been with Belfast.  
 
One can see is that there is opportunity to understand the wastes further by breaking down the 
content and use longitudinal data to understand the overall system drivers. There are however 
limitations to understanding the data and it is likely that Lean tools such as visual 





reporting gaps (Belfast December, 2016) that would have been missed without granular data 
therefore risks of data completion need to be highlighted.  
7.4.3.3 The Need for Contextual Awareness in Longitudinal Quantitative Data  
 
The diagnostic waits for Echocardiography, which is one of the largest volumes of Diagnostic 
tests specicially for Cardiovascular Disease related conditions, is available in figure 7.4.7.  
 
Figure 7.4.7 – Number of Patient Days Waiting for Echocardiography (Y axis reflects 
patient wait days) 
Belfast is a largest volume of the tests, but it is a lower percentage with approximately 38% 
of the test waits being in Belfast. Considering that the majority of patients live in Belfast this 
underrepresents the patient populations. Again reflecting a need for granular data and 
comparisons against the trusts own performance rather than another trusts. As the Belfast 
trust has a much higher throughput of patients it would be reasonable to claim that the patient 
value is higher there are less patient wait days evident.  
 
From the Lean healthcare perspecitive the issue to absorb if that blunt measures that don’t 
take into account the nuances of specific localities will miss critical factors related to 






7.4.3.4 Analysing Numbers of Patients  
 
The ECG length of wait in figure 7.4.8 reflects an alternative analysis method providing 
detail on the number of patients waiting for a defined period of time for and ECG diagnostic 
test. What is noticeable is the peak after the 9-13week period. While it is difficult at face 
value to note any reason for this it is known from publications discussed earlier in this section 
that there are 9 week targets for diagnostic tests. It would be reasonable to question if some of 
the drivers for addressing waiting times targets are therefore reactionary to 9 week 
performance targets rather than patient value. The system is effectively incentivising the HSC 
trust to put less priority into the 25% who would miss the target within their own 
performance target. The deductive logic then follows that there is a potential negative 




Figure 7.4.8 – Number of Patients Waiting for Echocardiography – HSC Trust 





The Lean potential revealed is that visual management tools may pay provide an ability to 
monitor system drivers that do not reflect patient value and adjust practice accordingly. Using 
the same data but analysing it slightly differently from a summation of the time buckets to a 
summation of the Health and Social care trust provider. One can see significant performance 
differences within trusts. The implications for Lean being standard work and lessons learned 
from one trust could be applied to other trusts. Within Lean, the scientific management 
principle is a key element with Plan-Do-Study-Act being reflecting a continuous learning 
approach which is a key element of improvement.  
 
 








7.4.4 What is Not Measured  
What is not measure but has impact on the patient value and the overall healthcare cost is the 
financial and health implications of a diagnostic wait. It is not clear in any of the open data or 
discussed in any of the reports of a method of measuring the impact of a diagnostic wait. The 
financial cost of a diagnostic wait is important as although the time for a weight is recorded, 
there is an underlying assumption that limited resources have resulted in a wait and the cost 
of a wait is neutral. This is not the case as a Diagnostic wait will result in other interventions 
and management overhead which include;  
 Additional GP visits  
 Administrative overhead of managing the waiting lists and communicating with the 
patient and GP.  
 Unplanned admission to hospital (selective measurement)  
 Additional wide spectrum medication awaiting the full diagnosis 
 Lack of patient productivity (perhaps missing work due to illness)   
 Patient comparisons of diagnostic tests to build up cases – most tests are single test 
which are capture at best on PDF.  
  
In addition to the financial cost of the diagnostic wait there is a potential for a cost of health 
outcomes. As a result of waiting for the diagnostic test and therefore beginning a targeted 






7.4.5 Lean Wastes / Lean Non-Value Add Activities 
Similar to the previous 2 sections (7.2 and 7.3) this section explores the Lean waste activities 
in healthcare identified from the literature review in Chapter 3 as a template of Lean wastes 
in healthcare and explores this application to Diagnostics for Cardiovascular Disease. The 
diagnostic related wastes below develop the response to the research questions linked to 
adapting Lean for Long Term Conditions, identifying non-value add activities and identifying 
where patient value is not delivered.  
Table 7.4.5 – Literature Review Lean Waste Categories Aligned with Cardiovascular 
Disease: Diagnostic Focus   
Healthcare Failure 
Area Identified in 
Chapter 3  
Evidence in Cardiology  
Waiting times   Waiting is a key waste in diagnostics with large number of 
patients waiting to complete a test or waiting for the 
results of the test to be written or communicated. 
(Emerged in quantitative data and qualitative analysis) 
 Evidence of growing volumes of waits for key diagnostics 
over the last 5 years. (Evident in quantitative data) 
 Performance targets appear to have a link to the waiting 
times which does not reflect patient value. Performance 
metrics appear to correlate with demand fluctuation and 
driving waiting lists.  
 High volumes of test impact on the turn-around time 
(TAT)     
Medical Complexity   Impact of delayed decisions is not clear as faster TAT in 
ED is not evidence of improved patient outcomes. Some 
studies showing improvement and some showing 
improved TAT but not outcomes such as reduced length of 
stay and no overall bed use. (the randomised assessment of 





(Goldacre, 2011)   
Additional Healthcare 
Visits  
 Multiple additional appointments being set up and 
resources to administer the wait by chasing up test results, 
healthcare activities to fill gap until full assessment, 
updating patients, answering progress questions from 
patients (Emerged in qualitative analysis – Northern Trust 
Focus group).  
Co-ordination of 
Healthcare resources  
 Linkage between effective community based diagnostic 
testing and hospital admission.  
Repeated Procedures  Limited IT systems can result in information on diagnostics 
completed not being shared which can lead to repeated diagnostic 
procedures. Use of shared ICT systems such as regional PACS 
systems (shared diagnostic information) and Electronic Health 
Record has been reported to reduce repeated procedures as 
clinician has access to previous test results (Emerged in 
qualitative analysis – Cardiology Focus group). 
Motion/Transport   Transport to the labs for blood and bodily fluid based tests 
are a common theme in consideration of diagnostic wastes 
(Emerged in qualitative analysis – medicines focus group). 
 Some use of Pneumatic delivery chutes in hospital.   
Length of Stay  Presence and absence of effective diagnostics are a key part of the 
length of stay in a hospital. For example effective diagnostics 
early may result in patient being discharged or effective early 
diagnostics may target treatment earlier therefore reducing the 
length of stay.  
Cost  Limited discussion in UK and NI based literature. (Brill, 2013) 
highlights perverse incentives in USA profit making hospitals to 
increase the number of diagnostic tests completed which increases 
cost to the patient/insurer.  
Quality   Test Failure – where the test results in a failed result. Can 
be picked up by a control line fail process which is built 
into the test.  





qualitative analysis – Cardiology focus group). 
 Value is likely to be most evident in combination of data 
analytics and diagnostics in a scientific analysis  
Emergency 
Admissions  
 Slow or poor diagnostics at emergency can result in waste 
in the system while effective diagnostics can accelerate the 
process.  
 Issue of ED vital signs monitoring not revealing heart 
attack reflects limitations which may be adjusted with 
longer term monitoring. 
Death   High radiation risk from many diagnostic tests.  
Medication errors   Test does not identify issue -  Heart Attack Issue 
(Emerged in company discussions)  
 High false positive can cause excessive demand and false 
negatives can result in missed conditions and health 
deterioration.  
Infections   Opportunities to detect Infection –  
o ECG look at heart valves  
o X-ray see if heart enlarged  
o CT/MRI – Has infection spread?  
Emerging from this 
research and not 
covered in Lean 
Healthcare Literature 
 Multidisciplinary Pathology – Where a lab is doing a 
number of different test (Batch Processing/Machine 
exchange which reflects SMED manufacturing issues.)  
 Batching not covered in healthcare literature but a major 
theme in LEAN- Evidence in healthcare of batching of 
tests for collection  
 Limited understanding of home based monitoring with 
risk profiling to remove ED appearances - Is there a waste 
related to prevention?  
 Emerging technology in vital sign monitoring allowing 
longer more pervasive monitoring. 
 Emerging technology to allow quantification within 
POCD increasingly available 





quantification and digital reading and recording may be 
advantageous.  
 Excess or waste demand - stratify the demand 1) remove 
demand that is without value 2) use point of care tests for 
diagnostics which don’t have as high a quality thresholds 
3) address remaining complex demand.   
7.4.6 Discussion on the Diagnostics Analysis  
In line with the research questions we have considered in this section how a diagnostic for 
cardiovascular disease can reveal insights for Lean application. The section also considers the 
waste activities and where patient value is not being met in line with research question 2 and 
3. The analysis highlights key areas for considering how Lean can be adapted to long term 
condition and specifically cardiovascular disease.  
 
In addressing research question 2 about Lean non-value add activities, the analysis of 
diagnostics revealed that a significant amount of the key Lean non-value add activity or 
wastes that emerge are linked to the waiting time prior to completing the test and delays 
receiving the diagnostic results. Some cardiac diagnostic marker studies show improved 
faster diagnostic turnaround time but the consequence of the improvement don’t always lead 
to reduced length of stay and no overall reduction on the average length of stay (Goodacre et 
al., 2011). Emergency Departments also have issues with vital signs monitoring not revealing 
heart attacks which reflects diagnostic limitations which means that emergency department 
are required to consider a number of approaches with technology to reassure of either a true 
positive or true negative when assessing if some had a heart attack of just a mild pain. Classic 
Lean waits were evident with batching of tests to go to labs, transport to the labs and waiting 
results. Transport, batching and waiting are regarded as key issues in healthcare Lean reforms 





revealed significant waits for patients from cardiology related diagnostics which appear to be 
getting worse. While there are many unknowns within this there is a potential for Lean tools 
such as visual management to be used to begin to address this. Additionally the data reveals 
some issues of performance being driven by other measures than patient value which needs 
exposed and addressed. Opportunities also emerge in utilising technology identify and share 







7.5 Hospital Based Care 
The previous section of the thesis analysed diagnostics use for cardiovascular disease patients 
in the care pathway. This contributed to the aim of the thesis by analysing the role of Lean 
thinking application to integrated healthcare patient pathways. In figure 7.2.1 and duplicated 
in figure 7.5.1 below one can see hospital based care is the next set of activities within the 
patient value chain.  The hospital based interventions have a series of activities and outcomes 
which are a key element related to the patient pathway.  
 
It should be noted that although there is a logical flow from the GP through to diagnostics 
and to the Hospital this is not a complete picture of the complexity of patients. Patients may 
enter hospital care via an ambulance or emergency department as unplanned visitor as the 
result of a sudden heart attack of cardiac related episode. Equally the hospital may review the 
patient at a hospital outpatient clinic and send the patient to get diagnostic tests prior to a 
decision about admitting the patient for surgery or discharging them without inpatient 
treatment. The analysis of hospital based care in this section will include quantitative and 
qualitative analysis with some consideration of these additional sources of patients. To 
continue addressing the research question of how Lean can be adapted for long term 
conditions this section will review hospital based care activities and identifying Lean wastes 
within this. It will continue to use cardiovascular disease as an example of a long term 








Figure 7.5.1 – Cardiovascular Disease Data Set – Focus on Hospital Based Care  
7.5.1.1 Hospital Based Care Definitions 
Hospital based care is divided into outpatient and inpatients status. These definitions of the 
types of patients in the NHS website refers to “If you've been referred to hospital but don't 
need to stay overnight, it means you're being treated as an outpatient or a day case”. In the 
case of an inpatient they have the following description “If you've been referred to hospital 
for an operation or test and you need to stay overnight, it means you're being treated as an 
inpatient” (NHS Choices, 2018).  
Outpatient activity will be undertaken to assess the patient based on a clinical concern raised 
and referred by a GP. The outpatient clinic will be provided by a specialist and managed by a 
consultant for a speciality such as cardiology. The consultant led clinic will make an 





on the next steps on the clinical pathway. This could include advice to a patient or GP, 
referral to a diagnostic procedure, referral to inpatient procedures or review over a period of 
time. The outpatient clinic will also manage the review appointments post inpatient activities 
to review progress or recovery where necessary. The qualitative analysis revealed that in the 
case of heart failure, nurses were employed to monitor patients post discharge from hospital.  
 
Further categorisation of patients beyond inpatient and outpatient is recognised based on the 
admission type to hospital. Planned and unplanned (or unscheduled) admissions are key 
drivers impacting the patient and the care pathway. The NHS is a budget constrained 
organisation and Porter (2016, Pg. 90) notes that “fixed budgets inevitably lead to long waits 
for nonemergency care and create pressure to increase budgets each year”. The final 
definition of note is the Average Length of Stay (ALOS) which is a critical measure across 
the majority of hospitals globally. Specific specialities will have different standards with 
heart failure being a condition with a longer expected ALOS. Omar HR (2017) highlights 
discussion on the reasons for longer  
The length of stay for acute heart failure is a constant theme for literature as there is a link 
between a long stay and poor health outcomes however it is unclear if this is correlation or 
causation (Omar and Guglin, 2017). The purpose of the thesis is not to advance the 
knowledge of medicine but these types of admissions and patient status provide 
considerations for the research questions of the thesis. They reflect operational design and 







7.5.1.2 The Role of Hospital Based Care 
The role of hospital based care is to provide specialist assessment, intervention and 
monitoring. While the general practitioner is concerned with healthcare for the patient, the 
hospital is divided into specialist areas with supporting diagnostic activities. The hospital 
based care is particularly relevant to this thesis as many patients with cardiovascular disease 
attend hospital for assessment, interventions and in many cases readmission to hospital. 
Acute exacerbations of their condition such as through chest pain or heart attack will often 
result in a visit to hospital based care. Heart failure, which reflects the declining function of 
the heart, for example is the most common cause of hospitalisation in people aged over 65 
years (Mendoza et al., 2009). Heart failure patients in this study of Spanish patients had a 
readmission rate of 45% with on average 2 readmissions per patient.  
 
Cardiovascular disease activity in a hospital will focus on circulatory system but can require 
interventions which are not within the cardiovascular disease specialism. Examples of 
cardiovascular disease interventions include; angioplastry, transplantation, bypass, implants, 
coronary artery, bypass graft, and lipid modification (Yock et al., 2015). The role of the 
hospital may also extend beyond surgical interventions as clinicians will have outpatient 
activities which follow the patient to the home for a period after clinical intervention in the 
hospital. The key purpose is to improve the outcomes for the patient and prevent 
readmissions.  
 
The role of the hospital as part of the aims of the thesis will be discussed through this sections 





7.5.1.3 Hospital Based Care Future Development 
To understand the hospital based care implication on the research one must also reflect on the 
emerging configurations of services and the hospital based care of the future. Hospital at 
Home, remote monitoring services and self-management are some of the emerging as areas of 
interest in the hospital based future developments (Mendoza et al., 2009). Emerging 
technology, market developments and research studies are influencing decisions in these 
areas to change care models. Some technologies are emerging to create opportunities for 
potential new models which then undergo research scrutiny to take into account the clinical, 
operational and economic justification for the new models.  Understanding future hospital 
based care models is particularly important for the thesis research question 3 when asking 
“Can health technology from data focused technology assist in redefining patient value”. This 
will be reflected upon in the analysis and discussion of this section.   
7.5.1.4 Hospital Based Care in This Thesis 
With the definition, role and future direction explained, the remainder of section 7.5 will 
reflect the common approach of use in the previous sections of 7.2, 7.3 and 7.4 by analysing;  
 Current hospital based care interventions in academic and grey papers  
 Current measures and data within the Northern Ireland healthcare system 
 What is not measured  
 Hospital based care activities against the Lean non-value add activities identified in 
academic literature in Chapters 1-7. 
 
From this analysis we can then contribute to answering the research questions of how Lean 
can be adapted for Long Term Conditions (Research Question 1) and contribute to 





(Research Question 2). The analysis will also build some insight into addressing where health 
technology can assist in redefining patient value which reflects research question 3. Open 
data available is the most exhaustive in hospital based care as the standards and consistency 
across the hospitals is much more mature than other areas of health provision covered in this 
thesis. This may reflect efforts to compare and contrast performance across the hospitals in 





7.5.2 Analysis of Hospital Based Care in Academic Papers and Grey Materials 
As research question one focuses on understanding the Lean waste activities it is important to 
continue to investigate the value stream map of cardiovascular disease and specifically 
activities related to hospital based care. These activities will indicate the drivers that create 
value or waste to a cardiovascular patient. Academic papers and grey papers such as work 
instructions and best practice guidance provide significant insight on the activities and 
challenges that are known in the current working practice. Hospital based care is the most 
rich for this type of material as it reflects more similar activities across providers than in 
public health or community care. Insight from these has been discussed through the 
qualitative analysis to gain insight on what is best practice and what is actual practice.  To 
address the research questions the hospital based care will require analysis for Lean related 
issues and cardiovascular patient outcomes. The key points when analysing diagnostics are;  
 Emergency care  
 Emerging role of Specialist Centres  
 Reducing readmissions 
 Emerging hospital models and condition Management  
The strategic direction of many health policies is to reduce the dependence on care in a 
hospital. This reflects various healthy ageing strategies such as mentioned in the Innovate UK 
Life Sciences Industrial Strategy (Office for Life Sciences, 2017, Pg. 17) where they state;  
 
“ As we move to a setting where almost 30% of the population will be over the age of 
65, a wide range of engineering, digital monitoring and technology based solutions 
will be required to maintain mobility, allow people to stay at home and provide much 






While it is accepted that the future progresses towards at home services, there remains a need 
for hospital based care as part of the delivery of care.  
7.5.2.1 Emergency Care  
Emergency departments are under extreme pressure and scrutiny. Target such as a maximum 
four hour wait for 95% of patients are monitored for all hospitals as part of the core standards 
set out in the NHS constitution (The Kings Fund, 2017). Despite the target, most 
organisations continue to fall below the 95% threshold and preparations for peak demands 
such as increasing staff and increased additional resources have had little impact on 
addressing the issues (The Kings Fund, 2017). Demand prevention is a significant topic for 
understanding value from a patient perspective and the purpose of this thesis. Value can’t be 
represented as a 4 hour wait from a patient perspective as the reason for them needing to go 
to an ED is not understood (Gubb, 2009). Emergency care issues are linked to the whole 
system with decisions to admit a patient to the hospital linking to the number of beds 
available which is directly related to the ability to discharge patients. Having a backlog of 
discharge patients will therefore lead to long waits in ED to be admitted.  Elderly, vulnerable 
people and complex needs patients in particular often require a multi-sector and multi-agency 
approach as social care assessments are made to ensure that adequate support is available 
when discharged to the community.  
7.5.2.2 Emerging role of specialist centres  
There is a significant role for consolidated specialised cardiology expertise where the most 
complex procedures can be completed in the safest manner possible. The NHS Five year’s 
forward review makes a statement (NHS 2014) about new care models. Specifically 
highlighting that greater standardisation can occur when services are consolidated. The 
concept of standardisation of best practice is a key Lean theme and if associated with 






As evidence of improvement within the consolidation, they highlight a 17% reduction in 30 
day mortality where 32 stroke services were reduced to 8 specialist units. Other studies 
highlighted improvements such as mortality rates, post-operative complications and patient 
length of stay.  The safety of procedures is often linked to the volume of similar procedures 
completed by a surgeon or clinician and this cannot be done with community based 
practitioners where the volumes of a specific procedure will be significantly lower.  
 
The concept of standardising is supported in many Lean applications and would be a common 
improvement strategy. Similarly sharing best practices is a key Lean approach and is 
advanced by best practice guidance. The organisation responsible for best practice guidance 
or standards is the National Institute for Health and Care Excellence (NICE, 2017).  The 
NICE guidance is an attempt to implement best practice within the NHS as an approach of 
standardising the best known methods. 
 
For cardiovascular disease the NICE clinical guidance had 58 separate documents with many 
of them being frequently updated and some addressing similar or overlapping areas. For 
example “Myocardial infarction: cardiac rehabilitation and prevention of further 
cardiovascular disease (CG172)” was created in Nov 2013. In Sept 2017 the website reports 
that the document is under review and likely to be updated with further emerging evidence 
around the use of beta-blocker treatments. This highlights the constant nature of update and 
change within the profession to maintain current best practice. The guidance also has a 
number of politically sensitive statements attached which releases the clinician from 
following the guidance as mandatory as they must take ownership of clinical decisions. 





this. The guidance is couched in language about needing to reflect local and national 
priorities as part of considering implementation of the advice. This softer language allows for 
local budget constraints. Similarly in the area of myocardial infarction there is further 
guidance available for “Myocardial infarction with ST-segment elevation: acute management 
(CG167)”. This therefore means that clinicians, even in a very specific area, must be aware of 
a series of guidance, standards and pathway related instructions which they must interpret for 
the needs of the patient and within the constraints of the local commissioner and hospital. 
NICE defined conditions and pathways related to cardiovascular conditions include 
pathways, protocols and guidance for preventing treating and supporting providers delivering 
care. NICE Pathways include;  
 Cardiovascular disease prevention 
 Identification of risk  
 Lifestyle changes for prevention of cardiovascular disease (diet, physical activity, 
weight management, smoking)  
 Lipid modification therapy  
The use of operational procedure in healthcare are however more complex and difficult than 
operational procedure in the Toyota Production Lines. Volume wise there are significant 
issues as in England there are more than 168 acute hospital trusts with a significant number of 
these trust having more than one hospital. In Northern Ireland there are 5 Health and social 
care trusts with all of the trusts having more than 1 hospital and Belfast having 5 hospitals 
(excluding mental health facilities). The logistics of managing and policing guidance would 
be a mammoth task.  Secondly there is variance of presenting patient with racial genetics, 
diets, sex and many other factors having a significant impact both on the conditions and the 
ability to respond to interventions or therapy. This requires the guidance to revert to the 





changing landscape with advances in medicine, changes in medication, evolving patient 
characteristics. This means that what was previous best practice will be superseded, the 
medication will have been replaced and the patient may be living 10 years longer than before 
with more complex conditions. This leads to a need to constantly question guidance against 
the latest finding which can undermine confidence and adherence to guidance.  
 
All of which have an impact on key operational issues. The challenges of the guidance and 
operation practice are;  
1. Keep up to date with the multitude of NICE guidance work instructions. 
2. Balancing the commissioning needs and priorities for your area against the guidance. 
3. In addition a hospital or specialist centre may be addressing the needs of a numbers of 
commissioners due to overlapping boundaries and each may have slightly different 
needs.  
There is however mitigation against the risk of all clinicians ignoring the guidance which is 
the potential to be deemed to be clinically negligent and secondly the influence of peer 
influence. The NICE guidance documents have a substantial backing within the clinical 
community as they have been created by their peers. On the negative of this a clinician who 
wilfully goes against the guidance and ends up in a negligence case will be the subject of 
scrutiny and on the defensive against their clinical behaviours.  
 
In summarising the key areas of relevance for this thesis in the emerging role of specialist 
centres one can find the following areas being of relevance 
 The role of the specialist is being developed which supports Lean and transformation 





 Guidance and work instructions are developed and being used which reflects at a high 
level the need to seek best practice and improve from there 
 Guidance and standards are discretionary and subject to clinical adjustment and local 
priorities. 
 Large volumes of updated guidance material may make the system unworkable 
without technical assistance or decision support.   
7.5.2.3 Readmissions and Condition Management 
Hospital readmissions, which are an unplanned admission to hospital following an inpatient 
episode1, attract a significant amount of attention both in literature and operational focus. 
The USA centre for Medicare and Medicaid services data, reports that two of the three 
highest volumes of readmissions are from cardiovascular related patients (Berenson et al., 
2012). Heart Failure, Acute Myocardial Infarction (Heart Attack) and Pneumonia are the 
three conditions with the highest readmissions within 30 days and jointly make up 12% of all 
hospital admissions. The NHS also recognises readmissions as a serious financial and health 
outcome challenge and readmissions reflect Lean principles of failure leading to rework.  
Prevention is a key focus for hospitals; however there are many documented reasons why a 
patient will readmit with many of these being linked to either patient behaviour (Greene, 
2012). The resolutions are not simple and some interventions have led to increasing 
readmissions as access to the clinicians had increased (Joynt and Jha, 2012). The challenge is 
made more complex by the nature of the types of patients this impacts as this is some of the 
sickest patients being kept alive. There is a need to risk adjust the measures to understand 
poor quality service versus sick patients (Berenson et al., 2012). Measures and understanding 
of which readmissions could be avoided vary heavily between clinical opinion and 
managerial data (Joynt and Jha, 2012). Related to previous discussions in this thesis about the 





hospitals control and within the community (Joynt and Jha, 2012). Additionally communities 
with higher levels of deprivation will have higher levels of readmissions reflecting a need to 
personalise discharge approaches (Berenson et al., 2012).A significant number of studies 
have broken down large amounts of data over tens of thousands of patients to attempt to 
understand cardiovascular patients with a focus on heart failure profiles and potential reason 
for readmissions which are reflected in table 7.5.1.  





Description Data  Publication  
Use of Electronic 
Health Record 
(EHR) 
Study explores if electronic health 
record in hospital reduces 
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Ethnicity Ethnicity has linkage to responses to 
various therapies and drugs. Some 
studies even highlighting differences 
on blood pressure responses.   
85% white,  Patterson et 
al., 2014 






Comorbidity Having a number of health conditions 
is highly likely in a significant 




al., 2014 & 
Greene,  
2012 





Reconciliation right medicine and this being 
available to the patient. Known 
issues such as wrong medication 
being prescribed due to conflict with 
other conditions such as asthma or 
diabetes.  
inhibitors or 









Medicines compliance relates to the 
patient taking the medicines as 
prescribed. Patients may not take 
medication due to forgetfulness, toxic 
side effects of medication, distrust of 
the medicine or belief that they don’t 
need it.  
 
In some studies 
up to 51% of 
medications 








Deprivation  Demographics, deprivation, 
education and social status have 
impact on readmission levels.  
Poor and 
minority 







Contact with Your 
Community Doctor 
Post discharge contact with a primary 
care (GP) quickly after being 
discharged will have a significant 
impact on the levels of readmission.  
Post discharge 
contact doctor 




Length of Stay Longer lengths of stay have a 
relationship to the likelihood of 
readmission. Shorter stays being a 
proxy for less complication therefore 
a longer stay may reflect 











This reflects the discharge team 






ED visits in the last 
6 months. 
The number of emergency room 
visits in last 6 months has a direct 




Discharge and Post 
Discharge Risks   
Hospital acquired infections while 
not specifically related to the 
cardiovascular work can result in a 
reason for readmission.  
Premature discharge has been 
identified as a reason for some 
readmissions. This can be related to 
pressure on beds and reducing 
average length of stay in hospital. 
Indicators of upcoming readmissions 
include fluid build-up in lungs, 
tiredness, weakness, light head, short 
breath, chest pain and racing heart.   
 Berenson et 
al., 2012 
 
In analysing the literature covering readmissions in cardiovascular disease one can break all 
the factors impacting the likelihood of readmissions into two broad categories of care 
provision factors and patient factors as shown in figure 7.5.1. This is relevant to the thesis as 
within these reasons for failure are potential opportunities for healthcare technology to 






Figure 7.5.2 – Summarising the Readmission Risk Factors for Readmission  
In summarising the area of readmissions it is clear that re-admissions are a Lean waste for 
both provider costs and patient health outcomes. The patient factors reflect a risk element 
which will be personal to the factors of birth, behaviour and lifestyle. From these a 
personalised prediction can be made about the likelihood of readmission and compliance.  
This is not typical Lean reform approach as risk profiling of the individual is not a common 
response although there is some use of risk metrics based on symptoms. The closest that 
could be found in Lean literature would be around maintenance of machinery or similar. 
From the risk profiling new activities may be drawn to address the patient value. Technology 
may have options of simplifying and supporting decisions through risk profiling and 
personalisation.  
Provider waste is also evident in areas such as clear discharge instructions, assessing specific 
functions of the heart prior to discharge; ensuring prescriptions are available, addressing 
smoking cessation and issuing beta blockers where Left Ventricle Systolic Dysfunction is 
present. There does however need to be more research to prove the effectiveness of these 





adherence results in better outcomes. This is highlighted in the following quote from 
Paterson;  
"Only conformity with a measure for prescription of a beta blocker for left ventricular 
systolic dysfunction was significantly associated with a lower risk of 60 day to 90 day 
mortality...." (Patterson et al., 2010, Pg. 6)  
It still stands to reason however that best practice is implemented, measured and improved 
through a continuous improvement cycle. Finally, the area of linkage between the hospital 
and the community is evident as an area that is resulting in patient value not being achieved. 
This supports the Lean literature gaps that Lean healthcare needs to address patient value 
across the care provision silos.  
7.5.2.4 Emerging Hospital Models and Condition Management  
Care providers have sought to innovate by seeking to establish home based and community 
care programmes that align with hospital programmes and attempt to either provide a step 
down service from hospital or complement hospital programmes to avoid admission or 
readmission. Some are referred to as “hospital at home” to reflect more complex care 
provision in a home setting with Heart Failure clinics being a significant home based care 
programmes (Mendoza et al., 2009). Studies of the effectiveness of the home based care are 
limited. They are difficult to compare due to changing inclusion criteria for patients and don’t 
provide a complete view of the costs and outcomes. The trials and studies are highlighted in 






Table 7.5.2 – Emerging Cardiology Healthcare Alternative Models  
Author  Location  Notes  
Patel et al., 
2008  
 
Sweden  Home based care provided until the patient was improving. 
Some exclusion of specific types of patients. Specific 
parameters around weight, swelling and clinical health 
identified to mark the end of the service. Telephone escalation 
available after the service had ended.  
Mendoza et 
al., 2009  
Spain  Targeted at early diagnosed Heart Failure. Use of New York 
Heart Association classifications of patients to agree criteria for 
patients who could participate. Narrower scope of patients than 
Swedish work.  
Tibaldi et 
al., 2009  
 
Italy  Targeted at narrow scope of patients with Heart Failure. Use of 
New York Heart Association classifications. Some additional 
criteria around previous diagnostic investigations.  
 
The studies focus on three core areas of costs, health outcomes and patient related quality. In 
terms of the costs the studies showed saving in the early phases in general and comparable 
costs in the longer term.  Health outcomes had no real impact on the number of readmissions 
however there was some improvement in the time to first readmission (longer). The patient 
quality aspect however was much more positive as health linked quality of life was measured. 
The studies have known limitation in that there are not significant number of trials that have 
been reviewed with academic rigour despite the hospital at home service being developed 
across many hospital trusts. The comparisons often struggle to operate clinical trials as 
comparison to control groups can be somewhat difficult. The above trials have patient groups 
of less than 100 patients therefore the volumes and are not significant in overall health terms 
and withdrawal from the research and deaths can impact the studies significantly. The studies 
however are relevant to this thesis in three specific areas. Firstly they expand their 





which are highly relevant to the Lean concept of value defined by a patient. The measure is 
not limited to the completion of the clinical intervention but the impact on the patient. 
Secondly, the measurements looks at longer term measurements such as 1 year after surgery 
which allows a more holistic view beyond a specific treatment both for the outcome of the 
surgery from a clinical perspective but also from the patients view. This outcome measure is 
more closely aligned to a Lean value perspective and is often absent from feedback to 
continuous improvement initiatives and Lean as seen in most healthcare literature. In 
summary, these concepts of extended measures and patient quality of life measures feeding 
into continuous improvement are very relevant when looking at cardiovascular disease and 
how Lean can be used in long term conditions. In addition technology has options to address 






7.5.3 Analysis of Current Measures and Data within the System  
This section analysis quantitative data focused on hospital based care. The majority of 
hospital based care related to cardiovascular disease in Northern Ireland is found within the 
health and social care trusts. Some activity is completed in the private sector but this is of a 
significantly smaller scale therefore has been determined as out of scope.  
 
Quantitative data is available through a number of open data sources with the main challenge 
being to identify and navigate to the relevant information. The selection of data used for 
analysis can present a number of challenges as different sources of data will group and 
present data in different ways depending on the collection purpose. For example the Northern 
Ireland Statistics and Research Agency (NISRA, 2017) has a large amount of data which is 
grouped in various categories. Utilising a grouping based on a local government boundary, 
for example, will remove the ability to understand a hospitals performance due to hospital 
patients crossing local government boundaries. NISRA statistics may additionally focus on 
consistent measures for year on year comparisons but subtle changes in year on year 
healthcare relevance, which the health trusts will capture, will be missed. The healthcare 
trusts however may change a measure from one year to the next and the ability to compare 
year on year is lost. In summary, each of the big data sets must be understood for content and 
context.  
 
To access the relevant data on cardiology one must navigate through a multitude of 
information on other clinical specialisms which reflect the overall hospital performance. For 
example “New to Review Comparisons”, required navigation through over 650 pages of 
other data. This is highlighted to emphasise that although data may reveal clinical and 





the exact meaning of the data. This point emerged in qualitative focus groups where the 
participants were very interested in the breadth of the data and wanted to know how to 
navigate and get this. Similarly when working with cardiologist during the early part of the 
thesis a small sampling of data required the input from the cardiologist, hospital ICT 
specialists and waiting list specialists as the multitude of joining systems, with internal names 
and codes were not understood by even the clinician operating on the patient and the 
subtleties of clinical codes were not understood by ICT staff or administrators.  
 
The core data which is analysed and presented in this section relates to open source data from 
within the 5 Health and Social Care Trusts. The data has been processed to draw out further 
information. To present this, the thesis will cover;  
 Outpatient Waiting Times  
 New to Review Comparisons  
 Cancelations  
 Inpatient Waiting Times  
 Cardiovascular Disease in the Context of Hospital Activity  
 Demographics of Cardiology Patients  
 Bed Utilisation for Cardiovascular Patients  
 Comparisons across hospital trusts  
 
Table 7.5.3 is provided to highlight that the data is not provided in an easy to use format but 
must be separated from other data, reprocessed from potentially other formats (such as PDF 




















































7.5.3.1 Outpatient Waiting Times  
Waiting is a classic waste in Lean (Bicheno and Holweg, 2016). In healthcare waiting has an 
immediate impact on the utilisation of healthcare resources for no value and reduced value 
for health outcomes therefore having both a financial and health disadvantage. To analyse the 
outpatient waiting time processing of the data was completed to convert the waiting 
categories and patient counts to a total number of days waiting. This is not typically done as 
comparisons across years are note completed and the categorisation into groupings, such as 
12-15 weeks is more common. This however lacks the year on year performance comparison 
of total waiting time. The data has been processed to address some of the changing categories 
over the 5 years and the figures have use proxy data based on mid-point of a time category to 
allow a fuller number. For example where 10 patients were waiting 12-15 weeks then a mid-
point of 13.5 weeks was used to multiply by the number of days and number of patients 
waiting that duration. While this has some limitations due to the nature of the reported data, 
this does however paint an interesting picture which is show in the figure below.  
 
By using this data it was possible to calculate that in the last reporting quarter 1.6 million 
(1601454) days are used in Northern Ireland waiting for an outpatient appointment across the 
5 HSC trusts. Calculations across the time periods are not possible as the figures do not 
provide unique patient identifiers so there is no way to identify where a patient may have 







Figure 7.5.3 - Days waiting for Cardiology Outpatient Appointment 2011-2016 (Source 
data: Department of Health, 2017, Outpatient Activity) 
If this figure is then calculated for the individual patient there is an average of 109 days 
waiting across the 5 trusts in the final measurement. To cross correlate this with other figures 
and analysis was done of the mid-point of waiting list. In Belfast in the final measurement the 
mid-point would be the 1921
st
 patient. This patient was found to be waiting in the category 
18-26 weeks or in day terms 126-182 days therefore taking into account the variance across 
the trust the 109 days figure appears to largely in line with the other figure and possibly a 
little conservative.  
 
Figure 7.5.4 Average Number of days waits for Cardiology 2011-2016 (Source data: 





The longitudinal trend is also alarming as this appears to be increasing significantly in 
particularly for the high volume trusts. The trends however do not reflect a continually 
decline in performance but shifts and changes within the 5 years which would require further 







7.5.3.2 New to Review Appointments 
When analysing the data for outpatient activity there are a number of factors which can be 
useful in understanding how a service is being delivered and the types of appointments being 
performed is one of these. Health and social care trust figures report data that can be used to 
identify variance in approaches and Lean and six sigma approaches utilise variance as a tool 
to identify where there is potential for waste or improvement. Comparisons will need some 
level of context as this is not comparing the performance of two machines in a factory and 
patient cohorts or user needs may require some variance but there is still a key assumption 
that variance and waste will be linked as the best practice has not been identified and 
translated to be standard practice.  
 
Figure 7.5.5 for the new cardiology outpatients compares the volume of new appointments 
over the period 2011- 2016 and utilise comparisons across the trusts. Over the 5 year period 
there is evidence of some growth in the number of outpatient appointments with the Belfast 
Trust having the largest number of appointments. As Belfast is the largest trust based in the 
largest city in Northern Ireland this in itself is not surprising. The diagram below highlights 
that Belfast trust is completing the largest number of outpatient activities with approximately 
44% of the activities and over 4 times the volume of the smallest provider which is the South 
Eastern Trust. Not easily detected in the graphs however is the growth in the number of new 
appointments during this time period. In 2011 there was 17,954 new appointments compared 
to 23,188 in 2015-16 which reflects as 29% growth in the number of new appointments. This 
is relevant for Lean as it reflects an understanding of expanding capacity to address demand. 
This however does not appear to be keeping pace with either the diagnostics waits or the 





the demand. In addition the qualitative analysis revealed some questions about the quality of 
the referrals with a belief that the volumes were growing due to inexperience of the referrer.  
 
 
Figure 7.5.5 – New Cardiology Outpatient Appointments (Source data: Department of 
Health, 2017, Outpatient Activity)  
Unlike the growth in the number of new appointments, the number of review appointments 
has fallen by 2454 from 35,490 to 33,036 which represent 6.9% decline in the number of 
review appointments. This means that in total there is a net gain of 2780 appointments being 
available over the 5 years. What is not clear in the data however is the impact of the less 
review appointments being made available? This is particularly relevant as the focus of the 
thesis is in the growth of long term conditions. Long term conditions are by definition not 
healed and therefore will require continuous input from clinicians over time. There is 
potential that this input is being completed by the GP. From a Lean perspective there is a 
potential of more value add activities being reduced although this can’t be quantified by the 









Figure 7.5.6 – Review Cardiology Outpatient Appointments (Source data: Department 
of Health, 2017, Outpatient Activity) 
Further analysis of the number of review appointments reveals that a reduction in the total 
number of review appointments is not universal. Three out of five of the trusts have actually 
increased the number of review appointments. This detail therefore highlights that the total 
number is masking variance within the trusts the Belfast trust being the only trust to maintain 
a falling number over the 5 years. This is highlighted in the Table 7.5.5 where one can see 






Table 7.5.4 – Number of Cardiology Review Appointments (Source data: Department of 
Health, 2017, Outpatient Activity) 








2011-12 18029 5581 2663 3274 5943 
2012-13 17469 6004 2723 2734 6012 
2013-14 17392 5471 2886 2617 5547 
2014-15 16780 6022 2675 3701 5543 
2015-16 16026 5804 2504 3502 5200 
 
Explorations of new-to-review ratios are also of interest in the analysis of variance. 
Theoretically a group of patients being treated under a similar care pathway would have a 
similar level of review appointments. Over a 5 year period one would also expect the ratio to 
stay reasonably static as patients would be discharged at similar points. This comparison is 
not a standard measure that would be completed within any of the open data information and 
therefore actions or investigations are unlikely to have been completed to understand this 
variance. In the chart below the % of appointments which are reviews is provided and 
compared across the 5 years and across the trusts.  
 
Across the five trusts one can see that there is substantial variance in the ratios with a 
difference of approximately 29%. When looking at one year we find that a Minimum 43 and 
maximum 72 and similar cases during the time period. The Western Trust and the South 
Eastern are the outliers at 42 and 72. It is possible that when looking at these Trusts, the 
services have been configured in ways which explain and justify the difference however there 
is still a question of identifying best practice for patient value, outcomes and costs. In the case 
of readmissions (patients being readmitted after being discharged) which is known as key 





reduced readmissions or has evidence of larger number of readmissions. Lean is focused on 
scientific management and this reflects opportunity to improve which has not been realised.  
 
 
Figure 7.5.7 –Outpatient Appointments as a Percentage of the Total Appointments 








7.5.3.3 Cancelations  
The previous figures have all looked at appointments that have successful taken place but the 
open data also gives us access to appointments that have not taken place. These fall into three 
categories of DNA, CNA and Cancelations. The term DNA in healthcare is a standard 
healthcare term meaning “Did Not Attend”. This means a scheduled appointment has been 
missed by the patient without any apology or attempt to cancel or move the appointment. The 
term CNA means Can Not Attend and reflects a cancelled appointment where notification has 
taken place. In the cases of a CNA, an attempt may have been made to fill the appointment 
with another patient therefore there is a lower likelihood of waste but additional resource will 
be used attempting to fill vacant slots. Cancellations are the third category and in this case 
this will be a failed appointment due to the healthcare organisation rather than the patient.  
 
From a Lean perspective, cancelations across the HSC trusts are all non-value add within the 
system as the patient has not received the care that was needed. This issue is not a new issue 
attempts have been made of the last couple of decades to reduce this number through various 
initiatives. Despite the issue being highlighted and written about over the last 25 years it 
remains a constant issue with the evidence being highlighted below in the last 5 years figures.  
  
The figures for DNA’s, shown in figure 7.5.8,  as a % of attendances provides a mechanisms 
of putting a scale to the issue in relation to the number of successful appointments. Belfast 
clearly stands as an outlier although improvements appear to be evident. Similarly the 
Northern Trust appears to have made the most progress in improvement to the lowest level of 
DNA’s. Although it is useful as a context to make benchmark comparisons one needs to be 
mindful that a benchmark of failure is not a Lean approach as Value is not being delivered 






Figure 7.5.8 – Did Not Attend appointments as a Percentage of the attendees count 
(Source data: Department of Health, 2017, Outpatient Activity) 
Similarly CNA’s are highest in the Belfast Trust but equally the Northern Trust is 
substantially higher than the other 3 trusts for CNA. Notably the Northern Trust were one of 
the best performing trust at DNA which may indicate an ability to reduce DNA’s by possibly 
moving these to CNA. While not ideal a CNA still is better than a DNA and provides 
opportunity to rearrange appointments and make use of later stage appointment slots. Some 






Figure 7.5.9 – Could Not Attend appointments as a Percentage of the attendees count 
(Source data: Department of Health, 2017, Outpatient Activity) 
The hospital cancelations, unlike the DNA/CNA, are the responsibility of the hospital. The 
figures in figure 7.5.10 highlight significant levels of cancelations. In particular Belfast in 
2011-12 and 2012-13 has high level of cancelations. The cancelation represent a significant 
level of patient dissatisfaction and not delivering value as the appointment will have been 
deferred to another time leaving a vacuum in the patients expectations.  These also lead to a 
longer “wait” which represents one of the key definitions of classic Lean waste.  The delay 
will also absorb additional resources in managing and administering the waits.  
 
 
Figure 7.5.10 – Hospital Cancelation Appointments as a Percentage of the attendees 
count (Source data: Department of Health, 2017, Outpatient Activity) 
Taking into account the three areas of waste, the table 7.5.5 analysis combines all of the 
appointments both new and reviews and all of the new and review categories for DNA, CNA 
and hospital cancelation. The analysis then considers that for every successful appointment 
how many appointments are unsuccessful. The Belfast trust in 2011-12 and 2012-13 has 





chart previously. These have been highlighted in red below and what this analysis shows that 
in the two highlighted years for every successful appointment 1.5 and 1 respectively were 
unsuccessful either by patient or hospital. What was not clear until the below was completed 
was that the Norther trust had reached a higher level more comparable to Belfast in 2011-12  
and the Western Trust has displayed a higher peak in 2015-16 which had not been evident in 
the other figures. The reason that then became evident was when it compared successful 
volumes alongside unsuccessful volumes which had initially been masked by the overall 
higher volumes of the other hospital trusts. This is highlighted in amber below. Note that the 
rest of the figures are not highlighted in green to reflect success as although these are lower 
number the number still reflect failure and waste in the system rather than patient value.  
 
Table 7.5.5 – Ratio of Unsuccessful Appointments to Successful Appointments 
 2011-12 2012-13 2013-14 2014-15 2015-16 
Belfast HSCT  
 1.5 1.0 0.8 0.7 0.7 
Northern HSCT  
 0.6 0.5 0.4 0.5 0.4 
South Eastern 
HSCT  
 0.4 0.2 0.2 0.2 0.2 
Southern HSCT 
 0.3 0.3 0.2 0.3 0.3 
Western HSCT 0.2 0.2 0.2 0.2 0.8 
 
The reason for cancelations, as shown in figure 7.5.11, provides some early insight as the 
HSC trusts are only beginning to measure this. The full data set is not available for the 5 
years and the data that is available is incomplete. Initial data sets had a large % of data lines 





To give a snapshot of the type of information available the 2016-17 data for the Belfast Royal 
Victoria recorded the following reasons for cancelation.   
 
Figure 7.5.11 – Reason for Cancelation of Appointments in Belfast Royal Victoria 
Hospital 
Summarising the cancelation one can find that comparisons across hospitals has some benefit 
in identifying trends. This must be viewed with the caution of not assuming that the lowest 
number reflects value for the patient. The longitudinal data profiles across years can be useful 
in identifying trends and evidence of changes in practice, response to interventions and 
changes to funding but they can mislead in assuming lower numbers represent value. Lastly 
comparisons of success and failure can bring some level of context to the value discussion 
which is lost in the larger trend information. This could be useful in putting a value and 







7.5.3.4 Inpatient Waiting Times 
Similar to analysing the outpatient waiting times, the data was processed to convert the 
waiting categories and patient counts to a total number of days waiting. This is not typically 
done and comparisons across years are not frequently completed. The data has again been 
processed to use a mid-point of a time category. There was also some grouping of categories 
across the 5 years as the year on year categories varied to meet internal reporting issues.  
7.5.3.4.1 Cardiology Inpatients  
The data analysis provided a calculation that in the last (Dec 16) reporting quarter 43,451 
days are used in Northern Ireland waiting for inpatient appointments across the 5 HSC trusts. 
This equates to an average wait time of 114 Days. The single quarter is reported as it is not 
possible to identify unique patients across the 5 years to calculate the total days waiting over 
this time. A patient waiting in the quarter may also be in the next quarter’s figures and this 
could represent double counting if you multiply across quarters or years. There is a 
substantial difference between Belfast and any other HSC trust in the figures. This may be 
related to the Belfast Trust being a regional centre for cardiology. In addition some of the 









Figure 7.5.12 – The Number of Cardiology Patient Days Waiting Inpatient Treatment 
(Source Data: Department of Health, 2017, Inpatient and Day Case Waiting Times) 
Further analysis of cardiology day cases as an alternative to inpatients hospital stays was 
completed. The day case patients are waiting a total of 222,325 days on the 31 December 
2016 which meant the average a patient is waiting 104 days. Charting the figure over the 5 
years highlighted large changes in late 2013 and through 2014 which are shown in figure 








Figure 7.5.13 - Number of Cardiology Patient Days Waiting for Day-Case Procedures 
(Source Data: Department of Health, 2017, Inpatient and Day Case Waiting Times) 
Cardiac surgery similarly has a waiting list but this is uniquely Belfast as the regional 
specialism during the time period.13, 624 days are used waiting across all patients in the 
December16 quarter hospital data returns. The average wait is 63 days.  
 
Figure 7.5.14 - Cardiac Surgery Inpatient Waiting Days (Source Data: Department of 





7.5.3.5 Cardiovascular Disease in the Context of Hospital Activity  
The area that this thesis has selected is cardiovascular disease. This is an area of significance 
as it represents two of the three largest reasons for readmissions and has one of the largest 
specialisms in hospital based care. The assumption therefore is that an intervention in 
cardiology will have a large impact on the overall performance on a hospital. The data in 
table 2 in appendix 7 however puts some context around the volume of activities in a 
hospital. The reason this is highlighted is to ensure that cardiovascular reform or changes are 




What is clear is that the hospital system is made up of a large number of specialism. Focusing 
on a single patient pathway within the hospital will result in improvements within 5.7% of the 
overall activity. What it will not result in is large scale reform impacting significantly across 
the system. In cardiovascular disease a hypothetical 50% reduction in bed utilisation, 
removing weeks from the waiting time or removing 50% of the waste activities will have an 
impact on individual patients and substantial costs but this is not going to reflect a significant 
change across the system as ultimately this will be a 50% improvement of 5.7% of the 
activity. This however must be balanced with understanding that the huge resources being 
invested in healthcare as NHS England in 2016 had a £120.516 BN (NHS Confederation, 
2017) spend. This means that even small changes have large impacts on the national budget 
as Health consumes a disproportionately high % of the National budget. Two points emerge 
in considering this, firstly can learning from the cardiovascular disease care pathway be 
transferred to other conditions and specialisms or are they limited and secondly is it better to 





7.5.3.6 Demographics of Cardiology Patients  
Open data available focused on the episodes of care includes age information which allows 
analysis of the profile of the patients. Over the period of the data the average age for the 
patients increased by 1 year from 64 to 65. This is relevant as global trends reflect an ageing 
population. The age profiles of a service can have an impact on the service design, 
consideration of what value means for a patient and the patient’s ability to respond to new 
technologies. The male to female ratios of patients also changed by 1% as 38% of the patients 
were female at the beginning and 39% at the end. Similar to age, sex has implication on the 
personalisation of care as factors such as female medical conditions; response to medication, 
presence of dementia, and responsiveness to technology will have a relationship between age 
and sex. These may not be direct correlations but will become relevant in risk profiles such as 







Figure 7.5.15 – Age Profile of Cardiology Episodes – Line Graph (Source Data: 
Department of Health, 2017, Acute Episode Activity) 
The largest volume decline was in the 40-49 categories which had 131 less episodes and 
biggest increase was in the 80+ category with 1311 extra episodes. The learning from the 
analysis over the 5 years is that 3913 extra episodes took place in 2015-16 compared to 2011-
12. This is not frequently used as a measure as the data is provided for an individual year 








Figure 7.5.16 – Age Profile of Cardiology Episodes: Profile (Source Data: Department 
of Health, 2017, Acute Episode Activity) 
Figure 7.5.16 provides further details on 2015-16 to provide a profile of the age of patients. 
The diagram highlights that while the year on year comparisons show growth in the younger 
ages, over 85% of episodes are with patients over 50 years old. Only 8.2 % were below 40 
years of age. Again this raises question about the focus on Lean and healthcare technology 
and can it respond to the wide variety of needs and challenges that could impact the vast 
majority in the 50+ but also address the 8.2% below 40.  In the qualitative analysis the 
Northern Trust focus group frequently referred to “elderly-elderly” to differentiate between 
people who were perhaps retired but reasonably mobile and those with more extreme frailty 
and elderly. This is not well defined in age categories but reflects the front line experience of 
a number of client groups with various distinct needs that not reflected in age breakdowns 









Figure 7.5.17 – Demand Changes of Age Categories – 2011-2016 (Source Data: 
Department of Health, 2017, Acute Episode Activity) 
Over the 5 years there is clear evidence of change both positively and negatively as shown in 
figure 7.5.7. Smoking bans in public places (2007), rising obesity, reduced physical activity, 
changes to clinical intervention or medicines all have potential impacts. It is not the purpose 
of this thesis to provide root cause analysis of the changes but highlight the Lean root cause 
analysis potential through Lean tools. The Lean and healthcare technology solutions must 
reflect a personalisation of care understands the diversity of reasons to make an impact on the 







7.5.3.7 Emergency Admissions  
Emergency admissions are a key measure for healthcare systems as an emergency is an 
unplanned admission. Initially one can look at the data and note a degree of stability in the 
numbers with a slight decline over the 5 years. This however needs to be taken in context of a 
number of other changes during the period. Firstly the volume of admissions to hospital 
during this time had increased 8% in total over the 5 years therefore the volume of emergency 
admission was against a higher total. This is illustrated in 2012-13 where despite a significant 
growth in the total emergency patients by 344 patients, the percentage of the total patients fell 
from 31% to 30%. Secondly the biggest impact that emergency patients have is in removing 
resources from planned activity. Section 7.5.3.3 discussed the hospital outpatient 
cancellations and during the period there was overall reductions in cancelations but these 
were not replicated across all trusts as some increases were seen in the Southern trust. While 
it cannot be seen in the data available there could be further exploration to collect data to 
understand the relationship between emergency and cancelations.  
      
Lastly the level of stability in the emergency figures is an interesting point. One of the key 
principles of Lean is about designing a system that “pulls” to customer demand (Womack 
2010). The assumption behind most healthcare system design is that emergency is 
unpredictable and therefore difficult to plan for. The figure highlights that a degree of 
predictability and therefore planning is possible that could address and impact on the levels of 
cancelation in the hospital. This degree of stability also reflects some challenge that the root 
cause of emergency is not being addressed and there continues to be opportunities to identify 
patients earlier and move them from emergency to planned admissions. This will be much 
wider than a hospital issues and reflects the overall care pathway of patients at risk (public 





Within this are significant issues in missing data as we are not clear for example about how 
many patients on a waiting list ended up as an emergency admission or if technology or 
process could be used to identify escalation in a patient condition that will result in an 
emergency patient.        
 
Figure 7.5.18 – Emergency Admissions (Source Data: Department of Health, 2017, 







7.5.3.8 Bed Utilisation for Cardiovascular Patients  
The episodes of care for cardiology also provide a level of detail about the bed days used by 
cardiology patients. This is relevant as bed days utilisation impacts the overall flow of a 
hospital and impacts on waiting time. The analysis in figure 7.5.17 shows a worsening 
position but what this masks is that from 2012-13 through till the 2015-16 period the average 
number of bed days used per episode of care had reduced from 3 in 2011 to 2. These figures 




Figure 7.5.19 – Bed Utilisation Days (Source Data: Department of Health, 2017, Acute 
Episode Activity) 
To provide a finer level of detail there need to be a breakdown of the specific diseases and 
conditions that are being managed within the system in order to make a more informed 
analysis. The following highlights the primary diagnosis episodes of care related to 






A Pareto Analysis or Pareto charts is one of the common quality improvement approaches 
and in this case identifies the bulk of the bed days by a category. By using the diseases of the 
circulatory system the analysis highlights that just over 81% of the bed days are accounted 
for by 3 diseases. This separation between the bed days and the finished episodes is 
particularly important point as bed days are often a direct proxy of cost. In a reform initiative 
the tendency would be to chase the volume of episodes without considering the costs and 
patient impact in the system. Pareto analysis has drawn a new conclusion to highlight that any 
significant improvement in these three conditions will provide a significant return.  
 
 
Figure 7.5.20 - Acute Programme of Care: Primary Diagnosis Pareto Analysis Chart 






7.5.3.9 What Data is Not Captured? 
There is a lack of long term outcomes measured in all of the data. Linked to this is an absence 
of value based decisions measured to reflect quality from the patient’s perspective. The data 
that was used was open source and anonymised data which means that the number of 
engagements a patient has with care providers is not possible. This would be useful to see if 
this is changing as an ageing population has to interact with multiple care providers. Finally 







7.5.3.10 HSC Feedback on the Analysis 
The research methodology was a mixed method approach and significant data had been 
gathered. There was also a risk that although the analysis may bring some insight on a 
question or challenge the operational providers may discount the evidence as being irrelevant 
or the underlying data as being flawed. To explore these potentials the Ulster University 
provided an opportunity to present a summary of the thesis to an MSc Innovation 
Management class made up primarily of healthcare leaders through a workshop. This was an 
exceptional opportunity and built on feedback from presenting at the  
 International Conference on Engineering, Technology and Innovation in 2015  
 European Lean Educators Conference in 2016  
While the previous presentations were peer reviewed from experts in technology and lean, 
this group represented experts from a healthcare setting. They also had the ability to 
challenge the healthcare position and the Lean as this included experts with significant 
experience of performance management within healthcare. They were also very familiar with 
the data being presented as this was sourced from their healthcare organisations. The 
attendees and roles of those taking part on the 25 October 2017 are included in appendix 5. 
The overriding comments from the feedback was that they did not have access to the level of 
information across the value stream, they agreed that there was opportunity and their 
understand was that there would opportunities to use this approach however the tools to either 
view this level of information or analyse it were not available to them.  
 
In summarising the analysis of data within the hospital based care discovered significant 
waste in form of waiting with such as; 
 Outpatient waits of 109 Days  





 Day patient wait of 104 
Measure which gather the total waits for all patients highlight a significant growth in the 
number of days patients across Northern Ireland are waiting. Within these waits there are 
trigger point dates that appear to escalate issues which suggest underlying issues beyond the 
ageing population. Viewing the full patient journeys may assist in commissioning decisions 
which could be influencing changes in patient volumes and waits. High levels of unplanned 
admissions indicate waste within the system yet there is heavy variance in the new to review 
appointments ratios suggest lessons learned could be quantified and repeated across the HSC 
trusts. Cancelations both from the patient and the hospital are a significant scale and indicate 
potential room for improvement. Lessons learned from understanding the patient population 
may assist in personalisation of care and interventions that could assist in improving care and 
addressing waste such as missed appointments. 
 
Cardiovascular disease although significant in the operation is only a small piece of a large 
complex system and reforms should consideration if focusing on fixing one patient stream or 
alternatively one cross cutting element of the whole system would have bigger impact. Some 
caution on the use of data was also evidence as internal trusts measures for the quality of the 
data have changed over time. The ability to sustain improvements was a significant 
qualitative feedback and the consideration of technology within this was welcomed as an 
approach.  
7.5.4 Lean Wastes/ Lean Non-Value Add Activities 
This section explores Lean failures in healthcare identified from the literature review in 







Table 7.5.6 - Literature Review Lean Waste Categories Aligned with Cardiovascular 
Disease: Hospital Based Care Focus   
Healthcare Failure 
Area Identified in 
Chapter 3  
Evidence in Cardiology  
Waiting times   Documented evidence of growing outpatient waiting 
times. Some consideration to be given to changes in 
commissioning leading to expanding waiting lists.  
 Documented evidence of growing inpatient waiting 
times.   
Diagnostic   Patients with an undiagnosed heart condition (structural 
or congenital condition) lead to unplanned interventions. 
(Yock, 2015) 
Medical Complexity   Patients with a number of long term health conditions 
can result in conflicting treatment – chronic kidney 
disease, diabetes, cancer and asthma evident in the 
causes of readmission literature often linked to the 
medication conflicting and causing symptoms (Emerged 
in qualitative analysis – Cardiology focus group). 
Additional Healthcare 
Visits  
 Inconsistent number of review appointments leads to 
questions on over-processing or under-processing 
patients in certain hospitals.  
Co-ordination of 
Healthcare resources  
 Readmissions reduction requires coordination of service 
provision to ensure the patient has all requirements 
covered. Evidence of heart failure nurses being unaware 
of readmissions before their scheduled appointment. 
(Emerged in qualitative analysis – Cardiology focus 
group). 
Stress/overload of staff   Demand is significantly outstripping capacity therefore 
waiting lists.  
Repeated Procedures   Readmissions as a key repeat of procedures.  





consider alternative models which have been successful in 
maintaining quality outside of hospital. 
Cost  Readmissions results in additional costs to the system. USA 
Medicare and Medicaid programme financially penalise hospital 
for readmission.   
Quality   Clinically related quality issues such as recoiling of 
angioplasty, scarring called restenosis, AF treated with 
stroke medication with some side effects of bleeding, 
scar tissue associated to stents resulting in more surgery, 
stents introduced to balloon to address issue, ttransplant 
rejection and patient takes a stroke related to surgery 
(Yock, 2015) 
 Readmissions of patients can be regarded as a quality 
issue in a number of cases. Further treatment is required 
as the underlying issue has not been addressed or the 
therapy which has been provided is not suitable to 
address the condition. 
Emergency Admissions  High levels of unplanned admissions.  
Death   High levels of cardiovascular disease related mortality.  
 Failure to consider the adoption of palliative care for 
patients who have signs that this may be the best course 
of action. Result is that a patient may be treated for 
surgery or aggressive intervention that won’t benefit the 
patient but cause distress.  (emerged in qualitative 
analysis with cardiology focus group) 
Infections  Infection related to some of the reasons for readmissions. In 
particular hospital acquired infection is a specific waste.  
Emerging from this 
research and not 
covered in Lean 
Healthcare Literature 
 Lack of Continuous Improvement - due to the drive for 
cost cutting any innovation has focused on either proof 
of service delivery, addressing a target or reducing costs 
with limited focus on continuous improvement.  
 Limited use of technology to complement service 





 Limited use of data to personalise and inform the care 
needs  
 Personalised therapies and interventions not widely 
understood and lacking evidence 
 Non-value from monitoring of patients who are 
responding to treatment and don’t require further 
intervention.  
 
7.5.5 Discussion on the Hospital Based Care  
As research question one addresses Lean for long term conditions we find that the outpatient 
clinics are the source of expertise related to the condition. These are important areas to 
analyse as patients are requiring a longer engagement throughout their life. As patients’ lives 
longer with a condition there is a question of how to support a patient requiring specialist 
insight for a long term and if the outpatient clinic is designed to manage this level of patient 
engagement. What we can’t see in the data is the number of engagements a patient has over 
their lifetime and if this has increased as patients are living longer. Lean may have some 
options of considering this new type of demand and the implication on service design and the 
fitness for purpose of the traditional outpatient clinic. In the literature; Patel et al.(2008) , 
Mendoza et al.( 2009) and Tibaldi et al.( 2009) provide clinical trial evidence against 
alternative models of care in hospital at home type service design. There are Lean options of 
redesigning the outpatient service to address long term conditions or upskilling of the GP to 
be able to address specialist cardiology based monitoring and interventions and therefore 
reducing the demand on outpatients.  
 
Additionally, research question 2 explores the non-value add activities and it is important to 
analyse the emergency admissions which could have been avoided as non-value add activity. 





of unplanned admission and the other being the long waiting lists for outpatient and inpatient 
service. Lean can define both of these as waste but there is limited evidence of attempts to 
address this waste as there is a culture of accepting that waits and a public health system are 
connected. Reform initiatives focus on putting a target on the waste of a number of weeks but 
this fails to address the patient value perspective and fails to consider opportunities to change 
the approach based on intelligent data and potentially reducing demand. For example, data 
was not available about the number of patient who admitted as an unplanned admission but 
was on the waiting list. There is potential to utilise data to bring an intelligent waiting list 
which prevents an unplanned admission. The technology options will pick this discussion up 
later but from a Lean perspective the waiting lists are wastes, current measurements are not 
reflecting patient value and continuous improvement is focused on a system derived measure 
rather than patient value.  
 
This leads to the third research question addressing the area of redefining value from a patient 
perspective. As technology enables the provision of healthcare monitoring remotely, the 
blend of Lean addressing quality and patient value will be important to ensure that patient 
value is considered alongside clinical outcomes and cost. Technology also has a role on 
measuring missing data on the longer term effectiveness of treatment which can feed back to 







7.6 Medicines  
 
The previous section of the thesis analysed hospital based care for cardiovascular disease 
patients. This contributed to the aim of the thesis by analysing the role of Lean thinking 
application to integrated healthcare patient pathways. In figure 7.2.1 and duplicated in figure 
7.6.1 below one can see medications prescribed is the next set of activities within the patient 
value chain.  The medicines interventions have a series of activities but these are only a small 
part of understanding the implications of their use.  
 
The use of medicines rarely emerges in Lean literature except in its manufacture or 
dispensing. The cost of medicines, misuse and failures creates a fertile area for the research 
questions of this thesis. This chapter provides an overview of the medicines prescribed for 
cardiology and explores the Lean values, waste and emerging technology related to 
medicines.  
 
Medicine is being analysed within this chapter as a separate entity, however medication is an 
intervention throughout the patient flow. Patients may be given medication at the GP to deal 
with presenting symptoms and these medications can be amended, changed, added to or 
stopped as they progress along the pathway. Patients needs will also change as they age and 
other health conditions are detected. The analysis of medication prescribing in this section 
will reflect on these various interactions.  
 
As the aim of the thesis includes understanding the integrated healthcare pathway, it is 
appropriate to review medications impact to continue addressing the research question of how 





services that may be related to Lean wastes. It will continue to use cardiovascular disease as 
an example of a long term condition to provide focus and application.   
 
 
Figure 7.6.1 – Cardiovascular Disease Data Set – Focus on Medication  
7.6.1.1 Medicines Definitions 
Medicines used within the UK are classified through a standard called the British National 
Formulary (BNF). The BNF groups medicines for different conditions together with each 
grouping referred to as a chapter. Chapter 2 of the BNF is dedicated to cardiovascular system 
medicines which aligns with the focus of this thesis. The BNF chapter definitions are used 
widely on reporting medicine within open data information available in Northern Ireland. The 
BNF chapters, sub categories and detailed categories are broken down as shown in Appendix 





be grouped and makes it easier for clinicians to understand the type of drug and its purpose. 
GP’s and clinicians can therefore consider the risks and impacts of the various medications 
on the patient prior to selecting the drug they believe to be most effective with least side 
effects. This thesis will not analyse the clinical decisions around specific medication but 
looks at the trends, outcomes and costs associated to various decisions in the care pathway.  
7.6.1.2 The Role of Medication  
The use of medication is primarily to reduce patient risk of a clinical event, to manage an 
existing condition, to treat conditions, to reduce symptoms or alleviated pain.  The use of 
medication has expanded significantly both in volume and cost, related to this is the growth 
in the potential for delays and prescribing errors (Ker et al., 2014). Cardiovascular disease is 
a high user of medicines throughout the care pathway including all stages from prevention 
through to treatment. As many patients suffering from cardiovascular disease are elderly, the 
patient may have a number of conditions and therefore will have medication for a number of 
conditions which is referred to as polypharmacy.  
7.6.1.3 Future Development of Medication  
Medicines optimisation is the main term used in the Northern Ireland “Medicines 
optimisation quality framework” (Department of Health, 2017). This focus on optimisation 
was reflected in the establishment of a Medicine Optimisation and Innovation Centre (MOIC) 
at Antrim hospital. The framework presents five rights of medicines administration which 
are;  
1. The Right Patient  
2. The Right Medication  
3. The Right Dose  
4. The Right Time and Frequency of administration  





Qualitative discussions with the authors of the framework and the leads of the MOIC 
revealed that technology was at the centre of many of the future plans with trials ongoing or 
supporting medicines adherence and electronic prescribing. Beyond the operational 
improvements aspect, research is ongoing into the use of medicines in the prevention or 
reduction of the risk of cardiovascular disease (Yusuf et al., 2016). The term personalisation 
(sometimes referred to as precision) is used in many medication discussions for the future 
around using genetic information to target medication. For example Innovate UK, a 
government funder of future industry has established a number of large investments for the 
UK within centres known as Catapults (Innovate UK, 2016). One of these is a precision 
medicine Catapult.  
7.6.1.4 Medication Analysis in This Thesis 
With the definition, role and future direction explained, the remainder of section 7.6 will 
reflect the common approach of use in the previous sections of 7.2, 7.3, 7.4 and 7.5 by 
analysing;  
 Current role for cardiovascular disease medicines in academic and grey papers  
 Current measures and data within the Northern Ireland healthcare system 
 What is not measured  
 Cardiovascular disease medicines activities against the Lean non-value add activities 
identified in academic literature in chapters 2-4. 
From this analysis, the thesis can contribute to answering the research questions of how Lean 
can be adapted for long term conditions (research question 1) and contribute to identifying 
methods for health technology to address Lean non-value add activities (research question 2). 
The analysis will also build some insight into addressing where health technology can assist 





data utilised in medication is sourced from procurement related organisations rather than care 
provision data. As its purpose is somewhat different it can mean that there has been less 
analysis of its use in care provision.  
7.6.2 Analysis of Cardiovascular Disease Medicines through Papers and Grey 
Materials 
There is a significant wealth of papers on the creation and use of medication in general 
healthcare literature but very limited academic work linking Lean to medicines. Some 
exceptions to this included Lean applied to various drug dispensing application in hospitals 
(Ker et al., 2014). Similarly Hintzen et al., (2009) reported on cost savings of $289,256 with 
waste reduction and improvements in another hospital pharmacy. Other research searches 
have revealed Lean in medicine manufacture which is outside the scope of the thesis. In all 
these cases the criticism which was discussed in chapter 3 remains that Lean in healthcare 
focuses on the provider silo of the service rather than the patient. This is in contrast to the 
opportunity presented where there are patient value failures within the medicines. The gaps in 
knowledge about the outcomes of medicines in real life are not known despite the high cost 
and factors such as adverse genotype and clinical factors can impact significantly on success, 
failure, dose requirements and toxicity (Cavallari and Limdi, 2009). With medicine being a 
high cost area of healthcare delivery, with a large amount of known failure, there has been 
limited Lean intervention which leaves opportunity for the research question one to consider 
Lean can be adapted for long term conditions. As Lean has not analysed this area the 
remainder of this section will focus on key opportunities for improvement and the 
identification to non-value add activities and wastes. 
7.6.2.1 Adherence to Medication and Reconciliation  
Adherence to medication is a significant issue for healthcare with many academic 





who self-administered medication take only about 50% of the prescribed medication. In 
Northern Ireland alone this means that about £0.25bn of public medication is dispensed but 
wasted. That cost only relates to the medication and does not put a value on the cost of 
managing suboptimal health outcomes as a result of not adhering to the prescribed medicines. 
A key controlling factor in the readmission of patients is medicines adherence (Patterson et 
al., 2014). A major factor in avoiding hospital readmission is to ensure the patient has all 
their medicines within one week of discharge (Greene, 2012). This risk of readmitting to 
hospital is therefore linked to reconciling the medication, ensuring the patient has the right 
medicines and they take the medicines as prescribed.  From a Lean perspective this 
introduces a challenge that is not present in the car manufacturing businesses in that the 
consumption of the car is not linked to creating the value. If we assume that patient value is 
to be healthy then the adherence to medication is part of that yet the healthcare system is 
removed from this activity. Lean applied to long term condition must consider where the 
patient and the provider must co-create value. This provides some opportunity for healthcare 
technology as this can be deployed to support the patient and clinician.   
7.6.2.2 Cost 
While cardiology patients within Northern Ireland, during the period of the study, have not 
paid for the medicines it is recognised that pressure on the public financial system is 
significant. Cost is becoming a growing issue with affordability and the outcomes of 
medicine under increased scrutiny (Naylor and Cole, 2010). There is a need to look at new 
ways to find and prove value. Clinical decision makers are often unaware of cost implications 
between drugs of similar patient value (Time, 2013) therefore a doctor who may not have a 
preference between 2 drugs will randomly choose with no knowledge of the cost difference. 
Some of the implications of cost decisions are highlighted in the section 7.3.3 but what is 





ending the issue of medications which do not provide value and addressing wastes in the 
system such as overprescribing, non-adherence and the use of lower cost generic drugs where 
clinically safe. This is evident in the Northern Ireland “Medicines optimisation quality 
framework” (Department of Health, 2017).  
7.6.2.3 Emerging Medication Models  
There are some emerging medication models which provide opportunity for improvement. 
Prevention is a key topic for healthcare and the use of medication for this is an emerging 
trend. If a medication can reduce your cholesterol or blood pressure once you have been 
identified as being at high risk to prevent future intervention then medication could be 
considered. Yusuf et al. (2016) highlights research which used statins and cholesterol 
lowering drugs on healthy people as a way to reduce cardiovascular disease risk for healthy 
people. This research highlighted that the use of medicines to reduce risk must be balanced 
with the risk of creating alarm and the costs of side effects on the populations taking them. 
This is become a balancing of risks between prevention or screening high risk groups of 
individuals against negative or toxic respondents potential respondents. This could adopt the 
use of technology including machine learning and data mining techniques and has the 
potential to identify high risk patients who could benefit and also consider identifying those 
at risk of adverse drug reactions (Dominic et al., 2015).  
 
Related to the risk stratification is the use of personalised medicine approaches for long term 
conditions as there is significant waste and non-value add in the current activities of medicine 
which are not targeted. Fox (2015) reported on a USA precision medicine initiative which 
brought together various data sources including genotyping together to personalise the 
medicine choices. Personalised medicine or precision medicine reflects the current failures of 





targeting the drug to only those that will respond positively (Lee et al., 2013). Personalisation 
addresses this by attempting to identify the individuals who will be responders, non-
responders and toxic responders. This personalisation may use genetic attributes, racial 
characteristics, age or sex to determine if you are a responder. Personalisation could include 
target treatment by organ, prognostic biomarker to determine if you need treatment, 
predictive biomarker to determine what treatment will work and identifying those who won’t 
respond (Van’t-Veer and Bernards, 2008).  
 
This is relevant to this thesis and Lean for a cardiology patient as some patients will be 
administered medicines that provide no value and some will be administered drugs which 
will result in a toxic impact such as causing them to bleed. Aside from errors of administering 
the wrong medication or wrong dosage, about 7% of hospital admissions are related to toxic 
drug impacts (Cavallari and Limdi, 2009). Personalised medicine to identify if the medicine 
will work is still immature technology and accuracy has significant technical issues which 
make it open to misinterpretation (Lee et al., 2013). Linked to personalised medicines is the 
use of companion diagnostics. The FDA “In Vitro Companion Diagnostic Devices” guidance 
(2014, Pg. 5) makes reference to the use of companion diagnostics as a means of “selecting 
appropriate therapy for a particular patient or to optimize a dosing regime”. The advantage of 
using companion diagnostics to identify those who will benefit, remove those that are at risk 
of adverse reaction, monitor treatment response and identify groups of people where targeted 
clinical trials could be seen to be adequate for drug use approval (FDA, 2014).  The main 
Lean healthcare point of the promise of companion diagnostics is to remove quality failure 
and waste in the system, however the diagnostic itself can introduce new errors as the 






In summary; the papers, qualitative analysis and grey materials reveal a significant amount of 
waste in the use of medication with some opportunities emerging in the technology to address 
a personalised approach for testing if the medication will work for you or not. The adoption 
of personalised medicines for long term conditions must therefore be a key part of a Lean 
long term condition management as outlined in research question 1 as personalised medicine 
reflects patient value. Without this personalised care treatment approach, care will be given 
that raises hope falsely or causes toxic effects. Within this one has to be mindful of the early 
nature of personalised medicines as scientists are only beginning to link genetics to 
responders or non-responders and there is some way to go before this becomes mainstream 





7.6.3 Analysis of Current Measures and Data within the System  
In this section Northern Ireland open data sources have been used in quantitative data 
analysis for medicines in cardiovascular diseases. Different from previous quantitative 
analysis sections is that data is sourced from procurement information.  Some medicines may 
be procured outside of the scope of this data where it has been privately acquired by a patient 
and this has been determined as out of scope of the data being investigated as it is a small 
scale and related to not controlled medicines such as over the counter tablets and herbal 
remedies. The source of the data is through the Business Services Organisation (BSO). The 
BSO is a shared service for the health service in Northern Ireland. It has responsibilities for a 
number of shared services in the Northern Ireland public health Service include the 
procurement of medicines.  
 
Data from the BSO the “Analysis of the Prescription Cost Analysis Northern Ireland 2016” is 
detailed in Appendix 7 - Table 4 and reveals that cardiovascular system prescriptions (BNF 
Chapter 2) are the 2
nd
 highest in terms of volume at just over 22%. In addition they are the 2
nd
 
highest cost although at a much lower percentage of just below 12%. Central nervous system 
(BNF Chapter 4) is the highest for both volume and cost. The top three for cost and volume 
are highlighted below.  The total medicine cost is listed over £439 million before discount. 
This context of what the cardiology spend is and how medication fits within the overall 
medication spend is relevant to this thesis as improvement via Lean and the application of 
technology requires this cost context.  
The analysis of a longitudinal view of the data, specifically related to cardiology, shows that 
over the period for 2011-16 there was significant change. There was a 9.67% growth in the 
volumes of cardiology related medicines which had an average year on year growth over the 





prescription items. These items are multiple per person as the chart highlights over eight 
million prescription items. The growth reflects previous data of more patients being treated 
and initially identifies a trend of growth which appears unsustainable at face value if cost and 
volume are matched.  
 
Figure 7.6.2 – Line Chart of the Number of BNF 2 (Cardiovascular system) Prescription 
Items (Source Data: BSO Pharmaceutical Statistics, 2018) 
 
The cost analysis reveals a more complex picture with a 26.45% reduction in the 
"INGREDIENT COST (BEFORE DISCOUNT)" over the period of the analysis. This reflects 
£18.7m less spends between the start of the analysis and the end. The analysis reflects further 
complexity as far from being a constant pattern the cost increases in three of the six years. 
The largest increase for the period was 6.80% and the largest decrease was -17.7% which 
reflect significant fluctuations. The volume increases and the cost decreases highlight a 
complexity and the importance of data rather than assumptions. Further exploration of the 









Figure 7.6.3 – Line Chart of the Ingredient Cost (Before Discount) of BNF2 
(Cardiovascular system) items (Source Data: BSO Pharmaceutical Statistics, 2018) 
 
As previously mentioned the analysis has been completed using the BNF Chapter 2. A further 
breakdown is available which is referred to as a “section” and this breakdown is illustrated in 
figure 7.6.2. “Lipid-Regulating Drugs” (Section 12) and “Drugs Affect. Renin-Angiotensin 
System+Other Antihypertensive” (Section 5) have the largest growing volumes. “Antiplatelet 
Drugs” (Section 9) and Diuretics (Section 2) both show a slight decline in volume. The 
analysis highlights an opportunity to utilise a Lean tool about identifying the runners, 
repeaters and strangers. This approach can provide some efficiency in ensuring the most 
common demands (Lean Term Runners) are standardised and improved from a standardised 
base. Repeaters then follow a common approach which is developed to become more 
standardised and the less common demands (Strangers) are managed with identified 
resources.  
 Lean Runners - Lipid-Regulating Drugs (Section 12) and Drugs Affect. Renin-
Angiotensin System + Other Antihypertensive (Section 5) 






 Lean Repeaters – All other Medicines 
 
Figure 7.6.4 – Stacked Bar Chart to Highlight the Volume of Prescription Items:  2011 – 
2016 (Source Data: BSO Pharmaceutical Statistics, 2018) 
 
The earlier data highlighted that volumes alone can provide a misleading picture. The cost 
analysis of the chapter data reveals some dramatic new information. The overall picture was 
of cardiovascular disease medicines reducing significantly over the time or analysis within a 
period of volume growth. The cost data however paints a more detailed picture with the most 
dramatic change over the same time period in cost is LIPID-REGULATING DRUGS from 
section 12. The cost reduction during this period was approximately £22.79 million. It should 
be noted that the cost reduction from this one section is higher than the overall cost reduction 
for the whole chapter which means that other medicines are increasing in cost at the same 
time. The chart shows ANTICOAGULANTS AND PROTAMINE (Red) in series 8 
increasing heavily over the time period. This is equivalent to an increase in cost of £11.72M 








Figure 7.6.5 – Stacked Bar Chart to Highlight the Ingredient Cost (Before Discount) of 
Prescription Items: (2011 – 2016) (Source Data: BSO Pharmaceutical Statistics, 2018) 
 
The above chart highlights that the following prescriptions are increasing in cost during the 
time period;  
 Positive Inotropic Drugs   
 Sympathomimetics 
 Anticoagulants And Protamine                                
 
Figure 7.6.6 highlights that the following prescriptions are decreasing in cost during the time 
period;                    
 Diuretics                                                    
 Anti-Arrhythmic Drugs                                        
 Beta-Adrenoceptor Blocking Drugs                             
 Drugs Affect.Renin-Angiotensin System+Other Antihypertensive 
 Nitrates,Calcium Chan.Blockers+Potassium Channel Activators                                          





 Antifibrinolytic Drugs And Haemostatics                      
 Lipid-Regulating Drugs                                                                                                                                             
Figure 7.6.6 reveals that the following have very low volumes  
 Local Sclerosants 
 Sympathomimetics 
Further analysis exposes that although Sympathomimetics reflects a low volume, the volume 
increased by 1590% between 2015 and 2016. This reflects the changing nature of medicine 
discovery where new drugs go through approval to formal acceptance and roll out. This 
highlights the need to have a Lean continuous improvement process identifying changes in 
demand and supply. The analysis highlighted that Anticoagulants and Protamine are a key 
area of growth adding both £11.72M cost increase as well as a volume growth of over 71%.  
 
Further data from the BSO was available in the Prescription Cost Analysis from Northern 
Ireland to allow the analysis to define the exact medicines within any chapter and section. A 
selection of this has been analysed by selecting the Anticoagulants and Protamine section 
data which has been presented in the below. The analysis takes a large volume of prescribing 
data and consolidates these into drug names which group various volumes and costs.   
Consolidating the data allows a focus on this particular medicine without the distraction of 
volumes and methods of delivery. By focusing on the Anticoagulants and Protamine section 
within this analysis it reveals 23 named drugs in this category used within the HSC. Analysis 
of the increasing volumes reveals that just under 80% of the medicines cost is made up of 
three specific drugs which have been highlighted below in the Pareto analysis of all the 






The data itself is insufficient to make informed decisions about good practice or inform 
reform but this type of root cause analysis considering both volume and cost has potential for 
addressing patient needs better and considering the cost implications of decision making. A 
common approach in Lean would be the 5 Whys. For example further understanding on why 
it is necessary to have 23 drugs may be relevant as Lean operations have found value in 
reducing their available suppliers and building more strategic relationships. Table 3 in 
appendix 7 reveals technical details about the volumes of medicines with 3 drugs making up 
over 79% of the costs.   
A second point emerging in the data above is that the highest volume use is warfarin yet it is 
only 3.93% of the total cost. Warfarin is known to be a significant risk to patients and the 
patient is often monitored heavily as high dosage can result in thinning the blood too much 
and has significant and fatal implications. The NHS website highlights that patients must 
follow guidance very carefully and testing;  
 
“You'll have regular blood tests at your GP surgery or local anticoagulant clinic to 
make sure your dose is correct.” – (NHS Choices, 2016)  
 
The Lean challenge is that the warfarin represents a low cost solution used by a large volume 
of patients. The cost however is not a full cost as the patient must attend various clinics to test 
blood regularly. The NHS website however reveals that rivaroxaban, apixaban and dabigatran 
are alternative emerging solutions that do not require the monitoring clinics.  
 
In a simulation scenario for this thesis, where the same volume of warfarin was replaced by 
Rivaroxaban this would increase the cost for medicines in this category from £13.7M 





purchases and other factors may mean that the volume is not a 1:1 replacement. The concept 
of hidden costs in the value stream is an important factor for Lean reform considering long 
term conditions. The cost of the failure of warfarin in terms of death and monitoring of 
patients is difficult to quantify yet the scenarios of new medicines reveals significant cost 
hikes that may be beyond the reach of a struggling health budget at face value.  
7.6.3.1 What Data is Not Captured? 
Linkage between the medicine and other health data such as readmissions and hospital 
admissions would be useful analysis to understand if medication is leading to lower costs 
elsewhere in the system. Opportunities are lost as the activity of the rest of the treatment is 
not available which means that one can’t triangulate with the implication of bed days or other 
costs. The full cost of a medicine is not available as the cost of supporting activities such as 
clinics to monitor the INR measurements of patients are not provided.  
 
Relationship between medications is not explored as patients with co-morbidities require 
multiple medications which may conflict leading to poor value. This was revealed in 
qualitative analysis where patients approaching end of life were removed from medication to 
then significantly improve revealing the medication causing part of the condition rather than 
being a value add. Linked to this are medicines adherence issues and the link to the good 
practice of discharging clinicians. Patterson et al. (2010) highlights that prescribing of data 
blockers at discharge resulted in lower mortality rates but this assumes the patient is taking 
the medication as prescribed. Adherence is not measured routinely and technology does not 
provide an adequate solution to address adherence effectively. 
 
The outcomes of medication are not measured and this is one of the largest failures in the 





based on the fact that some drugs don’t work on some people but in practice it is not known 
who they don’t work on. For this reason the outcomes of real world use of medicines is 
largely not known.   
7.6.4 Lean Wastes/ Lean Non Value-Add Activities 
This section explores Lean failures in healthcare identified from the literature review in 






Table 7.6.1 – Literature Review Lean Waste Categories Aligned with Cardiovascular 
Disease: Medicine Focus   
Healthcare Failure 
Area Identified in 
Chapter 3  
Evidence in Cardiology  
Waiting times  Literature reference to drugs not being available at discharge 
resulting in readmissions for heart failure patients.  
Delays  Delays in identifying decline in patients’ health due to titration of 
medication after discharge results in patient readmitting in heart 
failure.     
Diagnostic  Companion diagnostics provides opportunities to diagnose the 
impact of the medication. This is largely not done today therefore 
there is a waste associated to lack of diagnostics.  
Medical Complexity  Drugs issues (BMA concise guide to medicines and Drugs fourth 
edition 2012) 
 Oxygen supply in blood  
 Flushing headaches  
 Dizziness fainting  
 Dangerously Lower blood pressure  
 Swelling  
 Kidney issues  
 Blood levels rise in acids  
 Risk of Gout  
 Blood sugar levels risk to diabetes  
 Overactive Thyroid  
Related diseases/symptom (BMA concise guide to medicines and 
Drugs fourth edition 2012) 
 Hypertension  
 Blood pressure  
 Angina 
 Stroke  





 Breathlessness due to excess fluids related to drugs not 
working to remove fluids.   
Additional 
Healthcare Visits  
Incorrect or ineffective medicines leading to additional 
appointments with doctor.  
Co-ordination of 
Healthcare resources  
Impact of medicines leading to co-morbidities issues not 
addressed.  
Length of Stay  Ineffective use of prescribing in early stages will result in longer 
lengths of stay.  
Cost   High cost of drugs  
 Hidden costs of having to monitor biomarkers for specific 
medications that can be dangerous, addictive or have 
negative side effects.  
  Overprescribing (significant discussion in qualitative 
analysis – medicines focus group).  
Quality   Providing drugs or treatments to non-responders of 
medicines. This is not known at time of prescribing and 
will not be an error but does reflect overall quality.  
 Medication leading to poor health outcomes – toxicity. This 
is not known at time of prescribing and will not be an error 
but does reflect overall quality. 
 Staff turnover within the care sector reflects lower 
knowledge transfer and skills for medication. This is 
relevant as many patients care sector will have cardiology 
related conditions many medicines. (Discussion in 
qualitative analysis – medicines focus group). 
Emergency 
Admissions  
Significant numbers of emergency admissions are linked to 
medication issues. (discussion in qualitative analysis – 
medicines focus group). 
Death  Medications can result in a threat to life with warfarin and 
blood thinning medications of particularly high risk.  
Medication errors   Wrong drugs or dosage prescribed based on not following 





 Drugs selection not considering other health conditions 
such as diabetes, asthma or kidney issues. (co-morbidity). 
Infections  Antimicrobial resistance is an issue in drug prescribing policy. 
This is linked to not having the right drugs to address an 
infection (Significant discussion in qualitative analysis – 
medicines focus group). 
Emerging from this 
research and not 
covered in Lean 
Healthcare Literature 
Service provision often fails to address client choices of 
individuals who may want to trade-off longevity or symptoms 
against quality of life aspirations. E.g. tolerate pain but avoid 
side-effects of medications which prevent family engagement. 
 Limited use of technology to complement service delivery 
 Limited use of data to inform the care needs – no single 
view of medications prescribed today. (discussion in 
qualitative analysis – medicines focus group). 
 Examples of medicines technology have struggled to define 
route to adoption  
7.6.5 Discussion on Medication 
Medication has a high failure rate which is not fully understood by the patient and is accepted 
by the medical establishment due to being perceived as doing more good than harm across 
patient groups. Within the medical establishment however while there is acceptance that in 
approving a drug a calculation has been made that side effects will be evident for some 
groups but what is not understood is the actual outcome for all patients. This is not measured 
beyond returning patients with side effects or lack of progress where at that stage the doctor 
may change to an alternative drug.  
 
Lean and technology have opportunities to start to measure those outcomes over longer 
periods in real time outside of the clinical trial. Emerging technology in the form of 





address the waste through identifying toxic and non-responders with more accuracy using 
genetics and other factors. In addition technology has options of providing prompts and 
advice to prescribers who are about to prescribe drugs that conflict with other conditions. 
Technology can support drugs reconciliation against best guidance and presenting conditions 
to provide options to address the waste of bad prescribing patterns and provide clinical 
decision support for doctors. In these points research question 2 is starting to be addressed as 
technology can identify the Lean wastes and begin to address these.  
 
The data analysis also reveals some significant changes in costs that have the potential to be 
unsustainable in a budget constrained health service. Lean healthcare technology could assist 
in modelling and making decisions around this as full patient focused value streams could 
assist in keeping focus on patient value rather than additional cost drivers.  
 
Finally, the engagement with the patient is a significant gap not explored in Lean healthcare 
and has significant impact on long term conditions. This comes in two places with the first 
being related to adherence to medication and the second being in decisions about treatments 
that create value for a patient. The medication adherence is a complex area with many issues 
about why medication is not taken. Some of it may be related to forgetfulness, bad advice, 
side effects, public news on the specific medication and a belief that they don’t need it 
anymore. Within this is a mixture of fact and perceptions and Lean has a potential to 
understand the root cause in order to identify steps forward. A specific Lean tool around the 5 
whys is an option with patient groups. The second point about decisions around treatment is 
again a complex issue as a patient may make a perfectly logical decision to not be treated or 
not take medication. A patient may feel that further surgery or intervention is not welcome 





family. Similarly medicines to thin the blood which are risk reducers may result in dizziness 
or lack of confidence that is unwelcome to a patient and they may prefer the higher risk with 
less daily side effects. In both cases patient value is emerging which may not be the medical 
professions first choice but in long term conditions identifying value for the patient will be 
paramount. In this point research question 3 is beginning to be addressed as health 
technology and data can begin to redefine patient value. This can also assist in answering 









7.7 Healthcare Technology  
The previous section of the thesis analysed medicines for cardiovascular disease patients in 
the care pathway. In this section the thesis moves away from activities within the value 
stream to supporting technology.  In figure 7.2.1 and replicated within figure 7.7.1 below one 
can see healthcare technology is the final focus area to be analysed. In chapter 4 of this thesis 
the use of technology within healthcare revealed opportunities to address patient value and 
the absence of technology within Lean healthcare publications. This section will assist in 
addressing research question 2 about if healthcare technology can assist in identifying and 
addressing Lean non-value activities. In addition research question 3 can be addressed by 
considering of healthcare technology from data focused technology can assist in redefining 
patient value.  The focus will be on the use of technology in cardiovascular disease to avoid 
replicating any findings from chapter 4.  
 





7.7.1.1 Technology Definition in Cardiovascular Disease  
The NHS strategic document “Five Years Forward View” (NHS, 2014) is the current strategy 
documents for technology in the NHS. In the foreword it states that we should “take 
advantage of the opportunities that science and technology offer”. It also refers to technology 
giving us the ability to “predict, diagnose and treat”. The World Health Organisation defines 
healthcare technology as “the application of organized knowledge and skills in the form of 
devices, medicines, vaccines, procedures and systems developed to solve a health problem 
and improve quality of lives” (WHO, 2016). Within these two different organisations one can 
see healthcare technology definitions can be specific to care intervention or wider impact on 
the organisation of care and supporting a patient. For the purposes of this thesis the definition 
will cover specific care provision and the organisation of care. This wide definition is 
necessary as the research questions asks about non-value add activities, dealing with long 
term conditions and patient value which is inclusive of specific care intervention and system 
to assist in organising healthcare delivery.  
7.7.1.2 The Role of Technology  
Technology, systems and digital provide a role in organising care which can be within a 
specific clinical group or across clinical boundaries and promoting the sharing of information 
between professionals (NHS, 2014). The technology can also be suitable for clinical purposes 
such as scanners and determining DNA types. Beyond the organising of care and clinical 
utility there was also a role for technology to engage patients through managing their data, 
accessing information and sharing data with clinicians. Finally there is an operational use in 






7.7.1.3 Future Development of Technology  
The future technology in health emerges from a sense of previous failures and the National 
Advisory Group on Health Information Technology in England (Wachter, 2016, Section 4) 
said “overly centralised decision-making, combined with a lack of local engagement, meant 
that users’ needs were poorly understood and providers were directed to implement at pace 
systems they had little say over”. The failures recognises two extremes which have both not 
worked which is a highly centralised approach linked to the NHS England “Connecting for 
Health” programme resulting in no local ownership and ‘letting a thousand flowers bloom’ 
which meant that there was thousands of different systems and standards (NHS, 2014).  
 
Enabling and enhancing care which is out of hospital, supporting community based care and 
integrating systems appear to be the key directions which support an ageing population and 
by default the cardiology patient. While these aspirations make some degree of sense they do 
also mention a need for more evidence of the effectiveness to support the use of technology. 
Within this lies a number of tensions for technology which are that technology is disruptive 
and clinical evidence is slow at best and often inconclusive. Additionally technology can cost 
money for cash constrained organisations (Currie and Finnegan, 2011).  
7.7.1.4 Technology Analysis in This Thesis 
With the definition, role and future direction explained, the remainder of section 7.7 will 
adopt a similar approach of use in the previous sections 7.3 through to 7.6 by analysing;  
 Current role for healthcare technology in academic and grey papers  
 Emerging measures and data healthcare systems 





 Cardiovascular disease healthcare technology against the Lean non-value adds 
activities identified in academic literature in chapters 2-4. 
What will be different from previous sections however is that this will not focus on specific 
patient data but on information about the use of technology at the various stages of the 
cardiovascular disease value stream. The section on the current role for healthcare technology 
will look at the current use of technology across the value stream and the mapping of 
technology onto the sections of the patient value stream that have been explored in section 
7.3-7.6. The emerging measures and data section for technology is a modification from 
earlier chapters as instead of looking at the patient data it will look at data to suggest 
emerging technologies that may be of relevance. In previous chapters this was limited to 
Northern Ireland but to be relevant to the research questions this will be expanded beyond 
Northern Ireland to technology searches of emerging technology of relevance to Northern 
Ireland cardiovascular disease care provision. Again the emerging technologies will be 
mapped against value stream activities explored in sections 7.3 – 7.6.  
 
From this analysis one can then contribute to answering the research question 2 about if 
healthcare technology can assist in identifying and addressing Lean non-value activities and 
research question 3 about addressing if healthcare technology from data focused technology 
can assist in redefining patient value.  Figure 7.7.1 illustrates the source of data used to build 






Figure 7.7.2 – Developing a Health Technology Data Landscape  
7.7.2 Analysis of Cardiovascular Disease Technology through Papers and Grey 
Materials 
This section considers the technology application related to cardiovascular disease. This 
analysis will focus on the current use of technology either in current healthcare practice, in 
papers or identified in grey papers. The analysis will utilise the chapter topics along the 
values stream as identified in section 7.3-7.6 which are;  
 Prevention, primary care, community care and personal health  
 Diagnostics 
 Hospital based care  
 Medicines 
By linking together the value stream activities with the use of technology in this section it is 





provision. In figure 7.7.2 technology has been identified from a number of strategic 
documents and mapped against the thesis section headings which represent the cardiovascular 
patient journey. What becomes clear in doing this is that although there are strategic 
intentions to include certain aspects of technology there are gaps. What is learned from this is 
that many of the items of current provision are relevant to patient value however there are 
large gaps in the provision of that technology. In particular these unmet needs related to what 
is happening outside of the hospital and are blind spots to the clinicians and decision makers. 
The clinician can for example see what is happening to the patient within their care but they 
are unable to have any real-time feedback on response to therapy outside of the hospital 
(Sharon, 2017). In addition the area of prevention is a large gap. Technology has had some 
impact on prevention strategies with mobile health addressing diet, education, risk reduction, 
surveillance and disease screening. Franklin et al. (2015) paper on “Personal health 
technology: A new era in cardiovascular disease prevention” highlights that ICT offers 
“affordable, approachable and accessible” mediums for delivering healthcare for 
Cardiovascular disease. A key phrase appearing in the paper is behaviour change which is 
reflected in strategies but is often seen as a missing ingredient in the outcomes of public 







Figure 7.7.3 –Technology of Use Case for Cardiovascular Disease 
7.7.3 Analysis of Current Measures and Data within the System  
Technology is evolving at a rate that makes it difficult to utilise academic or current practice 
publications alone as a good barometer of the future adoption. Exploring technology 
identified in emerging technology conferences and other areas outlined in 7.7.2 may address 
some of these gaps. To address this, an analysis of emerging technologies from suppliers and 
other providers will be used. This section does this by analysing;  
 Supplier conference trends  
 Funded emerging innovations  





This analysis will continue to be focused on cardiovascular disease as an example of a long 
term condition and the research questions 2 and 3 where addressing non-value and utilising 
technology to assist in redefining patient value in important.  
7.7.3.1 Emerging Supplier Commercial Offerings 
Trends in commercial and healthcare focused conferences can provide insight as they reflect 
emerging products from suppliers. Many of the conferences provide supply side technologists 
a platform for interested parties to see their solutions. The four following conference 
represent a mix of European and International conferences with relevance to cardiovascular 
disease.  
Table 7.7.1 –Sample of Health Tech Conference in 2016  
Conference Medica, 
Dusseldorf – 
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In summarising the supplier’s interests one finds a number of common areas emerging across 
the various industrial conferences;  
 Laboratory Equipment  
 Medical Devices  - Including Diagnostic Devices  
 Digital Tools   
 Electronic Health Records  
 Communication  
 Informatics  
 Healthcare Apps  





Similar to the previous section from the healthcare providers; laboratory equipment and 
medical devices form a key part of technology related to cardiovascular disease. When 
exploring from the supplier side there are clearer product related to the integration of 
technologies that are not specific to cardiovascular disease but are needed to link systems and 
administer patients. These can be absent from strategy and related documents as they reflect 
back office systems which are needed but aren’t somewhat unattractive for a strategy 
document.  
In private healthcare markets such as the USA and the Republic Ireland, the linking of data is 
not as mature as the UK and forms a bigger part of the demand from healthcare provider’s 
aspirations. The American strategies refer to the Hi-tech Act which outlined an electronic 
health record strategy with various incentives and penalties. Informatics plays a larger role in 
the supplier conversations but is present in both.  
The use of data is seen as core to the future for all localities but this has some caveats around 
the sharing of data. “Care.Data” is an example of a UK government initiative which was 
largely rejected by the public due to fears over security and decision making. This is in 
contrast to progress in other parts where the sharing of data has occurred without the same 
levels of controversy.  The use of apps and consumer focused technology has however been 
sporadic and lacks high levels of adoption. In this area we see a mismatch between supply 
side and the demand from providers.  
Diagnostic equipment has largely been an accepted part of healthcare for some time now. The 
equipment has gone through a slow evolution with the identification of various bio markers 
being a constant theme. The number of biomarkers in clinical practice or how they are used 
has not undergone significant change despite the discovery of new biomarkers. In 





which are used. The introduction of novel measurements can be slow and difficult to drive 
mainstream adoption. This point emerged in qualitative analysis with the cardiology focus 
group where it emerged there were very few accepted new biomarker of shared value among 
the cardiologists. Point of care diagnostics to take the “lab” closer to the patient is of interest 
but this again does not have widespread adoption at this stage.   
Medical devices have been in used as a technology for some time and form a large part of 
today’s healthcare pathways in cardiovascular disease. Diagnostic procedure to measure the 
heart in various states is a core of the decision making.  
One can also see that technology is already in use for risk scoring systems, decision supports 
and automated ECG interpretation attempt to assist in managing the complexity presented 
and the tools aim to reduce the risk of inappropriate discharge as part of a clinical assessment.  
7.7.3.2 Emerging Innovators (Funded by Innovate UK) 
Innovate UK fund the technology industry (mainly SME’s) for emerging projects. Data on 
summaries of these projects is available in an open data format for projects since 2004 
(Innovate UK, 2017). The data from this is useful to identify potential emerging products and 
interests from a technology push perspective. For this analysis 2011- 2016 has been focused 
on and the terms cardiology, cardiac, cardiovascular and heart failure have been used as key 
search criteria. An analysis of each of these technologies was completed to link the 
technology to Lean failure potentials and a summary of the learning is available from the 








The analysis of the emerging technology from Innovate UK reveals number of interesting 
overlaps with previous Lean cardiology studies from 7.2 – 7.6.  
 The lean failures of medicines, diagnostics, infections, decision are overlapping with 
the technology push from the Innovate UK technology projects.  
 Training is an area that has not emerged on the Lean side of the analysis but appears 
in the Innovate UK technology projects.   
 Implantable devices which are relevant to cardiac surgery are covered in this list but 
not identified in the Lean discussions as clearly due to the focus on higher level flow 
of patients.  
7.7.3.3 Emerging Digital Trends  
Beyond the specific Innovate UK technology projects one can see a number of emerging 
digital trends in analysis and throughout the qualitative discussions. These include interest in 
social media, IOT, data analytics, machine learning and virtual reality.  
 
The use of social media is not widely explored in the patient journey or patient value. This 
seems counter intuitive as patients are using mobile phones and search engines frequently as 
a symptom checker. To illustrate its potential a number of the key medicines for 
cardiovascular disease identified in 7.6.3 which were showing growth in volumes and costs 
included warfarin, Rivaroxaban, Apixaban, Enoxaparin were analysed on social media. The 
following google data analysis was then completed to illustrate google trend analysis and its 






Figure 7.7.4 - Google Trends for Warfarin, Rivaroxaban, Apixaban, Enoxaparin 2011-
2017 (Source: Google, 2017) 
 
Figure 7.7.5 Google Related Queries for Warfarin, Rivaroxaban, Apixaban, Enoxaparin 
2011-2017 (Source: Google, 2017) 
What is clear is that the high volume of google search interest reflected in the trend data is 
related to warfarin however one can see that over the 5 years the other three medicines are 
growing in their relevance. With this analysis, it starts to build the frequently asked questions 
related to Warfarin which may be an appropriate route for personalised education. The 
analysis highlights the ability to look at geographic localities and there are opportunities to 





of digital and social media data may therefore be useful in understanding patient behaviours, 
patient queries and potential emerging patterns of non-adherence to specific drugs or 
treatments. The use of social media data in healthcare is not without issue as flu surveillance 
used social media data from over 50 million search terms data. This however predicted more 
than double the proportion of doctor visits for influenza like illness than the Centre for 
Disease Control and prevention (CDC) which bases its estimates on laboratory reports (Lazer 
et al., 2014). Additional issues are raised around the widespread adoption of social media due 
to changing algorithms by providers and influence of manipulation from commercial 
organisations with marketing campaigns.  
 
Augmented reality has found some use cases for healthcare education due to the cost and 
resource intensive nature of medical training although this was mainly linked to early 
explorations and lacked scale or widespread adoption (Zhu et al., 2014). Remote healthcare 
also made some attempt to utilise augmented reality with the focus on bring better healthcare 
to remote locations (Heyes et al., 2017). In addition, the WISH conference referred to in the 
market analysis had an example of augmented reality supporting remote supervision of hand 
surgery. In summary the area has some potential but it us very early stages to create valuable 
and scalable products.  
 
The use of analytics and machine learning has a lot of potential for learning behaviours and 
relationships which are not fully understood by clinicians today. A significant amount of 
literature is emerging on the topics of big data, machine learning and artificial intelligence in 
healthcare which is beyond the scope of this thesis. Within the thesis scope a number of 
explorations are being completed with the use of machine learning in cardiovascular disease 





gathered from clinical disease datasets. These explorations see potential in bypassing clinical 
trials, reducing admissions, finding adverse drug reactions, reducing hospital acquired 
infections and reducing fraud by using data analytics (Dominic et al., 2015) 
 
The Internet of Things (IOT) is a term that is frequently on the market strategy documents of 
many technology organisations. Emerging behind the IOT devices are novel networks which 
have the ability to communicate over a long range with low levels of power. At its simplest 
level, the technology provides a means of inexpensive secure long distance communication 
between a sensor based in the community and the owner of the sensor.  Examples include 
LoRa and Sigfox. The communication requires very little power so a sensor may have a 
battery attached which is sufficient for the life of a device. The sensor could be measuring, 
temperature, location, movement, air quality or many other pieces of data. The data can be 
passed back to a server and presented to a decision maker with other similar pieces of data. 
Businesses are exploring new solutions with this inexpensive data collection to monitor 
tourism, improve agriculture, streamline health service delivery, improve service delivery and 
drive up operational efficiency. This is the Internet of Things, but many of the business 
applications are still to be discovered. Specifically for cardiovascular disease there are 
opportunities linked to smart cities about health promotion which has a direct impact on non-
communicable diseases such as cardiovascular disease due to the promotion of healthy 
activities which reduce risk factors. This has been evident in Belfast City Council Smart 
Belfast initiative where health is one of five challenges for a smart city (Belfast City Council, 
2017).   
Other trends such as wearables have some interest but recognition that 60-70% variability 
between devices is not appropriate for clinical grade data. GI Medicine is also technology 





with vital signs again have also some futuristic opportunity when refined and applied to the 
clinical challenges in a robust manner.  
7.7.4 Lean Wastes/ Lean Non Value-Add Activities 
This section explores Lean failures in healthcare identified from the literature review in 
Chapter 3 in technology for cardiology patients.  
Table 7.7.2 – Literature Review Lean Waste Categories Aligned with Cardiovascular 
Disease: Technology Focus   
Healthcare Failure 
Area Identified in 
Chapter 3  
Evidence in Cardiology  
Waiting times   Technology to reduce reporting waiting time of diagnostics 
tests.   
 Long waiting time for technology such as MRI scans, ECG 
testing, and  
Delays   E-referral to remove delays   
 Information exchange via electronic health care records   
Activity Transaction 
Speed  
 Point of care testing can remove delays in diagnostic 
information therefore accelerating the decision time for 
beginning treatment.  
Diagnostic   Technology available to provide rapid diagnostics to remove 
waiting delays.  
 Technology can create wastes in false positives and false 
negatives which can lead to unnecessary investigations or 
treatment.   
Medical Complexity  Technology can assist in clinical decision support for complex 
decisions requiring insight from different clinical specialties.  
Additional 
Healthcare Visits  
Patient groups can receive activities which do not add value to 
them as individuals - medicines for example improve patient 
groups, not individuals.  





Healthcare resources  medication record, shared allergy information all contribute to 
the coordination of staff.  
 Updating of electronic records can add additional activities to a 
busy healthcare worker compared to ticking a box on a paper 
based system. Issues identified in technology implementation 
of additional time requirement and also loosing 
patient/clinician contact time while clinician updating records.  
Length of Stay  High ALOS related to heart failure patients. Opportunity to 
consider alternative models which have been successful in 
maintaining quality outside of hospital.  
Quality   Biomarker related technology to focus intervention to 
specific needs.  
 Innovate UK (2017) new products emerging identified 
various clinical measures that were not of a high enough 
accuracy – such as cardiac output measurements.  
 Diagnostic technology depends on high sensitivity (identify 
those with the disease) and specificity (identify those 
without the disease) or waste and failure will be created.  
 Stents and pacemakers both address quality issues but 
procedures can then create quality failures such as clotting, 
incorrect procedures or responses from specific patient 
groups.  
Medication errors   Companion diagnostics can identify the patients who will p 
respond to medication and non-responders to remove 
errors. (Lee et al., 2013) 
 Medication compliance technology in its infancy with 
IOT/smart homes technology providing some options 
around reminders.  
Infections   Use of technology may be a source of some infectious 
disease spread as machines and technology are passed 
between professionals (Design consideration and cleansing 
processes needed).  





infection, staff behaviors in a hospital that may have led to 
infection spread, patterns of drug dispensing that would 
encourage drug resistance leading to infections and data 
relationships to environmental factors.   
 Technology can be used to keep people away from 
infectious disease areas but still gain access to professional 
clinical advice remotely.  
Emerging from this 
research and not 
covered in Lean 
Healthcare Literature 
 Promotion of wellness, education and engagement with 
patients to address poor behaviours about their condition. 
Missed in Lean healthcare as focus is on activity. Emerging 
opportunities in augmented reality and virtual reality to 
encourage better engagement in education.   
 Social media provides insight to the “patients” queries and 
issues that will need addressed yet this is not actioned or 
acted upon. As demonstrated with warfarin in the previous 
section.  
 Diet and exercise related technology missed in Lean 
healthcare as method of addressing risk factors for patients. 
High impact due to obesity leading to most non-
communicable diseases.   
 Emergent models such as telehealth, telecare, hospital at 
home missed by Lean healthcare approaches.  
 Self-care and self-management. With technology help.  
 Overload of data from technology can result in further 
confusion. 
 Waste opportunities in the patient information due to not 
aligning data leading.  
 Technology which does not consider the use within a 
working hospital may result in too many alarms which are 
known as alarm fatigue by staff. 
 Risk scores to identify patients at higher or lower risk can 
be dynamically supported by technology – for example e.g. 





cardiology as a measure of risk for specific heart rhythms 
or stroke. (Svendsen et al, 2013) 
 Waste opportunities in the patient information due to not 
utilising data to inform when to begin end of life or 
palliative care planning and change in emphasis of care.  
7.7.5 Discussion on Technology 
By applying technology to the activities in cardiovascular disease in sections 7.3 – 7.6 it is 
possible to identify contributions to research questions 2 & 3 as technology a number of 
technologies have been identified that can assist in identifying Lean non-value add activities 
and assist in redefining patient value. The analysis shows that prevention, primary care, 
community care and personal health have a lack of technology embraced in targeting 
exercise, wellness and community based use cases that could prevent cardiovascular disease. 
Prevention of the disease would address significant portions of the World Health 
Organisation (2015) reports “Action Plan for the Global Strategy for the Prevention and 
Control of Non communicable Disease”. Technology provides opportunities address the 
missing links in public health between activities and outcomes. Data related technologies and 
in particular big data, deep learning or machine learning also has potential to address poor 
patient adherence to guidance and medication through personalising interventions. Through 
machine learning an algorithm may be able to provide relevant prompts or reminders which 
are targeted at an individual’s needs. Some mixed results on the use of data to date should 
however provide some caution about overfitting data (Lazer et al, 2014).  
 
The clinical and business case evidence for adoption of new technology in care provision in 
the hospital, diagnostics and in the community can be a significant issue which emerges in 
many of the qualitative focus groups. Evidence of effectiveness and efficiency are required to 





must look at the clinical evidence, business case and adjustments to the care pathway which 
collectively create a significant barrier to introducing new technology. The cost of equipment 
leads to a need to justify sufficient return on investment which can be difficult to attain. They 
require the technology provider or assessor to put numerical or financial values on a life or 
quality in a life which can be challenging. Separate from medical effectiveness is operational 
effectiveness which is increasingly addressed with technology and has been free of the need 
for clinical trials to benefit even though there is a clinical benefit available from their use. For 
example a device which makes recommendations on the amount of medication will require a 
clinical trial and various assessments however an electronic health record that accelerates the 
speed of passing information to the clinician will not require a clinical trial. There are 
however grey areas where the data collection leads to selection of what data to present, 
advice related to the data and the boundaries between presenting data and providing clinical 
guidance. The result of both of these types of technology can be measureable in patient 
outcomes and the EHR may even have a large clinical utility as faster decision making as a 
result of having the right information, sharing of data within clinicians and more immediate 
access to clinical diagnostic information can alter care significantly. In addition some of the 
non-clinical systems which capture operational procedure, diagnosis, and prescribing patterns 
can reveal evidence of poor practice and non-adherence to best guidance which have been 
somewhat hidden in paper based systems.       
The debate on quantifying the benefit of technology has been advanced by the introduction of 
economic assessments associated to technology. The most dominant work in this area has 
been in the QALY (National Institute for Clinical Excellence, 2011) as a tool which although 
not perfect provides some measure and comparator between approaches. QALY stands for 
Quality Adjusted Life Year. This calculates the cost versus the benefit of a new intervention 





documented around the gathering of data based on existing technology. QALY in some cases 
is struggling to address emerging technology which will require a rethink of the application 
of technology and its value for patients and may need further adjustment (Campbell et al., 
2017). For example, new technology such as “companion diagnostics” allows for genetic or 
personalised diagnostics to determine if a treatment will be effective for your genetic profile. 
A cancer drug may not work on a percentage of patients with a specific gene expression. The 
identification of the gene may result in a decision not to treat with that drug. The decision not 
to treat is of value to the patient as a non-effective treatment is not used, therefore avoiding 
potential side effects, and the secondary approach can be considered for effectiveness in a 
shorter time window.  There is additional benefit through the saving of wasted resource by 
the healthcare provider and patient yet the QALY doesn’t recognise this value and new 
measures are going to be needed (Husereau et al., 2014). This then creates problems of 
comparing a traditional technology with a newer companion diagnostic technology which has 
stratified the patients. Lee et al. (2013) suggests The QALY model for companion diagnostics 
would therefore need to be adjusted to take into account the whole cost benefit of both those 
who receive the treatment and those that have been excluded as a result of the test.  For the 
adoption of technology of this nature all costs, including the identification of new costs and 
wastes due to the emergence of new biomarkers, must be under constant review and 
accounted for in the wider adoption and business case.  
Data protection is an additional issue for widespread deployment of technology, use of data 
and trending of information. There is a lack of clarity on how to use personal data within the 
emerging solutions. In the medicine section 7.6.2, Fox (2015) Nature biotechnology article 
reported on the President Obama launch of a precision medicine initiative. While the 
initiative drew out the positives of a new medicines approach using technology it also 





fitting clinical ethics for research, patients maintaining control of their own data and the lack 
of focus of “data driven races” that go many directions at once. Data sharing and 
management is an issue today and is likely to grow as an issue as we move from big data to 
genomic data being a key part of our care pathway. Discussions at the World Innovation 
Summit for Health: Doha, Quatar in 2016 (which the thesis author attended see appendix A) 
extended the data questions to security and safety questions for individuals. Political shifts in 
volatile countries can be linked to ethnicity and the health requirement to capture your 
genetic details may provide unintended consequences of creating databases suitable for 
example to support ethnic cleansing. Even if it is clinically relevant the data risk may not 
acceptable to many countries with a troubled past or where the government has been shown 
to access data without permission.  
In summary there are many opportunities in healthcare technology to address waste within 
the research questions and redefine patient value within long term care however technology 







Chapter 8 - Thesis Discussion  
8.1 Introduction  
Chapter 2-5 focused on understanding the Lean, healthcare and technology literature and  
chapter 8.1 provides a short summary of the purpose of each chapter.  
Table 8.1 – Chapter Summary Reminder 
Chapter  Purpose of Chapter  
2 Literature review of Lean in the public services 
3 Literature review of Lean in healthcare 
4 Literature review of technology in healthcare literature with a focus on the UK 
and USA.  
5 Theoretical development of the chapter 2-5 reviews and developed a theoretical 
model with gaps in the literature. This highlighted that healthcare literature was 
focused on healthcare providers rather than value for patients (Porter and Lee, 
2013) 
The literature review identified that Lean in public services was being deployed in a 
disconnected system of providers who often had limited process knowledge (Antony, 2015) 
and a lack of customer focus (Radnor and Osbourne, 2013). This creates waste rather than 
value. In healthcare the demand for integration reflects a growth in ageing citizens with long 
term conditions (Dannapfel et al., 2014). This is relevant for the prevention and management 
of long term conditions, as they require clinical intervention and therapy both in the hospital 
and in the community over a prolonged period of time. The literature reviews, also 
highlighted a gap for technology being used in Lean healthcare interventions identify waste, 
remove waste and improving value for patients.  
A mixed method research approach was chosen to analyse the care pathway for 
cardiovascular disease as an example of a long term condition. This utilised the healthcare 





wastes. New waste activities from cardiovascular disease were also identified and recorded. 
The information on current activity focuses on the Northern Ireland cardiovascular disease 
healthcare delivery. It uses quantitative analysis which has been created from open data 
sources and qualitative analysis from focus groups and healthcare experts. Literature from 
working practice guidance and grey literature material were also analysed to provide a richer 
analysis of cardiovascular disease activities and related wastes.  
This thesis discussion chapter brings together the literature and the research of cardiovascular 
disease from chapter 7. It will summarise the contribution to knowledge that have been made 
and revisit the research questions that have been laid out in chapter 6. These research 
questions are;  
 How can Lean be adapted for long term conditions? 
 How can healthcare technology assist in identifying and addressing Lean non-value 
add activities?  
 Can healthcare technology from data focused technologies assist in redefining patient 
value?  
To address these three questions, the thesis discussion will utilise the Lean literature five core 
Lean principles (Womack et Al., 1991) of; defining value, value stream mapping, making it 
flow, pulling to patient demand and continuous improvement. Within the five core principles, 
the research questions will be addressed based on the analysis from chapter 7 and the earlier 
literature findings. The structure of the discussion is presented in figure 8.1 with the sections 
references included. Question 1 will be addressed last to reflect the summary nature of the 













8.2 Defining Value  
In this section, the thesis discussion will focus on research question three which asked “How 
Can Healthcare Technology from Data focused technologies assist in redefining patient 
value”. Defining value is the first of the five Lean principles (Womack et al, 1991) and this 
has been analysed in the healthcare literature and in the cardiovascular disease research.  
 
While there are many examples of Lean healthcare deployments (Moraros et al., 2016), what 
is questionable is their focus on patient value rather than focusing on provider value. Where 
Lean tools or approaches are used it is often within the context of a specific silo of the patient 
journey and rarely representing the patients complete value stream. This is further 
complicated by a lack of understanding of who the customer is within a Lean deployment 
(Radnor, 2012).  Porter and Lee (2013) reinforce this by stating that reforming healthcare has 
pursued the “wrong goal” or “narrow goals”. The findings of this thesis are that Lean value is 
not fully considered in delivering healthcare and the implementation of Lean must start by 
defining value for the patient. In particular this applies to long term care patients who are 
likely to engage across a number of care providers. Within this gap, of value for a long term 
condition patient, the research has explored the activities and the healthcare technology 
which may begin to redefine value for a patient. The research question will be discussed 
using the structure outline provided in figure 8.2  
 





8.2.1 What is Value for Long Term Conditions?  
Value for Lean starts with a customer. A key discovery of the thesis in section 7.2 was that 
for Lean healthcare the customer was unclear, this was due to the separation between the 
consumer of healthcare and the payer. This thesis developed a position that the patient must 
be the Lean customer. Replacing the principle of the patient as the customer will ultimately 
results in the wrong goals for any healthcare system (Porter and Lee, 2013). Despite this 
emerging principle of the patient being the customer, there was an absence of Lean healthcare 
literature defining value for the patient and then creating the Lean value stream. The majority 
of Lean healthcare literature is focused on healthcare service providers which is only one 
element of the Lean customer value stream.  
 
In addition to the lack of literature considering the current value stream there is emerging 
demand from long term condition patients which will exacerbate the situation and lead to 
overloaded emergency services. The lack of value stream thinking means that healthcare 
providers do not have visibility of the long term condition patient’s interactions with the 
healthcare service and therefore can’t plan accordingly. The data collection for the 
quantitative analysis reiterated this as there were no measurements reflecting the patient 
journey but only sections of the journey such as the time in hospital. The qualitative analysis 
confirmed this gap as healthcare providers had little concept of the whole journey for a 
patient, no access to data to understand it and no understanding of the impact of changing 
decisions made by commissioners. The care providers will not understand the data 
sufficiently to understand if demand increases at this time are causation or correlation. 
Cardiologists admitted that they had no understanding of the level of waits or delays and 
focused on the patient in the clinic in front of them. Performance improvement managers 





this level of information was not available to them therefore they were not making decisions 
based on the full value stream. Cardiac nurses were again unaware of readmissions being a 
significant issue, reporting that they have been visiting patients around day 30 due to their 
workload despite the literature suggesting that patients readmit around day 16. Their focus on 
the next patient on the list removes visibility of the patient group across the value stream. In 
Lean tools the concepts of visual management across the value stream is frequently used to 
provide this missing visibility. For long term condition patients, visual management is not 
available along the value stream to the clinicians which means that issues cannot be 
quantified or addressed through continuous improvement. To illustrate this, a number of the 
qualitative analysis groups were shown data (Figure 8.3) which had been gathered through 
the quantitative analysis.  They were surprised about the level of data available and some of 
the trends emerging. When asked for a potential hypothesis on the growth in waiting list 
demand starting around 2014, a cardiologist was able to put forward a number of potential 
ideas around the procurement from the independent sector and replacement of GP’s with 
locums leading to more referrals due to the inexperience of the locums. When asked if 
changes in GP measurements in QOF during 2014 may have incentivised extra demand, he 
stated that he was unaware of the GP QOF information which he described as a “dark art” 
and unknown to him. He did believe that despite his lack of knowledge of what the GP does 
this would be a good hypothesis to test. The point of the qualitative analysis was not to 
explore the 2014 issue or do a route cause analysis but to understand the gaps in current 
knowledge and impact on the patient value stream. The current provision means that visual 
management was not available to them to make informed and collective decisions across the 
value stream. Changes to resourcing, procurement adjustments or commissioning decisions 
all could contribute to negative downstream impact on patients and clinicians without ability 






Figure 8.3 –Value Stream Continuous Improvement 
 Beyond the value stream, a patient contributing to their own healthcare value creation is a 
gap that has emerged in the Lean literature. Cardiovascular disease is defined as a non-
communicable disease that can be prevented (WHO, 2017) therefore the clinician is not the 
only producer of value but the patient as well. Lean literature makes no reference to this and 
focuses on the healthcare workers activity. For long term conditions such as cardiovascular 
disease; diet, exercise and adherence to medication will result in the creation of good or poor 
health outcomes. Lean reform must address this co-creation of healthcare value where the 
patient is contributing to their own value. Linked to co-creation is a need for personalised 
approaches which understand the motivation and behaviour of individuals and tailor the 
interventions to the needs of the patient (Thompson, 2013). Similarly quantitative data from 
section 7.3 highlighted that specific patient groups may not be impacted by public health 






Unmet value is also present in Lean cardiovascular disease treatment, in particular around 
choices a patient may make about treatment options. Unmet value is not a concept appearing 
in Lean healthcare theory but it reflects a patient value that has not been met. A patient may 
want to withhold, delay, and adjust treatment choice based on personal choices. In particular 
in the final stages of life where painful interventions may have a limited return when 
measured against quality of life or personal preferences.  This emerged in both the qualitative 
clinician discussions and the heart failure nurse interview from the qualitative analysis as the 
cardiologists recognised that many signs are present that the patient is entering the end of life 
yet the clinician’s instinct is to continue to treat the condition. One clinician described that 
“The patient will stop responding to the drugs and the biomarkers will not improve as 
expected. The evidence is there that the patient is moving to end of life. We can continue to 
treat them, but that might not be in the patient’s interest as it may be better to manage the 
pain relief rather than treat”. Despite value for a patient potentially being different than what 
is being delivered there is a lack of Lean literature or operational coverage of indicators or 
decision making tools that would assist this change in the value stream activities. Other 
examples of missing values included a link between psychological factors, such as stress, 
anxiety and depression and poor health outcomes.  Diagram 8.4 summarises the missing 







Figure 8.4 – Diagram of Missing Value  
8.2.2 Measuring Success  
Measurements in healthcare can reflect national priorities, short term politics and available 
financial resources rather than patient value (Ham, 2017). Throughout the research the 
Northern Ireland health service data has been used in the form of waiting lists, targets and 
activity. Many of these are not measuring patient value but some proxy of perceived patient 
value. This thesis would argue that this drives the wrong behaviour in the system as the 
providers do not focus on perfection as a Lean principle but rather on the performance metric. 
This reflects some of the earlier literature searches where Gubb and Bevan (2009) highlighted 
that Lean can expose “the fallacy of targets”. Similarly Seddon’s (2003) book freedom from 
command and control is critical of public service measurements that drive the wrong 
behaviours. Porter (2016) notes that in the USA healthcare providers work towards “the 





creation or outcomes. All these measures are based on activity despite a strategic interest in 
moving to outcome based care (Porter and Lee, 2013).  
Examples emerging from the quantitative research where the measures may be driving the 
wrong behaviours include; 
Public Health Measures – Smoking cessation quantitative data in section 7.3 in this thesis 
identified a year on year decline on interventions and the lack of progress in hard to reach 
high deprivation communities yet this was not highlighted in public health reports which 
congratulated itself on a job well done as the total smoking figure had reduced. Similarly, 
obesity measurements were halted midway through the longitude data despite them revealing 
a problem. It would appear that success in the measures from a PR perspective seemed more 
important than the data driving improvement in a Plan-Do-Study-Act improvement approach.  
Hospitals and Diagnostics – Targets do not reflect patient value. For example the 6 week 
target or reporting on a diagnostic test in 4 weeks reflects resourcing issues in the system and 
not patient value. Targets such as 75% completed in 6 weeks again reflect a large failure for 
25% of the patients even if the target did represent patient value. In a resource constrained 
organisation a better driver for behaviour would be to reflect on the demand and activities 
rather than put measures that do not reflect patient value.  
Missing Measures – Many of the patient values around quality of life or patient outcomes 
are not measured. The focus on measuring activity and lack of outcome focus means there is 
very little understanding of the impact of interventions. Similarly the medicines outcomes are 
not measured therefore the high cost of medicines has no understandable return on the 
investment in patient value. There are known issues emerging in the qualitative focus groups 
around under prescribing, overprescribing and toxic impact of most medicines but no 





Measuring the Cost of Waste – There is no information in the system on the cost of the 
Lean wastes. As a simple example, the waiting time for an outpatient appointment is clearly 
recorded but there is no assessment of the cost of managing this patient. The patient will 
likely become a more costly emergency patient or will absorb temporary cost through 
medicines or additional GP visits. This means that economic choices about investing to save 
are not available.  
8.2.3 Utilising Healthcare Technology to Redefine Patient Value?  
Research question 3 asked if health technology from data focused technology can assist in 
redefining patient value. To answer this there are three specific areas of technology interest in 
redefining value which are;  
 Data analytics  
 Machine learning  
 Decision support 
These will at times overlap but for the purpose of this thesis they will be discussed separately 
and illustrated in the diagram 8.2.3. 
Data analytics and the sharing of information through electronic systems have the potential to 
contribute to redefining value. The ability to see across silos of healthcare providers to 
understand the journey was absent in a large amount of the activities but with use of 
technology this could be fully realisable. The use of a new electronic health record which has 
been implemented across the 5 HSC trusts over the last 5 years was praised in many of the 
qualitative groups for sharing data. The concept of using this to see groups of patients across 
the silos was not available as the system looks at one patient and doesn’t focus on waits or 





technology. This would require significant work to address barriers which emerged while 
investigating access to cardiology data for quantitative analysis. The systems meta-data 
language and general expertise of working across care organisations was very limited and 
required input from a number of experts for even basic analysis. When this long term 
condition value stream is available through technology, Lean concepts such as visual 
management and continuous improvement could be aided. It should be noted that the 
combination of technical capability, Lean knowledge and healthcare knowledge would be 
required to make this a reality.   
Machine learning through longitudinal databases of healthcare data could also begin to 
address value through personalisation of healthcare, understanding interventions and assisting 
in developing the concepts of co-creation for value. Machine Learning could be used to 
predict outcomes, personalise, and consider preferences for individual patients. It could also 
start to quantify the risk or impact of interventions based on real data from patients in real 
time. From this it is possible to predict what the potential outcomes are likely to be and to 
personalise the care interventions. Machine learning is used in other sectors to understand 
engagement with retail, websites or manufacturing performance but has had limited 
application to healthcare despite the known issues of areas such as exercise adherence, 
medication adherence and smoking cessation. Machine learning works by defining the 
outcomes and identifying the optimum path that helps lead to these outcomes and this could 
be applied in healthcare.  The following machine learning outcome could be pursued to 
increase patient value.  
 Public Health Measures – Capture data to support appropriate interventions through 
social media data, tailor messages to specific communities and target engagement 
messages. This could utilise machine learning to understand the approaches which 





 Hospital and Diagnostics – activity and wait measures can be replaced or 
complimented by value stream data in electronic health records to join patient journey 
data across providers. Rapid diagnostics can be used by decision support and point of 
care diagnostics to remove waiting, batching and transportation wastes.  
 Missing Measures – Technology can support medicines outcomes and adherence 
issues to address known wastes in the system. Machine learning can assist in 
understanding toxicity and non-responder patients to avoid waste in the care delivery.  
The final technology for considering the research question is from decision support 
technology. Within this, many more technologies such as diagnostic data devices, clinical 
monitors, vital signs devices and information sources can feed data in on the patient’s 
condition, history, and genetic profile and life choices. Collectively these data points can 
assist in defining the likely choices available to a clinician and patient. This decision support 
can be used to ensure the clinician has considered all the patient data but also to provide 
information on options for the patient to allow more control by them. For example decision 
support may lead to presenting data that specific treatment may reduce mobility which may 
be more important than pain management. A patient may want to choose between less 
mobility or the same level of pain based on their personal preference.  
 
Radnor (2013) warned that Lean will fail unless there is a clearer focus on the customer (or 
patient) value. Technology provides an opportunity to address this failure by capturing and 
quantifying value which can then be used in the continuous improvement element of 
assessing if value has been delivered. This links back to a need for both Lean and technology 







Figure 8.5 – Use of Technology to Assist in Redefining Patient Value 
8.3   Value Stream Mapping for Long Term Conditions  
The second of the Lean principles relates to value stream mapping (Womack et al, 1991). 
Addressing value stream mapping in the cardiovascular disease research provides an 
opportunity to consider research question 2. This asked how healthcare technology can assist 
in identifying and addressing Lean non-value add activities.  
 
Prior to discussing value stream mapping across the cardiovascular disease, it is worth 
highlighting the complexity of crossing the value stream of the cardiology patients. To put 
this in perspective, the data on “New to Review Comparisons” which is one of the many 
measures in the hospital data, required navigation through over 650 pages of other data. The 
author of this thesis has significant experience in navigating health data and systems for the 
Northern Ireland health service. This is highlighted to emphasise that although data may 





where to look and this will not be navigated in a rapid improvement or Kaizen events 
(Moraros et al., 2016). Technology will be needed to assist in navigating the value stream in 
ways that are not available to Lean deployments with sticky notes, flip charts and good will. 
The current Lean deployments reflect this limitation by keeping to small section of the value 
stream. In chapter 6, the honest broker service (service providing anonymised data in the 
HSC) data was described as being of value but difficult to access due to the ethics application 
requiring clear outcomes prior to approval. This highlights that data which assists in drilling 
down into patient behaviour and outcomes is difficult for Lean research as often the 
explorations require an ability to navigate organisations and ethics barriers. Early 
explorations with the Honest Broker Service also revealed that diagnostic data from medical 
devices is not stored and therefore not available in the health service for comparison. The 
diagnostic procedure is completed and reported but there is no storage of the test data 
electronically. Opportunities to compare patient’s data using ECG (Heart Rate Data) 
information are not available today.  
 
While the complexity is a barrier or challenge for long term conditions, continuous 
improvement across the full journey is possible with technology. The data could also begin to 
create full cost of the system and identify areas not known in the measurements. For example, 
warfarin (blood thinning medication) is known to have costs in the community to monitor 
that the right levels are being used and the patient’s body is responding but this is not part of 
calculation of medicines costs today. This data would provide opportunity to seek 
improvements in the system based on more complete pictures with evidence. Emerging care 
models could also be further explored and expanded such as Hospital at home or Step down 






In summary, the creation of value stream maps based on available data across long term 
conditions is likely to be too complex without the aid of technology. Many data points from 
cost or deep clinical symptom information may be useful to the value stream maps but are not 
available today. Developments could make this valuable information available in the future.  
The combination of the current data and future data could provide significant opportunities to 







8.4  Making it Flow  
As the third of the Lean principles relates to understanding flow (Womack et al, 1991), this 
section discusses flow in the cardiovascular disease research to provide an opportunity to 
address research question 2. This asked if healthcare technology how can assist in identifying 
and addressing Lean non-value add activities. Specifically this addresses the waste being 
created in the care delivery.  
 
Analysis of Lean healthcare activities in Chapter 3 identified Lean wastes and a template of 
healthcare wastes created. This was then applied to the cardiovascular disease areas 
throughout the analysis to model Lean for long term conditions. 8.2 summarises the findings 
with the left hand column being from the literature review chapter 3, the middle column from 
cardiovascular disease research in sections 7.2 to 7.6 and the right hand column addressing 
these wastes from research section 7.7.  
 
Table 8.2 – Waste in Cardiovascular Disease as an Example of a Long Term Condition 
Healthcare Failure 
Area Identified in 
Chapter 3  
Description  How Can Technology Identify or 
Address Waste 
Waiting times  Unplanned admissions which 
includes emergency admission and 
readmissions. Evidence of high 
unplanned admissions for 
cardiovascular disease from the 
community. 
 
Quantitative data highlighted 
growing waiting lists to outpatients, 
diagnostic test, diagnostic reporting 
Technology to address 
monitoring of those on waiting 
list and discharged at high risk.  
 
Visual management technology 
of waiting time over time could 
be used in root cause analysis 
and continuous improvement 






and hospital procedures. Potential 




Point of care diagnostics to rule 
out patients not needing further 
investigation.  
Delays  Awaiting test results, interventions 
and next steps can cause 
deterioration in conditions and poor 
quality of life while awaiting 
intervention.  
 
Delays due to cancelations.  
 
Electronic referral to remove 
delays in information exchange 




Decision support to provide 





Diagnostic procedure may not be 
available near the patient or the lab 
therefore increasing diagnostic 
turn-around time.  
  
Point-of-care testing can remove 
delays in diagnostic information 
therefore accelerating the 
decision time for beginning 
treatment. 
 
Diagnostic  Evidence of duplicate tests, over-
ordering of tests and tests which are 
driven by commissioners rather 
than patient value. 
 
Batching of tests to go to regional 
labs and no test logistics over the 
weekend result in lost patient value.  
 
No diagnostics to detect if drugs 
will work with the patient genetics.   
Technology available to 
provide rapid diagnostics or 
point of care diagnostics. 
Remove waiting and need to 





opportunities to diagnose the 
impact of the medication 
Medical 
Complexity  
Increasing evidence of patients with 
a number of long term health 
Technology can assist in 





conditions can result in conflicting 
treatment – chronic kidney disease, 
diabetes, cancer and asthma evident 
in the causes of readmission 
literature often linked to the 
medication conflicting and causing 
symptoms. 
complex decisions requiring 
insight from different clinical 
specialties. 
Additional 
Healthcare Visits  
Inconsistent levels of review 
appointments leads to questions on 
over-processing or under-
processing patients in certain 
hospitals.  
 
Incorrect or ineffective medicines 
leading to additional appointments 
with doctor or emergency 
readmission to hospital.  
Technology and Lean can 




Technology can address 




Coordination of care does not cross 
providers and provide patient value. 
Readmissions reduction requires 
coordination of service provision to 
ensure the patient has all 
requirements covered.   
Shared care records, activity lists, 
shared notes; shared medication 
record and shared allergy 
information all contribute to the 




Evidence of lack of capacity to 
deliver value for the patients. 
Demand is significantly 
outstripping capacity resulting in 
waiting lists. 
 
Technology to assist in removing 
demand and identifying where 
activity is not leading to 
improved outcomes.  
Repeated 
Procedures  
Data captured in the community not 
shared with hospital or social care 
providers requiring repeated test or 
data capture. 
The use of shared ICT systems 
such as regional PACS systems 
(shared diagnostic information) 





 been reported in qualitative 
analysis to reduce repeated 
procedures as clinician have 
access to previous test results. 
Further opportunity to reduce 
waste available.  
 
Cost  Evidence of not addressing overall 
value leading to higher costs base  
as care in community deemed to be 
more cost effective. (Mendoza, 
2009) 
 
High cost of drugs and hidden costs 
of having to monitor biomarkers for 
specific medications that can be 
dangerous, addictive or have 
negative side effects. 
Overprescribing medication. 
 
Technology emerging to assist in 
hospital at home.  
 




Quality  Maintaining current best practice an 
issue for clinical guidance due to 
the number of guidance documents 
and rate of change.  
 
Readmissions of patients can be 
regarded as a quality issue in a 
number of cases. Further treatment 
is required as the underlying issue 
has not been addressed or the 
therapy which has been provided is 
not suitable to address the 
condition. 











Issue of ED vital signs monitoring 
not revealing heart attack reflects 
limitations. High volumes of 
readmissions. 
Significant numbers of emergency 
admissions are linked to medication 
issues. 
 
Medication errors  Every medication does not work for 
a % of patients (non-responders) or 
can have toxic effect.  
 
Medication titration a key issue for 
readmissions. This was revealed in 
qualitative discussions where it was 
shared that patients need close 
monitoring on discharge.  
 
Evidence of doctors prescribing 
medicines based on advice that is 
outdated. Drugs selection not 
considering other health conditions 
such as diabetes, asthma or kidney 
issues. (co-morbidity). 
 
Companion diagnostics can 
identify the patients who will 
respond to medication and non-




technology with IOT/smart 
homes technology providing 
some options around medication 
reminders. 
Infections  Hospital acquired infections is 
related to some of the reasons for 
readmissions. In particular hospital 
acquired infection is a specific 
waste. 
 
The use of technology may 
be a source of some 
infectious disease spread as 
machines and technology are 
passed between professionals.  
 
Data analytics and machine 
learning can identify patterns 





in a hospital that may have 
led to infection spread, 
patterns of drug dispensing 
that would encourage drug 
resistance leading to 
infections and data 
relationships to 
environmental factors.   
 
What is clear from the research is a number of wastes presented are emerging due to a lack of 
coordination across the silos. Lean healthcare literature has tended to focus in the silo and 
would not identify these long term condition wastes. For example prevention, readmissions 
and understanding the commissioning decisions impacts on other parts of system. These 
wastes require interaction along the long term care value stream.   
 
Emerging from the research is technology that can address waste where there is complexity 
that requires more than the current Lean healthcare interventions. Related to these waste can 
be the need to understand the demand in the system and pulling to patient demand which are 








8.5 Pull to Patient Demand 
The fourth of the Lean principles relates to pulling to customer demand (Womack et al, 
1991). This section analyses the cardiovascular disease demand to provide an opportunity to 
consider research question 2 which asks how can healthcare technology can assist in 
identifying and addressing Lean non-value add activities. 
 
Pulling to customer demand may seem somewhat alien to healthcare providers in the UK as 
the public health provision often means that they are working on waiting lists which implies 
demand has outstripped supply. Understanding demand is however a gap in Lean literature as 
often there is an assumption that the demand for a service is linked to value. Demand is more 
complex in cardiovascular disease treatment or healthcare in general, than in other industries. 
Clinicians have many choices in providing tests and therapy options which can result in over 
processing or alternatively result in a missed clinical intervention. Figure 8.6 provides a 
summary of the demand experience in the cardiovascular disease found in this thesis.   
 





What emerges in the research and illustrated in figure 8.6 is an understanding of demand for 
long term condition services. Value based demand can be seen within the baseline demand 
for people with a cardiovascular disease (1) and additionally there is a demographic shift 
through a growing ageing population (2) which is creating additional value based demand 
(Dannapfel et al., 2014). Demand which is not value driven has also been identified in the 
research as preventable demand (3) and Lean waste demand (4). A number of these are not 
addressed in Lean healthcare literature such as GP incentives driving additional demand for 
diagnostics. This could relate to the Lean healthcare literature being focused on one element 
of care delivery and not seeing the implication of changes in demand in another part of the 
system. This reflects John Seddon (2003) work on failure demand in public services where 
bad levels of service in one client facing section results in a demand elsewhere.  Preventable 
demand due to factors such as obesity is documented in healthcare (World Health 
Organisation, 2017) but not documented in Lean healthcare. This could be developed further 
as a Lean waste category and provide a contribution to Lean literature.  
Healthcare technology could begin to identifying and address Lean non-value add activities 
illustrated in Figure 8.6. As preventable disease is a large element of the long term condition 
waste (World Health Organisation, 2017), data related technologies linked to prevention have 
an ability to personalise the patient engagement and address their needs in a way not 
available today. Visibility of the full patient journey could assist in creating improvements, 
monitoring technology for patients outside of the hospital could bring intelligence to earlier 
intervention to prevent unplanned admissions and decision support could be used both to 
address the issues of bad decisions and develop adherence to best practice. This was 
emphasised in discussions with the Cardiologist where it was revealed that there is limited to 





“The patient may turn up in my outpatient clinic after being on the waiting list for many 
months with no knowledge of why they are there or if the referral is still needed. Other 
patients will end up in an ambulance and bypass my outpatient clinic. We don’t have 
information on either beyond the initial referral letter”- Cardiologist, Western HSC trust.  
 
Figure 8.7 –Technology Opportunities in Long Term Condition Demand (Non-Value 
Demand)  
Many of the technologies mentioned in figure 8.7 provide an opportunity to create visual 
management and understanding of data within a long term condition. The data in itself does 
not improve the care delivery and is only a tool. Continuous improvement must therefore 
adopt the technology opportunity and utilise this within a wider programmes of improvement 






8.6 Continuous Improvement  
 
The fifth of the Lean principles relates to understanding perfection or continuous 
improvement (Womack et al, 1991). This section seeks to discuss continuous improvement in 
the cardiovascular disease research to provide an opportunity to consider research question 2 
which asks how healthcare technology can assist in identifying and addressing Lean non-
value add activities.  
 
Two key areas emerge from the research, which are around the short sighted nature of Lean 
deployments which lack a continuous improvement aspiration (McCann et al., 2015). Linked 
to this is lack of sustainability for improvements that have been made. The sustainability 
issue, although related to continuous improvement emerged heavily in the qualitative analysis 
as a key criticism in Lean deployments with the improvement managers (Section 7.5.3). This 
can be partially linked to the fact that there is no definition of a Lean deployment (Samuel et 
al., 2013). Deployments which are labelled as Lean may be short term improvement 
initiatives to address a specific budget or demand pressure with no view or plan to embrace 
continuous improvement. Additionally the lack of capability building for continuous 
improvement is a factor in addressing both continuous improvement and sustainability 
(Smith, 2016). Capability and organisation buy-in to make and sustain improvements was 
also identified in “Data Analytics Workshops” where it was recognised that even if cost 
savings and improvements could be identified by technology the change management roles 
were not available to implement and manage the changes. In particular, complex changes that 
will cross organisations or departments require engagement skill sets that are not readily 
available. This is highlighted in the Accenture (Global professional services & Technology 






“It is important to engage clinicians, health managers and health oversight bodies to 
get the most out of analytics. Leveraging their different perspectives on data will help 
deliver richer solutions and deeper insights” – Kevin Duffy, Accenture Health and 
Public Sector Lead, Northern Ireland.  
 
As noted above, the opportunity is not in a short term fix but requires the introduction of a 
continuous improvement cycle which is targeting outcomes rather than activities. Smoking 
cessation being an example of this within areas of high deprivation as non-smoking clinics 
(activities) or other approaches appear not to be having a significant impact on non-skilled 
workers as noted in section 7.3.3. however a continuous improvement approach could utilise 
technology to iterate and change approaches to maximise outcomes.  
 
This reveals a question about if technology can be used to firstly monitor outcomes rather 
than interventions over a longer period of time and secondly can technology identify patterns 
of intervention that lead to better results through approaches such as machine learning. The 
measurement of outcomes is missing for both medicines and preventative healthcare 
activities as the full patient journey data is not available. For example, we may know that a 
patient has been prescribed a medicine but not understand if the medicine worked. This 
means that the medicines effectiveness is not known for this patient but also it is not known 
for other patients also taking the same medication. Technology has opportunities to develop 
continuous improvement cycles in areas such as health improvement interventions (smoking 
cessation clinic), self-reported reported outcomes (e.g. exercise and diet) and medicine that 






Technology also has the potential for continuous improvement to understand variance in 
service delivery. The data in chapter 7 revealed significant variances across trusts with “new 
to review” having substantial variance in the ratios with a difference of approximately 29%. 
This implies that one healthcare trust is seeing their patients a significantly larger amount 
than another trust and this will have a knock on effect on the available new clinic slots. When 
looking at one year we find that a minimum 43% and maximum 72% during the time period. 
The Western Trust and the South Eastern Trust are the outliers at 42% and 72%. It is possible 
that when looking at these Trusts, the services have been reconfigured in ways which explain 
and justify the difference however there is still a question of identifying best practice for 
outcomes and costs which are only going to be available as part of continuous improvement 
cycles. Similarly examples in the data show where a trust has lower cancelations which could 
be investigated for cause and effect. Lean is focused on scientific management and this 
reflects opportunity to improve which has not been realised.  
 
Linked to the activity variance is the adoption of best clinical practices or medication 
prescribing patterns. NICE clinical guidance (NICE, 2017) as highlighted in the hospital care 
section of the thesis is a positive step towards standardisation which would be supported by 
Lean however the sheer volume and changing nature of the guidance makes it impossible to 
monitor or deliver adherence to the guidance. The NICE guidance is however large in volume 
and constantly changing therefore leaving significant room for error. In addition, the 
combination of diseases is making the guidance more difficult as the clinicians must take into 
account both the presenting disease but also the other conditions and their response to the 
medication or treatment. Technology provides opportunities for decision support to address 
this. Complex decision making could be supported by technology and reminders or alerts 







While Lean has short term positive results which have been published (Burgess and Radnor, 
2012) there is a lack of quality literature which gives evidences of the benefits of Lean and 
the return for investing in Lean programmes (Antony et al., 2016). Additionally the topic of 
sustainability and scalability emerges as literature suggests that the improvements can 
become eroded over time and result in the perception that Lean is a management fad to be 
weathered rather than adopted (McCann et al., 2015). There is a lack of ability to sustain 
improvements and a need to engage people and leadership and not see the change phase as 
the end (Lucey et al., 2005). The ability to translate the improvement to business as usual and 
deploy across other locations is rare and difficult. Initiative such as the Sustainability and 
Transformation Plan (STP) from NHS England have highlighted this gap and the intention to 
address this (NHS England, 2018). Where Lean has failed however in sustainability, 
technology has the opposite issue as technology which has been adopted and deployed 
becomes the operational standard and can be difficult to replace. Many hospitals report on 
systems that are 20-30 years old and refer to the difficulty of replacing legacy systems. Lean 
therefore has a potential to be a tool for identification of waste with technology as a tool for 
sustainability. Examples of where this merging of thinking could occur include;   
 Visualisation Dashboards 
 Value Stream Reporting  
 Evidence Gathering 
 Addressing Waste 
 Quantifying Waste  
 Standardisation  





8.7 Summary, Adapting Lean for Long Term Conditions 
Returning to research question 1, which asked about how Lean can be adapted for long term 
conditions? The thesis research analysed cardiovascular disease related activities in the 
various silos of care provision and sought to understand the link between them that represents 
the patient care pathway or in Lean terminology the value stream.  
 
Lean in a healthcare setting has been proven to be effective where it has been deployed. Lean 
literature has widespread use of Lean in healthcare as a performance management tool. 
Radnor’s (2010) review of business process improvement methodologies in public health 
services highlighted Lean’s use in many locations including Bolton, Scotland, Australia and 
Nebraska. Moraros et al. (2015) article highlighted that a large number of articles from Lean 
and healthcare were available but was critical of the number which had been peer reviewed 
with quantifiable data. The articles do provide evidence of removing steps, reducing waiting 
times, rapid improvement events and less space use and fewer resources being used. The 
healthcare deployments have focused on provider rather the patient. This limiting of scale and 
scope has ultimately developed additional wastes as silo based providers seek to enhance 
their own service and meet organisational goals without keeping patient value at the centre of 
service design. Long term conditions will cross the silos of healthcare provision and 
addressing patient value will require Lean programmes which reach beyond the silo of a 
hospital ward or GP surgery. Some of the main wastes emerging from analysis of 
cardiovascular disease as an example of a Long term condition include; 
 Prevention Waste  
 Public Health Waste  
 Personalisation waste   





 Medicines Outcomes  
 Unplanned Admission  
Despite these wastes there is little consideration of utilising technology to identify patients in 
the community on a waiting list about to be admitted as an emergency unplanned admission. 
Technology could be used to do predictive analysis of large data sets yet there is no 
predictive use case consideration in Lean healthcare literature. Cancelations cost the 
healthcare service a significant amount of money yet technology could address this with more 
personalisation of the engagement with the care provider. Community based data collection 
and machine learning from wider data sets could assist in understanding changes to a patient 
that can identify early intervention opportunities. In addition machine learning linked to non-
healthcare data, such as weather and air pollution could assist in identifying changes that may 
lead to worse health outcomes such as respiratory condition escalation. Combinations of data 
collection and machine learning could develop intelligent waiting list which prevent 
unplanned admissions and reduce cancelations.  
 
Classic Lean car manufacturing lines had quality failures as a core focus of Lean 
manufacturing with the “Andor Cord” to stop the process until what was failing was resolved. 
There is no equivalent in healthcare terms and although people are not machines and the next 
emergency victim can’t wait for a meeting there is limited exploration of the root cause 
analysis or the lessons to be learned. Waste within the cardiovascular disease value stream 
there did not have lessons learned of failure or root cause analysis. Technology could assist in 
providing decision support for clinicians dealing with increasingly complicated symptoms 
and co-morbidities. Additionally monitoring decisions for variance from best practice to 






Specific bio-markers and risk factors are known which could be used to target both planned 
discharge and monitoring in the community to avoid readmission. Technology exists that can 
measure various bio markers and vital signs at the point of care or via mobile devices more 
easily away from the hospital. There has been a limited use of data to put in place actionable 
predictive models which identify patients at high risk of readmission patients.  
 
Patient engagement and empowerment are both possible through technology. Education and 
the patient’s opinions about “how they feel” could be captured and addressed remotely to 
both address concerns and also alert to potential changes highlighting a need to intervene. 
Education could potentially be tailored to the patient’s ability to absorb the information and 
the timing of when it is relevant rather than a tsunamic leaflet overload at discharge. Equally 
peer-peer communities have proved successful in educating past clients on how to adjust to 
life with a condition and providing “life-hacks” which go beyond the public health notices 
which can be difficult to translate to living with a condition.  Empowering patients - 
increasing the role and the responsibility of the patient is vital in providing positive 
outcomes. Diet, exercise, activity, medicines compliance and monitoring of a patient’s own 
vital signs are essential but can be challenging both for professional and patients. Tools to 
support self-management, improve understanding, increase adherence of patients, support 
care givers and provide a continuum of care are needed.  
8.7.1 Validating the Model in Practice  
 
The model that is being proposed challenges the current method of Lean healthcare reform 
which focuses on reforming a provider. The later qualitative analysis work during the thesis 
has validated and refined how a new model could be implemented and what would be the 







8.7.2 Barriers and Boundaries for Technology  
A concluding remark for the thesis discussion is that technology has been explored as a very 
positive opportunity for change but it is recognised that it does have barriers and boundaries. 
The ethics and ownership of personal data is a key area for focus impacting decisions on the 
sharing of data within care professionals and also with external research and commercial 
organisation. The ethics of ownership of genetic data is an area of emerging interest as the 
longevity and implications of the data has far reaching implications for the citizen today, 
potentially for the rest of their lives and potentially to their family. This may also have 
different implications in different countries. Qualitative analysis in Qatar realised that ethnic 
minorities in countries which have been subject to political uncertainty are particularly 
concerned about the use of genetic data for health as this can reveal ethnicity which may have 
personal security threat implications in the hands of a volatile government.  
 
Technical maturity of communication, quality of readings, battery power and security are all 
constant issues being considered in developing products. A nurse that cannot get a connection 
for the device will quickly discard the device as not working, or a doctor receiving too many 
false positive messages will abandon the device as inaccurate. Technology adoption therefore 






Chapter 9 – Revised Theoretical Model, Thesis Contribution and Conclusions 
9.1 Introduction  
The thesis has defined the current practice of Lean healthcare through a critique and synthesis 
of the literature, identifying significant gaps therein in relation to the delivery of value for 
patients and gaps in the use of technology focussing on Lean wastes in healthcare delivery 
activities. From this review and critique of the literature an initial theoretical model was 
identified (Chapter 5, Figure 5.3) and through the research (Chapter 7) and discussions 
(Chapter 8) a revised framework has been developed which focuses on the emerging needs of 
long term condition patients. This section discusses and explains this revised theoretical, 
framework illustrating how the aim and research questions have been addressed within the 
framework. The chapter also details the original contributions made by the thesis to 
knowledge and practice.  
 
Figure 9.1 – Chapter 9 Overview 
 
9.2 Revised Theoretical Framework  
 
The development of a theoretical framework for Lean healthcare technology models which 
utilises the learning and approaches of Lean and opportunities presented by technology was 





Lean and technology literature to fulfil the requirement (Objective 1) to then develop an 
initial theoretical framework (Objective 2) to guide the empirical research which focused on 
cardiovascular disease as an example of a long term condition (Objective 3). The 
development of the theoretical framework recognises there was three phases with phase 1 
being the current Lean healthcare provision, phase two being an initial framework based on 
assumptions and the phase 3 being a revised framework which has been developed based on 
empirical research as based on chapter 7 and chapter 8 The essence of this further 
conceptualisation is developed throughout chapter 7 and chapter 8 in line with the theory 
building methodology outlined in chapter 5.   
The current Lean healthcare provision was found to be provider focused on a ward, an ED 
department, or group of staff, but not around a patient (White et al. 2017). There is no view 
available across the patient value stream from a GP through to diagnostics, hospital treatment 
and monitoring the patient’s condition in the community as Lean is applied to the hospital not 
the patient (Mannon, 2014). This gap is exacerbated when looking at a long term condition-
based patients journey where the current system measures starts and stops in line with 
provider metrics (section 7.5.3), turn-around times for diagnostic (section 7.4.3) and fails to 
address full patient value. Complexity in healthcare across the value streams appears to be a 
contributing factor with less success for Lean for more complex interventions (Mazzocato et 
al., 2014). The use of technology has emerged in the current healthcare framework as 
technology was absent from the majority of Lean literature even though it was emerging in 
healthcare improvement initiatives to address quality, reducing error, increase productivity 
and support best practice adherence (Seblega et al., 2015).  
The initial framework (chapter 5, figure 5.3) was developed to fulfil objective 2 and was 





was identified which attempted to join the patients activities across the care providers. Within 
this initial framework was also a recognition that consolidated data utilising healthcare 
technology could attempt to identify and address known wastes. The known wastes had been 
consolidated from Lean healthcare literature. The initial framework also recognised that by 
creating and analysing the long term condition value stream that new wastes would be 
identified. Additionally, opportunities for technology to address waste would be identified as 
literature had indicated that opportunities existed in the use of large data sets to support the 
development of evidence and decision making (Riezebos and Klingenberg’s, 2009). The 
potential for big data analytics to support rapid improvement events was also recognised in 
the development of the initial framework (Bowerman and Fillingham, 2007).   
The third phase of creating the revised theoretical framework utilised the research 
documented in chapter 7 on cardiovascular disease as an example of a long term condition. 
The use of quantitative analysis alongside qualitative analysis provided significant insight 
both on the use of technology and on the Lean non-value add activities emerging which are 
not identified in Lean literature. The underlying assumption of the initial framework was that 
by exploring the patients value stream across the silos of care providers, additional Lean 
wastes would be identified was proven to be correct. New non value-add activities 
representing the long term condition patient were identified and new areas for improving 
value were identified. Specifically the patient as co-creator of value emerged as a theme 
which is not covered in Lean healthcare, similarly the need to personalise messages to 
remove failure, a requirement to address prevention to remove demand and the patient value 
around medical decisions that may adjust the care requirement from treatment to management 
in end of life care, emerged as key areas from the empirical data and analysis. All of these 
areas built on the development of the initial framework but were discoveries of the research 





complexity of healthcare (Mazzocato et al., 2014) and personalise treatment for long term 
conditions (Holiday et al., 2015) emerged both as an opportunity to identify waste and also to 
improve value for the patient in the overall Lean process.  
Figure 10.1 provides a theoretical diagram incorporating these points and reflecting an 
adaption of Lean to long term conditions where healthcare technology contributes to the 
identification of non-value add activities and creation of value.  
 
Figure 9.2 – Revised Theoretical Framework for Long Term Conditions   
The six areas highlighted in the diagram represent a revision to the current method of 
addressing Lean healthcare and patient value. The first area of capture recognises that for 
many patients the data about their condition and disease and what represents value is not 
currently available. The research in chapter 7 identified that 1.3M days are utilised waiting on 
specific appointments and within this there is no data on the patient or changes to their 





despite the high levels of unplanned admissions to hospital. Technology exists to capture and 
quantify patient conditions prior to seeing the clinician. The capture and quantification of live 
data could allow for prediction and personalisation utilising data analytics and machine 
learning as shown in Chapter 7 and 8. This prediction could highlight that patients exceeding 
a specific data threshold of a certain age is likely to end up in an ambulance in 48 hours and 
therefore intervene earlier to adjust medication, control the hospital admission or adjust the 
community treatment. Related to this is the ability to personalise messages based on the 
highest likely outcomes. If for example eating more vitamin C and taking your blood pressure 
medication is the target behaviour then personalisation of engagement to meet this outcome is 
possible through machine learning. For example the diet reminder could utilise an algorithm 
which calculates the times of the day where the patient is more vulnerable to abandon the diet 
or it utilises peer to peer support to produce better outcomes. Management and continuous 
improvement relate to the value stream as technology can assist in both providing visual 
management across the value stream and also in the management of the patients being 
progressed. Increase in demand and changes in patient behaviours were all evident in the 
chapter 7 and 8 analysis yet the clinicians were unaware of the overall impact or the root 
causes. In summary the theory building leading to the revised theoretical framework show 
that Lean and technology provide opportunities to learn, investigate and support continuous 
improvement, with key avenues for further research as discussed in Chapter 10. 
9.3 Contribution to Knowledge  
 
The thesis has made a contribution to Lean healthcare knowledge by identifying gaps and 
areas which are rarely addressed in Lean literature. The originality that the author has brought 





added to Lean theory and knowledge. A specific contribution to knowledge has identified a 
series of gaps for Lean healthcare which has application in developing Lean theory.  
The principle finding that the research identifies is that Lean literature is focused on 
healthcare providers and not patients which is evident across the multitude of healthcare 
studies (Moraros et al., 2016). The majority of Lean literature represents an improvement 
initiative in a clinic, a pharmacy, ED, or other healthcare department. On occasion it 
addresses a hospital but rarely follows the patients journey (Manon, 2014). This gap is 
exacerbated when analysing a long term condition patients journey where the healthcare 
measurements starts and stops in line with the healthcare provider such as (section 7.5.3), 
turn-around times for diagnostic (section 7.4.3) and fails to address a full patient value 
streams from the initial referral to treatment or beyond. This failure to focus on the patient in 
Lean, results in waste being created in the handovers between healthcare providers and 
elements of the patient value stream is missing from Lean intervention. 
 
A further contribution builds on Lean literature where it was stated that there is a lack of 
definition of what Lean is (Samuel et al., 2015). The lack of definition means that 
interventions can’t be sufficiently measured and this will lead to a lack of quality evidence 
(Antony et al., 2016). Any criticism of the lack of Lean evidence is fair due to a lack of 
common approach that could allow deployments to be compared or validated against to 
ensure a deployment in implementing an effective approach rather than a “Lean” deployment 
by name only. Related to this gap of understanding what a complete Lean healthcare 
deployment should include, are two missing Lean principles of continuous improvement and 
patient value. There is a lack of understanding of the full value stream for the patient and 
what value for the patient means along this value stream. Continuous improvement can 





some providers (Mannon, 2014). However this cannot address real value such as avoiding the 
need for treatment through prevention or personalisation of care to avoid inappropriate 
interventions which do not add value to the patient. 
 
Linked to understanding the full patient focused value stream is a contribution to the lack of 
understanding of demand. Lean literature will focus on the ability of staff to cope with chaos 
in healthcare (Serr-Roszell, 2014) and building resilience in a system (Mannon, 2014) but fail 
to explore the possibility that the demand is not real demand but created by other failures in 
the value stream (i.e. failure demand, Seddon 2008). The research in 7.5.3 highlighted high 
levels of unplanned admissions and the qualitative analysis of spikes in outpatient waiting list 
revealed potential root causes being locum GP’s over-referring due to inexperience or 
wanting to avoid any professional risk (appendix 4). Additionally, GP incentives in the 
system may be the root cause of referral spikes (appendix 4) yet the Lean healthcare literature 
does not address the potential for demand being avoidable. Thus healthcare may be creating a 
false demand in the system caused by the patient value stream creating wastes.   
 
A further contribution is made in relation to Lean and technology. Lean literatures failure to 
be sustainable is an issue which leads to improvements that have been made, eroding over 
time rather than continuously improving or at least sustaining (McCann et al., 2015). The 
absence of technology in Lean literature is a gap as increasingly standards, processes and 
error prevention is either sustained or removed by technology. There is a contribution to 
knowledge in identifying the gap of why Lean does not utilise technology to identify waste, 
address waste, sustain improvement and deploy best practice. Due to the complexity and 
scale of healthcare this seems to be a significant defect in Lean application to healthcare if the 






These contributions have coalesced in leading to a contribution to theory using a theory 
building approach which builds further on the literature critique and initial theoretical 
framework (Chapter 5, Figure 5.3) The final theoretical framework (Figure 9.2) shows the 
key elements of this theoretical development and contribution. This includes the adaption of 
the value steam model utilised in Lean literature to apply to the whole patient pathway. The 
patient pathway should include prevention activities which are understood to stop a patient 
needing care and patient supporting activities such as medication and exercise which are 
essential to maintaining the health of a patient with a long term condition. This revised 
theoretical model covers a complex series of activities over a number of organisations and 
will benefit from the use of technology. The technology should be used with Lean principles 
to support visual management across the value chain and to build up an evidence base for 
analysis of live activities and root cause analysis to support continuous improvement. 
Technology should also be utilised for decision support to improve standardisation of best 
practice, personalisation of healthcare activities to maximise value for patients and the 
measurement of patient outcomes for healthcare activities and medicines.   
9.4 Contribution to Practice  
 
 
The thesis has made a contribution to practice in three key areas of; healthcare providers, 
industry and policy makers. This was completed by focusing on the research question of how 
can Lean be adapted for long term conditions? Can healthcare technology from data focused 
technology; assist in redefining patient value? And can healthcare technology assist in 
identifying and addressing Lean non-value add activities?  
The research identified Lean healthcare wastes in chapter 3 and then developed these further 





areas in healthcare were identified throughout the thesis in areas such as waiting times, 
medication errors and repeated procedures which although known as waste in the healthcare 
literature have been developed further due to the application to long term conditions. What 
has also emerged as new contributions to knowledge are wastes such as prevention waste, 
public health waste, personalisation waste and social care waste which are not documented in 
Lean healthcare literature and have significant impact on healthcare practice. These reflect 
activities which do not add value or have not been addressed by activities within the value 
stream.  
In the area of technology the thesis identified that healthcare is based on a series of decision 
and technology can capture and quantify data that is not available today to assist in making 
decisions earlier, faster and more accurately. This can both identify waste and increase value 
for patients in ways that are not addressed in Lean literature (Antoñanzas et al., 2016). In 
addressing the future of healthcare there is a drive towards preventative activities and self-
management of many conditions (Ham, 2017) which will require engagement with patients in 
ways which are not possible today but can be addressed with technology. This can improve 
patient outcomes and remove waste in particular for an ageing population (Holliday et al., 
2015). Technology also offers opportunities to predict patient behaviours and personalise 
intervention therefore removing the wastes of inappropriate interventions. Technology can 
address gaps in service provision such as understanding outcomes for medicines and other 
therapies (Antoñanzas et al., 2016). The contribution to practice focused on the capability of 
data technologies that could lead to continuous improvement and the reduction of waste if 
appropriately targeted. Technology alone can result in a technology push approach which 
fails to meet the needs of clinicians or patients however with the use of Lean to identify waste 
and deliver value there can be a more advantageous position for future healthcare and 





9.4.1 Implication for Healthcare Providers  
 
At the beginning of the thesis, healthcare provision was stated to be under increasingly 
extreme pressure as people were living longer with multiple healthcare conditions (Dannapfel 
et al., 2014). The behaviour of patients however was not assisting in reducing the healthcare 
demand as low patient adherence to treatment and factors such as diet, alcohol and smoking 
were not being fully addressed (Moraros et al., 2015). The additional demand is resulting in 
an unsustainable cost inflation (Reijula et al., 2016). The thesis has revealed that healthcare 
providers are absorbing significant wastes which if identified and addressed could provide 
opportunities to address the additional demand and cost constrained environments. This could 
both improve patient outcomes and reduce costs per patient. The complexity and scale of 
healthcare, demands that technology should be used in conjunction with Lean to ensure 
sustainability of improvements and prevent initiatives being treated as temporary fads 
(McCann et al., 2015) and to enable effective decision support necessary for managing long 
term conditions. Additionally technology provides opportunities to address failures in 
adherence to treatment, lack of understanding of outcomes and behaviours through 
personalised approaches to treatment that utilised machine learning which focuses on positive 
patient outcomes.  
9.4.2 Implication for Industry   
The implications for industry are that healthcare is under cost pressure therefore all 
technology investments must address a business value for the organisation which has a 
significant return on investment. Lean can assist in identifying healthcare wastes which relate 
to business value and related costs. If wastes and quality issues can be addressed with 
technology, this creates compelling products and services for healthcare customers. These 
products and services will potentially lead to cost savings and improve patient outcomes 





The healthcare wastes which have been identified could create a multitude of commercial 
products that will have financial success globally. Discussions with healthcare technology 
providers reveals a real interest in identifying evidence based insight on healthcare failures 
which could both assist in defining relevant products and also in assisting to tailor existing 
technology to specific healthcare needs. This level of detail is not available to companies and 
the evidence base behind this would be beneficial to industry as it relates back to specific 
healthcare providers globally.  
9.4.3 Implication for Policy Makers  
The implications for policy makers are that in cash constrained organisations the 
identification of waste creates an opportunity to improve outcomes and reduce budgets. The 
use of Lean across long term conditions is complex due to the scale but could be fruitful in 
developing better services. The use of Lean long term conditions also questions the 
commissioning choices which may need to be considered as it appears that decisions to 
intervene in specific areas is creating implications elsewhere. Technology that can assist in 
helping to understand these relationships would be worthwhile exploring further.  
Appendix 6 provides examples where the outputs of the thesis and research finding are being 
used to influence the Northern Ireland Life & Health Sciences action planning, the UK 
Industrial Strategy Challenge Fund (ISCF) healthy Ageing agenda and smart city 
developments for Belfast. The underlying theme is that the economic growth of the Lean 
based technology businesses can lead to both economic growth and improvements in 
healthcare for citizens.   
9.5 Implementation Considerations   
Important question emerged in the qualitative analysis when attempting to validate the model 





begin to implement such a model and what would be the key steps. An outline approach that 
has emerged from the analysis and qualitative analysis would include the following outline 
steps;  
1. Identification of a medium to high risk patient group who have frequent engagement 
with the healthcare services.  
2. Quantify patient focused measures on poor health outcomes to create a baseline which 
is currently not available - such as unplanned hospital admissions. 
3. Identify relevant technology and service offerings that have a potential to contribute 
to patient value through earlier interventions that promote health.  
4. Implement a new patient commissioning service that procures new services and 
technology to seek to deliver value based outcomes. 
5. Implement technology that can measure the health outcomes and identify patients 
with escalating risk 
6. Implement Lean continuous improvement based on new data from technology which 
focuses on patient value instead of interventions.  
7. Implement machine learning to assist in understanding which combination of 
interventions lead to better outcomes.  
The proposed model presents significant challenges for the current provision of care as it 
would require different ways of commissioning service providers, measuring activity and 
how services are delivered. It would be recommended that a demonstrator was established 
which allowed an ability to explore and compare a number of technologies and approaches in 






9.6 Conclusions and Recommendations  
 
The key conclusion from this research is that Lean healthcare is focused on providers and not 
patient value which is counter to the principles of Lean. Long term conditions, such as 
cardiovascular disease, are a growing trend in healthcare demand and are these poorly served 
by provider or silo based healthcare systems represented in Lean literature. By focusing on 
Lean long term conditions, such as cardiovascular disease, wastes which are not reflected in 
current Lean healthcare literature can be identified across the patient value stream. Emerging 
technology which is often excluded from Lean approaches can assist in building visual 
management of the value stream, identifying waste and addressing this waste.  As healthcare 
providers attempt to address growing elderly populations with increasingly complex needs 
(Hwang et al., 2014) while maintaining the buy in of staff (White et al., 2017) technology 
offers an opportunity to enhance visibility of data from the patient, provide decisions support 
for clinicians, to enable and empower staff and provide machine learning evidence based on 
patient outcomes.  
  
Research question 1 asked how can Lean be adapted for Long Term Conditions and the thesis 
has shown that Lean can be adapted by returning to a core Lean principle of focusing on 
value for the customer, or patient in the case of healthcare, and moving away from short 
sighted organisation based improvements (McCann et al., 2015). Research question 2 asked 
how healthcare technology from data focused technology can assist in redefining patient 
value and the thesis has shown that firstly there is significant value not being delivered. 
Healthcare technologies can assist in addressing this. The redefined patient value stream, 
supported by technology, can deliver integrated care in a way which is often absent today and 





management technology (Ham, 2017). The focus on Lean and technology can also address 
barriers which have prevented better healthcare delivery by recognising that patient 
adherence to medicine, activity and diet result can be improve through personalisation of the 
engagement between the health providers and the patient. This will be particularly important 
in engaging with the needs of an ageing population with a growing number of long term 
conditions (Holiday et al., 2015). The third research question asked if health technology can 
assist in identifying and addressing Lean non-value add activities which the thesis has shown 
can be achieved by joining together the disconnected care pathway to provide a view of the 
patient’s activities and non-value add activities. This provides healthcare leaders an 
opportunity to understand and address waste within the system to develop an evidence base 
for decision making and root cause analysis (Riezebos and Klingenberg’s, 2009).   
 
Answering these three research questions assisted in addressing the objectives of the thesis 
which led to the contribution to knowledge and practice outlined in section 9.2. The 
combination of meeting the research objectives and addressing the research questions has 
fulfilled the aim of the thesis by completing an exploratory study of healthcare technology 
development using a Lean thinking perspective.  
9.6.1 Recommendations for Further research  
The research focused on the use of cardiovascular disease as an example of a long term 
condition. This was necessary for the scope and timescales of the project; however the 
exploration of other long term conditions, such as diabetes, would be of value. Big data sets 
are available which would support this focus on other health conditions. It is expected that the 
knowledge and approach gained in this thesis has application and can be transferable to other 
chronic or long term conditions. Further research could explore if cardiovascular disease has 





transferability. For example cardiovascular disease has a high average age for patients but 
other diseases, such as diabetes, which are also long term conditions, will have a different age 
profile for the patients and a different view of what value for a patient means.  
 
Healthcare technology is exciting and interesting as novel technologies related to data, IOT, 
genomics and many other areas are emerging. These have the potential to revolutionise 
healthcare delivery and change the way that patients engage with the healthcare providers. 
These technologies are being developed and it is too early to understand their full potential. 
Given a period of maturity for these technologies it would be worthwhile to revisit the 
research and to explore how they can be integrated within a Lean approach. This may reveal 
a different model for Lean healthcare or a further refinement to the theoretical model. 
  
The research focused on the use of the Northern Ireland healthcare service data. This is a 
public healthcare service which has specific characteristics on how patients consume 
healthcare provision. Further research could explore other UK geographies and healthcare 
providers which have alternative models of care provision in other global locations using the 
approach used in this thesis. A further limitation of the use of the Northern Ireland data was 
that this was data gathered from available open source data. This did not allow an ability to 
cross compare patient data as the linkage between activities and data sets was not available. 
Further research in partnerships with health providers could utilise real patient data and allow 
linkage between patient activities.  
 
Finally, there is limited literature linking quality issues to cost beyond Spear (2005). Cost 
data was not available in the cardiovascular disease information in this thesis. Further 





waste. In an environment where technology must provide a return on investment justification, 
the cost of managing a waste would be a valuable measure and provide a new exploration on 
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Appendix 1: Peer Reviewed Publications, Academic Conferences and 
Industry Publication  
 
This appendix provides an overview of the formal dissemination that has taken place to date 
from the thesis.  
Table A1.1 – Research Dissemination 
Dissemination of Knowledge  Dissemination Type 
International Conference on 
Engineering Technology and 
Innovation (IEEE), Belfast - June 
2015  
Peer reviewed submission: Conference presenter 
European Lean Educators 
Conference – September 2016  
Peer Reviewed Submission: conference presenter 
 
Lean Educators Conference - Presentation at the 
conference on the thesis topic – Participants at the 
conference include key Lean Educators such as John 
Seddon and John Bicheno and companies such as TWI.  
Synnott, J., McComb, S., Nugent, 
C. and McLaughlin, J., 2015, 
December. NI-CHIC: A Model 
for Academic Engagement with 
Industry. In Ambient Intelligence 
for Health (pp. 258-263). 
Springer, Cham. 
Published paper (contributing author)  
Catherwood, P., McComb, S., 
Little, M. and McLaughlin, J., 
2017, July. Channel 
Characterisation for Wearable 
LoRaWAN Monitors. In 
Loughborough Antennas and 





Propagation Conference (LAPC). 
IET. 
Microsoft Sponsored Roundtable 
Discussion on Transforming 
Healthcare with Leaders. 
Discussion recorded and 
published in magazine - Paul 
Duffy (Co-Director for IT and 
Telecommunications in the 
Belfast Health and Social Care 
Trust), Louise Skelly (Head of 
Operations at the Patient and 
Client Council), Sean Donaghy 
(Director eHealth at the Health 
and Social Care Board), John 
Woods (Chair of the Northern 
Ireland Council, British Medical 
Association) and Frank 
O’Donnell (Public Sector Lead 
for Microsoft Ireland) 













Appendix 2: Qualitative Data - Northern HSC Trust Innovation Focus Group  
This appendix provides an overview of the main qualitative data focus group meetings for the 
Northern Trust Innovation Group as explained in the research approach in section 6.3.  
Meeting January 2015 
Focus: Considering technology opportunities for community based long term conditions 
 
Participants: Director of PCCOPS (NHSCT), Information Systems Project Manager 
(NHSCT), Assistant Director Person Centred Practice (NHSCT), Innovation & Development 
(NHSCT),Research Governance Manager (NHSCT), Project Manager TCC (NHSCT), 
Business Service Development & Governance Manager – Mental Health & Disability 
(NHSCT) and  Researcher, Ulster University.  
 
Discussion Notes: Discussion on the use of a report stating that 2/3 of the trusts resources 
were being used on 1/3 of the patients. Focusing on resource intensive patients was a relevant 
direction. Director reported on data analytics progress on an internal initiative application. 
There were discussions on regional interest in risk stratification which would identify high 
risk patients. There was further discussion on data analytics on regional data.   
 
There was interest in domiciliary care use of technology for addressing areas of waste such as 
duplication, sharing best practice and sharing of information.  
 
Discussions took place regarding the appropriate ethical consideration in trialing new 
technology. Partly this relates to patient ethics and partly with the procurements ethics due to 






Discussions took place regarding the regional tele-monitoring contract and the possibility of 
any capacity within that contract to extend to include vital signs monitoring. Assistant 
Director (Person Centred Practice) discussed the “In-Reach” initiative into Nursing Homes. 
There was a potential extension of tele-monitoring within these homes.  
February 2015  
Participants: Performance Improvement Programme Manager (NHSCT), ICT Senior 
Manager (NHSCT), 
Key discussion focused on outcomes for domiciliary care with long term conditions and frail 
elderly. There was a discussion on the use of apps within the care setting. “Long Term Care” 
pre-procurement competition (SBRI) was of interest to the Trust to explore technology to 
address their needs. Cognitive development and assessment of technology would be of 
interest due to the needs of dementia patients emerging with long term conditions. There was 
interest in Heart Failure care due to the volumes of patients and impact on hospital 
readmissions.  
December 2016  
Focus: Rapid Diagnostics in the Community  
Participants: Northern Trust Representatives from Laboratories (David Farren), Reform (Gill 
Smyth) and community health (Karen Harvey). Local Commissioning Leads, Local GP 
representative and (Dr Ian Kernohan).  
 
There was a discussion on rapid diagnostics technology and its use in primary care. Areas of 
interest expressed around the ability to complete the tests in the GP surgery that could 
prevent the need to send tests to the labs. GP concern of fitting this into workload but 
recognised they are already using resources in this area. GP interest areas would be UTI and 





rapid diagnostics for gestational diabetes monitoring in particular. Prototyping technology 
and the process of integrating this to patient pathways was a significant part of the 
conversation. The lack of resources available to explore new approaches was raised as a 
concern and governance issues such as validating the quality of any test would need to be 
addressed before starting any exploration.  
Meeting June 2017  
Focus:  Diagnostics and use of Data in the Labs 
Participants: Dr David Farren - Consultant Medical Microbiologist, Northern HSC Trust  
 
Northern HSC Trust process 135,278 urine based tests a year. 30 % are from the hospital and 
70% are from the community. 27% of UTI tests require culture analysis however 73% do not 
require further testing and could be tested with point of care devices. This data is important to 
understand the volumes going through the labs. It was also important to understand the 
volumes coming in from each GP as a change in process would impact the workload with the 
each practice as well. It was discussed that in many GP practices they are already doing some 
dip testing but they are still sending the test to the lab on a large number of occasions. This 
creates extra demand in the lab and a patient delay. Lack of transport from community to the 
lab over the weekend also emerged as a disconnect between community and diagnostics 
which is likely to result in weekend hospital admissions of patients who need a test.  
 
GP Example discussed based on some numbers on the lab computer screens. 3500-4500 
samples a year (based on 2 practices,20 a working day (estimate), unknown how many 
shouldn’t have been sent and 44% from >65 age group). Figure A2 created as a note to reflect 






Figure A2.1 – Urine Based Test Flows and Timing  
The known issues with the process are;  
• Education: Lack of understanding on issues and confusion on issues such as foul smelling 
urine.  
• Adherence to process:  While there is guidance on when not to send a sample this is often 
not followed.  
• Adherence to process:  Dip tests are part of process but unclear of adherence levels.  
• Adherence to process: Advice on pregnant woman, age of patient, asymptomatic patients, 
renal patients and catheter patients may not be followed or may not be commonly 
understood.  
• Manual Error: Community dip tests may not follow process adequately but there is no 
method of identifying bad practice.  
• Decision Support:  Anecdotal evidence that a GP will send for test as a way of creating 
evidence trail for decisions.  
• Test Availability: No tests from community received over weekend as delivery is Monday 
to Friday therefore a patient will likely be admitted to hospital at the weekend to allow 






Use of technology to address issues were discussed and it was agreed that electronic 
alternatives to dip test may provide evidence base required by GP therefore providing 






Appendix 3: Qualitative Data - Cardiology Focus Group  
This appendix provides an overview of the main qualitative data focus group meetings for the 
Cardiology focus group workshops as explained in the research approach in section 6.3.  
April 2016  
Focus:  Use of technology in cardiovascular disease activity 
Participants: Co-chairs of the cardiovascular network & Philips technology 
The discussion focused on the Cardiology Network of Northern Ireland, heart failure and the 
reduction of hospital readmissions. Heart failure is recognised as a growing condition 
impacting a large number of patients either as a primary or secondary diagnosis. Discussions 
explored technology and healthcare interventions. The main areas of interest for using 
technology in cardiology included reducing heart failure readmissions, reducing average 
length of stay for heart failure and allowing intelligent monitoring of cardiology waiting-list 
patients to provide opportunities to escalate (reducing unplanned admission) and reassign 
patients to community services (reducing hospital attendance). As Philips were part of the 
discussions it was revealed that their CVIS system was in use across all 5 HSC Trusts in 
Northern Ireland. The implementations were independent implementations and data analytics 
although technically possible had some areas needing addressed as each implementation was 
not the exact same as Philips had essentially 5 separate customers. Governance over the 
sharing of data would need to be explored. Potential future interest includes  
• Prediction/Risk Data Analysis  
• Internet of  Medical Things Devices 
• Point of Care Diagnostic Readers  
• Medication Optimisation 
• Patient – Self Reporting 





• Ethics, Regulatory and Governance  
Meeting June 2016  
Focus:  Use of technology in cardiovascular disease activity 
Participants: Dr Patrick Donnelly, Professor Jim McLaughlin and the majority of PIs from the 
NI Clinical Research Network (4 out of 5 trusts represented) 
 
There was a discussion on the use of technology to address heart failure gaps and failures. 
Debate on the figures for heart failure were inconclusive as there were a number of figure and 
some concern that the figures did not paint the complete picture. Discussions around the USA 
readmissions data were also debated as it was believed that local initiatives may have had a 
potentially beneficial outcome of reducing readmissions.  
The thesis data around the care pathways was largely agreed to be new data to the 
cardiologists and most had not seen the open data available to the thesis. The area of 
comorbidities (multiple diseases) was relevant to the clinicians as some were becoming 
specialists in niches such as Cardiology and Cancer. Some examples of technology were 
discussed with a lot of discussion (and disagreement) on specific biomarkers used and their 
value. 
 
Further discussion on predictive models, the value of specific markers and emerging 
technology. Topics such as patient engagement and empowerment were of less interest in the 
conversation and perceived to be dealt with by their nurses. Remote monitoring was of some 
interest although concerns about governance and expectation management to patients and 






March 2017  
Focus:  Use of Technology in Cardiovascular Disease Activity 
Participants: Cardiologist Dr Patrick Donnelly, Dr Liam Burns (Connected Health Innovation 
Centre), and 2 Cardiac Lab Nurses in Ulster Hospital (names not available).  
Significant fast paced discussion on heart failure and cardiac pathways and the consideration 
of novel technology for medication titration. Exploration of the impact of community based 
diagnostics for heart failure which could lead to further reduction in readmissions. 
The emerging initiatives across the region utilising technology to develop intelligent data sets 
that could assist in understanding patients better were debated. There was some scepticism 
about the time available for clinicians to look at all the initiatives and the challenges of 
getting funding behind investments. Previous work he had been involved with had looked at 
the need for a patient disease register which has not been taken forward despite its value to 
cardiologists.  
 
May 2017  
Focus:  Use of technology in cardiovascular disease – heart failure community nurse opinion 
Participants: Charlie Ataliotis (Cardiac Nurse Specialist, Heart Failure Service, Downe 
Hospital) and Dr Liam Burns (Connected Health Innovation Centre).  
There is an initial patient review appointment after about 2-4 weeks for most patients (mostly 
around 4 weeks). Some patients will take longer for first appointment depending on resource 
availability. Initial feedback from the HF nurse indicated that patients who are deemed to be 
more stable may be of lower priority and may be closer to 6 week before first appointment. 
This means that first appointment is beyond the time most published research highlights 
readmissions have occurred. In the discussions we did not have data on readmissions taking 





completed. The HF team can read ECG’s although they don’t use them after the initial review 
unless there is a specific reason. 
 In reviews the main activities are  
a. BP  
b. ECG for initial Review  - Pulse (simple HR number) for follow on reviews.  
c. Respiratory rate  
d. SPo2  
e. Weight  
f. Adema/Fluids  
g. Bloods – Kidney function and BNP. BNP seen as a longer term chronic 
measurement and can guide therapy.  
h. Respiratory/UTI Infections are not seen as their responsibility and they pass 
them on. Can have an impact on BP which can lead to HF.  
i. Asthma – careful of beta blockers 
j. Diabetes – careful of blood sugars  
k. General questions on Sleep, exercise, Medication, Diet and fluids, alcohol 
reduction are discussed with the patient.  
l. Temperature not a common measure. Pain not raised as a key measure.  
After the initial review, the patient is met every 2-4 weeks until stable, then appointments 
reduced to 3 months medium term reviews and then 6 months long term reviews. Details of 
reviews main activities documented above still apply except in most cases the full ECG is not 
repeated at future appointments unless there is a specific reason such as AF. Palliative care 
spoken of frequently in discussions with the HF Nurse. Some clues about moving to 





aggressive treatment, LV function, chronic BNP. Left ventricle function measured through 
Echo if required  
No data was collected outside of the times the nurse has visited and there may be value in 
more frequent monitoring. If technology could bridge this gap for escalation of declining 
patients then there is a potential for better health outcomes and the hospital could reduce 
readmissions. There is no data on the speed to stabilisation of HF medications. If for example 
a patient can be stabilised within 6 weeks instead of 12 weeks there could be both patient 
outcome benefits and capacity benefits. There is little data on the patients not receiving 
support as they are perceived to be stabilising. Monitoring these patients remotely with faster 
escalation routes due to profiling could be of value. These patients are off the radar of the 
specialist nurses and the only escalation route is unplanned admission.  
February 2018  
Focus:  Specific discussion on the data emerging from the quantitative analysis 
Participants: Cardiologist Dr Patrick Donnelly   
Data emerging from the quantitative analysis was shared which showed a sharp rise in 
waiting list number around 2014. The discussion was to understand if there was a known 
underlying issue that would explain the rise. His response was that despite considering this 
overnight between receiving the information and the meeting there was no definite response 
that would immediately explain this. Two suggestions were put forward but he emphasised 
that these were suggestions. The independent sector supply had been reduced significantly 
around that time is one suggestion. Additionally a group of GP’s had retired around that time 
and the locums who replaced them would be more likely to refer as they did not have the 
experience or skills to make an informed decision locally. This also reflects risk avoidance by 





incentives in the QOF may have encourage more GP’s to send patients for tests. He agreed 









Appendix 4: Qualitative Data - Medicines Focus Group 
This appendix provides an overview of the main qualitative data focus group meetings for the 
medicines focus group, as explained in the research approach in section 6.3.  
April 2015  
The thesis author led the establishment of the Northern Ireland Antimicrobial Resistance 
Network with Dr Patrick Dunlop (Ulster University). As part of the launch event a survey 
was made available to companies and researchers with one of the questions asking about the 
challenges (unmet needs) that the participants would like solved in the area of drug 
resistance.  
Participants including DARD, HSC, CIGA Healthcare, Exploristics, Norbrook Laboratories 
Ltd, Public Health Agency, QUB, Randox Laboratories Ltd and  Ulster University 
completed the questionnaire.  
The responses are provided below and are relevant in understanding the challenges in 
medicines from both a government and industry perspective; 
 Reliable platforms for discovery of lead compounds 2) Evidence base for 
antimicrobial selection clinically 3) Biofilm susceptibility analysis - still unclear if 
selection of antibiotics on the basis of biofilm susceptibility is a valid approach 
 understand and counteract the bacterial stress responses upon chronic infection and 
sub lethal levels of antibiotics 2) find means to increase the permeability of the outer 
membrane to boost the antimicrobial efficacy of existing antibiotics 
 Adoption, adoption, adoption. Randox already provide a 22 pathogen respiratory 
array for the correct identification of pathogens that cause respiratory infections 
including co-infections to ensure appropriate treatment is given. Also a 10-plex 
pathogen array is available for sexually transmitted infections. The 10 plex sexually 





cause other problems including infertility which may require expensive IVF treatment 
in the future. Both are CE marked and provide results in 5 hours compared to the 
current >24 hours required to culture bugs but are not used by the NHS. Would HSC 
actually adopt a point of care analyser if it was available? 2. Improvement of HSC 
procedures (including allocating clinician time to research projects) to work with 
industry not only to be involved in research but to adopt new products developed 
through the research. Do we need to involve the decision makers at this early stage to 
identify the issues they face with regards adoption? 3. Identification/prioritisation of 
the most important health and environment issues to be addressed. 
 Better and quicker methods to tell us if a patient has an infection or not. 2. Laboratory 
methods to detect AMR 3. New treatment options 
 Access to data, collaboration with key stakeholders and access to funding 
 cheaper, quicker diagnostics, reduced regulatory burden, greater funding for novel 
actives specifically for veterinary use 
 Cost of point of care diagnostic devices Speed at which results can be obtained 
 Faster & more accurate diagnostic tests that do not require bacterial culture... 
Reducing laboratory turnaround time (using existing tech.). Improved use of mobile / 
smartphone tech. 
 Funding for research; better ICT systems to improve quality and value of surveillance; 
funding for initiation of the STAR implementation plan. 
 I think that there needs to be representation on any future networking/collborations 
from GP's. Each Trust should have a Medical GP Director- Dr Brian Hunter 
represents the NHSCT and his role is to further develop links between General 
Practice and colleagues in Trust Services. There perhaps needs to be more 





 Improve empiric antimicrobial policy Improve antimicrobial stewardship Make better 
use of existing data 
 Providing appropriate TAT for acute diagnostics providing molecular assays for AMR 
testing Integrating data generation and decision making 
 Reduce bureaucracy. Increased access to: Funding Talented stakeholders 
(lab/clinicians/business/industry) 
 The correct treatment Non prescribing when not required early identification of the 
particular condition or the make up of the ecosystem of infection 
 understand levels of AMR in farmed animals in NI 
Further AMR workshops have been held during 2017 and 2016. These have been of interest 
in the general context of healthcare but have not been documented due to not adding 
significantly beyond what has been stated above.   
May 2016 
Focus:  Understanding Medicines and Technology  
Participants: Cathy Harrison (Assistant Chief Pharmacist) and Professor Mike Scott 
(Medicines Optimisation Innovation Centre)  
Topics discussed included the rising volumes of medicines and the falling prices. 2010 -2014. 
They shared that Lipid Regulating Drugs were known to come off a patent cliff during this 
period however the increase in Anticoagulants were the result of changes in NICE guidance. 
This is highlighted in a falling overall cost and the later years starting to rise again.  
The second topic discussed was the role of the SBRI in looking for medication technologies. 
In their view, since they had begun an innovation quest with SBRI, the market had changed 
from very little available to quite a number of apps and technologies available. There was still 
however a gap for "solutions" rather than products. The search for solutions is evident in the 










Appendix 5: Qualitative Data - Continuous Improvement Managers Clarification of 
Quantitative findings 
This appendix provides an overview of the main qualitative data focus group meetings for the 
continuous improvement manager’s clarification of quantitative findings. This reflects the 
approach explained in the research approach in section 6.3. 
November 2017  
Focus:  Understanding the continuous improvement manager’s response to the findings of the 
thesis. Gaining an insight into potential gaps in the thesis approach or analysis that has not 
been considered.  
 
Participants: 
Table A5.1 – Research Dissemination 
 Organisation  Name  Title  
Public Health Authority  Jeni Rosborough  Cancer Screening Programmes Manager  
Northern Health and Social 








Customer Care & Performance Officer  
Western Health and Social 
Care Trust  
Michelle Kelly  Business Manager  




Strategic Change & Performance Manager  
Western Health and Social 
Care Trust 





Southern Health and Social 
Care Trust  
Yvonne Murphy  Senior OT  
Southern Health and Social 
Care Trust 
Alan Metcalfe  Assistant Director, Estate Services  




Head of Continuous Improvement  
Belfast Health and Social 
Care Trust  
Natalie Magee Senior Dementia Nurse Specialist  
Belfast Health and Social 
Care Trust 
Emma Ross  Family Nurse Supervisor  




Business Support Manager  
South Eastern Health and 
Social Care Trust  
Helen Moore Assistant Director of Performance, 
Improvement and Commissioning  
South Eastern Health and 
Social Care Trust 
Ruth Gray  Senior Dental Nurse  
South Eastern Health and 
Social Care Trust 
Scott Hyvart  Quality Improvement & Audit Facilitator  
South Eastern Health and 
Social Care Trust 
Justin Stephens Organisation and Workforce 
Development  
South Eastern Health and 
Social Care Trust 
Damien Carson  Consultant Anaesthetist 
 
During the workshop there was significant opportunity for exchanges of ideas and the key 





1. The health providers were surprised at the breadth of the data which was presented. 
They stated that they struggle within the health service to get access to that level of 
data and analysis. This highlights barriers to the data access and skills.  
2. Many of the participants with experience of operational improvement were sceptical 
about the Lean literatures success as there was an underlying belief that the only 
“Lean” that gets published are the successful examples. Their view was that there was 
a publication bias as many attempts to implement Lean initiatives in healthcare had 
failed but they never became publications.  
3. General agreement that by looking across the value chain of healthcare for long term 
conditions there was many opportunities for improvement. Within this, points about 
wastes within the system were agreed without challenge.   
4. Specific agreement that commissioning decisions are being made without 
understanding the implications through the whole value stream and that systematically 
viewing the data across the full patient value stream may assist in addressing this.  
5. The key discussion within the exchanges was however on the topic of sustainability. 
They recognised that although some success was made in Lean and other operational 
improvement initiatives this was not transferable and not sustainable. Time pressure, 
changing management personnel and attempting to survive between various crisis’s 
meant that sustainability was just not possible. Discussions about using technology to 
translate and sustain improvements were well received as a potential opportunity as 
many had seen improvements with initiatives such as the Regional Electronic Health 
Record. This system had shared information between professionals, saved lives and 
prevented operational waste such as phone calls, chasing up for data and duplicate 






March 2018  
 
South Eastern Health and Social Care Trust – “Curry Club” 
The thesis author was invited to present the finding from the thesis and wider innovation to a 
senior gathering of the South Eastern Health and Social Care Trust at the “Curry Club”. This 
event was run by the HSC’s Trusts Chief Executive office. The event happened just after the 
thesis submission and before the viva for this thesis.  
The presentation included;  
- Challenges facing healthcare  
- Technical opportunities  
- Discussions on an alternative way of measuring patient value to allow services to be 
driven focus on patients 
- Presentation on available data from the thesis 
- Presentation on data that was not available but create value  
- Presentation on what emergin technology could offer  
- A proposed outline approach to taking the model forward 
Feedback was positive with discussion around how much of the issues were falling budgets 
versus performance measures driving the wrong behaviour and resulting in missing patient 
value. Additional discussions emerged around prison healthcare being a potential candidate 








Appendix 6: Qualitative Data – Significant Meetings and Conferences  
This appendix provides an overview of additional qualitative data focus events and meetings 
that have contributed to the context of the thesis. Each of these reflects health, technology 
and process that have been relevant to the context of the thesis. In the majority of these the 
thesis author had a contribution or leadership role rather than a passive observing role. 
Table A6.1 – Additional Significant Events and Meetings of Influence to the Thesis  
Event  Participation  Benefit to Thesis 









NI Life and Health Science Leadership 
group including the Permanent Secretary 
for the Economy, Chief Medical Officer, 
UK Office of Life Science representative, 
Universities and Industry.  
View on the future of Life and 
Health sciences and emerging 










Select group of NI Industrial and 
Academic leads with Government 
representatives from Invest NI and 
Innovate UK. Innovate UK leader of Life 
and Health Science, Dr Ian Campbell took 
part.  
Workshop to distil and consult 
on the future UK direction for 
supporting innovation. Specific 
interest in future Health 



















HSC, BSO, Accenture, Aridhia, Kainos 
and Boehringer Ingelheim.  
6 companies and 2 Universities 
were provided data from across 
the HSC to explore the health 
services understanding of the 
possibilities of healthcare 
analytics and machine learning. 
Key discoveries were that there 
are significant capability gaps 
in the health service in data 







Hosted in partnership with the Future 
Cities Catapult and attended by 
government industry, council and other 
stakeholders.  
Insight on emerging technology 
interests impacting health in a 







Two interdisciplinary gathering of 
academics with a focus on Mental Health 
and Public Health led by the PVC of 
research.  
Debate and discussion on the 
merits and demerits of 
technology, public policy and 
future interventions. Also 
discussions on emerging themes 















55 Participants from technology companies 
including Intel and Aepona and partnered 
with the IOT Alliance. Speakers included 
Colin MacHale, Director Health and Life 
Science EMEA, Intel Corporation, Dr 
Philip Catherwood (UUJ) and Prof Jim 
McLaughlin (UUJ). Event organised by 
thesis author with IOT Alliance.  









Assessment of 15 applications to the NHS 
England competition on cancer and patient 
flow. 
December 2016 – Assessment 
of SBRI procurements.  





Mid 2016 - 
Permanent Secretary of Health, Permanent 
Secretary of Health, Invest NI CEX, Chief 
Medical Officer, ABPI, Randox, Almac, 
O4 Research, QUB, UU and other officials.  
Confidential discussions and 
report contribution,  related to 
the future of Health and Life 
Sciences in Northern Ireland. 
Relates to future technology 







Healthcare. Outputs ongoing 






in UK )  
 
Nov 2016  
Targeted at health ICT leaders. Event 
attended with David Watwood (CIGA 
Healthcare), Leeann Monk (Elemental 
Software), Deepak Samson (Connected 
Care Solutions), Gareth Morrison (Lava 
Group). The event has a mixture of 
company displays and various talks from 






Topics of interest to the thesis 
included: personalisation in 
healthcare in line with the 
Sustainability and 
Transformation Plan (STP) 
from NHS England, data 
mining patient notes with 
natural language processing, 
data for forecasting, Wearable 
interest but recognition of poor 
quality inappropriate for 









Targeted at academia, business and health 
technology in Northern Ireland and 
Southern Ireland 
Attended event to discuss 
various health technology 





Event attended with permanent secretary 
Dr Andrew McCormick. Invitation only 
event for healthcare leaders. Meetings 
Areas of significance in the 
meeting with the various 











included:   
- Healthcare UK  - COO (Ilaria Regondi) 
and MD (Deborah Kobewka)  
- Abbvie – Focus on Drug Therapies  
- Novartis – Drug Therapies. Some 
interest in Drug Trials around Diabetes 
and Chronic Conditions -  
- Teradata – CTO – Stephen A Brobst –  
- McKinsey – Healthcare Consultant  
- Hamad Medical Corporation   
- British Heart Foundation   
- Otta Project – Cerebral Palsy support 
product – 
- Express Healthcare – India Journalism   
- AMMI – pregnancy educator for rural 
illiterate Pakistan  
- Proximie – Augmented Reality Surgery  
- ‘Bac-Kits’,  - AMR Focus  
condition management, patient 
behaviour, use of data, 
infectious diseases, drug 
resistance, and genomics. The 
first three being of direct 










Companies participating; Lucro, CIGA 
Healthcare, Shimmer Sensing, Momedx, 
Analytics Engines, See.Sense, 
GoWalkTalk, MyWoundDoctor, Santovia, 
Moveo, Kainos, Digital Catapult, NI 
Connected Health Innovation Centre, 
Belfast City Council, City of Boston, 
Focus on Health and Economic 
Growth in the Sister Cities of 
Boston, Nashville and Belfast. 
Main areas of common interest 
included; Connecting economic 
innovators in the area of Digital 








ARCH, Ulster University, Nashville Metro 
Council and Chris Cunningham 
 
Organised and led by thesis author with 
participating councils (mainly Belfast CC).  
utilising data in novel ways to 
create data rich conversations 
which lead to better city 
management, economic 
opportunities and improvement 
of health for citizens. 
Addressing health inequalities 





Connected Health Conference Discussion and Presentations on 
Health Technology use from 
American perspective.   
Digital 
Catapult 
Tom Gray (Digital Catapult Leader for 
Northern Ireland)  
Sept 2016 – Meeting with 
Digital Catapult Leader to 









Workshop led by Dr Ruth McKernan – 
CEO of Innovate UK on behalf of innovate 
UK and Research Council UK.  
  
 
Confidential (at time) workshop 
to guide future government 
strategy on funding for 
Industrial Strategy Challenge 
Fund. Healthy Ageing was 
bidding within government to 
prioritise funding in midst of 10 
other options.  
Healthcare 
Innovation 
Healthcare Leaders from across all 5 HSC 
trusts in Northern Ireland.  
Successful application to most 
















Nesta Longitude Prize competitors and 
leaders.  
Discussions on a £10m award 
to tackle AMR resistance. 





Manchester AHSN. This included 
palliative and end of life specialists from 
clinical, service improvement, quality 
improvement, social work, care facilitators, 
commissioners, ICT, Data analysts and the 
third sector organisations 
The workshop, led by the thesis 
author, utilised a Lean and 
system thinking approach of 
aligning resources to patient 
value where there is interaction 








Appendix 7: Qualitative Data – Significant Meetings and Conferences  
This appendix includes specific technical details that are referenced throughout chapter 7. To 
aid the flow of the thesis for the reader they have been included in the thesis for reference 
with a relevant table reference number which is referred to in chapter 7. 





QOF Code  Description  Patient 
Number For 
NI  
AF   AF002  The percentage of patients with atrial 
fibrillation in whom stroke risk has been 
assessed using the CHADS2 risk 
stratification scoring system in the 
preceding 3 years (excluding those whose 
previous  
29,901 
CHADS 2 score is greater than 1)  
AF   AF005NI In those patients with atrial fibrillation in 
whom there is a record of a CHADS 2 score 
of 1 (latest in the preceding 3 years), the 
percentage of patients who are currently 
treated with anti 
6,761 
-       coagulation drug therapy or 
antiplatelet therapy  
AF   AF004 In those patients with atrial fibrillation 






greater than 1, the percentage of patients 
who are currently treated with anti-
coagulation therapy  
Heart Failure  HF002NI The Number of patients with a diagnosis of 
heart failure (diagnosed on or after 1 April 
2006) which has been confirmed by an 
echocardiogram or by specialist assessment 
between 3 months before and 15 months 
after entering on to the register 
9,842 
Heart Failure HF003 In those patients with a current diagnosis of 
heart failure due to left ventricular systolic 
dysfunction, the percentage of patients who 
are currently treated with an ACE - I or 
ARB  
3,116 
Heart Failure HF004 In those patients with a current diagnosis of 
heart failure due to left ventricular systolic 
dysfunction who are currently treated with 
an ACE-I or ARB, the percentage of 
patients  
2,553 
who are additionally currently treated with a 







Table A7.2 – Cardiovascular Disease in the Context of Healthcare Activity 
(Source Data: Department of Health, 2017, Inpatient and Day Case 
Waiting Times) 
Title  Number  %  
General Medicine 120,505 19.3 
Nephrology 96,831 15.5 
General Surgery 80,171 12.8 
Cardiology 35,358 5.7 
Gastroenterology 34,969 5.6 
Urology 27,697 4.4 
Paediatrics 24,968 4.0 
T&O 24,243 3.9 
Haematology Clinical 21,243 3.4 
Thoracic Medicine 19,338 3.1 
Gynaecology 17,660 2.8 
Ophthalmology 17,562 2.8 
Clinical Oncology 17,011 2.7 
ENT 14,116 2.3 
A&E 10,836 1.7 
Medical Oncology 9,109 1.5 
General Practice Other 7,120 1.1 
Dermatology 6,288 1.0 
Plastic Surgery 5,846 0.9 
Rheumatology 4,926 0.8 





Oral Surgery 4,394 0.7 
Neurology 3,770 0.6 
Endocrinology 3,420 0.5 
Rehabilitation 2,354 0.4 
Neurosurgery 2,351 0.4 
Paediatric Surgery 2,218 0.4 
Anaesthetics 2,041 0.3 
Thoracic Surgery 1,418 0.2 
Cardiac Surgery 1,151 0.2 
Palliative Medicine 622 0.1 
Paediatric Dentistry 445 0.1 
Radiology 340 0.1 
Paediatric Neurology 237 0.0 
Restorative Dentistry 205 0.0 
Infectious Diseases 131 0.0 
Genito-urinary Medicine 37 0.0 
 
Table A7.3  – Prescription Cost Pareto Analysis Identifies 3 Drugs in 79% of 
Costs (Developed from Source Data: BSO Pharmaceutical Statistics, 
2018) 






Cost  Pareto Analysis  
Apixaban 6114028 5991440.928 43.60 43.60 
Rivaroxaban 1781404 3202830 23.31 66.91 
Enoxaparin 328258 1708750.151 12.43 79.34 





Dabigatran 681703 593414.108 4.32 89.70 
Warfarin 16542783 540523.883 3.93 93.63 
Clexane 63446 291508.472 2.12 95.75 
Eliquis 245247 238640.239 1.74 97.49 
Xarelto 51841 93062.7 0.68 98.16 
Edoxaban 34363 63571.55 0.46 98.63 
Phenindione 2823 52425.125 0.38 99.01 
Pradaxa 48834 41508.9 0.30 99.31 
Lixiana 18107 34737.2 0.25 99.56 
Heparin 13260 21581.333 0.16 99.72 
Fragmin 2883 14734.85 0.11 99.83 
Arixtra 979 8183.887 0.06 99.89 
Alere 2866 7167.972 0.05 99.94 
Innohep 1158 6022.126 0.04 99.98 
Tinzaparin 422 1596.185 0.01 99.99 
Dalteparin 60 338.73 0.00 100.00 
Acenocoumarol 6288 290.511 0.00 100.00 
Sinthrome 1612 74.484 0.00 100.00 







Figure A7.1 – Representation of Cardiology Medicine Definitions with the 





Table A7.4 –Prescription Cost Analysis Northern Ireland 2016 (Developed 
from Source Data: BSO Pharmaceutical Statistics, 2018) 
 














Gastro-intestinal system 1 3,952,729 21,851,486.881 9.54 4.98 
Cardiovascular system 2 9,136,162 52,013,780.272 22.05 11.86 





Central nervous system 4 10,301,746 109,966,070.653 24.86 25.07 
Infections 5 2,190,320 10,949,460.972 5.29 2.50 
Endocrine system 6 3,324,681 55,871,279.594 8.02 12.74 
Obstetrics,gynaecology & 
urinary-tract disorders 
7 1,077,645 17,758,153.098 2.60 4.05 
Malignant disease & 
immunosuppression 
8 158,839 10,443,934.368 0.38 2.38 
Nutrition & blood 9 1,861,431 30,409,191.792 4.49 6.93 
Musculoskeletal & joint 
diseases 
10 1,571,300 11,048,369.266 3.79 2.52 
Eye 11 646,590 4,784,903.319 1.56 1.09 
Ear, nose & oropharynx 12 719,551 4,408,862.943 1.74 1.01 
Skin 13 2,185,639 17,262,504.032 5.27 3.94 
Immunological products & 
vaccines 
14 42,875 984,878.144 0.10 0.22 
Anaesthesia 15 65,971 2,819,880.327 0.16 0.64 
Other drugs & 
preparations 
19 694 3,095.228 0.00 0.00 
Dressings 20 454,435 9,242,133.252 1.10 2.11 
Appliances 21 180,918 6,459,709.559 0.44 1.47 
Incontinence appliances 22 57,725 1,662,755.182 0.14 0.38 
Stoma appliances 23 117,467 8,791,331.123 0.28 2.00 
Unclassified 99 249,154 14,400,306.197 0.60 3.28 








Table A7.5  – Emerging Healthcare Innovations related to Cardiovascular Disease 
(Source Data: Innovate UK, 2017) 




1 A Deep Learning Algorithm To Eliminate 





2 Kiosk Automated Screening 





3 High Sensitivity Chemiluminescent Point 
of Care Tests for Cardiac Troponin 
Remove wait for 
tests by using 
point of care 
testing 
2016/17 
4 Patient-Specific Simulation of the Heart 
Organ for Diagnosis 
Better training – 
Failure in training  
2015/16 
5 Development of a 4Mhz suprasternal 









monitoring of vital 
signs  
2015/16 
7 In car Health Monitor Heart attack 
drivers  
2015/16 
8 ICURE Aid for Start Ups Cohort 3 Medical implants  2015/16 
9 Clinical Proof of Concept of Agluna 




10 Wearable Acoustics Novel feedback 2014/15 
11 Renephra Ltd. Validating commercial 
opportunity for a novel medical device to 








12 InoCardia: Cellular Work-Loop Proof of 
Concept 
Adverse Drug 
impact measure  
2014/15 
13 Guide Cardiac Resynchronisation Therapy 




14 Predictive phenotypic assays to better 




15 A high resolution gamma camera for 
earlier tumour detection 
Imaging related  2013/14 





17 The Combined Catheter: Integrating drug 
delivery and pressure measurement to 
improve stratification of therapy in 










19 New Technology of Navigation and 
Guidance in Cardiac Arrhythmias 
Clinical Guidance  2012/13 
20 Diasolve Investigation of Market Potential 
for a Novel Vasodilator and Delivery 
Device for use in Cardiac Stress Testing 
and Stenting 
Cardiac Devices  2011/12 
21 New drug dosage formula for the 
treatment of hypertension and heart failure 
in children 





22 Real-time Simulation of Cardiac 
Electrophysiology for Medical Training 




23 Demonstration of the potential application 
of Agluna anti-infective surface treatment 










multiplexed clinical diagnostics 
 
 
